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Summary
The field of genetic toxicology has recently undergone reform which has limited or banned 
the use of animal models within a number of different industries (cosmetics). Consequently, 
greater emphasis has been placed on developing novel, highly sensitive, in vitro test systems 
which can generate robust data to aid regulatory hazard and risk assessment.
The main aims of this project were i) to develop a highly sensitive and specific, high 
throughput mammalian in vitro PIG-A gene mutation assay to enable quantitative dose 
response modelling and further investigate the potential use of in vitro data within human 
health assessment, ii) Investigate the genotype to phenotype relationship, a potentially 
delaying step within future OECD guideline drafting for the current in-vivo Pig-a mutation 
assay and iii) help develop and optimise a preliminary comprehensive human PIG-A bio­
monitoring platform.
During in-vitro and ex-vivo PIG-A assay development, flow cytometry was the fundamental 
technique utilised. Multiple additional laser excitation platforms were evaluated for use, 
including Amnis ImageStream ™ and laser scanning confocal. Proteomic as well as 
genomic techniques were used during the supplementary investigations surrounding assay 
development, with microbiological groundings throughout.
The finalised in-vitro assay protocol was established within human, metabolically active, 
MCL-5 cells. Using the refined assay design, proof of principle experimentations were able 
to show the potential for future quantitative work and the general promise with this novel 
approach. The genotype to phenotype relationship validation is currently still on-going 
following the preliminary work described herein and recent publications. The ex-vivo 
human PIG-A assay platforms were shown to require further optimisation in terms of 
sensitivity, excluding red blood cells, but showed good aptitude for future use.
Currently it looks promising that further refinement could lead to a comprehensive high 
content, high-throughput assay system with the potential to be used within future hazard and 
risk assessment.
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Chapter 1: General Introduction
1.1 Genetic Toxicology
Genetic Toxicology is the study of the interaction, direct or indirect, mechanism and 
subsequent damage to the genetic material, located within the cell [1]. DNA consists 
of four nucleotide bases, the purines; adenosine and guanine as well as the 
pyrimidines; thymine and cytosine, each attached to a sugar (deoxyribose) phosphate 
backbone. Following enzymatic assembly, via the DNA polymerase family of 
enzymes, a comprehensive, intricate, polymer of multiple nucleotides are joined 
following linear covalent phosphodiester bond formation (condensation reaction) 
(Figure 1.1). Due to the conformed, highly regulated structure of double stranded 
DNA, a direct consequence of the specificity of base-to-base interactions, minute 
alterations to the overall structure of DNA can result in irreversible catastrophic 
damage. Such damage can threaten the viability of the host organism, not solely that 
specific somatic or germ-line cell [2] or result in deleterious disease phenotypes such 
as cancer.
Cytosine
H
GGuanine
Adenine
H2N
Tliyniine
Deoxyribonucleic Acid (DNA)
Figure 1.1. The DNA molecule and its respective nitrogenous base building blocks, 
adenine, thymine, guanine and cytosine - adapted from [3].
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1.1.1 Mechanisms of DNA Damage
DNA damaging agents are often grouped into two main categories, i) DNA reactive; 
chemicals which physically orientate, associate and/or interact with the central DNA 
double helix (direct gene expression regulation) at specific base related locations. 
[4]. II) Non-DNA reactive; agents which often are associated to DNA replication 
machinery and/ or other mechanisms related to gene expression and maintenance. 
Irrespective of the nature of the DNA damage mechanism, each specific category of 
DNA damaging agent for example, Reactive Oxygen Species (ROS) [5] has the 
ability to induce a wide plethora of results. Such results vary in terms of acuteness as 
well as longevity, and have effects ranging from mildly aberrant to catastrophic on 
the phenotype. Phenotypic alterations are based on i) the nature of exposure, in terms 
o f length and severity ii) oncogenes or tumour suppressor gene expression 
alterations, leading to long term carcinogenesis [6] and a whole abundance of genetic 
diseases (e.g. Deletion Syndrome [7]) and iii) irreversible genomic instability, 
leading to apoptosis and non-transmission of hereditary material (cell death) [8]. 
Accumulated DNA damage can be considered a direct contributor to some of the 
features of aging, single strand breaks have been identified as such a feature within 
the brain [9]. DNA damaging agents originating from within the human body are 
referred to as endogenous sources of damage; these include ROS, and often are 
generated as bi-products of routine biochemical synthesis or biological pathways. 
Such pathways include the electron transport chain within the mitochondria [10]. 
However, the body can also be exposed to deleterious sources of DNA damage 
which originate from the environment; these are referred to as exogenous agents and 
include such well known human carcinogens as Benzo(a)pyrene (B[a]P) [11], and 
cyclophosphamide [12, 13]. Deleterious pathology, cancer, aging, cell death, are 
often observed when the homeostatic DNA repair mechanisms become saturated and 
are no longer capable of efficient repair (Figure 1.2), hence why repair rate is a direct 
determinant of cell pathology [14].
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Figure 1.2. General overview of the complex relationship between endogenous and 
exogenous sources of DNA damage and their respective repair mechanisms. Adapted 
from an image generated by Harold Brenner.
l . l . l . l  DNA Reactive Compounds
Alkylating agents are a subgroup of DNA reactive compounds that physically 
interact with the DNA double helix through either a single (mono) or bi-functional 
mechanism. The reactivity and specificity of such compounds are graded by the 
Swain Scott constant value (S) [15]; the higher the value, the less reactive and more 
specific the nature of potential base adduct formation occurs.
The mono-functional alkane sulfonates, such as methyl and/or ethyl methane 
sulfonate (MMS and EMS respectfully), tend to be more highly selective than the 
nitrosamines, and primarily react with N7G, N3A and 0 6  guanine (3 common 
adducts to both alkylating agents) at a rate 4-5 x fold higher [16]. Nitrogen based 
alkylation is associated with chromosome aberrations such as single and double 
strand DNA breakage. Whereas, oxygen based alkylation has been demonstrated to 
be the only lesion induced by EMS which leads to direct mutagenic events (Figure 
1.3); miscoding of thymine opposite of the adducted guanine base resulting in DNA 
sequence alterations GC -> AT transitions [17].
Bi-functional alkylating agents such as nitrogen mustards (mustard gases) have 
multiple functional/active groups able to facilitate multiple points of 
contact/interactions being same strand or adjacent DNA strands and often result in 
DNA adduct formation or inter-strand cross-linking [18]. The results of exposure 
often highly affect DNA replication, as a result wound healing is heavily inhibited 
and hence severe cytotoxicity is often observed [19]. The specificity of the alkylating 
patterns induces unique DNA adduct formation and hence, subsequent mutation 
spectra revealing hot spots upon miss-regulation [20].
Nitrosamines such as ethyl-nitrosourea (ENU) or methyl-nitrosourea (MNU) have a 
much lower Swain Scott constant and are deemed more reactive substances [21], for 
example, they do not distinguish between areas of high or low nucleophilicity (i.e. 
areas abundant with electrons) and therefore, often do not distinguish between 
oxygen or nitrogen atoms as their specific target atoms for alkylation within the 
DNA double helix [22]. As a result of this, they are often associated with a plethora
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or alkylated base effects including the most common N7G, N3A and 0 6mG (repaired 
by methyl guanine -  DNA methyl transferase (MGMT)).
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Figure 1.3. Formation of O6 methyl/ethyl-guanine mutagenic lesions following, EMS 
and MNU, model alkylating exposure. Homeostatic DNA repair mechanisms, 
including MGMT, have been omitted to enable simplistic clarity of mutagenesis 
within the DNA molecule. Adapted from [23]
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1.1.1.2 Non-DNA Reactive Compounds
Not all compounds that result in potential genotoxicity directly react with DNA, non- 
DNA reactive genotoxicants are a category of compounds which can be just as 
potent as DNA reactive compounds at inducing carcinogenesis or related deleterious 
end points/mechanisms of damage [24].
Common targets appear within this category of compounds, which often relate to 
DNA replication machinery and/or DNA re-arrangement, epigenetic. A good 
example of such a compound is Vincristine which is a vinca alkyloid (similar to 
Vinblastine) originally isolated from the Catharanthus roseus (Periwinkle Plant), 
which specifically targets and inhibits tubulin production and hence, correct micro­
tubulin attachment and DNA replication, potentially resulting in un-even DNA 
distribution to daughter cells through mitosis [25] or even cell death. The end result 
of this can be loss of genetic material, entire chromosome loss [26], and can result in 
genetic disease within somatic cells, i.e. carcinogenesis and other disease related 
phenotypes. Non-direct DNA reactive agents, due to not directly altering base 
chemistry, cannot directly impact on the germ-line cells; failure to under mitosis and 
subsequent cell division does not facilitate propagation of genetic damage through 
this mechanism. However, un-even distribution of genetic material, non-disjunction, 
leading to such conditions including Klinefelter syndrome (XXY) can be observed 
[27].
1.1.2 M utagens, Aneugens and Clastogens
As mentioned above, there are two main categories that can be used to separate or 
identify any genotoxic chemical/compound (DNA reactive, or non-DNA reactive 
damaging agents). However, additional to this level of classification, there is an 
additional level of identification; which makes a commentary of the detailed 
mechanism of DNA damage as a result o f such chemical exposure. W ithin the DNA 
reactive compounds, one can further sub-categories compounds based on their actual 
method of DNA damage; mutagens, which alter the sequence of nucleotides within
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the nuclear DNA and clastogens, which cause chromosome breaks and often result in 
dose dependent micronuclei formation [28].
Mutagens are compounds or high energy electromagnetic waves, such as radiation, 
as mentioned above, which physically interact with the DNA molecule and result in 
an alteration to the linear DNA sequence, mutagenesis. The consequences of this can 
be silent, i.e. there are no alterations in the amino acids sequence, due to the 
degenerate nature of the genetic code, within all regions of the specified gene and 
hence, the protein product remains unchanged. Alternatively, the alteration or 
numerous alterations can result in protein truncation, via premature stop codon 
transcription, or on the other hand a completely different polypeptide sequence via 
alternate splicing, exon exclusion [29]. This can result in progressive loss of protein 
functionality, due to the nature o f the codon change or polypeptide structure, or in 
the case of an acute change; with regards to hydrophobicity and stoichiometric 
differences between the reference and novel amino acid, total loss of protein 
functionality [30].
As mentioned above, any chemical which interacts directly with the DNA molecule 
and alters the nucleotide sequence can be termed a mutagen; typical examples of 
such mutagens are the alkylating agents. Following alkylating agent exposure, 
depending upon the functionality o f the alkylating agent and specificity, a number of 
mutagenic lesions can form. In the example of ethyl methanesulfonate (EMS), a 
typical mono-functional alkylating agent, the ethyl group from the hydrocarbon is 
highly electron deficient, electrophile, and actively associates to the electron rich 
moieties, nucleophiles, w ithin the DNA structure [31]. Due to EMS being a 
relatively strong alkylating agent, via Swain-Scott constant grading, it is able to 
undergo both a Snl and Sn2 nucleophilic substitution reactions [32]; Sn2 
mechanisms promote the specific targeting o f strong polarised nucleophiles 
(Nitrogen) within the DNA double helix which have at least a single lone pair of 
valence electrons. However, in this case, due to additional S n l mechanistic 
capability of EMS, the oxygen atom at the 6 position within guanine is also able to 
be targeted and subsequently results in the main mutagenic lesion following 
exposure (06-ethyl-guanine) [33].
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Clastogens, as the name suggests, operate under a clastogenic mechanism, which 
alludes to their nature of DNA damage. Clastogens act via physical alterations to the 
DNA molecule [34] which result in chromosome aberrations, often attributed to 
disease phenotype and progression. Clastogenic lesions are able to be repaired, at a 
fidelity dependent upon the repair mechanism and therefore, are not solely restricted 
to deleterious cellular pathology, however, any DNA lesions which become fixed 
within the DNA molecule are highly associated to deleterious effects including cell 
death and DNA damage. The reasoii for this is that even though abasic sites and 
other structural abnormalities resulting from clastogenic lesions are typically not 
heritable and hence, do not confer any genetic consequence, close proximity of such 
DNA structural damage can induce a hypermobility and hence, induce DNA strand 
breakage [35].
There are a plethora of mechanisms in which clastogens can induce DNA damage; 
Acrylamide is an example of a clastogen [36] which generations chromosome 
aberrations via such a mechanism. Acrylamide exposure induces an increased 
frequency o f adducted nitrogen based alkylations within the nitrogenous base 
guanine. As a direct result o f this, DNA repair mechanisms such as the nucleoside 
excision repair (NER) and base excision repair (BER) are often self-sufficient in 
order to remove such adduct formation and aid the re-synthesis of the corresponding 
nucleotide base within the adjacent strand in order to further chromosome aberration 
events [37].
Finally, aneugens are in-direct acting compounds which have been demonstrated to 
increase the frequency of specific DNA damaging events which alter the total 
number of chromosomes. The resultant conditions are referred to as aneuploidy; a 
deviation from the correct number of species specific chromosomes. Aneuploidy can 
be caused by such events as non-disjunction, errorous sister chromatid exchange and 
mitotic spindle apparatus inhibition. As well as aneugens generating daughter cells 
with chromosome number abnormalities, they often increase the frequency of 
micronuclei formation. Micronuclei generating as a result of an aneugenic 
mechanism, commonly as a result o f chromosome lag during mitosis, are centromere 
positive and often contain the whole chromosome [12].
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1.1.2.1 Genotoxicity: Mutagenic Lesions
06eG adducts have been demonstrated repeatedly to be the most prominent cause of 
mutagenesis during in-vivo studies at various gene loci [17]. Since the 1980s 
increasing evidence has been put forward to support that GC-TA transitions form as 
a direct result of EMS exposure [38], with a positive correlation between the levels 
o f ethylation at the O6 guanine base and mutation frequency has been reported within 
standard genotoxic test systems [17]. Following the addition of the ethyl group to the 
guanine base at the 06 position, the base takes on a new structural/stoichiometric 
identity which mimics that of the purine base, adenine. As ensuing and direct results 
of this adduct formation, a miss alignment occurs during DNA replication and an 
adenine base is incorporated mistakenly into the non-template strand. At this 
moment in time, there is potential repair via a miss-match repair (MMR) mechanism, 
however, saturation of such mechanisms will consequently lead to a mutagenic event 
occurring (Figure 1.4). Following subsequent synthesis a transition mutation occurs 
in-which the initial GC base coupling is replaced with an AT within one of the 
subsequent daughter cells [39].
1.1.2.2 Genotoxicity: Clastogenic Lesions
Following ingestion of acrylamide (formed during the heating of certain foods), 
metabolic activity via P450 enzymes converts AA into the genotoxic epoxide 
metabolite, glycidamide (GA). GA forms DNA adducts, primarily 
at N7 of guanine (N7-GA-Gua) [40]. An additional example which follows a similar 
path as described above is the clastogenic lesions following EMS treatment. During 
alkylation of specific base moieties within the DNA double helix, most prominently 
nitrogen atoms, the base under goes a structural change which results in a potential 
clastogenic event [41]. N7 Guanine lesions, induced at relatively high frequency 
following EMS exposure, are deemed innocuous; there is no immediate deleterious 
affect post alkylation. Yet due to their novel chemical instability which often leads to 
such downstream processes as de-protonation, decomposition, depurination and C-8-
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Guanine adduct formation, leading to potential DNA strand breakage [42]. However, 
such lesions can be initially identified and repaired by N-methylpurine DNA 
glycosylase (MPG) [43], an initiator of the base excision repair pathway (BER). 
MPG directly binds to the DNA lesion and removes the adduct forming an abasic 
site (potential for strand breakage due to proximity to additional abasic sites). 
Obviously if BER saturation occurs (Figure 1.4), abasic site formation can lead to 
primarily DNA strand breakages and chromosomal aberrations [44] however, 
mutagenic events can also occur at a much lower frequency.
The distribution and potency, in respect to carcinogenesis, of an adduct spectra 
following chemical exposure is highly variable; this is highly dependent upon the 
specific types of end point, i.e. mutagenic or clastogenic as well as the efficiency and 
saturation limit of the homeostatic repair mechanism. DNA reactive chemicals more 
often than not do not operate by a single mechanism of DNA damage, due to the 
heterogeneity of target moieties within the DNA molecule.
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Figure 1.4. Mammalian cell -  DNA repair mechanisms; inclusive of direct reversal 
MGMT activity, scavenger enzyme, targeting mutagenic oxygen lesions (06 
methyl/ethyl guanine) as well as glycosylase induced BER for non-mutagenic 
nitrogen lesions (N3-Methyl Adenine and N7-ethyl guanine) -  Use of box to 
highlight the potential clastogenic lesions -  Adapted from [45].
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1.1.2.3 Genotoxicity: Aneugenic Mechanisms
Following acute aneugenic chemical exposure, cells have a much greater probability 
of undergoing an errorous mitosis as a direct consequence of potential mitotic 
machinery inhibition (Figure 1.5); daughter cells have a greater frequency of an 
aneuploidy phenotype [46]. Aneugenic alterations in the total number of 
chromosomes have been associated with a great number of genetic diseases, such 
conditions include Trisomy 21 (Down syndrome), caused primarily by incorrect 
separation, non-disjunction, of chromosome 21 during early development [47]. 
Aneugenic chemical treatment and hence, micronucleus frequency are directly 
proportional due to the mechanism of DNA damage i.e. specific inaccuracies during 
mitosis generating micronuclei. However, as micronuclei have two distinct 
mechanisms of formation; one being clastogenic in origin and the other aneugenic, it 
is a necessity to utilise centromere specific fluorescence probes to provide evidence 
of the mechanism of formation (Figure 1.5).
C h e m ic a l  T re a tm e n t
Non-disjunction M icronudcus FormationNormal
Separation
Loss o f  whole Loss of chromosome
chromosome fragment
(Aneugenic) (Clastogenic)
Figure 1.5. Micronucleus formation as well as observed errors during mitosis 
following acute chemical treatment. For illustration purposes multiple colours have 
been included to aid explanation; yellow -  centromere structures associated to whole 
chromosomes, green -  correctly separated and orientated chromosomes and red -  
inaccuracies in chromosome orientation and/or separation during mitosis - Adapted 
from 146 ].
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There are many additional forms of DNA damage, modes of action as well as DNA 
repair mechanisms which have not been included within this brief commentary [48], 
as they fall outside of the primary focus of this specific research project. Examples 
o f these include; DNA cross linkers/ intercalating agents, a large number of 
nucleotide specific fluorescence molecules used to measure DNA content and/or 
cellular viability operate under this mechanism, which will be discussed in greater 
detail within the flow cytometry application constraints. Pyrimidine dimers, induced 
following UV radiation [49], double strand breakages [50], homologous 
recombination [51] as well as specific detailed examples of endogenous sources of 
DNA damage, including the generation of ROS, oxidative stress and aging [52].
1.2 Hazard and Risk Assessment: Regulatory Guidance for Safe Operating 
Exposure Limits (OELs)
Toxicology as a field of research is utilised extensively in defining safety assessed, 
biologically insignificant, operating levels following prolonged or acute exposure to 
chemical substances, xenobiotic or foreign antigens. Routes of exposure can include 
respiratory inhalation, intra-venous/muscular/peritoneal injection, topical application 
and physical ingestion.
Exposure in itself is interesting and complex; exposure duration, route of exposure 
and the substance of exposure each are critical in collecting enough biologically 
significant data to ensure an acceptably low risk of hazard is defined complying to 
the REACH obligations [53].
Hazard and risk are intimately intertwined in one and another, hazard is a 
commentary or definition of the deleterious mechanism or result which can result 
post exposure. Risk on the other hand, is the likelihood or frequency of that hazard 
actually being exposed to a biological system and hence, causing such biologically 
deleterious effects [54]. W ithout one and another, each definition is biologically 
insignificant without the content the conjunctive commentary provides, similar to the 
idea of antagonistic muscles. In the example of the typical research laboratory,
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known genotoxic chemicals or bacterial toxins, which has an acutely high hazard 
potential and a human lethal dose 50% (LD50) value within the micro or nanogram 
scale, for example Abrin [55]; implying that minute amounts of such compound are 
fatal in humans. However, as the toxin is in-frequently used and is freely soluble in 
water, non-volatile, exposure is limited to a single route (ingestion); the risk 
associated with use is particularly low. Correct personal protective equipment (PPE), 
such as a laboratory coat and nitryl gloves are sufficient to reduce the potential 
exposure to minimal risk -  highlighting the necessity for context.
Prior to routine exposure, either acutely or over an extended period of time, the 
initial experimental work is carried out extensively within rodent models, primarily 
rat and mouse. However, one must always consider the caveat that rodent models are 
a satisfactory model of human exposure; although, humans have a different genome 
and hence, have subsequent different gene expression and protein presence within 
somatic and germ line cells. In order to associate said sources of limited and 
potentially human irrelevant data the use o f correlation factors and extrapolation 
calculations are implemented to artificially create a buffering affect to limit further 
risk. Historically some of the safety (correlation factors) included were i) a factor 
from 1 to 10 for animal to human extrapolation (if NOEL is based on animal data), 
ii) a factor from  1-10 for human to human intra-species variability and iii) a factor 
from 1-10 to consider study duration [56-58] in order to generate a conservative 
human OEL, airing on the side of caution. The field still relies on this traditional 
dogma to create safe exposure limits, however, due to the advancements within 
genetic toxicology, a potential paradigm shift could be seen in the near future 
through the inclusion of qualitative dose response data within OEL definition.
14
1.3 Safety Assessment and Drug Development
Each and every drug which progresses from theoretical compound, through 
manufacturing and eventually into the domestic or global market has to undergo a 
strict and thorough hazard and safety assessment to ensure safety following regulated 
progress. The global pharmaceutical market was estimated to be worth 
approximately 170-180 billion US dollars in 2012 [59], with an estimated peak of 
880 billion US dollars by 2014 [60]. The surge in the global market over recent years 
is primarily down to a massive increase in the third world markets; Chinese market 
contributed an additional 50 billion dollars, 25% of the entire global market and 
secondly due to increased spending on nationalised healthcare in the developed 
market [59]. However, the United Kingdom, an example of a typical western market, 
has been steadily falling down the global rankings, in terms of market size, of the 
pharmaceutical industry since 2007 (Table 1.1).
Table 1.1. Statistical summary o f  the global pharmaceutical market fo r  2010 and 
2012 respectively, highlighting observed trends — adapted from  [61]
2010 2012
Country W orld
Ranking
Size of 
Market 
(Mill $)
Growth
(% )
World
Ranking
Size of 
Market 
(Mill $)
Growth
(% )
USA 1 319,552 6 1 326,892 -1
Japan 2 96,355 7 2 112,067 0
China 3 54,865 21 3 81,698 22
Germany 4 42,181 2 4 42,333 -6
France 5 38,529 -5 5 36,674 -8
Brazil 7 26,259 38 6 29,112 -6
Italy 6 26,639 -2 7 26,231 -8
Canada 9 21,655 13 8 21,877 -2
UK 10 20,297 2 9 21,635 0
Spain 8 22,220 -2 10 19,935 -12
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1.3.1 Safety Assessment and Drug Development: Standard Battery of Genetic 
Toxicology Tests
New molecular entities (NMEs) is the term given to novel drugs as they leave the 
drug discovery phase, a novel compound that has been shown generally to be highly 
promising as a potential therapeutic target to a disease, the initial judgm ent often 
occurs within in-silico methods, such as Quantitative Structure-Activity 
Relationships (QSARS) for example, Derek-Nexus[62]. However, the strengths 
associated with in-silico approaches are often limited to the database which the 
software sources it’s information, often resulting in much lower specificity and 
sensitivity when applied to novel classes of compounds [63]. NMEs are coming to 
market at a consistent rate each year, a direct result o f numerous independent private 
bio-technology companies; often graduate spin out companies, however, at the drug 
discovery phase little is known about the toxicity, pharmacodynamics and kinetics of 
the compound. W ithin the field of genetic toxicology, a standard tiered test system of 
genotoxic assays is utilized extensively in order to cover the wide variety o f potential 
genotoxic end points; mutagenicity, chromosome aberrations etc. enabling the 
investigator or regulatory committee to generate sufficient data in order to construct 
a complex, in context, overview of the ensuing hazards following environmental 
exposure [64, 65].
The above assessment programme is often referred to as the Genotoxicity Test - 
Battery and consists of the following; i) “Crude” bacterial reverse gene mutation 
assay; the Ames test [66] -  in which Salmonella histidine mutants, often combined 
with human or rodent S9, are utilised to detect mutagenic carcinogens. The resultant 
Ames test is highly sensitive, ideal for hazard identification, however, is often 
criticised for being overly sensitive; due to some bacterial tester strains harbouring 
additional mutations other than the histidine synthesis genes. These include 
lipopolysaccharide synthesis, resulting in the cell membrane becoming more 
permeable [67], and excision repair pathways common to Eukaryotes [68].
ii) Mammalian in-vitro genotoxicity; either the a) in-vitro micronucleus test (mono 
and bi-nucleus with or without recovery) [69]or the b) thymidine kinase (TK) -  MLA 
[70]/ hypoxanthine phosphoribosyl transferase (HPRT) gene mutation assays [71].
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iia) The micronucleus test is a highly validated chromosome aberration assay in 
which chemicals operating under a clastogenic and aneugenic mode of action can be 
detected and identified via the sequential use of centromeric stains, post micronuclei 
induction [72].
iib) The H PRT  gene is located on the X-chromosome of mammalian cells, and 
subsequently used as a model gene to investigate gene mutation. The test follows a 
very similar methodology to the thymidine kinase (TK) -  mouse lymphoma assay 
(MLA), with the additional of aminopterin to promote the purine DNA salvage 
pathway and both are included in the guidelines for mammalian gene mutation tests 
(OECD (1997) [73]. The MLA  methodology is such that mutations which destroy the 
functionality of the TK  gene and or/protein are detected by positive selection using a 
toxic analogue (6-thioguanine), and TK ~ mutants are seen as viable colonies. Unlike 
bacterial reverse mutation assays, mammalian gene mutation assays respond to a 
broad spectrum of mutagens, since any mutation resulting in the ablation of gene 
expression/function produces a T K ~mutant [74]; common mammalian cells 
routinely used: L5178Y -  M ouse lymphoma [70], TK6 and AHH-1 -  Human B- 
lymphoblastoid immortalised cell lines [71, 75].
Finally iii) M ammalian in-vivo test for genotoxicity; either micronuclei (peripheral 
blood and bone marrow) [76], chromosomal aberrations, or gene mutation; either in 
vivo Pig-a  [77] or transgenic: GPT MutaM ouse of BigBlue ™ [78] or finally, the 
COMET assay (all tissues) [79]. Rodent transgenic mutation assays are well- 
established assays that utilise transgenic rats and mice which contain multiple copies 
of chromosomally integrated plasmid or phage DNA. Concealed within the DNA 
molecules are reporter genes for the detection of mutation. Mutations occurring 
within such a rodent are subsequently scored by recovering the vector and analysing 
the phenotype of the reporter gene in a bacterial host [80]. DNA extraction from any 
tissue type therefore, circumvents many of the existing limitations associated with 
the study of in-vivo gene mutation.
The test battery is currently outlined by the Food and Drug Administration (FDA) 
[81], presented at the International Committee for Harmonization (ICH) [82], 
summarising OECD guidelines in order to facilitate a global template for assay 
protocol; enabling homogeneity within test protocols and subsequent comparable
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data acquisition [65]. The reason for such a document is due to the nature of global 
genotoxicity testing, as each country or continent is often regulated by a different 
committee or governing body; for example Europe: European Environmental 
Agency (EEA) [83], now formally known as the European Medicines Agency 
(EMA), and the United States of America: Food and Drug Administration (FDA) 
[81], the subsequent data generated by individual regions often cannot be compared 
against like data sets from a different continent. Assay protocol varies heavily 
depending upon the governing body which quality assures the data; standard 
recovery time, dosing regime and cell type may be very different. The ICH ’s goal is 
to promote communication between global pharmaceutical industry figureheads to 
facilitate the standardisation of genetox testing; reducing heterogeneity within the 
resultant data [82].
In the past 10-20 years the field of genotoxicity as well as other scientific disciplines 
has been steadily re-structuring in order to fit current governmental demands, as well 
as a direct reflection of the global economy. The National Institute of Health (NIH) 
had to cut their 2013 budget by 5% in March as a direct sequestration legislation 
brought in by the president [84]. Increasing numbers of governmental based 
legislations as well as initiatives have been founded in order to address budget cuts 
as well as to appease the global position on animal testing, especially within the 
cosmetic industry (Europe). Two specific examples of this would be the 3Rs 
initiative [85] and the Cosmetics directive [86]. The 3Rs initiative is a worldwide 
enterprise with the overall goals to replace, reduce and refine the use of animal 
models within drug testing. The goal o f the 3R ’s is more drastically reflected by the 
cosmetics directive, a legalisation which has banned the use of animal model within 
cosmetics testing.
1.4 Governmental Reforms within Genetic Toxicology Testing: New Direction
Due to the pressure applied by the introduction of this paradigm shift within 
government legislation concerning animal testing, within genetic toxicity and related 
health sciences, a consequential move in the currently implemented approaches to
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drug testing is inevitable. Increased resources are being allotted into the field of 
novel in vitro assays, not solely limited to genetic toxicology endpoints (Skin 
sensitisation [87]) as well as of quantitative in-vitro-in-vivo dose extrapolation [88]. 
Restrictions within in vivo testing has not only affected the cosmetic field, but 
increasing government driven cut backs and limitations has resulted in many animal- 
model based assays losing favour due to the associated pressure of animal usage as 
well as shear difficulty to acquire ethical approval [89].
As a direct consequence of these reforms, increasing focus is being placed upon 
alternative novel approaches to toxicology animal testing, i.e. in silico and in vitro 
based test systems [90] as well as integrating multi-end-point analysis, comet (all 
tissues) and erythrocyte Pig-a, within current 28-day toxicology studies [91]. For the 
scope of this project in vitro test system will be discussed at length; in vitro systems 
do not simply infer 2-dimensional traditional immortalised cell line assays, TK  and 
MLA for example. M odem, novel 3-dimensional tissue constructs, originally 
sourced from primary tissue samples, can be used to accurately represent the cell 
types as well as growth dynamics of combinations of cells making up specific tissue 
and even minor organ systems [92]. Currently favoured assays include the 3D skin 
tissue model [93] as well as numerous bronchial epithelial lung models [94] in which 
many preliminary toxicology publications have demonstrated initial robustness 
within primarily the micronucleus endpoint [95]. However, even though preliminary 
data looks promising, there are currently no consensus OECD guidelines published 
and further validation is required.
1.4.1 Advantages and Disadvantages of Novel Reforms
D m g delivery is not a fixed mono-direction interaction, it is not a simple easy to 
model system in which a potential therapeutic solely identifies and conjugates to its 
own highly specific target (pharmacodynamics). During drug exposure, the body in­
directly acts upon the drug simultaneously (pharmacokinetics) and therefore, 
constructs a much more complex interaction system with multiple high variable 
factors. Utilising mammalian models, during safety assessment, allows the
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investigator to explore the multifaceted relationship between the ability of a drug to 
act upon its target and the corresponding response the body has on said drug. The 
pharmacokinetic aspect of drug interactions can be categorised as follows; 
absorptions, distribution, metabolism and excretion (ADME) [96]. Take an orally 
administered antibiotic for example, initially the drug coating must first be 
considered in order to enable the drug to reach the target organ and extend the half- 
life to enable efficient distribution around the body. Failure to meet these 
requirements will decrease the likelihood of drug-target interactions, reduce the 
concentration of said drug at the target (increased cytotoxicity is often seen 
following increased therapeutic dose to counter this) and increase the chance of 
bacterial resistance [97]. Point o f initial drug contact and routes o f admission are 
contributing factors in modifying the dose of the therapeutic, higher doses applied 
topically can be better tolerated when compared to an intra-venous injection, for 
example (generally due to distribution and actual penetrable dose). Drug compounds 
once exposed to the human proteome can often become unstable, due to enzymatic 
degradation of the therapeutic compound, generally this aids elimination, however, 
in certain circumstances, for example paracetamol; the metabolites are extremely 
toxic, localised within the liver and can result in acute hepatoxicity [98]. Certain 
drug compounds, due to inefficient methods of elimination, have been reported to 
accumulate, bioaccumulation, within specific tissues or organ systems within the 
body. Reports suggest that human adipose tissue is a source of a whole host of lipid 
soluble compounds, for example pesticides [99], which are notoriously difficult to 
remove from the body.
Currently, this complex state is most viably modelled within animal exposure; 
interspecies variability is a known caveat associated with rodent to human 
extrapolation. The human genome and subsequent proteome, is highly conserved 
within other mammalian species, however, is larger and more complex than the 
rodent. The paradigm shift within toxicology away from in-vivo testing has led to 
increasing focus on novel predictive in silico and in vitro approaches [90], as 
previously mentioned. However, the pharmaceutical industry stands to lose a large 
amount of supplementary biologically relevant rodent data during safety assessment, 
and gain an abundant amount of in vitro safety data. Controversially, this will appear 
to have a detrimental effect on the overall drug development system, due to the
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caveats associated with in-vitro to in-vivo extrapolation as well as increasing 
limitations beings placed on animal pharmacodynamics and kinetic studies. 
However, recent studies have shown increased potential within in-vitro to human 
dose extrapolation; in vitro generated quantitative dose response data will be used 
more extensively in the future of drug development [100], as well as the in vitro 
genetic toxicology assays proving to be extremely sensitive to genotoxins and 
provide a cost effective approach to screening of large numbers of environmental 
xenobiotics [101].
1.5 Gaining Favour -  In vitro Test Systems
3-dimensional tissue models may be the distant future of genotoxicity testing, 
however, the mammalian cell in vitro immortalised cell lines host a wide variety of 
routinely used and OECD certified genetox assays, such as T K -M L A  (L5871Y)[70], 
H PRT  (AHH-l/77£6) [74] as well as the more traditional controversial, HGPRT 
(CHO/V79) [102]. Following decades of routine use within the tiered genetox test 
battery, historically in-vitro (cell line based) genetox assays have proven their 
requirement and practicality, and have the reputation and historical data to facilitate 
inclusion in future amendments to the ICH guidelines (S2B). However, as in the case 
of any genetox assay, specific forewarnings are applied directly to the in vitro 
assays, these include; sensitivity, crudeness to model human exposure and hence, 
biological relevance. Such resultant data should be used cautiously for anything 
greater than hazard identification and information on potency and modes of action 
[103].
1.5.1 In vitro Testing: The Future of Drug Development?
The majority of disadvantages associated with in vitro testing are directly 
consequential of comparing the test systems with in vivo animal models with 
analogous end points. As stated in the ICH guidelines [64] there is still a present 
need for in-vitro gene mutation and chromosome aberration assays; coupling this 
with the restrictions applied by recent governmental legislations, as mentioned
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previously, animal models could in the future play a much less prominent role within 
the standard genetox battery. Therefore, priority has been put into developing novel 
in vitro test systems which are in-expensive, high throughput, highly sensitive and 
able to generate stand-alone useable data. However, the following section will 
endeavour to provide a balanced overview of their potential advantageous and 
deleterious characteristics; improvements can be made in a number of areas.
Sensitivity, within this particular topic, refers directly to an assays ability to 
differentiate between spontaneous background and an induced increase in the 
measurable endpoint, when compared to negative controls. For example, within an 
in-vitro micronucleus assay [69], sensitivity refers to the assays ability to detect a 
compound induced statistically, biologically, significant increase in the frequency of 
micronuclei when compared to a con-current vehicle control. In-vitro test systems 
historically have been criticized for being overly sensitive, i.e. a number of in-vivo 
negative compounds have generated positive results within the in-vitro assay 
protocol [104]. Consequentially the in-vitro systems tend to generate lower PoD 
potency metrics when likened to the same chemical within in-vivo rodent models, as 
expected, due to crudeness of chemical delivery. However, due to this relationship, 
preliminary investigations into in-vitro to in-vivo dose extrapolation 
(Carcinogenicity PoD) look promising [28].
This elevated false positive rate when compared to in-vivo assays has led to 
criticism, within the pharmaceutical industry, and has potentially large implications; 
Ames positive potential therapeutic compounds can be abandoned due to their high 
likelihood of a corresponding positive result in subsequent in-vivo genetox assays. 
However, the relevance of the data as well as the test conditions utilised to generate 
the data have come under reproach; with suggestions of exaggerated dosing 
regimens at biologically irrelevant concentrations that can often cause such false 
positive results [105]. In-vitro test systems if suitably designed are cost effective and 
can be used as the first stage in pre-clinical safety assessment. Their often over 
sensitive and easily modified/manipulated experimental design [106] is highly 
beneficial for early stage drug attrition. Consequently, novel mammalian cell in-vitro 
genetox assays are being assessed for their use in follow up testing as more accurate 
predictive tools for genotoxic carcinogenicity [107] taking into account biologically 
relevant maximum test concentrations.
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The route of drug administration within basic in-vitro test system is often criticized, 
the fundamental approach within in vitro 2D mono-culture based test systems, direct 
exposure, does not take into account or facilitate the modelling and impact that route 
of admission (absorption), point of contact, drug half-life, distribution, metabolism 
(not true in all cases) and elimination have on dose response metrics following 
compound exposure f 108]; often resulting in elevated maximum dose concentrations 
and false positives. Therefore, in order to generate an environment more analogous 
to that of human exposure, 3D-tissue constructs provide an in-vivo mimicking 
microenvironment encompassing a number of pharmacokinetic physiognomies, for 
example, within the 3D-skin constructs (Figure 1.6), the point of contact, drug 
penetrance, reactivity of drug following penetrance (half-life) as well as distribution 
are all modelled 193].
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Figure 1.6. Two commercially available MatTek 3-D epidermis models, EpiDERM 
and the EpidermFT. The EpiDERM model (pictured left) consists of normal, human- 
derived epidermal keratinocytes, whereas the EpiDERMFT (pictured right) 
additionally consists of human-derived dermal fibroblasts. Note the supplementary 
presence of the Dermis as a direct result of fibroblast co-culture - Taken from [109].
However, the relative crudeness of an in vitro system actually radically increases the 
number of downstream applications said cells can be used within. Most cell/tissue 
types within in-vitro test systems can be processed on numerous downstream 
appliances, plate reader, flow cytometer, in-cell analyser etc. with minimal 
processing and hence, low levels of cellular attrition. At this point fixing the cells, a 
technique utilised to preserve the finer structure of the cell through the induction of 
protein polymerisation; cross linking between adjacent free functional groups 
resulting in a matrix like insoluble lattice 1110], for long term storage or microscopy
applications generates high quality end results. However, processing in-vivo/ex-vivo 
samples often requires more extensive protocol design; intense often deleterious 
homogenisation and high speed centrifugation [111] result in heterogeneity within 
the subsequent population decreasing assay reproducibility and robustness, tissue 
location depended.
Traditionally, mammalian cell (non-human) cell lineages, for example Chinese 
Hamster Ovary (CHO) cells as well as Chinese Hamster Lung V79 [102] were 
routinely used within genetox testing. In recent years criticism has been attributed to 
these rodent cell lines; unacceptable levels of genomic instability as well as 
questionable or no functional TP53 status, leading to progressive disuse [112]. 
Human biological relevance, especially in the context of in-vitro to human 
extrapolation, has gained significant aptitude and resultantly has advanced the field 
into using human-p53 competent cell lines (TK6) [113-115] instead of the traditional 
commercially available rodent alternatives.
TP53 is a tumour suppressor gene which has been reported to be mutated in the 
region of 10-99% (depending upon metastatic potential and aggression) of all cancer 
types [116]. The TP53 gene encodes a 53 kDa nuclear transcription factor - in its in­
active form, MDM2 associates to the protein (increasing the likelihood of 
degradation) and subsequently the protein complex is shuttled into the cytoplasm 
distal to any potential nuclear target genes [117]. In response to oxidative stress, 
DNA damage, hypoxia and osmotic shock p53 becomes active (Figure 1.7); 
conformational activation via a phosphorylation at the N-terminus domain (serine 
15) and is shuttled back into the nucleus (dramatic associated half-life increase) 
[118]. P53 has subsequent roles in apoptosis and cell cycle regulation, via the 
modulation o f nuclear proteins such as p21 (WAF1-CIP1) [119], and following 
Cyclin dependent Kinase 2 inhibition (CDK2) causes arrest within the G l/2  
regulation checkpoint, the cell is either able to facilitate p53 dependent DNA repair 
and fix said DNA damage or alternatively, the cell can begin to facilitate the initial 
stages o f apoptosis, programmed cell death [120].
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Figure 1.7. The p53-DNA damage response pathway. p53 is activated after DNA 
damage (cytoplasm) and shuttled to the nucleus, resulting in either of two cellular 
responses: induction of the CDK inhibitor p21, which leads to a G1/2-phase cell 
cycle arrest, allowing time to repair DNA damage before cellular division; and 
programmed cell death (apoptosis).MDM2 induces the normal degradation of p53 
protein, and amplification of MDM2 in some tumours results in loss of p53 function. 
p l9-A R F inhibits the effects of MDM2 and contributes to the activation of p53 in 
response to DNA damage. pl9-A R F is commonly deleted in human cancers, along 
with its neighbouring gene, pl6-IN K 4a - Taken from (1211.
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Somatic human cells are primarily homozygous p53 wild type (wt), however, 
heterogeneity at the p53 locus greatly increases the frequency of carcinogenesis 
[122]. The reasons for this are; firstly, there is only a single functional copy (allele) 
o f the p53 gene within each cell and secondly, the probability o f formation of the 
p53 protein is highly reduced, due to the homo-tetramer tertiary structure of the p53 
protein [123]. P53 competency is of major importance within genetic toxicology, not 
only for biological relevance; point of departure matrices are significantly dependent 
upon the functional p53 status, within the test system assayed. W ithin heterogeneous 
and homogeneous mutant genotype cultures, mutant p53 phenotypes such as the loss 
o f the G1 checkpoint and delayed apoptotic cell death are readily reported; 
characteristics which have been consistently observed in the AHH-1 TK+/- cell line 
following exposure to DNA-damaging agents [124]. P53 competency provides 
cellular cultures with a biologially insignifcant level of mutation, a buffer zone, 
which is not strictly deleterious in nature due to the fact that the mutation has not 
become fixed and is able to be potentially repaired and hence, the fate of the cell is 
not static.
For example, following MMS exposure, a typical somatic cell acquires a 
0 6methylguanine adducted base, which we know to be mutagenic in nature [16]. 
Functional p53 competency, if such DNA damage is identified, can result in p21- 
mediated checkpoint arrest and subsequently facilitates the cell to actively remove 
such a lesion via M GMT activity or altemativey subject the cell to programmed cell 
death; both mechanisms prevent the mutation from becoming fixed within the 
genome and preventing harm. Deleterious effects will only become significant, when 
either MMS concentrations saturate DNA repair mechanisms or cytotoxicity raises to 
a level which does not facilitate cell viability. However, when directly comparing 
this to dis-functional P53 cell line (heterzygous or more dramtically homozygous 
p53 mutant). Due to either limited p53 protein or dis-functional TP53 expression the 
subsequent somatic cells lack the ability to deviate the cell’s fate (apoptosis) or 
induce a checkpoint arrest to help enable DNA reapir of mutagenic or clastogenic 
lesions. As a result of this, p53 incomptency results in a cell being overly sensitive to 
compound exposure and hence, has a much lower point of departure metric. 
Subsequent highly conserved point of departure metrics have little biological
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significance in the context o f  human exposure. “Rigorous quantitative studies of p53 
dynamics in the context of differential activation of DNA repair, cell cycle arrest, 
and apoptosis pathways are urgently required. To determine the low -dose- response 
behaviour for mutation and the point o f departure to adversity” [125]
P53 status within cell lines routinely used for genetox assays ,TK6, AHH-1, MCL-5 
etc. have been debated consistently over the past 20 years [126]. Typical mutation 
hot spots, Codon 282 - exon 8 , have been assessed and analysed (restriction 
analysis) within the p53 genes; inconsistencies related to derivation of cell line and 
maintenace of cell stock have led to contradictory publications [124, 126].
Discrepancies observed during direct inter-laboratory trial data, mainly as a result of 
genetic drift post undocumented distribution, has resulted in numerous journals 
requiring supplementary certification other than the original purchase order prior to 
publication. This can partly be attributed to the lack of global harmonisation of assay 
protocol [82]; elevated genomic instability (e.g. loss of gain of whole chromosomes), 
hyper variable spontaneous mutant frequency (within the same or common ancestral 
cell lines [127]), lack of good clinical practice (GCP) and raised inconsistency within 
experimental repeats suggests a more fundamental problem.
The introduction o f nanoparticle research within the field of genetic toxicology 
generated a substantial problem for traditional in-vitro assays. The reasons for this 
are extensive [128], nevertheless in brief; nano particles often are small enough to 
enter the nucleus and hence, theoretically can interact directly with the DNA 
molecules [129] potentially resulting in replication error (aneugenic) and potential 
DNA damage lesions (mutagenic/clastogenic). However, in practice due to the 
heterogeneity of nano particles; surface charge, surface structure/coating, 
agglomeration status, loading capability and numerous other factors, typically 
standard in-vitro test systems are unable to accurately model such elements; often 
resulting in insignificant false negatives [130]. Taking agglomeration status as an 
example, nanoparticles have a tendency to associate and hence form agglomerates of 
varying shapes and sizes often due to surface charge or protein coating as a result o f 
serum containing media dispersion [131]. This subsequent net increase in size and 
charge frequently fundamentally alters the physical characteristics of the 
nanoparticle and for this specific example, lowers nanoparticle penetrance into the
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nuclear envelope and hence prevents direct DNA interaction, thus generating no 
significant positive result [132]. However, bio-accumulation of such foreign 
nanoparticles within the intracellular endosomal compartments is a potential source 
of oxidative stress, which can lead to the induction of reactive oxygen species 
(ROS), the up-regulation of Haemeoxygenase 1 (HO-1) expression, apoptosis and 
autophagy [133]. The net result is that nano particles can also induce secondary 
toxicity in macrophage lineages, due to their role in phagocytosis and subsequent 
clearance of damaged cells [134], Current in vitro test systems require substantial 
modification in order to try and address some of these issues; co-culture assay 
design, utilising human macrophage cell lines could be one potential adaptation to 
more accurately model secondary toxicity.
However, regardless of the potential caveats associate to the use of in-vitro test 
systems they maintain a distinctive role and facilitate a need for inclusion within 
future safety assessment. In vitro systems can offer high throughput, high precision 
and high content analysis which enable such applications as ToxCast™  to provide a 
chemical evaluation of a compound. A most important part o f  EPA ’s Computation 
Toxicology research is the Toxicity Forecaster (ToxCast™). ToxCast™  uses 
automated chemical screening technologies, high-throughput screening assays, to 
expose living cells or isolated proteins to chemicals. The cells or proteins are then 
subsequently assessed for variations in biological activity that may suggest potential 
toxicity [135].
Therefore, in conclusion in vitro test systems are relatively inexpensive, quick, high 
content and sensitive, however, there is a real need to develop more modem, 
equivalent assays to which take into account the limitations listed formerly and thus, 
can enable the generation and compiling of significantly more biologically relevant 
21st century genetox data. An example of such an initiative is the federal agency 
collaboration called Toxicity Testing in the 21st Century (Tox21), which pools such 
chemical research data and has successfully compiled high-throughput screening 
data on nearly ten thousand chemicals [136].
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1.6 P hosphatidyl Inositol G lycan Biosynthesis C lass A G ene (.PIG -A)
Paroxysomal Nocturnal Haemoglobinuria (PNH) is a clonally non-malignant 
acquired haematological disorder, which has been reproducibly shown to result from 
a somatic gene mutation within a bone marrow stem cell or early progenitor cell 
[137]. Bone marrow stem cells are the precursors for the entire haematopoietic 
system and thus, this specific gene mutation within such a fundamental cell type can 
effect numerous cell lineages; pluripotent characteristics demonstrated by the bone 
marrow stem cells facilitate a number of different genotoxicity assays being directed 
at tissues of haemopoetic origin [138]. Symptoms of PNH include the consequences 
o f complement-mediated haemolysis, venous thrombosis and bone marrow failure; 
anaemia, discolouration of urine (especially prominent within the first urination of 
the day), exhaustion and abridged patient life span [139]. PNH is easily diagnosed 
via immunocytochemistry staining, coupled with subsequent flow cytometry 
analysis, of a minute volume of peripheral blood; requiring no highly invasive 
investigatory techniques such as a colonoscopy. PNH effects approximately 1-2 
persons per million of the general population [140], however, the symptoms are 
severe enough to warrant investigation. Following the identification of the 
mutational event inducing the disease phenotype, primarily a silencing event within 
the Pig-A  gene [141]; deriving the biological implications this genotype has on 
functionality was the next logical goal of research.
The phosphatidylinositol glycan complementation group Class A (PIG-A) gene is 
located on the X-chromosome, X. p22.1 (Molecular Location on the X chromosome: 
base pairs 15,319,450 to 15,335,553) [142] and due to its X-linked location 
(heterozygous), makes it highly sensitive to mutational inactivation. The Pig-A  gene 
encodes a protein critical for the synthesis for a catalytic subunit of the N-acetyl- 
glucosamine transferase complex which is required for the first step of 
glycosylphosphatidylinositol (GPI) anchor biosynthesis [143]. GPI anchors are small 
membrane tethers which attached a whole plethora of surface antigens which make 
up the complement of GPI-linked cellular surface markers; each cell type has lineage 
specific GPI-linked proteins facilitating characteristic surface membrane trafficking 
and cellular function. The process of GPI anchor biosynthesis requires at least 12
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genes and, theoretically, silencing events of any of these would lead to GPI anchor 
deficiency [137]. However, the Pig-A  gene is the only gene involved in this process 
which is not autosomal, x-linked, thus requiring only a single silencing event to 
cause GPI anchor deficiency, and making it a potential candidate to act as a reporter 
gene within a gene mutation assay [144]. For autosomal genes critical within the 
GPI-anchor synthesis pathway, mutations on both active alleles must occur prior to 
an observed null phenotype, insensitivity of a homozygous reporter gene, and hence 
the probability o f such a linked event is low (lx lO ’20 -  2 x (Overall error of DNA 
polymerase (lx lO  8) multiplied by the fidelity of repair ( lx lO '2)) [145]. This double 
mutational event is extremely rare and it is therefore, perceived that the inability to 
anchor GPI-linked proteins to the cell membrane is equivalent to a Pig-A mutation 
[137]. To further cement this idea, continued research into the origins of the acquired 
genetic disease involving GPI anchor deficiency, known as (PNH), indicates that 
cells lacking GPI anchors or GPI-anchored cell surface proteins is almost always 
caused by a somatic mutation in the PIG-A gene [143], however, PIG -T  mutations 
recently have been shown to induce the GPI-AP deficient phenotype [146].
PNH presents itself as a highly variable, heterogeneous, disorder which has recently 
adopted the term  “PNH syndrome” in order to encapsulate additional disease 
phenotypes [141]. Due to the variability of the original silencing event, both in terms 
of cell lineage (clonal origin and expansion) and time of development (congenital or 
acquired) manifestations and subsequent prognosis is also highly variable [147]. 
Classical congenital PNH (silencing affect within the PIG-A gene locus) results in 
patients lacking the full complement of cellular surface antigens on the extracellular 
surface of the cellular membrane due to an inhibition of GPI anchor biosynthesis. 
Antigens on the cell membrane have numerous roles within signal transduction 
[148], receptor ligand binding, immunology (complement system regulation), cell 
trafficking, cellular uptake, cell signalling and identification [149]. Therefore, when 
a cell presents with such a phenotype, autoimmune response is common due to 
severe loss of cell functionality. Human erythrocytes (red blood cells) are initially 
differentiated from hematopoietic stem cells located within the bone marrow 
(Erythropoiesis) [150], with the ability to self-renew indefinitely in culture while 
also maintaining the aptitude to become almost any cell type in the human 
body [151].
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Somatic mutational silencing occurring within the PIG-A  gene of a bone marrow 
stem cell, or early progenitor cell, can potentially result in the clonal expansion of 
said PNH phenotype; systemic distribution of GPI-linked surface antigen deficient 
haemopoetic cells (erythrocytes and leukocytes). In the case o f human erythrocytes; 
there are a number of vital GPI-linked surface antigens, complement regulatory 
proteins, which are critical in homeostatic regulation of haemopoetic tissue [152]. 
CD59, also referred to as protectin, encodes a cell surface glycoprotein that regulates 
complement-mediated cell lysis, and it is involved in lymphocyte signal 
transduction. This protein is a potent inhibitor of the complement membrane attack 
complex (MAC), whereby it binds complement C8 and/or C9 during the assembly of 
this complex, thus preventing the incorporation of multiple copies of C9 into the 
complex which is thought to be necessary for osmolytic pore formation. Mutations in 
this gene, as well as GPI-anchor biosynthesis genes, cause CD59 deficiency; a 
disease phenotype exhibiting haemolytic anaemia and thrombosis symptoms, which 
can potentially cause cerebral infarction (stroke), due to licentious MAC mediated 
haematocyte lysis [153]. CD55 encodes a protein involved in the regulation of the 
complement cascade. The encoded glycoprotein is also known as the decay- 
accelerating factor (DAF); binding of DAF to complement proteins accelerates their 
decay, disrupting the cascade and preventing damage to host cells (mainly through 
lysis). Antigens present on the DAF glycoprotein constitute the Cromer blood group 
system (CROM) [154]. The combined action of CD55 and CD59 regulates 
homeostatic haemolysis within the peripheral circulatory system; this is critical due 
to the nature of erythrocytic maturation. Erythrocytes pass through an immature 
precursor stage in which they have an active RNA reticule, providing them with their 
classification -  Reticulocytes. Once matured, red blood cell (RBC) remain within the 
circulatory system for an estimated 100-120 days [155]. Remnants o f mRNA remain 
at this point (post nucleus expulsion at earlier stages) and therefore, if the RBC takes 
sufficient damage whilst within the periphery, functionality is comprised requiring; 
accumulation of damaged erythrocytes could increase risk of blood clotting, (stroke 
and myocardia infraction) and anaemia.
Compliment system mediated haemolysis of GPI-AP defective RBCs is an example 
of the auto-immune response within humans; attacking erythrocytes deficient with 
regulatory proteins (CD59/CD55). This phenomenon is not only observed within
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humans, mice express two analogous genes to human CD59 (hCD59) mCD59a and 
mCD59b and rats express a single analogous gene rCD59, both have been 
experimentally proven to induce protection from complement mediated lysis 
(haemolytic anaemia) [156, 157]. Therefore, when designing a rodent/human genetic 
toxicology assay based around GPI-AP deficiency (CD55/CD59 presence), one must 
take into account the caveat of potential GPI-AP mutant clearance via autoimmune 
complement mediated responses; theoretically making the task of estimating 
subsequent DNA damage post exposure very problematic within the haematocyte 
cell lineage.
1.6.1 Development of the Rodent Pig-a  Gene Mutation Assay
In the early 21st century Litron ™ began to file patents for the design o f a 
commercial kit, with the sole intent to in-directly measure the Pig-a  gene mutation 
frequency within rodent erythrocyte models [158-160]. The patents describe the 
detailed use of immunohistochemical staining (fluorescence polyclonal antibody 
conjugates) against GPI-linked cellular surface antigens (CD59, CD24 etc.) coupled 
to high throughput flow cytometric analysis [143, 161]. Wild type, presumed Pig-a 
gene proficient cells, retain intact functional GPI-anchor moiety biosynthesis; the 
anchor structure, comprising of three mannose, a glucose and a inositol sub unit, as 
well as the required extracellular proteins (CD24, CD59 etc.) are coupled together, 
within the endoplasmic reticulum, and transported to the cellular membrane [162]. 
At this point in the mechanism, the anchored proteins are attached to the membrane 
via fatty acid tail hydrolysis [163] and can be subjected to fluorescence antibody 
conjugation as a form of detection and qualitative assessment [143]. Therefore, the 
mutation rate at the Pig-a gene locus is in-directly measured by the direct 
quantitation of the absence or presence of GPI -  associated surface antigens, species 
specific (Figure 1.8).
32
nucleus / /
GPI an c h o r
protein
Normal cell
nucleus
proteins
PNH cell
Figure 1.8. The molecular basis of PNH; biosynthetic machinery produces the GPI 
molecule within the Endoplasmic Reticulum (ER) of a normal cell (left). An early 
step in this pathway is catalysed by an acetylglucosaminyl transferase: one of the 
subunits of this enzyme is encoded by the gene PIG-A. A number of cellular proteins 
become covalently linked to the GPI molecule that serves for conveying and 
anchoring them on the surface of the cell membrane. The PNH cell (right) has a 
mutation in the PIG-A gene that impairs acetylglucosaminyl transferase activity and 
causes a total (or partial) block in the synthesis of the GPI molecule. As a result, the 
proteins requiring a GPI anchor are unable to bind to the membrane and will be 
lacking on the cell surface - Taken from [164].
Continued development provided an initial in vivo rat Pig-a gene mutation assay 
protocol, employing both mature erythrocytes (RBCs) and the immature fraction, 
reticulocytes (RETs). Dual end point analysis was performed in order to assess the 
growth dynamic, i.e. do Pig-a deficient clones have a growth positive or negative 
bias [165], and relationship between mutational event and clonal origin within the 
haemopoetic tissue, during an extended international Pig-a cross laboratory trial 
[166, 167]. Initial results of such trial demonstrated an inadequacy in sample 
collection; limited number of RET events were able to be captured during analysis 
and therefore, sample sizes were required to be increased in order to provide more 
statistical robustness 1143]. In order to address this problem, due to the time 
contstraints working with haemopoietic tissue provides, a novel approach utilising
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magnetic beads to enrich for Pig-a mutants was implemented [168]. Enriched mutant 
data was directly compared against con-current total events, counting bead derived, 
in order to provide a more robust sample size and mutant frequency data. The 
subsequent modernised experimental design was able to capture enriched RET and 
RBC fractions, and provide adequate outcomes to warrant increased momentum 
from regulatory with the overall achievable aim of an OECD guideline [13, 91, 169, 
170]. Observations were made throughout the data acquisition stage; RETs 
expectedly were demonstrated to present induced mutant frequencies at an earlier 
time points (day 15) then their RBC counterparts [171] and the Pig-a assay was 
confirmed to be able to be incorporated into a routine 2 8-day tox study without 
compromising dose response metrics [91].
However, the erythrocyte-based analyses also highlighted a disadvantage; mature 
erythrocytes or reticulocytes do not contain a viable nucleus and therefore, definitive 
proof of genotype-phenotype relationship cannot be demonstrated via standard 
(Sanger) or novel (Next Generation) sequencing approaches. This postulation was 
deemed acceptable due to the sheer amount of published literature confirming the 
common PIG-A mutation exhibited within PNH patients [172, 173]. However, 
purists still remained sceptical about the origins of the presumed Pig-a mutants, 
GPI-AP deficient cells, any number of PIG genes (twenty-two) involved in either the 
GPI-AP biosynthesis pathway [174] as well as structural/transport or the individual 
surface antigen marker could be the cause of the observed phenotype [146], even 
though statistically unlikely. Measuring GPI-AP deficiency was not cell type reliant, 
but more GPI-AP dependent. Thus, assay portability into different haemopoetic cell 
lineages as well as transferability was something of great interest [144, 175].
Accordingly, analogous preliminary studies, utilising cells of haemopoetic lineage 
(erythroid and T-lymphocyte respectively), to the rodent Pig-a in-vivo assay have 
provided increasing evidence that mutational events within the PIG-A  gene are the 
fundamental cause of the GPI-AP deficient phenotype [77, 161]. Significant 
investment into a complimentary rodent leukocyte (nucleated) PIG-A  assay has been 
undertaken in order to facilitate, at least initially, parallel experiments to provide 
further classification of the GPI-AP deficiency mechanism [77, 144, 169, 175, 176].
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As stated above the Pig-a gene mutation assay has demonstrated great 
transferability within haemopoetic tissue; the highly conserved nature of GPI-anchor 
synthesis, there is a great degree of interspecies conservation of the PIG-A genes 
structure, function and locus and should facilitate the application of this basic 
methodology across any species of toxicological interest [177] -  recently, a study 
describing the development of an in-vitro P IG -0  assay in DT40 chicken cells was 
published, further emphasizing assay transferability [178].
The in vivo Pig-a assay still requires additional information to fully satisfy the 
regulatory community, subsequently leading to OECD guideline sanction. Single cell 
sequence and dose response data validating more ambiguous chemicals, historically 
proving the bane of number other test systems [179], will still need to be generated , 
however, the assay appears to be highly promising. One potential method of 
strengthening the mechanistic exploration of the assay, as well as to modernise the 
current mammalian in-vitro gene mutation test assays, would be with the 
development of an in vitro PIG-A correlate assay; utilising the equivalent high 
throughput flow cytometry based system of analysis (lineage specific GPI-anchor 
deficiency). Providing an in-vitro correlate assay could initially deliver a platform in 
order to produce additional evidence validating the true identity of presumptive Pig- 
a mutants [180] and hence, increasing the likelihood full assay acceptance. Utilising 
a biologically relevant human haemopoetic cell lineage, equivalent to Pig-a analysis 
of T-lymphocytes isolated from the spleens of rodents [144] -  B-Lymphocyte (TK6), 
and analogous immuno-cytological staining procedure, endeavours have been made 
to provide a suitable test system to generate in-expensive large quantities of 
quantitative dose response data and detailed mechanistic evaluation [181].
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1.7 Current Regulatory Mammalian in vitro Gene Mutation Assays: Do They 
Require Modernising?
The ICH, FDA, OECD and IWGT expert guidance and subsequent individual 
guidelines, still state the required need for in-vitro, mammalian cell, gene mutation 
assays within the early stages of pre-clinical drug development [65], Historically, 
this niche has often been filled by either the H PRT  (academia) or TK -  MLA  
(industry) assays [70, 71]; both assays are fully validated and are outlined in detailed 
within the published OECD protocol [73] and have been used routinely for decades 
generating reproducible genetic toxicology data following assay evolution.
However, both assays are known to have specific constraints and disadvantages 
within the scope of a quantitative genetox testing, initially let us consider the H PRT  
assay. Clonal expansion/growth in order to assess cytotoxicity, post mutation fixing, 
requires the assay to take place over a number of weeks, depending upon the specific 
method and/or cell type used. Allowing immortalised cells to achieve high passage 
increases the likelihood of genetic drift and subsequent genomic instability; these 
factors could elevate mutant frequencies (spontaneous and induced) and thus affect 
subsequent dose response data. The H PRT  assay has high transferability between in- 
vitro cell lines and in-vivo somatic cells, due to the conserved nature of the X-linked 
gene. However, the choice of cell line should demonstrate competent DNA repair 
and homozygous p53 status, a feature which has been debated within the AHH-1 cell 
line commonly chosen for the assay [182], The H PRT  can be described as a highly 
laborious 96 well plate assay requiring manual microscopic scoring and a high level 
of expertise in order to generate robust, reproducible data. Cost and time investments 
can rapidly multiply when utilising the assay for dose response investigations [39].
The (TK) Mouse Lymphoma Assay {MLA) operates under a similar principle to the 
H PRT  assay, however, due to subtle differences has dissimilar disadvantageous 
associated to the design. The use of a rodent immortalised cell line, L5178Y cells, 
with demonstrated dysfunctional p53 status [183] has led to the assay previously 
being described as overly sensitive and thus, generating false positive results [184]. 
The M LA assay shares an analogous design in terms of plating and cloning
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efficiency to the H PRT  assay and therefore, also shares the laborious manual 96 well 
plate scoring. The assay was first described in the 1970’s by Clive et al., [185, 186] 
and subsequently could benefit from utilising more modem technology in order to 
increase throughput and reduce subjectivity.
Therefore, providing an in-vitro correlate to the in vivo Pig-a assay in order to more 
fully investigate mechanistic studies could also have a larger impact on genetic 
toxicology testing. An in vitro PIG-A  gene mutation assay could also reform the 
more traditional manually scored genetox assays (TK/MLA and/or the HPRT)', 
conforming to current regulatory pressure and utilising 21st century technology to 
increase assay content, sensitivity, biological relevance (human cell p53 functional 
cell lines) and throughput [187].
1.7.1 21st Century Technology: Novel Genetic Toxicology Testing
In order to transport genetic toxicology testing into the 21st century, there is a 
potential need to utilise contemporary technological advances within the immediate 
field, as well as adjacent related fields, to facilitate this modernisation. Application 
of computational toxicology, more specifically in-silico QSAR packages [63], as 
well as the expanded use of toxicogenomics to illuminate mechanisms within safety 
testing are possible means for reducing the requirement for extensive animal testing 
and human clinical trials [187]. However, for the scope of this project we will focus 
upon the development of novel 21st century technology to facilitate the establishment 
of a potential highly sensitive, high content, high throughput, high precision, 
biologically relevant in vitro gene mutation assay which hopefully will coincide with 
other additional developing assays such as Ames 2 [188], H2AX [189, 190] and 
Bluescreen™  [191]. Generating such data through the ToxCast™  strategy, as well as 
compiling the data through such initiatives as Tox21, will provide increasing novel 
chemical evaluations [135, 136].
Flow cytometry is a technology which simultaneously measures and then records 
numerous physical characteristics of single particles within a fluid stream as they 
pass through a high energy beam  of light (Figure 1.9). Routinely used within
37
biological sciences, the particle is often a single whole cell or a small agglomerates 
of cells. The recorded properties include relative size of cell -  forward scatter (FSC), 
relative granularity/complexity, side scatter (SSC) and relative fluorescent intensity. 
As well as these three typical measure, most commercial flow cytometers now have 
to option to provide additional information about the actual properties of the detected 
resultant fluorescence light beam, these include a time of flight measurement 
(fluorescence width), the maximum intensity o f the light (fluorescence height) and 
the total fluorescence measured during the analysis period (fluorescence area). 
Commonly these parameters are measured via an optical (high energy laser) to 
electron (photocathode within a photon multiplier tube) capturing system which 
record how the subject element scatters the incident high energy laser light and emits 
and subsequent fluorescence [192].
Coupling this system with the use of immunohistochemical staining and the user is 
able to generate accurate data based on biological markers of interest including; 
cellular surface antigens, cell cycle, cellular viability, cellular proliferation etc., for 
each event within the population often greater than lx lO 6 total cells. This capability 
of high content/ high throughout analysis has radically enabled genetic toxicology to 
exponentially increase the sample size and number of measurable end points within 
the specific assay able to be recorded, when compared to traditional manually scored 
genetox assays [69]. Increasing the biological relevance as well as the sheer total 
number of events recorded has the effect of greatly increasing biological 
significance, statistical power and confidence within subsequently generated data 
sets.
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Figure 1.9. Flow cytometry basics: Particles or cells are subjected to high energy 
laser illumination in order to capture detailed information based on scattering of 
resultant light. Cell or particle size, complexity/granularity as well as emitted 
fluorescence profile, when utilised in conjunction with fluorophores, can be directed 
onto detectors and displayed in an electrical format via coupled computational 
software. Adapted from an image produced by Union Biometrica.
Traditionally, fluorescence microscopy and like techniques are highly labour 
intensive in terms of preparations as well as data interpretation, often conveying a 
sense of subjectivity especially during the latter stage of image interpretation and 
analysis. However, the modernisation of such techniques with the development of 
stage scanning microscopy [193] and more recently, ImageStream ™ [194] analysis 
has enabled the labour intensive preparation to be fully exploited to enable high 
content, multi-end point mutual analysis with fixed scoring criteria and objective 
results.
39
In terms o f the ImageStream ™ system, relatively high resolution microscopy 
(Figure 1.10) has been combined with simple flow cytometry to produce a system 
able to generate either 2-D or extended 3-D renders of each event as it passes 
through the point of laser interrogation.
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Figure 1.10. Confocal Microscopy Principles: Specimens are exposed to light, in this 
case high energy laser, and the resultant emitted light is re-focussed within a pin hole 
aperture. Confocal imaging approach provides a marginal improvement in both axial 
and lateral resolution, but it is the ability of the instrument to exclude from the image 
the “out of focus’' flare that occurs in thick fluorescently labelled specimens, which 
has caused the recent explosion in popularity of the technique - Taken from f 195].
This technology enables the user to benefit from most of the advantageous associated 
with flow cytometry, high content, high through put etc., without the associated 
disadvantage of not being able to see a render of the actual event to further increase
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confidence of the recorded data. Laser scanning confocal microscopy enables the 
user to prepare a sample in the traditional procedure however, allows the user to 
benefit from the scanning feature which progressively moves along the prepared 
slide capturing in excess of thousands of tiled images which can be re-constructed 
together retrospectively to generate image data for sample sizes comparable of flow 
cytometry workloads. This exponential increase in sample size, with minimal tweaks 
to methodology, has propelled somewhat of an advanced sample specific technique 
to a more general, easily accessible common laboratory technique whilst maintaining 
high integrity detailed image data.
In order to help modernise such a field as genetic toxicology into the 21st century, 
and potentially update the previous routinely used current assay the implementation 
o f such novel techniques/developments are essential. W ith the incorporation of novel 
technologies within genetox assays, a resultant positive feedback loop of technique 
incorporation, leading to technique interrogation and technical improvement should 
be observed further increasing assay transferability, sensitivity, robustness and usage 
within daily safety assessment and genetic toxicology applications.
1.8 Development o f an in vitro PIG -A  Gene M utation Assay: 21st Century 
Genetox?
If applying a blue sky thinking approach to 21st century genetic toxicology one could 
come to the following conclusions; the field requires a high content - providing high 
levels of statistical power and multiplex analysis to facilitate adequate content and 
depth of data, human - enabling more adequate pharmacokinetic and dynamic 
modelling, in-vitro - to coincide with recent governmental reforms, high throughput - 
facilitating greater sample sizes, highly transferable - cross-platform validation, and 
highly sensitive - to enable low dose quantitative response modelling, genetic 
toxicology assay as mirrored by the ICH guidelines [64].
W ithin this project of work, the development of an in vitro PIG-A  gene mutation 
assay is described. The assay was established with all of the potential advantages, as 
listed above, taken into account to attempt to provide a novel genetox assay which
will facilitate the modernisation of the current field. The assay is based on an 
analogous design to the current in vivo Pig-a  gene mutation assay [196], i.e. 
immunohistochemical antibody staining and subsequent flow cytometric analysis of 
GPI-anchored cellular surface markers. Flow cytometry provides the assay with a 
high content/throughput system enabling exaggerated sample size as well as 
significantly more contextual information than comparable current in-vitro assays 
[185]. The assay will utilise p53 competent B-lymphoblastoid human cell lines, in 
order to firstly, increase biological relevance within the data set, as well as allow a 
downstream sequencing approach to assay validation and avoid further animal usage 
within the industry. The conserved nature of the GPI-AP allows the approach to be 
mirrored into other species as well as primary human samples, highlighting assay 
transferability.
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Chapter 2: General Materials and Method
All work carried out in preparation and during the biological experiments which 
make up the body of this thesis project were carried out in an aseptic manor and 
hence, unless otherwise stated all consumables and apparatus can be assumed to be 
sterile, or sterilised prior to usage.
2.1 Human Cell Lines
All human cell lines used within this project, unless otherwise stated were purchased 
from American Type Culture Collection (ATCC) in partnership with LGC standards, 
Middlesex UK. Cell culturing conditions were undertaken as specified by the 
supplied information following original purchase of the cell line.
2.1.1 TK6 Cell Culture
Epstein-Barr viral transformed TK6 human B lymphoblastoid cells were isolated 
from the HH4 lymphoblastoid line [197] which in turn originated from the WIL-2 
cell line. TK6 cells express wild-type P53 and are heterozygous at the thymidine 
kinase locus [198]. The cell line was shown to test negative for Bovine Viral 
Diarrhoea Virus (BVDV).
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2.1.2 “Low Passage” TK6 Cell Culture
Epstein-Barr viral transformed TK6 human B lymphoblastoid cells originally 
isolated from the WIL-2 cell line, maintained at a much lower passage number and 
supplied by Masa Honma, National Institute of Health Sciences (NIHS).
2.1.3 AHH-1 Cell Culture
AHH-1 human B-lymphoblastoid cells were derived from a culture o f lymphoblasts 
supplied originally by Roswell Park Memorial Institute (RPMI), referred to as 
RPMI-1788 cells, for their high levels of mixed function oxidative activity; the cells 
were demonstrated to be highly sensitive to BaP exposure related cytotoxicity and 
hence, were selected for their basal and inducible oxidative activity. The cell line 
was shown to test negative for mycoplasma [199].
2.1.4 MCL-5 Cell Culture
MCL-5 cells were derived from a parental culture of AHH-1 B-lymphoblastoid cells, 
constitutively expressing human cytochrome P-450 CYP1A1 and also expressing 
five transfected human cDNAs encoding drug-metabolizing enzymes; cDNAs 
encoding CYP1A2, CYP2A6, and microsomal epoxide hydrolase (mEH) were 
introduced by using a vector conferring hygromycin B resistance, and cDNAs 
encoding CYP2E1 and CYP3A4 were introduced by using a vector conferring 
resistance to 1-histidinol [200]. The established MCL-5 cell line was demonstrated 
TK+/-, homologous to the parental AHH-1 cell line.
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2.1.5 HepG2 Cell Culture
The Human hepatocellular HepG2 cell line was originally derived from a 15 year old 
male Caucasian presenting with a liver carcinoma. Epithelial in nature, the cell line 
demonstrates a large portion of cellular functions such as, expression of hepatocyte- 
specific cell surface receptors and synthesis and secretion of plasma proteins [201].
2.2 Cell Culture Procedure
Cell culture was under taken within a temperature controlled micro-environment, 
aseptic conditions were established within a Scanlaf Mars Pro (LaboGene, Lynge, 
Denmark) class two safety cabinet. Daily the cabinet was pre-cleaned with 70% 
ethanol following a pro-longed UV sterilisation. Greiner Bio-One (Gloucestershire, 
UK) supplied the majority of sterile culture apparatus including, Pasteur pipettes as 
well as a wide variety of different sized culture flasks. Cellular cultures were 
incubated and maintained under an artificial humidified atmosphere of 37°C, 5% 
CO2 inside a NU-5510 DHD Autoflow incubator (The Nuaire Group, Caerphilly, 
UK). Centrifugation was undertaken using a temperature-controlled Eppendorf 
5810R centrifuge with a 180 mm radius (Eppendorf, Hamburg Germany). Culture 
medium was specific for each cell line utilised as well as each constituent pre­
warmed to 37°C; Normal TK6 and AHH-1 growth medium consisted of 89% 
(RPMI) 1640, 1% L-glutamine (Gibco®, Paisley, UK) and 10% horse serum 
(BioSer, Sussex, UK). Low Passage TK6 growth medium consisted of 89% RPM I 
1640, 1% Penicillin-Streptomycin (Sku, 1514012210,000 U/mL, Gibco®, Paisley, 
UK) and 10% heat-inactivated horse serum (Cat No. 26050-088, Gibco ®, Paisley, 
UK). MCL-5 growth medium consisted of 89% RPM I 1640, 1% L-glutamine and 
10% horse serum supplemented with additional Hygromycin B (Lot. No 
D00151132, 50 mg/mL, Merck, Hoddesdon, UK). HepG2 growth medium consisted 
of 90% Dulbecco’s Modified Eagle Medium (DMEM) (Gibco®, Paisley, UK) and 
10% Foetal Bovine Serum (FBS) (Cat No. 10091-148, Gibco®, Paisley, UK). Stock 
cell cultures were critically maintained between 1 x 105 and 1 x 106 cells/mL in 75
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cm2 culture flasks by routine sub-culturing, with exception of the normal TK6 cell 
line which was able to grow consistently from a 4 x 105 seeding concentration.
2.2.1 Cell Counting
All cell cultures were counted on either a Z1 Coulter Counter (Beckman Coulter, 
High Wycombe, UK); 100 pL aliquot of cellular suspension was diluted within 10 
mL of Isoton (Beckman Coulter, High W ycombe UK) and cells counted using cell 
line specific optimised classifiers based on the cell size (TK6, AHH-1 10-17 pm, 
MCL-5 5-17 pm  and HepG2 10-20 pm); or alternatively a glass Haemocytometer 
(Hawksley-Improved Neubauer, Depth 0.1 mm, 1/400 mm2, Sussex, UK) and cover 
slip (Hawksley, 0.13-0.17 mm, Sussex, UK) was used in conjunction with an 
Axiovert 25 light microscope (Carl Zeiss, Cambridge, UK); low resolution optics 
were utilised in order to count the average distribution of cells via capillary action 
under the glass cover slip, all concentrations generated were regarded as estimates 
and repeated for concordance.
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2.2.2 Dilution Equations
Equation 1 was initially used in order to generate a preliminary result, which was 
later cross referenced and checked against the result produced when using equation 
2 .
Equation 1
Vj * Cj = A 
A/C2 = B 
V1-B  = C
Equation 2
v , -  (Cj/Cj) * V,
Where,
A = Total number of cells required for seeding of new culture flask at desired 
concentration
B = Volume of suspension required to be aliquotted from the parental culture flask 
C = Volume of fresh growth medium required to be added to volume B in order to 
construct the new culture flask at the desired seeding concentration.
V C = The respective volume and seeding concentration of the new culture flaskI, 1
V2 C2 = The respective volume and cell concentration of the parental culture flask.
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2.2.3 Cell Line Sub-Culturing
Prior to any laboratory cell culture, all cultures were examined under an Ax iovert 25 
light microscope (Carl Zeiss, Cambridge, UK) for obvious signs of contamination 
and general cellular viability; routine testing for Mycoplasma using MycoAlert® 
mycoplasma detection kit (Cat no: LT07-318, Lonza, Slough, UK) and 
corresponding controls (Cat no: LT07-518, Lonza, Slough, UK), was also under 
taken.
2.2.3.1 Suspension Cell Lines
Cell cultures were removed from incubation, moderately shaken and counted prior to 
a volume of cell suspension, corresponding to the desired reseeding concentration, 
being aliquotted into a sterile 50 mL centrifuge tube, centrifuged and supernatant 
aspirated. The cellular pellet was agitated utilising a large bore pipette in a minimal 
volume of new growth medium, preceding transfer to a new sterile 75 cm2 culture 
flask. New growth medium was added to the culture flask to a final volume of 50 mL 
in order to reach the desired concentration and cultures returned back to incubation; 
sub culturing in this manner was repeated every 2-3 days. Wash steps entailed of 10 
mL of pre-warmed Ca2+, Mg2+ ion free phosphate buffered saline (PBS) (Gibco®, 
Paisley, UK) being added to the cellular pellets, inverted 2-3 times, followed by 
centrifugation and removal of supernatant.
2.2.3.2 Adherent Cell Lines
Cell cultures were removed from incubation, the existing growth medium discarded 
and the cells washed in excess pre-warmed pH 7.4 PBS, addition of the PBS was 
administered to the adjacent side of the culture flask to the adhered cells. 2-3mL of 
pre-warmed dissociating trypsin solution (Cat No. 25300-054, Gibco®, Paisley, UK) 
was added to the cells, dispersed evenly across the monolayer of adherent cells, the 
flasks rotated and then returned to incubate for a further 2-5 mins. W hen >90% of
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cells were deemed to be detached, excess pre-warmed PBS or growth medium was 
added, pipetted across the base of the flask. Flask contents were then transferred into 
a 50 mL centrifuge tube, centrifuged and the supernatant aspirated. Prior to cell 
counting, minimal volumes of growth medium was added to the cell pellets, and the 
required volume of cells for re-seeding was initially removed and then diluted to the 
desired seeding concentration with new growth medium before being aliquotted into 
a new sterile 25-75 cm culture flask. Cells were returned back to incubation and 
monitored every 48 hr for growth and sub-cultured 1-2 weekly in this manner.
2.3 Long Term Cellular Storage
Approximately 50 mL volume of confluent (lx lO 6 cells m L '1) cell culture was 
centrifuged at 800-1100 rpm (cell line dependent), within conical bottomed 50 mL 
centrifuge tubes (CellStar® Tubes, Greiner-Bio, Gloucestershire, UK), the 
supernatant aspirated and discarded. Cell cultures were re-suspended in 25 mL 
storage solution consisting of 1:9 volume ratio of dimethyl Sulfoxide (DMSO) 
(Sigma Aldrich, Gillingham, UK) to horse serum (Gibco ®, Paisley, UK) and 
carefully aliquotted into labelled (Cell line, Passage, Date and Operators initials) 
cryovials (Elkay Laboratory Products, Basingstoke, UK). Each cryovial was placed 
within an iso-propanol containing Nunclon (Thermo Scientific, Hampshire, UK), 
facilitating cooling at a l°C/min rate, and housed within a -80°C freezer (Innova 
U725, New Brunswick Scientific, Hamburg, Germany) for 24 hr. Cryovials were 
independently removed from within the Nunclon and placed within liquid nitrogen 
(Locator SR Plus, Thermo Scientific, Hampshire, UK), primarily -196 °C liquid 
phase, for long term storage. Cryovial resurrection was undertaken at the start of 
each new experiment and involved a rapid thawing of the preserved culture at 37 °C, 
within a temperature controlled water bath (Sub Aqua 18, Grant, Cambridge, UK), 
immediately post thawing the culture was transferred to 49 mL of fresh culture 
medium within a 75 cm2 culture flask.
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2.4 General Handling and Preparation of Chemicals
Genotoxic chemicals as well as general laboratory solutions were handled within a 
controlled environment, either aseptically inside a Scanlaf Mars Pro class 2 safety 
cabinet or alternatively for volatile chemicals a AFA1000 (Clean Air Ltd, Bolton, 
UK) fume cupboard. All necessary personal protective equipment (PPE) were used 
according to the material safety and data sheet (MSDS) supplied on purchase of such 
chemical under assay, including arm length soft latex gloves (Cat No. 260685, 
KRUTEX, KRUUSE, Langeskov, Denmark), laboratory coat (65% Polyester, 35% 
Cotton), suitable protective eye wear and face mask (Disposable Respirator, 3M ™, 
Bracknell, UK).
All substances on arrival were assessed for correct storage conditions, optimum short 
term storage conditions were identified; light sensitive substances were wrapped in 
aluminium foil and the use of a temperature controlled (2-4 °C) cold room, -20 °C 
(Liebherr, Bulle, Switzerland) or -80 °C freezer where appropriate. For solutions 
requiring dilution with sterile water an autoclave (Prior Clave, London, UK) was 
utilised, alternatively filter-distilled water was prepared using a Milli-Q water system 
(Merck Millipore, Nottingham, UK). W here necessary, weighing out of chemicals 
was completed using a Sartorius LA120S Analytical Balance (Sartorius Group, 
Surrey, UK) coupled with weighing boats and pH value measured by way of a 
Jenway 3510 pH meter (Bibby Scientific Ltd, Staffordshire, UK). Stock solutions 
were prepared in varied sized glass ware, generally 0.25L-1L, bottles (Sigma Aldrich 
Gillingham, UK), suitably buffered and stored at appropriate temperature as 
necessary to enable optimum usage conditions. All items regardless of preparation 
required were stored at optimum conditions, double contained to prevent accidental 
leakages and labelled; name, date on arrival, expiration date, storage conditions and 
initials.
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2.4.2 General Dosing Regime of Hazardous Genotoxic Chemicals
Cultures were established as described in (Section 2.2.), cell counts were initially 
recorded prior to culture seeding, 10 mL total volume at 1 x 105 cells/mL. At this 
point, additional precautions were under taken to ensure personal safety; long arm 
latex gloves, polycarbonate clear safety spectacles (Safety4eyes, Dorset, UK) and a 
supplementary outer layer of latex free nitrile gloves (Samper Guard, Semperit 
Technische P roduk te , Vienna, Austria) were worn. The hazardous chemicals were 
then removed from storage, doubly contained, and placed within the class two 
biosafety cabinet and serial diluted within a suitable solvent in order to construct 
smaller quantities of known concentration stock solutions. The required doses were 
assembled from the stock solutions, with the addition of further solvent, and 
aliquotted from either glass or plastic “Biju” or McCartney bottles (Greiner-Bio- 
One, Gloucestershire, UK). 100 pL  aliquots of the chemical were then administered 
to the cultures, solvent dependent; via a 20-200 pL  pipette, ensuring an even 
distribution and incubated for 24 hr. All cellular culture flasks post treatment, were 
placed within a cuboid Perspex box during initial incubation. Ensuing incubation, 
cultures were microscopically assessed and washed as outlined in (Section 2.2.3.1). 
All cellular pellets were manually dislodged prior to re-suspension in excess new 
growth medium and counted as described in (Section 2.2.1). Sterile, labelled, 25 cm2 
culture flasks were then established, seeding the flasks at a concentration suitable to 
maintain optimal growth, and replaced back into incubation for future use within a 
conjunctive downstream application, including RPD or mammalian cell in vitro PIG- 
A  gene mutation assay.
2.5 Preparation of Cellular Cultures Prior to Experimentation
At least 72 hr prior to experimentation start date, generally 96 hr, a fresh 
cryopreserved vial of stock cell culture was removed from liquid nitrogen long term 
storage and immediately placed within a temperature controlled water bath set to 37 
°C (Section 2.2). Once thawed, the contents of the vial were transferred into a new
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sterile culture flask (75 cm2), using a sterile Pasteur pipette, and pre-warmed cell line 
specific culture medium was added to the flask to a total volume of 50 mL. The 
culture flask was then labelled accordingly and placed within a humidity controlled 
environment for a minimum of 48 hr with routine (24 hr) microscopy based 
assessment. Once 72 hr incubation had completed the cell culture was removed from 
the incubator, counted (Section 2.2.1) and sub-cultured (Section 2.2.3); re-seeing the 
culture to a concentration suitable to test exponential growth phase. The culture was 
incubated for an additional 24 hr and re-counted to ensure exponential growth phase 
was achieved. At this point, the cultures were deemed suitable for usage within 
biological experimentation or alternatively exposed to Virkon® (Potassium 
monopersulphate (49.8% wt/wt) Anachem Ltd., Bedfordshire, UK) for 20 min - 24 
hr prior to disposal, adhering to University policy on disposal of genetically 
modified biological material.
2.6 Assessment of Chemical Genotoxicity -  Dose Range Finding Studies
2.6.1 Controls for Relative Population Doubling (RPD) and in vitro Mammalian  
cell PIG -A  Gene Mutation Assay
W ithin the RPD and PIG-A studies the use of a known genotoxin in order to induce a 
significant decrease in cellular viability, was deemed not to be necessary due to the 
nature o f the chemicals being used within the assays. The use o f  “G4” chemicals as 
validatory compounds within the assay design pre-disposes the subsequent generated 
data and hence, removes ambiguity. Negative control cultures were dosed with 100 
pL  of solvent controls (vehicle controls) and/or filter prepared water, mimicking the 
growth conditions of the assessed cultures.
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2.6.2 Relative Population Doubling
Cultures were constructed as described in the (Section 2.2), and subsequently 
exposed to model genotoxins for 24 hr according to (Section 2.4), washed and 
allowed an additional 24 hr recovery period (1-1.5 cell cycles). Cellular counts were 
initially recorded at the time of seeding/exposure, post 24 hr (recovery), 48 and 72 hr 
post exposure. Relative Population doubling, Relative Cell Counts (RCC) and 
Estimated Mean Generation Time (EMGT) were all calculated according to the 
equations 3 ,4  and 5 outlined below.
2.6.2.1 RPD, RCC and EGT Equations
Equation 3 (No. of Population doublings in treated cultures)
Relative Population Doubling = ---------------------------------------   x 100
(No. of Population doublings in control cultures)
Where:
[log io(Post-treatment cell number -r Initial cell number)] 
Population Doubling = ---------------------------------------   —
lo g  2
Equation 4 (Cell number of Treated Flask)
Relative Cell Counts  ...........................................................x 100
(Cell number o f Control Flask)
Where:
All cell counts are expressed as vales with a common 10 to the power function.
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Equation 5
(0.301 * (Experimental Length)) 
Estimated Mean Generation Time = ---------------------------------------------------------------
(Logio(Post-treatment cell number)-Logio(Initial Cell Number))
Where:
0.301 is the conversation factor for using Logio instead of log2
2.7 Preparation of Fixatives for the use of Flow Cytometry and Microscopy 
Applications
Fixative formulation required the use of an AFA1000 fume cupboard, due to the 
reactivity and volatile nature of the chemicals used, additional PPE including eye 
protection and long arm gloves were also worn. Accurately measuring the mass out 
such chemicals was achieve via the use of an external balance and sealed glass 
McCartney bottles, pre weighed empty, to adhere to health and safety regulations.
2.7.1 4%  Paraformaldehyde (4%  PFA)
4g of 95-105% paraformaldehyde powder (Cat No. 158127-500G, Sigma Aldrich, 
Gillingham, UK), weighed in a sealed glass McCartney bottle, was transferred into a 
250 mL conical flask and temporarily sealed using parafilm (SPI, W est Chester, 
USA). 100 mL of PBS was added to the powder within the conical flask, shaken 
thoroughly and magnetic flea added. The conical flask was then transferred onto a 
HC1202 Ceramic Hot Plate/ Magnetic Stirrer (Bibby Scientific, Staffordshire, UK), 
moderately heated and mixed until an observed colour change was apparent (-10-30 
min). Once the solution had changed from turbid white to a clear colourless solution, 
heat was removed, cooled and aliquotted into pre labelled plastic biju bottles. 
Fixative was stored at 4°C, if intended for long term storage the use of glass 
apparatus is required.
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2.7.2 BD Cell Fix
1 mL o f 10X BD Cell Fix (BD CytoFix™, BD Biosciences, Oxford, UK) was 
diluted 1:9 with pre-filtered dFLO within glass McCartney bottles, constructing a 
final working solution of 1 X BD Cell Fix. BD Cell Fix is light sensitive; all work 
was carried out in the absence of direct light and stored at 2-4°C for immediate short 
term storage.
2.7.3 Dulbecco’s 4% Paraformaldehyde (4-Para 4)
4g of 95-105% paraformaldehyde powder (Cat No. 158127-500G, Sigma Aldrich, 
Gillingham, UK), weighed in a sealed glass McCartney bottle, was transferred into a 
250 mL conical flask, repeated and both flasks temporarily sealed using parafilm 
(SPI, W est Chester, USA). Either 100 mL of Dulbecco’s PBS Ca2+ and Mg2+ ion 
free (21600044, Gibco®, Paisley, UK) or alternatively Dulbecco’s PBS Ca2+ and 
Mg2+ ion present (14040133, Gibco®, Paisley, UK) was added to the powder within 
the conical flasks, shaken thoroughly and magnetic flea added. The conical flask was 
then transferred onto a HC1202 Ceramic Hot Plate/ Magnetic Stirrer, moderately 
heated and mixed until an observed colour change was apparent (-10-30 min). Once 
the solution had changed from turbid white to a clear colourless solution, heat was 
removed, pH measured and adjusted to -7 .2 , cooled and aliquotted into pre labelled 
plastic biju bottles. Fixative was stored at 4°C, if intended for long term storage the 
use of glass apparatus is required.
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2.8 Flow Cytometry
All flow cytometry, unless stated differently, within this project was carried out 
using a BD Biosciences FACS Aria I flow (BD Biosciences, Oxford, UK) cytometer 
utilising FACS DIVA™ (BD Biosciences, Oxford, UK) software versions for 
subsequent analysis. Prior to flow cytometric analysis, the cytometer was initially 
run through the start-up process consisting of the following; lasers were switched on 
and allowed to warm to a consistent temperature, PC was switched on and all 
necessary passwords entered, fluidics were primed, the nozzle was microscopically 
assessed and often sonicated to remove blockages, the inlet system and stream were 
decontaminated using a combination treatment o f FACS Clean, FACS RINSE (BD 
Biosciences, Oxford, UK) and filter prepared dFLO and finally calibration was 
passed using the BD Biosciences supplied multicolour fluorescent calibration beads 
(Cat No. 642412, BD Cytometer Setup and tracking bead, Cat No. 340486, 
CaliBRITE™ 3 BD Biosciences, Oxford, UK). Additionally, manual assessment o f 
stream alignment, O-ring integrity, detector sensitivity and voltage requirement was 
carried out daily when running the instrument calibration standard (ICS) sample 
(Figure 2.1). Cell cultures were loaded onto the machine within either 5 mL flow 
cytometry tubes (BD Falcon ™ round bottom tubes, BD Biosciences, Oxford, UK) 
or alternatively 15 mL BD Falcon ™ tubes were also used in conjunction with a 
small adapter applied to the sample carrier. Unless otherwise stated, all fluorescence 
analysis was carried out utilising a 70 pm  nozzle with corresponding 70 pounds per 
square inch (PSI) sheath pressure, excited with either a 405 (UV/Blue), 488 (Blue) 
and/or 605/635 (Red) nm laser and subjected to a standard threshold applied to the 
forward side scatter (1,000) in order to ensure debris was removed from data 
acquisition and ensuing analysis. A minimum of 10,000 cellular events were 
recorded for each sample, with each dose being conducted in triplicate where 
possible from independent cryopreserved cell cultures.
The use of an instrument calibration sample was required for every experiment as 
well as single stained fluorescence controls, when multiple fluorophores were to be 
used, to facilitate the correct calibration of the flow cytometer prior to analysis, in 
terms of gating and compensation accuracy.
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Flow Cell - containing the focussing 
equipment utilised in stream formation
Quartz block Nozzle and O-ring 
maintaining stream integrity
Deflection Plates - Adjustable pates 
which when electrified in conjunction 
with the nozzle (drop charging) induce 
side stream formation
Waste Drawer - removable when 
samples are intended to be sorted into 
collection vessels
Figure 2.1. Overview of the internal components of the BD FACS Aria Flow Sorter, 
excluding the optics system. Critical elements within the generalised running and 
upkeep of the machine are highlighted.
2.8.1 Suspension and A dherent C ellu lar C ultu res F luorescent 
A ntibody/F luorophore T rea tm en t
All fluoresce associated work was canned out under the assumption of light 
sensitivity and therefore, in the absence of direct light. Aluminium foil was used in 
order to maintain these conditions where appropriate. Cell cultures were established 
as outlined in (Section 2.2) and counted (Section 2.2.1). The equivalent volume of 
culture to 1 x 106 single cells was removed, using a 100 pL -  1000 pL pipette 
(Finnpipette®. Thermo Scientific, Hampshire, UK) and conesponding pipette tip, 
aliquotted into a sterile 15 mL centrifuge tube (BD Falcon ™, BD Biosciences, 
Oxford, UK), centrifuged and supernatant carefully aspirated. The cellular pellet was
58
re-suspended in 50 pL  of new culture medium and treated with the desired amount 
of the fluorescence conjugated antibody. Treatment consisted of the initial depositing 
pipette followed by a minimum of five re-suspensions in order to achieve maximum 
distribution. The culture sample was incubated for 30 min in a temperature 
controlled (2-4 °C) cold room, protected from direct light, transferred into a 
centrifuge, spun down, supernatant removed and washed (Section 2.2.3) a minimum 
of twice. The cultures were re-suspended in a final volume of 1 mL pH 7.4 PBS, 
ensuring a suitable concentration for flow cytometry applications, and stored on ice 
for a maximum of 1 hr prior to flow cytometric analysis.
2.8.2 Assessing Fluorescence Properties using Flow Cytometry
Cell cultures were prepared as outlined by (Section 2.2) and treated with 
fluorescence conjugated antibodies or directly fluorescent chemicals, such as DNA 
targeting intercalating agents, in an analogous manner to (Section 2.8.1). Following 
treatment, cells were washed twice with pre-warmed PBS and then re-suspended in a 
minimal volume of PBS/Medium at a suitable concentration for flow cytometric 
analysis.
2.8.2.1 Flow Cytometry Compensation Analysis
Single stained samples for each fluorophore utilised within the experiment were 
constructed (Section 2.8.1) loaded (Section 2.8) and analysed on the flow cytometer. 
Fluorophores with known similar or overlapping emission spectra were of particular 
interest; once a single stained sample was loaded into the flow cytometer the 
corresponding pre-selected specific detector as well as the neighbouring detectors 
were assessed for any potential signal pick up. A histogram/dot plot was drawn for 
each detector and individually assessed for a positive signal as defined by instrument 
calibration standard (ICS). If a positive signal was detected within a neighbouring 
detector the PMT voltage corresponding to the excitatory channel was reduced until 
the positive nature was deemed negligible (Figure 2.2).
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However, if the reduction within that specific detector was greater than 30%, the 
combination o f  fluorophores were assessed for '‘goodness o f fit" within that specific 
experimental design to prevent insensitivity to actual positive signals. This process 
was repeated for each fluorophore within the experimental design until adjacent 
detectors displayed negligible traces of positive signals; at this point detectors were 
assessed for positivity for their own specific fluorophore to maintain detection 
integrity and then dual stained standards were often utilised for further confidence.
2.8.2.2 Flow C ytom etric D ata Analysis
Data analysis was carried out using the supplied BD Biosciences approved FACS 
DIVA™ software, initially a sequential template o f a combination o f 2-D 
histograms, 3-D density plots and scatter plots (Figure 2.3) for a variety of variables 
were constructed in order to facilitate the accurate identification, separation and 
analysis of subpopulations within the cellular cultures.
Irfitnalon
DavO-ICS
Tube. ICS E
Population ♦Events %Parent %Totai
|  All Events 40,104 **** 1000
a ? ! 10,099 45.1 451
3  Doublet Discrimination 17,688 97.7 441
■  Single Cells 16,070 90 9 401
■  Dead Cells 1 0.0 00
□  N0T(Dead Cells) 16,069 100 0 401
■  CD5S/59 Positive 0 00 00
|  NOT(CD55/59 P. 16,069 100.0 401
Figure 2.3. Generic process of cell type classification and subpopulation distribution 
for an unstained instrument control sample. The order in which each stain is 
retrospectively analysed provides a greater level of depth and biological content to 
the analysis; A) Generalised gate for all potential single cellular events conforming 
to a normal morphology. B) Localised gate excluding cells which could potentially 
be debris or doublets. C) Specific gate categorising cells based on their time of flight 
measurement for the cellular surface antigen. D) Gate to exclude cells positive for 
loss of membrane integrity.
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Cellular events, which were deemed single cell in nature (Figure 2.3 A and B) not 
including debris or aggregates, were then defined to be viable (Figure 2.3 D) and 
then assessed for their respective GPI-AP status (Figure 2.3 E). Flow cytometry 
gating was based on the data acquired from the use of an ICS, un-stained mimicking 
sample, and prior to every experiment in order to obtain accurate and reproducible 
data (Figure 2.4).
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Figure 2.4. 2D histograms displaying the distribution of cells following anti- 
CD55/59 PE antibody treatment; A) An instrument calibration standard and B) A 
wild type untreated cellular population.
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2.8.3 Fluorescence Activated Cell Sorting (FACS)
Cellular samples were treated with anti-GPI-AP specific fluorescently labelled 
antibodies (Section 2.8.1) and analysed on the flow cytometer (Section 2.8.2).
The BD FACS ARIA flow cytometer was set up (Section 2.8), once completed an 
additional sterilization process consisting o f a “long clean” ~ 20 min clean using 
70% ethanol, was undertaken. The fluidics start up procedure was repeated, and all 
internal surfaces cleaned with bleach (10% Virkon solution) and dried thoroughly, 
removing any salt build up. At this point the standard sheath pressure and nozzle 
were adjusted to fit the application needs. Generally, a larger nozzle and lower 
pressure (100 pm  and 20 psi respectively) were selected; the nozzles were sonicated 
prior to the O-ring fitment.
The nozzle was inserted within the quartz block, at the base of the flow cell, and the 
stream was established (Figure 2.1). The intercepting diode laser, used primarily for 
drop delay calibration, was attuned and the sorting related parameters adjusted; 
“Gap”, “Amplitude” and “Frequency” . For stability reasons, 20-30 mins 
probationary period was deemed necessary to account for temperature and voltage 
variations associated with the flow cytometry laboratory (Figure 2.5). During the 
probation period, the “Sweet Spot” function was utilised, flow alignment and 
critically the sorting voltages were adjusted to enable side stream formation. Side 
stream adjustment continued until the point of contact with the collection tube was 
directly in the centre of the vessel. Prior to running the Accudrop ™ flow cytometry 
beads a test sort was under taken to check all the parameters were correct, a sorting 
template loaded onto the software, automated cell deposition unit (ACDU) adapter 
(96 well plates) or collection tube holder loaded and manually the drop delay was 
calculated.
Once satisfied with the prerequisite system calibrations, sorting was commenced and 
the recovered cellular population/s were collected within 5 mL polystyrene (12 x 
75mm) sorting tubes (BD. Biosciences, Hertfordshire, UK) within fresh cell line 
specific growth medium (1 mL) or 15 mL BD Falcon Tubes. Consecutively cells 
were sub-cultured (Section 2.2.3) within 25 cm2 culture flasks prior to long term
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cryopreservation (Section 2.3). Quality assurance (QA) FCM based PIG-A 
phenotype assessment was carried out prior to and 72-96 hr. following enrichment.
Camera -  displaying the 
stream component images 
in which the drop distance. 
drop gap, amplitude and 
frequency are adjusted.
Diode Laser and Camera — 
illuminating and
displaying the stream 
integrity images in which 
the drop delay side and
Absence o f stream formation are
waste drawer adjusted.
Interchangeable Collection 
Tube holder -  samples 
collect in a variety o f 
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Figure 2.5. The internal components of the BD FACS Aria sorter continued; a more 
detailed look at the internal components which are essential for optimum FACS
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2.9 Amnis ImageStream ™  Flow Cytometry
All ImageStream flow cytometry during this project was undertaken on an Amnis 
IS 100 imaging flow cytometer in conjunction with Amnis INSPIRE® software 
versions 4 and 5 (Merck Millipore, Nottingham, UK). The cytometer was switched 
on, software loaded and calibrated. 100 pL  aliquots of cell suspension at the correct 
concentration to facilitate analysis ( lx lO7 cells/mL) were transferred into 0.5 mL 
eppendorf allowing direct loading onto the sample uptake tube. A minimum of 
10,000 cells were assessed for each experimental sample.
The use of an instrument calibration sample was required a necessity for every 
experiment as well as single stained fluorescence controls, when multiple 
fluorophores were to be used, to facilitate the correct calibration of the flow 
cytometer prior to analysis.
2.9.1 ImageStream™  Data Analysis
Following image collection, all ImageStream data analysis started initially with a 
sequential template of a combination of 2-D histograms and scatter plots (Figure 2.6) 
for a variety of variables were constructed in order to facilitate the accurate 
identification, separation and analysis of sub-populations within the cellular cultures.
Cellular events, which were deemed single cell in nature (Figure 2.6 A) not 
including debris or aggregates, were then defined to be focussed (Figure 2.6 B) and 
then assessed for their respective GPI-AP status (Figure 2.6 C). Flow cytometry 
gating was based on the data acquired from the use of an ICS, un-stained mimicking 
sample, and prior to every experiment in order to obtain accurate and reproducible 
data. The finalised output was broken down into the large scale statistical analysis as 
well as the visualisation of the individual events as demonstrated above; this feature 
is unique to the ImageStream™ platform.
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2.10 Generic, 5-Day, in vitro PIG -A  Gene Mutation Assay Protocol
All data generated following daily PIG-A  mutation assessment were evaluated for 
normality and variance (P value >0.05) using the Shapiro-W ilk and Bartlett’s Test 
respectively, carried out within DrSmooth through the R-Software Package (R-3.0.2, 
Free Software Foundation’s GNU project). Following assessment, data was either 
defined as normally distributed or non-normal and subsequently, parametric 
(Dunnett’s Two-Tailed T-Test) or non-parametric (Dunn’s Two-Tailed T-Test) 
statistical analysis was undertaken within an extension of the R-software. The use of 
two-sided analysis was to facilitate the detection of both increases and decreases 
within the number of PIG-A phenotypic mutants as well as to prevent disputed 
results. Statistical analysis was implemented to state at what dose, if any, rejection of 
the Null hypothesis was to be assumed (P-value <0.05). At such a dose, variation o f 
the PIG-A  mutant frequency was a direct result of a noteworthy factor and not as a 
result of chance.
2.10.1 Background Analysis
Cell cultures were established and maintained as outlined in (Section 2.2), the 
parental cell culture was counted and subsequently 25 cm culture flasks were 
constructed at a concentration of 4 x 105 cells/mL in accordance to the number of 
doses within the assay design. Established 25 cm flasks were successively exposed 
to acute chemical treatment, under the standard genotoxic chemical treatment 
protocol (Section 2.4.2), and placed within a temperature and humidly controlled 
environment for the 24 hr incubation. A t this point, PPE associated with toxic 
chemical usage as well as the initial toxic vials was disposed of safely and correctly 
according to health and safety protocol. Simultaneously, three 1 x 106 cellular 
samples were extracted from the un-treated parental culture, transferred into sterile 
15 mL BD Falcon centrifuge tubes, centrifuged (250 x g for 7 min) and supernatant 
aspirated and discarded. Excess 1 x PBS solution was added to each tube in order to 
wash the cellular pellets. The samples were then centrifuged (250 x g for 7 min),
67
supernatant aspirated and discarded and the cellular pellets re-suspended in 100 pL 
of pre-warmed (37 °C) culture media. 20 pL  of anti-human CD55 R-PE antibody 
was added to each sample excluding the ICS, and incubated at 2-4°C for 30 min 
protected from light.
Following the incubation, cultures were centrifuged (250 x g for 7 min), supernatant 
removed and re-suspended in 10 mL of 1 X PBS solution. Samples were centrifuged 
for an additional time, forming sufficient pellets, supernatant carefully aspirated, 
removing any residual excess antibodies, and re-suspended within 5 mL of 1 X 
annexin binding buffer (made freshly that day to prevent deterioration). Samples 
were centrifuged, supernatant aspirated and re-suspended in an additional 100 pL  of 
1 X annexin binding buffer. 5 pL  of Alexa Fluor® 488 annexin V was added to each 
sample, excluding the ICS and incubated for 15 min at room temperature, protected 
from light. Post incubation, excess 1 X annexin binding buffer was added, cultures 
centrifuged, supernatant aspirated and re-suspended in 200 pL  of annexin binding 
buffer. 5 pL  (0.25 pg) per test (per million cells) of 7-AAD was added, mixed 
thoroughly and incubated for 20 minutes, protected from light, on ice. Samples were 
maintained on ice protected from light for a maximum of 4 hr prior to analysis.
2.10.2 Day 1 Analysis
Post 24 hr chemical exposure within a temperature controlled incubator (Section 
2.4), whilst wearing the correct PPE and suitable disposal methods ready, cultures 
were transferred directly into 15 mL Falcon tubes and centrifuged (250 x g for 7 
min). Carefully, presumed toxic supernatants were aspirated and discarded safely. 10 
mL o f 1 x PBS solution was added to each tube, in order to wash potential residual 
chemical treatment out of the cellular pellets, centrifuged (250 x g for 7 min), toxic 
supernatant aspirated and re-suspended in 10 mL o f fresh culture medium. At this 
point PPE associated with toxic chemical usage as well as the collected toxic 
supernatants and culture flasks were disposed o f safely and correctly according to 
health and safety protocols. Cells were counted as described in (Section 2.2.1) and 
volumes containing 1 x 106 cells per culture were transferred into sterile 15 mL BD
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Falcon tubes and set aside. Sterile corresponding 25 cm2 culture flasks were labelled 
correctly and constructed from the parental cultures to a concentration of 1 x 105 
cells/mL within a final 10 mL volume of supplemented culture media. Culture flasks 
were placed within the incubator for 24 hr ready for the ensuing following day’s 
PIG-A  mutant assessment.
The set aside cellular samples were centrifuged (250 x g for 7 min) and supernatant 
aspirated and discarded. Excess 1 x PBS solution (10 mL) was added to each tube in 
order to wash the cellular pellets. The cultures were centrifuged (250 x g for 7 min); 
supernatant aspirated and re-suspended in 100 pL  of pre-warmed (37 °C) culture 
media. 20 pL  of anti-human CD55 R-PE antibody was added to each sample 
excluding the ICS, and incubated at 2 - 4°C for 30 min protected from light.
Following the incubation, cultures were centrifuged (250 x g for 7 min), supernatant 
removed and re-suspended in 10 mL of 1 X PBS solution. Samples were centrifuged 
for an additional time, forming sufficient pellets, supernatant carefully aspirated, 
removing any residual excess antibodies, and re-suspended within 5 mL of 1 X 
annexin binding buffer (made freshly that day to prevent deterioration). Samples 
were centrifuged, supernatant aspirated and re-suspended in an additional 100 pL  of 
1 X annexin binding buffer. 5 pL  of Alexa Fluor® 488 annexin V was added to each 
sample, excluding the ICS and incubated for 15 min at room temperature, protected 
from light. Post incubation, excess 1 X annexin binding buffer was added, cultures 
centrifuged, supernatant aspirated and re-suspended in 200 pL  of annexin binding 
buffer. 5 pi (0.25 pg) per test (per million cells) of 7-AAD was added, mixed 
thoroughly and incubated for 20 minutes, protected from light, on ice. Samples were 
maintained on ice protected from light for a maximum of 4 hr prior to analysis.
2.10.3 Days 2-5 PIG -A  Analysis
Post 24 hr incubation (Section 2.2), cultures were counted as described in (Section
2.2.1) and volumes containing 1 x 106 cells per culture were transferred into sterile 
15 mL BD Falcon tubes and set aside. Sterile corresponding 25 cm 2 culture flasks 
were labelled correctly and constructed from the parental cultures to a concentration
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of 1 x 105 cells/mL within a final 10 mL volume of supplemented culture media. 
Culture flasks were placed within the incubator for 24 hr ready for the ensuing 
following day’s PIG-A mutant assessment.
The set aside cellular samples were centrifuged (250 x g rpm for 7 min) and 
supernatant aspirated and discarded. Excess 1 x PBS solution (10 mL) was added to 
each tube in order to wash the cellular pellets. The cultures were centrifuged (250 x g 
for 7 min); supernatant aspirated and re-suspended in 50 pL  of pre-warmed (37 °C) 
culture media. 20 pL  of anti-human CD55 R-PE antibody was added to each sample 
excluding the ICS, and incubated at 2-4°C for 30 min protected from light.
Following the incubation, cultures were centrifuged (250 x g for 7 min), supernatant 
removed and re-suspended in 10 mL of 1 X PBS solution. Samples were centrifuged 
for an additional time, forming sufficient pellets, supernatant carefully aspirated, 
removing any residual excess antibodies, and re-suspended within 5 mL of 1 X 
annexin binding buffer (made freshly that day to prevent deterioration). Samples 
were centrifuged, supernatant aspirated and re-suspended in an additional 100 pL  of 
1 X annexin binding buffer. 5 pL  of Alexa Fluor® 488 annexin V was added to each 
sample, excluding the ICS and incubated for 15 min at room temperature, protected 
from light. Post incubation, excess 1 X annexin binding buffer was added, cultures 
centrifuged, supernatant aspirated and re-suspended in 200 pL  of annexin binding 
buffer. 5 pi (0.25 pg) per test (per million cells) of 7-AAD was added, mixed 
thoroughly and incubated for 5 minutes, protected from light, on ice. Samples were 
maintained on ice protected from light for a maximum of 4 hr prior to analysis.
This process occurred every 24 hr for 5 days in order to generate daily PIG-A  mutant 
frequency data to facilitate dose response modelling.
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Chapter 3: The Concept and Development of an Early Stage in vitro PIG-A  
Gene Mutation Assay 
3.1 Introduction
The work presented within this chapter was carried out in order to develop a 
rudimental mammalian cell in vitro PIG-A gene mutation assay, analogous to the in 
vivo Pig-a gene mutation assay developed by Litron ™ Laboratories [196]. Once the 
conceptual idea was established, and shaped into a qualitative assay, much effort was 
put into investigating the additional features of the assay to establish robustness and 
reproducibility. Critical validation of the assay at each point of development was the 
driving feature which enabled the assay evolution and subsequent increments in 
content and complexity.
3.1.1 X-linked Gene Mutation Assays and their Role in Safety Assessment
Gene mutation assays, both in vitro and in vivo, are utilised as fundamental features 
of drug development; their respective assay sensitivity is the vital pre-requisite 
characteristic which ensures their necessity and future inclusion. Gene mutation has 
been identified as the current most relevant end point for assessing carcinogenicity 
[202] when likened to dissimilar DNA damage end points, including chromosome 
aberrations [103]. Thus, DNA damage can be detected at lower doses utilising a gene 
mutation end point and therefore, more precisely predicting potential hazard and risk 
assessments. However, due to the diversity of the endpoints, it is clear that potential 
genotoxicity and/or mutagenicity of a compound cannot be assessed by a single 
assay system [203], a battery tier system is required.
X-linked gene loci have been routinely utilised as highly sensitive reporters for gene 
mutation within the field of genetic toxicology for a number of decades; the HPRT 
assay [204] being such an example. X-linked reporters benefit from the heterozygous
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nature o f gene expression o f the target gene, resulting in “one hit” sensitivity; based 
on Knudson’s “Two hit” hypothesis for early onset retinoblastoma [205]. A single 
functional copy of the gene is present on the X-chromosome and hence, a single 
deactivating DNA damaging event can result in loss of genotype, a paradigm of 
"single genetic hit" inactivation-mediated carcinogenesis [206]. However, biological 
context, sensitivity and specificity (especially relevant with the use of rodent cell 
lines [113]), human relevance as well as the laborious manual scoring techniques 
adopted by the subsequently designed assays has proven to restrict their use within a 
safety assessment environment [105], with the exception of MLA. Such assays lend 
themselves well for routine qualitative/quantitative dose response modelling, often 
carried out within academic institutes, but are not favoured when compared to pre­
existing validated standard test battery assays. Pre-clinical pharmaceutical safety 
assessment requires cost effective, reproducible assays which often have debatable 
human relevance [184] but uncompromising sensitivity in order to maintain an 
optimum detection of genotoxic characteristics within drug compounds. During 
safety assessment a compound progresses through in vitro assessment in parallel to 
more thorough and costly in vivo and long term carcinogenicity assessments with the 
aim of subsequent first time in human (FTH) exposure and the pharmaceutical 
market.
Current in vitro gene mutation assays presently within the standard test battery [65], 
during early drug development, have uncompromising assay sensitivity which often 
triumphs over other features such as biological relevance, specificity and p53 status 
[113-115]. This situation has recently become more apparent, with increasing critical 
review, as the subsequent data generated has potentially limited usage within the 
wider context of safety assessment and human health risk assessment [207-209]
[210]. However, high sensitivity does facilitate quantitative dose response modelling 
and lends itself well to traditional methods of qualitative hazard and risk assessment
[211]. An established maximum no adverse observed effect level (NOAEL) 
following dose response analysis, typically in vivo, ensued by a variety of safety 
factors in order to extrapolate a figure deemed applicable to human exposure [212]. 
This assessment traditionally assumed a linear dose response for genotoxicity for 
direct acting DNA-reactive compounds, including alkylating agents such as Ethyl-
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methanesulfonate; resulting in a correctly conservative hazard and risk assessment 
for calculated exposure levels.
There has been a recent move in the field away from the assumption of linearity for 
specific cases depending upon mechanistic data, and dichotomous qualitative 
evaluations may be superseded by a more system based derivation of PoD based on 
non-linear models [211, 212] Point of departure metric calculation using novel 
software packages, PROAST, Bench Mark Dose Software [213] and DrSmooth 
[214] including the BMD, BMDS and Slope transition dose (STD) are currently 
being evaluated for their inclusion within quantitative evaluations of hazards [28, 
100, 213]. Although, pre-existing assay platforms are able to generate the quality of 
data required for comprehensive dose response modelling [215], they appear overly 
sensitive [210] and lack the refinement and biological contextual data which can be 
generated using novel high content, high through put methodologies [113-115]. 
Combining the use of novel high content assays, to generate human pertinent 
quantitative dose response data, with highly composite data modelling packages, to 
derive more precise and relevant point of departure metrics, in an analogous fashion 
to supplementary fields of toxicology could hypothetically advance the field of 
genetic toxicology [100, 216].
3.1.2 Drug Attrition within the Pharmaceutical Industry
W ithin pharmaceutical safety assessment, drug attrition is a major factor on the 
overall financial health of the company. Early stage drug attrition of potentially 
“misleading” compounds is critical to prevent over spending and loss o f potential 
profit [217]; enabling the company to continue long term therapeutic drug 
development and therefore, maintaining their service to public health and 
shareholders. The Ames test, a historically modest bacterial reverse mutation assay 
designed in the early 1970s is still the prominent early stage core genetic toxicity test 
in which all drug compounds are assessed. The assay is extremely sensitive [218], as 
mentioned previously, inexpensive and throughout its development and validation 
has been modified to incorporate minor pharmacodynamics features such as human
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or rat S9 presence [66] to mimic phase 1 (cytochrome p450s) and 2 metabolism 
(transferase). The Ames test does not detect all carcinogens and hence, the 
development of the extensive mammalian cell in vitro assay systems [73] was 
commenced to identify the hazard of human specific carcinogens [105].
The Ames tests ability to detect the majority of carcinogenic risk within pre-clinical 
assessment validates its continued inclusion decades after first implementation 
within the standard test battery. A positive outcome within the Ames test is almost 
certain to halt the development of a NME [105], even though the test system is 
prokaryotic based and very limited biological data is known at the time of 
assessment. Therefore, there is a potential niche within the pharmaceutical industry 
which is yet to be fulfilled; no single genetic toxicology test system encompasses all 
features required to provide a quantitative risk assessment approach and not just 
hazard identification within pre-clinical safety assessment. A statement backed by 
the continued reform of current test systems [130] as well as the re-direction [128] 
and advances within alternative pre-clinical assessment tools [100, 125] such as in- 
silico approaches [90], even though they still provide cost effective, highly sensitive 
hazard assessment. This niche could be filled by a supplementary novel in vitro 
assay which meets the criteria pre-defined by the current historically used in vitro 
assays [219], however, also include such benefits as high throughput, high content 
(multiplexing), high precision and a greater amount of human relevance, facilitating 
a higher specificity of carcinogen detection and potential in vitro to human 
extrapolation, to supersede the data generated by the currently favoured assays.
3.1.3 The Introduction of the Rodent Pig-a Gene Mutation Assay.
The introduction and early stage validation of the in vivo rodent Pig-a gene mutation 
assay has demonstrated its potential to be incorporated within the core standard 
battery of early stage drug development assays [167]. The assay design lends itself 
very well to full integration within safety assessment [180]; a combination of un- 
invasive sample harvesting, facilitating routine incorporating within 28 day 
toxicology studies [91], highly sensitive and vital reporter partnership, within the
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erythrocyte and the cellular surface marker [141], as well high content flow 
cytometric analysis and quantitative dose response modelling [160], However, the 
assay utilises only rodent haemopoetic tissue, primarily the erythrocyte sub 
population and therefore, the pre-existing question about direct human relevance and 
limitations induced via in vivo rodent to human extrapolation [220] still remain.
The major advantage of the rodent in vivo Pig-a gene mutation assay which aren’t 
shared by analogous transgenic gene mutation assays, BigBlue™  or MutaMouse™ 
[80], is the highly conserved nature of the reporter system, i.e. the GPI-anchor 
moieties themselves are highly conserved amongst most mammalian species [162] as 
well as the ease of modification to the flow cytometric analysis. This feature 
provides potential transferability of assay design throughout mammalian species, 
retaining the current associated benefits as well as potentially significantly increasing 
data integrity and human relevance. Therefore, as well as having a cost effective in- 
vivo assay which can be integrated into current 28 day tox studies with no additional 
cost [91], an in vitro or ex vivo equivalent assay within human tissue can also be 
utilised; extensive low dose quantitative dose response modelling, academic setting, 
as well as a future potential novel test battery assay, pharmaceutical pre-clinical 
safety assessment.
3.1.4 PIG -A  Assay Development and Compatibility to the Current State of 
Affairs
W hen designing novel test systems or bio-monitoring tools one must always take 
into account the running costs and autonomy of such a system. Current in-vitro gene 
mutation assays such as the MLA  (TK) are perfect examples of systems which have 
uncompromising high sensitivity to detect rodent carcinogens but also limited have 
specificity, increasing the likelihood of false positive results [210]. In addition to 
this, debatable human biological bearing [113] also limits use, but due to the 
minimal expense of the test as well as robust historical data the test system still 
remains in use within the core standard test battery [65].
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Designing such a novel test system is therefore, not purely a combination of 
favourable, beneficial characteristics and features all bundled into a test system but 
an elaborate balancing act in which one must adhere to achieve as many of the 
beneficiary features within a system whilst always complying to the limitations and 
restrictions placed upon the system by the current environment [85]. The subsequent 
development of a mammalian cell in vitro PIG-A gene mutation assay is no different 
to previously stated; the assay endeavours to achieve high content and high 
sensitivity to enable robust, stand alone, cost effective data. Providing such an assay, 
once validated, could potentially alleviate the need for drug compound attrition 
based purely on positive Ames test data [112], and provide an alternative to pre­
existing rodent and clonal expansion based in vitro gene mutation assays [72].
The in vivo and in vitro PIG-A  gene mutations assay currently share a homologous 
in-direct reporter system for mutagenesis [77] and therefore, there is no direct 
method of assessing the certainty of the stated results. An assumption is made about 
the PIG-A genotype based on physical observation, presence or absence of the 
specific cellular surface marker acting as the reporter [221] and due to the likelihood 
of such an observation as well as the supporting published literature, weight is 
credited [77, 141, 143, 144, 173, 175]. However, the in-direct nature of measurement 
can always be scrutinised especially from a regulatory point of view due to the lack 
of definitive evidence validating the mechanism; extensive validation is ongoing in 
order to assess the likelihood of implementation within 28 day repeat tox studies 
[91], particularly appropriate within the in vivo assay, and broad mechanistic 
investigation [146, 172, 222], heavily focussing on Pig-a sequence data, to evaluate 
the identity of putative mutant events in alternative haemopoetic tissue.
Immunofluorescence labelling is a technique, used in conjunction with flow 
cytometry , in which antibody molecules are conjugated to a specific fluorophore for 
the purpose o f antigen detection and quantification [223]. In brief, antibody 
molecules (circulatory immunoglobulin), in this particular case IgG, are proteins 
which are produced in response to the introduction o f a specific pathogen into the 
body, and due to their unique structure can bind in a highly specific manor to their 
triggering antigen. All antibodies share a consensus structure, and in the most basic 
terms are “Y” shaped; two hyper variable regions at the upper extremity comprised 
of an interlocking light and heavy chain (VH and VL regions) constituting the
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antigen binding site [224], with a further constant region (CH and CL) held together 
by di-sulphide bonds.
The Pig-a assay hinges on assumption that X-linked characteristics provides both 
adequate sensitivity as well as fundamental biological reasoning to why a mutational 
event within the Pig-a gene is equivalent to the absence of GPI-AP markers on the 
cellular surface [141]. However, unlike currently validated mutagenicity assays, 
presumed mutants are unable to be directly sequenced due to the limited amount of 
mRNA and no nuclear DNA present within either reticulocyte or mature red blood 
cell populations. Therefore, is no definitive proof, in-vivo, the actual measurable 
mechanism within the Pig-a gene mutation assay is mutagenesis; however, 
sequencing data is beginning to emerge within other haemopoetic lineages validating 
the reporter mechanism [144, 173, 178, 222, 225]. Although, within published data, 
experimental design and use of mutant enrichment methodologies can equally be 
criticised for potential induced bias. Therefore, until further fundamental sequence 
data is derived, or the mechanism disproved, mutagenesis is the presumed 
measurable end point.
Pre-clinical drug development is not the only target area for the assay, providing an 
assay system able to generate reproducible dose response data facilitates the further 
investigation into the possibility of in-vitro-in-vivo dose extrapolation [28] and 
correlation. This would further increase the alignment of future drug development 
with novel governmental reforms to reduce animal usage within pharmaceutical 
testing [85, 86]. Also, increasing support is being generated for in-depth research 
into mutagenesis as a potential apical end point for carcinogenesis; based on 
quantitative low dose response modelling, Point of Departure (PoD) [212]. PoDs are 
calculated threshold-like-doses which can be extrapolated to human risk assessment 
utilising specific uncertainty factors [226]. Mutation has long been thought of as a 
highly sensitive end point for carcinogenesis, preceding chromosome aberrations 
[202], however, novel research has demonstrated potential correlation between in 
vivo mutagenesis (tissue independent) and genetic toxicology cancer metrics [227]. 
Therefore, the in vitro PIG-A gene mutation assay could provide a test system able to 
further research within this novel area, evaluating the potential of in vitro to in vivo 
extrapolation for the use of human carcinogenicity prediction.
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Typically, cryopreservation is utilised to enable long term genotoxicity testing; the 
cell stock to be stored in a stable manner to prevent the continuous culture of all cell 
lines, at all times. W ithout the method of stock preservation, continual culturing 
would dramatically increase the passage number and increase the likelihood of 
genetic variation across laboratory stocks. A long term preservative/storage method 
should reduce the risk of contamination, enable consistent passage number, adhering 
to good cell banking practices and reduces costly overheads. However, there are 
potential deleterious disadvantages associated with the technique which include 
cytotoxicity as a result of solute concentration post freezing [228], which are 
significantly outnumbered by the advantages
3.1.5 Heterogeneity of GPI-Anchored Cellular Surface Antigens
Within the scope of designing a novel mutation assay, there is often a lot of focus 
attributed to the criteria required for success; high sensitivity and specificity appear 
to feature heavily. Aspiring to meet these criteria as well as learning from the 
restrictions of analogous assays within the literature [210] can potentially secure the 
assay regulatory acceptance and eventual OECD guideline drafting. Therefore, 
failing to recognise potential flaws in early stage assay development can be a critical 
oversight which will fundamentally weaken the developmental process.
Within all gene mutation assays, sensitivity, the assay’s ability to classify a 
compound as hazardous, is often quoted as the most desirable feature. All current 
assays are aspiring to reach a level of sensitivity in line with the mutation rate 
observed at a random nucleotide within humans (2.5 x 10'8) [145]. The early concept 
of the in vitro PIG-A  gene mutation assay was no different. Spontaneous background 
mutant frequency, the number of observed putative PIG-A mutants within an un­
treated parental test population, governs the overall sensitivity of the assay system 
and was predicted to be a known issue. Heterogeneity of the candidate GPI-APs for 
analogous cell lines had previously been reported [229].
The human Lymphoblastoid cell line, TK6, was the initial candidate following 
praises within recent publications as being a prominent proficient cell line within
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genetic toxicology [113-115], In short, TK6 cells have been shown to demonstrate a 
stable genotype, intact DNA repair, active p53 status and favourable generation time 
and culture conditions. However, one consideration be aware of is the non-crucial 
nature of the specific GPI-anchored proteins chosen to report mutation at the PIG-A 
gene locus within human leukocytes. W ithin the erythrocytic rodent Pig-a assay, the 
cellular surface antigens chosen as reporters for mutation are vital antigens to 
prevent haemolysis [141]; naturally, homologous cellular surface antigens are 
present on the surface of leukocytes however, the presence of absence in this case 
does not trigger a complement protein response. Lymphoblasts are renowned for 
their variable cellular surface expression, especially prominent within auto-immune 
disease phenotypes [230-232] as well as physiological disease states such as cardio 
vascular disease [233] and antigen presenting mechanisms within the immune 
response [149, 234].
Therefore, following highly varied and often lower than predicted, -75%  GPI-AP 
wild type, expression of homologous GPI-AP to the rodent in vivo Pig-a assay [229]. 
Investigations were initiated into the integration of a mutant depletion step, 
analogous to the HAT (Aminopterin) treatment within the HPRT or TK assays [75], 
within the assay design.
3.1.6 Considerations and Limitations of Flow Cytometry
Flow cytometry has been demonstrated in recent years to be a fundamental technique 
used throughout biological research [235]. The nature of the high content analysis 
allows a holistic approach facilitating the development of exciting new research 
fields including systems biology [236], which deviate from the reductionism norm. 
However, as often is the case with the introduction of high through-put new 
technology, the quality of data analysis methodologies often lags behind the 
developmental approaches [237]. This observation is often exaggerated by 
subjectivity existing within data acquisition; the user is often forced to make 
assumptions based on the limited contextual data available at the time [238]. In the 
context of the in vitro PIG-A gene mutation assay, flow cytometry is the backbone of
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data capture as well as both real time and retrospective analysis. Therefore, sufficient 
understanding of the major considerations and limitation associated with the 
technology as well as the sample is needed to ensure optimum use of the novel 
technique and high quality data generation.
The BD FACS Aria Flow sorter was the major platform on-which the in vitro PIG-A 
assay was developed and it has its own unique specifications [239]. The sorter 
utilises a complex “detector wheel” configuration, comprising o f sequential long 
pass filters (LPF) as well as corresponding band pass filters (BPF) enabling emitted 
light to strike a detector suitable to measure a photo event, and hence convert such 
event into an electrical signal able to be intensified, manipulated and analysed with 
the respective flow cytometry software. The detector wheel set up is laser specific 
and is exposed to all emitted light post illumination; light travels through the fibre 
optic bundle and passes through the initial LPF, this enables light of specific wave 
lengths to travel towards a corresponding BPF and then onto a PM T to record the 
signal [192]. Any light not able to pass the LPF is deflected towards the next LPF 
and BPF set up with a wave length lower than the previous, this system continues 
until a minimum wavelength is reached. The minimum wave length for each laser 
specific detector wheel directly corresponds to the excitation frequency (wave 
length) of the source laser.
However, due to the nature of fluorophore fluorescence emission, i.e. a gradual 
slopped curve with an exaggerated range of wavelength, when compared to synthetic 
quantum dots; multiple fluorophores used within a specific experiment can have 
partial emission within a single detector, causing signal overlap and ambiguous 
results (Figure 3.1). This occurrence can be detected, analysed and compensated 
against; however, diminishing returns are associated.
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Figure 3.1. The nature of fluorescence emission spectra following 488 nm laser light 
excitation. Overlapping fluorescence spectra is a potential source of ambiguity or 
false positivity within flow cytometric analysis, the schematic highlights the 
minimum wavelength required for detection. Fluorescein isothiocyanate (FITC), 
Phycoerythrin (PE), Peridinin chlorophyll (PerCP), Phycoerythrin-cyanide 5 (PE- 
Cy5), Peridinin Chlorophyll -  cyanide 5 conjugate (PerCP-Cy5.5) and Phycoerythrin 
Cyanide 7 conjugate (PE-Cy7).
Fluorescence compensation is the term given to this process; single stained flow 
cytometry samples are analysed within adjacent detectors of similar wavelengths 
ranged to identify signals of a positive nature. Subsequently, if a signal is detected, 
the voltage of the perpetrating fluorophore is reduced until the signal loses its 
positive characteristics.
Fluorescence emission overlap is not just observed within high-end flow cytometers, 
the problem is often more acute within lower specification systems or equally more 
complex systems. The ImageStream ™ system, even though hailed as a multicolour 
cytometer has no band pass filters or specific detectors. Therefore, the need for 
highly sophisticated masks as well as user defined features is required in order to, 
post capture, remove said overlap from adjacent channels and provide fluorophore 
specific data 1240].
Additional technical limitations are also present within flow cytometry in terms of 
electrical noise and signal identification; however, for the scope of this thesis the 
only other major limitation which is significant is the lack of actual visualisation of 
cellular events, which is enabled when using ImageStream™ Technology.
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3.2 Materials and Methods
3.2.1 Antibody Optimisation in Conjunction with Cellular Surface Expression 
Analysis - Fluorescein Isothiocyanate vs. Phycoerythrin
TK6 cell cultures were established, counted (Section 2.2) and the equivalent volume 
of medium containing 1 x 106 cells removed and transferred into sterile 15 mL BD 
Falcon ™ centrifuge tubes. The parental cellular cultures were placed back within 
the incubator for future use; passage number was critically monitored to prevent 
clonal deviation from the phenotype (signs of cellular clumping). Cellular samples 
were centrifuged (~ 250-300 x g for 7 min), and the supernatant was aspirated. 50 pL 
of fresh pre-warmed media was added and the cell pellets thoroughly re-suspended 
via pipetting. 5 pL  of Human purified Fragment crystallisable (Fc) block (Cat No. 
564220, BD Biosciences, Hertfordshire, UK) was added to 50% of the samples and 
all samples were incubated for 20 min, protected from light, on ice.
Post Fc block incubation, samples were stained with 20 pL of their respective anti- 
CD59 fluorophore conjugate solutions; human anti-CD59 PE (Cat No. 555764, BD 
Biosciences, Hertfordshire, UK), human anti-CD59 FITC (Cat No. 555763, BD 
Biosciences, Hertfordshire, UK) or alternatively their isotype control antibodies; PE 
Mouse IgG2a, k  Isotype Control (Cat No. 555574, BD Biosciences, Hertfordshire, 
UK), FITC Mouse IgG2a, k  Isotype Control (Cat No. 555573, BD Biosciences, 
Hertfordshire, UK) and incubated for 20 min, protected from light, at 2-4 °C. Post 
antibody incubation, samples were centrifuged (-300  x g for 7 min), supernatants 
carefully aspirated and washed twice via the addition of lOmL 1 x PBS solution. 
Following the wash steps the samples were centrifuged, as above, and re-suspended 
in 1 mL of 1 x PBS in order to construct viable concentrations of cellular solutions to 
be analysed optimally on the flow cytometer.
FITC and R-PE fluorophores were both excited using the 488nm laser line and 
assessed within the pre-specified “FITC” and “PE”” detectors; FITC, 502LP 
combined with a 530/30 band pass filter and PE, 556 LP combined with a 585/42 
band pass filter.
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3.2.2 Enrichment Strategies to Optimise CD59 Expression with the Human 
Lymph oblastoid TK6 Cell Line
3.2.2.1 Dynabead ® Enrichment and Subsequent M agnetic Bead Retrieval of 
the TK6 cells expressing the CD59 Cellular Surface Antigen
DSB-X™ Biotin Protein Labelling Kit (Cat No. D-20655, M olecular Probes, Life™ 
Technologies, Paisley, UK) was utilised in order to fully biotinylate an anti-human 
anti-GPI-AP antibody. Prior to biotinylation, kit contents were stored at 2-4 °C as 
well as fresh PBS pH 7.2 and 1M sodium bicarbonate was prepared. The 
biotinylation of the anti-human purified CD59, clone P282 (H I9) Mouse IgG2a k 
antibodies purchased from BD Biosciences (Cat No. 555761, BD Pharmingen™, 
San Jose CA, USA) was undertaken as outlined within the accompanying protocol 
(Appendix Section 3.3.2.1). In brief, activated DSB-X biotin ester was conjugated to 
the purified anti-CD59 antibody, spin column purified and isolated. Bovine serum 
albumin (BSA) was added to a concentration of 1-10 mg/mL, the conjugate was 
stored at 2-4 °C for future usage.
Following preparation of the biotinylated antibody conjugate, Dynabeads ® Flow 
Comp™ Flexi Kit (Cat No. 1106ID, Molecular Probes, Life™ Technologies, 
Paisley, UK) was used to positively select the phenotypic PIG-A wild type cells 
(Appendix Section 3.3.2.1). In brief, cells were washed in pre-cooled isolation 
buffer, DSB-X conjugate antibody added and subsequently treated with Flow 
Comp™ Dynabeads. Post conjugation, Dynabead® bound cells were magnetically 
isolated and subsequently beads removed via the addition of release buffer. Putative 
bead free wild type cells were re-cultured and QA FCM  assessed for PIG-A 
phenotype. Recovered cells were cryo-preserved for future use.
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3.2.2.2 Clonal Expansion Enrichment of the TK6 cells expressing the CD59 
Cellular Surface Antigen
Cellular samples were treated with anti-GPI-AP specific fluorescently labelled 
antibodies (Section 2.8.1) and analysed on the flow cytometer (Section 2.8) in order 
to assess their phenotypic PIG-A status. Once the population selected met the desired 
characteristics, the parental cellular culture was removed from incubation and 
counting was repeated (Section 2.2)). A volume of culture was removed, centrifuged 
and the supernatant aspirated prior to being diluted with fresh growth medium in 
order to construct a final concentration of 200 cells/mL. 100 pL  aliquots of the 
culture were transferred into each well of a sterile 96 well plate (Ref 655090, Greiner 
-B io-O ne, Gloucestershire, UK) using a multichannel pipette (Finnipipette®, 
Thermo Scientific, Hampshire, UK) and repeated in order to generate six identical 
plates. The plates were labelled accordingly and placed within a Perspex box and 
incubated for 72 hr. Post incubation, each plate was removed and microscopically 
each well was assessed for colony presence and their respective efficiency of growth. 
144 colonies deemed to be well established, exhibiting optimum growth, were 
selected and transferred into 6 x 24 well plates using a 100 pL  pipette set to a total 
volume of 20 pL. 280 pL of fresh growth medium was added to each well in order 
standardise the final volume and each plate was incubated for a further 72 hr. Post 
incubation, each well was thoroughly examined and the ten largest colonies were 
identified and marked. Each marked colony (excess of -1000 cells) were transferred 
into separate sterile 25 cm2 culture flasks, excess growth medium to a total volume 
of 10 mL was added, and incubated for 48 hr. Post incubation, the cultures were 
deemed to be confluent (~ 1-7 x 105 cells/mL) and were flow cytometry assessed for 
analogous cellular surface protein expression (Section 2.8). Post analysis selected 25 
cm flasks were centrifuged, supernatant aspirated and prepared for long term 
cryopreservation.
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3.2.2.3 Fluorescence Activated Cell Sorting (FACS) Enrichment of the TK6 
Cells expressing the CD59 Cellular Surface Antigen
Cellular samples were treated with anti-GPI-AP specific fluorescently labelled 
antibodies (Section 2.8.1) and subsequently analysed on the flow cytometer (Section
2.8.2) and FACS sorted (Section 2.8.3). A larger nozzle and lower pressure (100 pm  
and 20 psi respectively) were utilised for the sensitive TK6 cells.
Post sorting, the recovered cells, pooled presumed homogeneous, population were 
collected within 5 mL polystyrene (12 x 75 mm) sorting tubes (BD. Biosciences, 
Hertfordshire, UK) with fresh cell line specific growth medium (1 mL) and 
consecutively sub-cultured (Section 2.2.3) within 25 cm2 culture flasks prior to long 
term cryopreservation (Section 2.3). Quality assurance (QA) FCM based PIG-A 
phenotype assessment was carried out prior to and 72 - 96 hr. following enrichment.
3.2.3 Proof of Principle Evaluation Utilising CD59 as a Phenotypic Reporter for 
Mutation at the PIG -A  Locus within the TK6 Cell Line Following EMS 
Exposure
A clonally expanded, pre-enriched for the CD59 cellular surface antigen, TK6 cell 
culture was thawed and maintained as outlined in (Section 2.2.) and exposed to EMS 
for 24 hr under standard chemical treatment as described within (Section 2.4.2). Post 
chemical exposure, cultures were washed, counted and seeded ready for initial flow 
cytometric analysis using anti-human CD59 PE conjugate (Cat No. 555764, BD 
Pharmingen ™, San Jose CA, USA). Flow cytometric analysis as defined in (Section
2.8.2) was undertaken within an hour of sample preparation, samples were stored on 
ice, protect from direct light, until analysis.
After gating for single cells on a SSC/FSC dot plot and/or counter map, a minimum 
of 10,000 events were analysed for the surface expression of the CD59 surface 
antigen (Section 2.8.2). PIG-A phenotype was assessed utilising an instrument
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calibration standard (ICS), an unstained sample used to set voltages and mutant 
gating. During ICS analysis, the mutant mimicking sample is utilised to detect auto 
fluorescence within the channel of collection in order to distinguish between a 
positive event and background noise at the channel’s photon multiplier tube (PMT).
All analyses within this section of work were performed using a standard 70 pm  
nozzle at the manufactures suggested 70 psi pressure. FACS Diva 6.0 software (BD 
Biosciences) was used for operating the cytometer and for data analysis. All 
fluorescence measurements on the FACSAria were recorded using the “area” 
parameter coupled with band pass emission filter of 585+/- 21 in the “PE” channel; 
excitation of PE fluorophore was achieved by the 488 nm argon laser. Following 
flow cytometric analysis, parental cell cultures were removed from incubation every 
24 hr for repeated PIG-A  mutagenesis assessment as described at length in (Section 
2 .10).
3.2.4 Long-term Cryo-preservation Assessment on CD59 Phenotype Stability
A clonally expanded, pre-enriched for the CD59 cellular surface antigen, TK6 cell 
culture was thawed and maintained as outlined in (Section 2.2.). The surface 
expression of the specific cryo-vial chosen was previously flow cytometry defined as 
99.8% CD59 positive, this analysis was repeated and confirmed following the 
construction of the to be assessed specific candidate preservation media.
Approximately 250 mL of confluent pre-enriched TK6 cells were counted; 81 
million cells were required for the experiment, as outlined in the table below, as well 
as an additional 1 x 106 cellular sample to confirm initial CD59 presence on the 
cellular surface of the heterogeneous population.
The 1 x 106 cellular samples were centrifuged, washed and stained as outlined in 
detail within (Section 2.8.1) and subsequently flow cytometrically analysed (Section
2.8.2), enabling detection of potential degradation of the surface expression due to 
the initial freeze thaw process, to act as a reference for the ensuing experiment.
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All potential candidate media were made with the constituents as described in Table 
3.1, however, the sucrose was bought in as a powder and required reconstituting into 
a solution prior to usage. 10 g of sucrose powder was weighed out accurately, and 
transferred into a 250 mL glass McCartney bottle. 60 mL of dt^O  was added to the 
sucrose powder and mixed thoroughly until the powder had dissolved, the final 
volume of the solution was adjusted to 100 mL via the addition of dt^O  constructing 
a 10% (w/v) solution.
Table 3.1. Description o f  the constituting elements within each candidate 
preservation media.
Sample Identifier M ajor Constituent (90%  
total volume)
Minor Constituent (10%  
total volume)
Sample 1 Serum DMSO
Sample 2 Serum Sucrose
Sample 3 Serum Glycerol
Sample 4 Heat Inactivated Serum DMSO
Sample 5 Heat Inactivated Serum Sucrose
Sample 6 Heat Inactivated Serum Glycerol
Sample 7 M edia DMSO
Sample 8 Media Sucrose
Sample 9 Media Glycerol
Each candidate media was made up o f two parts; a major constituent (90%) and a 
corresponding minor constituent (10%) to assess practicality o f long term cryo­
preservation of pre-enriched cultures. M edia (Serum free RPMI 1640), Heat 
inactivated Horse Serum, Serum (Horse), Dimethyl Sulfoxide (DMSO) (Cat No. 
D8418, Sigma Aldrich, Hertfordshire, UK), Sucrose (Cat No. S0389, Sigma Aldrich, 
Gillingham, UK) and Glycerol (Cat No. G5516, Sigma Aldrich, Gillingham, UK).
Each sample was constructed in triplicate, and made up in a sterile 15 mL BD Falcon 
™  centrifuge tube; the equivalent volume o f medium containing 3 x 106 cells was 
transferred into each centrifuge tube, centrifuged (-250  x g for 7 min) and 
supernatant aspirated. Each vial was reconstituted constructed at a final
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concentration of 2 x 106 per mL, requiring a total volume of 1.5 mL of preservation 
media. Each sample received 0.15 mL of the minor constituent (DMSO, Sucrose or 
Glycerol) and 1.35 mL of the major constituent (Serum, Heat-inactivated Serum and 
Serum free media) as outlined in Table 3.1.
The contents of each centrifuge tube were transferred into pre-labelled 2 mL 
cryovials, resulting in the construction of 21 samples in total, and placed within an 
iso-propanol housed Nunclon container to facilitate progressive l°C/min temperature 
decrease. Following initial 24 hr incubation within the - 80°C freezer, the individual 
cryovials were transferred into the liquid nitrogen dewer for long term storage, as 
described in (Section 2.3).
Following one, three and 6 month incubation periods within liquid nitrogen cryo- 
preservation a single sample from each batch, as outlined in Table 3.1 were removed, 
thawed quickly as outlined in (Section 2.2) and the contents transferred into a sterile 
25 cm2 culture flask. 8.5 mL o f fresh, pre-warmed growth media (RPMI 1640 
supplemented with 10% HS and 1% L-Glut) was added, via pipette and pipette 
controller, and the flasks placed into an incubator and monitored every 24 hrs, until 
normal growth dynamics were achieved.
Once log phase and subsequent revival was established, a 1 x 106 cellular sample 
was removed from each flask and transferred into a sterile 15 mL BD Falcon ™ 
centrifuge tube. Each sample was centrifuged (250 x g for 7 min), supernatant 
aspirated and re-suspended in 50 pL  of fresh pre-warmed growth medium. 20 pL  of 
human anti-CD59 R-PE conjugate antibody was added to each solution and 
incubated for 20 min, protected from light, at 2-4°C. A single ICS was also 
constructed, acting as a mutant mimicking control to enable flow cytometric 
calibration.
Post incubation the tubes were centrifuged (-250  x g for 7 min), supernatant 
aspirated and re-suspend in 2 mL of 1 x PBS solution. Samples were centrifuged, as 
above, supernatant aspirated and again re-suspended in excess 1 x PBS solution. 
This step was repeated in total twice to ensure removal of excess antibody titre. Post 
washing, the cellular pellets were re-suspended in 1 mL PBS and the contents of 
each centrifuge transferred into a separate 5 mL Flow tube (BD Biosciences, 
Hertfordshire, UK). Samples were stored on ice, protected from light, for a
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maximum of one hr prior to flow cytometric analysis, a brief re-suspension was 
required pre-analysis.
R-PE was assessed within the pre-specified “PE” detector; PE, 556 LP combined 
with a 585/42 band pass filter and analysed utilising the FACS DIVA® software..
3.2.5 Introductory Investigations into Potential Non-viable, PIG -A  Mutant 
M imicking Events
A fresh vial of TK6 cells pre-enriched for the CD59 cellular surface antigen were 
removed from cryopreservation and established as outlined within (Section 2.2). An 
expression level greater than 95%, CD59, was utilised within this experiment. Once 
the cellular culture had re-established itself, samples were prepared for each 
fluorophore, in an analogous fashion to the generalised multi-stained sample outlined 
below, and stored on ice, protected from light, until ready for compensation analysis. 
Also a single instrument calibration standard was prepared, facilitating auto­
fluorescence detection within the relevant detectors.
Cellular samples, post re-suspension, were treated with 20 pL  of the anti-CD59 PE 
antibody solution and incubated for 20 min at 2-4°C, protected from light. Post 
incubation, samples were centrifuged (250 x g for 7 min), supernatant aspirated and 
washed twice with excess 1 x PBS solution. Simultaneously to the washing steps, 
Annexin V-binding buffer 10X (Cat No. 14084, Abeam, Cambridge, UK) was 
diluted 1:9 parts respectively with dlUO and placed on ice to cool rapidly. Following 
washing, the cellular pellets were re-suspended in 1 m L of IX  constructed Annexin 
V-binding buffer, centrifuged (as above) and re-suspended in 100 pL  of the 1 x 
Annexin V-binding buffer.
5 pL o f Alexa Fluor® 488 Annexin V conjugate (Cat No. A13201, Life 
Technologies ™, Paisley, UK) was added to the 100 pL  cell suspension and 
incubated at room temperature for 15 mins, protected from light. Post incubation, 
excess 1 x Annexin-binding buffer (~1 mL) was added to each culture and 
centrifuged (250 x g for 7 mins). The resultant supernatant was aspirated, and the
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cell pellet re-suspended in 200 pL of IX  Annexin V-binding buffer. 
5 pL  (0.25 pg) of 7-Aminoactinomycin D (7-AAD) (Cat No. A1310, Life 
Technologies ™, Paisley, UK) was added to each sample, incubated for a minimal of 
5 mins on ice, protected from light and flow cytometrically analysed within 4 hr of 
initial antibody treatment.
Annexin V, Alexa Fluor® 488, R-PE and 7-AAD were assessed within the pre­
specified “FITC” , “PE” and “APC” detectors; FITC, 502LP combined with a 
530/30 band pass filter. PE, 556 LP combined with a 585/42 band pass filter and 
APC, No LP combined with a 660/20 band pass filter. Alexa Fluor 488® and PE 
were excited off the 488nm laser line, and the 7-ADD off the 633 nm laser line, best 
matching their excitation m axima’s.
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3.3 Results
The aim of the following section was to experimentally fully characterise the potential 
antibody candidates available for phenotypic CD59 PIG-A mutant reporting. In an endeavour 
to reduce further subjectivity within FCM analysis, extensive antibody optimisation was 
undertaken.
3.3.1 Antibody Optimization in Conjunction with Cellular Surface Expression Analysis 
- Fluorescein Isothiocyanate vs. Phycoerythrin
Initially focussing on the FITC data (Table 3.2), the results appeared to be fairly similar; 
average fluorescence intensity, 3688 and 3500, the number o f events defined positive, 7884 
and 7440 and the percentage of the parental population, 73.4 and 71.7% in the presence and 
absence of Fc Blocker respectively. However, in the absence of Fc block reagent; a 5.1% 
decrease in intensity, 5.6% decrease in the number of events defined positive and a 1.7% 
reduction in the parental population was observed when compared when compared to the Fc 
block reagent present samples.
Phycoerythrin demonstrated an analogous relationship when comparing the impact Fc block 
reagent had on the subsequent sample statistics; average fluorescence intensity was shown to 
be 6497 and 5761 arbitrary units, a decrease of 11% in the absence of Fc block reagent. The 
number of events attributed positive for a PE signal was again analogous within the inter- 
fluorophore comparison, 7068 to 7047 events presence to absence respectively. Finally the 
population statistics generated within this sample were highly reproducible, 70.7 to 70.5% 
identification post antibody treatment.
Comparing FITC against PE directly, summarising both Fc blocker positive and negative 
samples, the data demonstrates little differences with respect to the subsequent population 
sizes, in terms of number as well as the percentage of the parental un-refined population, 
following either antibody treatment. However, there is a more obvious difference in their 
respective fluorescence intensity following antibody treatment; the PE treated samples 
demonstrated an implicitly higher fluorescence intensity value, in regards to arbitrary units, 
when compared to the corresponding comparable FITC treated samples, 6129 to 3594 
respectively.
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Considering the FITC isotype treated samples; in the absence of Fc block reagent 19 
cellular events were deemed positive, constituting 0.2% of the parental population 
with an average fluorescence intensity of 697 (Figure 3.2 A). In the presence of Fc 
block reagent (Figure 3.2 B) 7 events were considered positive, constituting 0.1% of 
the parental population with an average fluorescence intensity o f 2489. Both samples 
were demonstrated to produce comparable data with an estimated binding efficiency 
of 0.06% in the presence of Fc block and 0.18% in the absence o f Fc block reagent 
respectively.
The PE isotype treated samples generated equivalent results; 36 and 38 cellular 
events were defined as positive, constituting 0.4 and 0.3% of the parental population 
and with an average fluorescence intensity of 8942 and 3790 arbitrary units in the 
absence and presence of Fc block reagent respectively (Figures 3.2 C and D). 
Binding efficiencies were estimated at 0.35% in the presence of Fc block and 0.36% 
in the absence of Fc block respectively.
Comparing the FITC and PE isotype data, an analogous trend was observed as 
previously demonstrated in (Table 3.2); little difference was seen between the two 
samples. The PE isotype data was consistently demonstrated to produce marginally 
larger population statistics than the comparable FITC data. However, all increments 
were negligible and therefore, not statistically significant in the overall context of the 
experiment. Average binding efficiencies, incorporating both Fc block present and 
absent samples, of the PE isotype control were again shown to be marginally higher 
than comparable FITC statistics, 0.355 to 0.12% respectively.
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Figure 3.2. Average fluorescence intensity values for Human TK6 lymphoblastoid 
cells following isotype control fluorophore-conjugate antibody treatment in the 
absence and presence of Fc block reagent. Antibody Specificity Assessment 
following (IX ) isotype control treatment for the two assayed fluorescent conjugated 
antibodies (FITC and PE). Direct visual comparison can be drawn between samples 
of like fluorophore; A) anti-CD59 FITC treated, Fc Block negative and B) anti- 
CD59 FITC treated Fc Block Positive or alternatively C) anti-CD59 PE treated, Fc 
Block negative and D) anti-CD59 PE treated, Fc Block positive. N =l, >10,000 
events captured per sample. The “P2" region is the defined positive signal region 
following ICS auto-fluorescence assessment.
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The FITC conjugate antibody data, in the presence of Fc block, exhibited a positive 
correlation between antibody concentration and the resultant average fluorescence 
intensity (Table 3.3). This correlation, although not directly proportional, was echoed 
within the FITC Fc block absence data (Table 3.3). A linear trend line was fitted to 
the Fc block negative data, and the resultant equation was y = 29.5x + 926.4 (Figure
3.3 A). The resultant gradient of the slope (29.5) and the intercept (926.4) 
highlighted the non-linear characteristics of the data.
The PE-conjugate antibody data, similar to the FITC data, equally shares and 
displays an analogous positive correlation observed between antibody concentration 
and subsequent fluorescence intensity within both Fc block present and absent 
samples (Table 3.3). Again, a linear trend line was fitted to the Fc block negative 
sample (y = 57.6x + 67.2) and was demonstrated equally not to be linear (Figure 3.3 
B). However, the PE antibody was shown to be more representative of a directly 
proportional relationship than the comparable FITC data, with “goodness o f fit” R 
values of 0.999 and 0.879 respectively.
W hen discussing the data as a whole, irrespective of Fc block presence, the top two 
antibody concentrations (0.5 and IX ) resultant in comparable fluorescent intensity 
data, all lesser concentrations demonstrated significant diminishing returns in respect 
to relative fluorescent intensity (Table 3.3).
In addition, PE data consistently had higher associated fluorescence area intensity 
values, at equivalent antibody concentrations, than the FITC data. However, this 
relationship is reversed as the concentration of the antibody decreases below 0.5X 
for all ensuing antibody concentrations, as shown in Table 3.3.
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Figure 3.3. Antibody Titration Analysis values following human TK6 
lymphoblastoid treatment with fluorophore-conjugate antibodies (A) FITC and B) 
PE. Average Fluorescence intensity values following FITC or PE conjugate antibody 
treatment, in the presence or absence of Fc block reagent. Linear trend line drawn for 
Fc block negative sample, with equation displayed on graph. N = l, >10,000 events 
captured per sample.
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3.3.2 Enrichment Strategies to Optimise CD59 Expression with the Human 
Lymphoblastoid TK6 Cell Line
W ithin the cryo-preserved TK6 stock cultures, used within this body of work, the 
CD59 cellular surface expression was routinely determined to be heterogeneous, 
approximately 3:1 in favour of CD59 presence. Therefore, ~ 25% of all cells 
analysed displayed limited or complete absence of the CD59 cellular surface antigen. 
The aim of the subsequent result section was to identify potential pre-enrichment 
strategies and compare their efficiency in order to deplete heterogeneous stock TK6 
solutions of phenotypic PIG-A mutants, in this case cells staining negative for CD59 
surface antigen presence.
3.3.2.1 Dynabead ® Enrichment and Subsequent M agnetic Bead Retrieval of 
the TK6 Cells Expressing the CD59 Cellular Surface Antigen
Initially, focussing on the Dynabead ™ paramagnetic enrichment data, Sample 1 was 
demonstrated to have an average CD59-PE expression frequency of 84.3% (Table 
3.4). 83.7% of the sample was demonstrated to be single cell in nature and therefore, 
applicable for subsequent flow cytometry based analysis. Sample 2 and 3 were 
shown to achieve moderately higher enrichment yields; with corresponding CD59 
expression frequencies of 96.5 and 95.9% respectively (Table 3.4). Both samples 2 
and 3 generated analogous heterogeneous populations in terms of basic cellular 
morphology and aggregation status as the initial sample, 82.2 and 83.5% single cell 
morphology respectively. The maximum enrichment, in terms of CD59 cellular 
surface antigen expression, was 96.5%.
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33 .2 .2  Clonal Expansion E nrichm ent of the TK 6 Cells Expressing the CD59 
C ellu lar S urface Antigen
Following clonal expansion enrichment, subsequent flow cytometric analysis 
resulted in varied heterogeneous yields in terms of CD59 cellular surface expression, 
ranging from 28-99.8% (Figure 3.4); reflecting the heterogeneity of the specific GPI- 
AP surface marker within the parental un-enriched populations. The majority of 
samples analysed constituted mainly of defined CD59 positive events for example, 
sample 1B was the exception. The maximum observed enrichment, in terms of CD59 
cellular surface antigen expression was 99.8%.
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Figure 3.4. Flow Cytometric Analysis of Human Lymphoblastoid TK6 cells 
following anti-CD59 R-PE conjugate antibody treatment post Clonal Expansion. 
Cells were clonally expanded (Section 3.2.2.2) and flow cytometry used to assess for 
CD59 cellular surface antigen expression following anti-CD59 R-PE treatment. 
Initially, an instrument calibration sample (ICS) was analysed in order to define the 
single cell population, based on forward and side scatter profiles, and positivity 
within the relevant fluorophore detector. The intersect between Q3 and Q4 was the 
resulting boundary of positivity, hence, events falling within Q4 were deemed 
positive for the CD59 surface antigen, and subsequently Q3 events were deemed 
negative. 10,000 presumptive single cell events were recorded for each sample; 1A 
99.8%, 2A 84.5%, 3A 54.7%, 4A 99.7%, IB 28%, 2 B 61.8%, 3B 54.4% and 4B 
83.8% relative CD59 positive presence.PE-A and CD59 PE-A - Phycoerythrin Area; 
SSC-A - Side Scatter Area.
3.3.2.3 Fluorescence Activated Cell Sorting (FACS) Enrichment of the Human 
Lymphoblastoid TK6 Cells Expressing the CD59 Cellular Surface Antigen
Finally, following FACS (Section 2.8.3) and the allotted subsequent recovery period, 
72-96 hr to enable re-establishment o f “normal” growth dynamics, flow cytometric 
analysis of three triplicate samples were shown to record an average CD59 
expression of 95.3% (Table 3.5). All three samples were analogous in terms of 
morphology and aggregation status prior to flow cytometric analysis and generated 
consistent expression/presence data. The maximum average recovered CD59 cellular 
surface expression using this technique was demonstrated to be 96.48%.
With the exception of clonal expansion, the two additional enrichment 
methodologies were demonstrated to generate highly reproducible results in terms of 
relative CD59 antigen presence. However, clonal expansion generated the highest 
mutant depletion efficiency as observed within sample 1 A within Figure 3.4.
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Table 3.5. Summary o f  the CD59 antigen expression status on the surface o f  
recovered, 72-96 hr, human lymphoblastoid TK6 cells following FACS. Samples de­
noted by the identical sample number were extracted from  the same homogeneous 
parental culture, different sample number represents a completely different parental 
sample; ~10,000 single cellular events were scored and each sample was analysed  
in triplicate.
Total 
Number of 
Single Cell 
Events
Number of 
Events 
Defined 
CD59 
Negative
Number of 
Events 
Defined 
CD59 
Positive
Number of Cells 
Defined CD59 
Positive 
(Percentage of 
Total Single 
Cell Events)
Standard 
Deviation 
of the 
Mean
Sample ID. FLASK 1
la. 9480 427 9053 95.50
lb. 9467 358 9109 96.22
lc. 9337 410 8927 95.61
1. Average 9428 398 9030 | 96 0.39
FLASK 2
2a. 9867 259 9638 97.68
2b. 10179 451 9762 95.90
2c. 10194 410 8927 87.57
2. Average 10080 373 9442 94 5.40
FLASK 3
3a. 10900 425 10475 96.10
3b. 9919 349 9570 96.48
3c. 9787 359 9428 96.33
3. Average 10202 378 9824 96 0.19
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3.3.3 Proof of Principle Evaluation Utilising CD59 as a Phenotypic Reporter for 
Mutation at the PIG -A  Locus within the TK6 cell line following EMS Exposure
Initial proof of principle experiments were carried out in order to assess the 
feasibility of qualitative or quantitative dose response modelling following acute 
model mutagen exposure within the in vitro PIG-A  gene mutation assay (Section 
2.10). The chemical selected for this initial experiment is a model mutagen, an 
alkylating chemotherapeutic agent, Ethyl M ethane Sulfonate (EMS), with 
comprehensive pre-existing dose response modelling reported in literature [39, 91, 
211, 241-243]. All “P/G-A mutants” are events phenotypic o f  CD59 absence 
(relative fluorescence negative) and therefore, presumptive genotypic PIG-A 
mutants. Identification of presumptive mutant events is highly dependent upon the 
specific gating strategy used.
Low dose EMS treatment of TK6 cells, clonally enriched for the presence of the 
CD59 cellular surface antigen, resulted in an apparent sub-linear dose response or no 
dose response for all days of PIG-A analysis, i.e. a number of test concentrations 
were observed not to significantly increase the respective PIG-A  mutant frequency 
(Figure 3.5) when compared to concurrent controls.
Initially, all data was tested for normality and only Day 3 was demonstrated to be 
normally distributed, p = 0.67, and thus was the sole day requiring parametric 
statistical analysis (Dunnett’s 2-sided t-test).
In terms of cytotoxicity, doses greater than and including 5 pg/m L demonstrated a 
significant toxic effect with resulting RPD values below 50%.; RPD values as low as 
21.7% were observed on Day 2 for the top dose (10 pg/mL) tested. However, it 
appears that at least 24 hrs are required to pass following EMS treatment, prior to 
any observed toxic effects (Figure 3.5 B).
Day 4 was the only day which demonstrated a significant increase or decrease in the 
average number of putative PIG-A mutants and hence, the resultant average PIG-A  
mutant frequency was observed to rise (Figure 3.5 D). The top dose on Day 4 
induced a significant increase in the PIG-A  mutant frequency (P<0.01, D unn’s Two- 
Tailed T-Test) (P=0.0003 and 0.73% respectively) with respect to con-current
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negative control values. Cytotoxicity was shown to be marginal at the top dose (10 
pg/mL) with an average RPD value of 78.6%.
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Figure 3.5. Human lymphoblastoid cells (TK6) PIG-A mutant frequency following 
24 hr low dose EMS exposure, Day 1 - 4  (A-D) respectively, CD59 antigen utilised. 
Frequencies of PIG-A mutant TK6 cells (Clonally selected) following 24 hr low dose 
EMS exposure (N=3, Error Bars ±1SD) PIG-A  mutants displayed as percentage of 
total single cellular events (0.1% PIG-A  Mutants = 1 mutant x 10"3 cells). Vehicle 
control data displayed within each graph. Statistical Analysis was undertaken 
following normality testing (Dunn’s or Dunnett’s Test (p <0.05*)(N=10,000 cells). 
A single replicate for Day 4 top dose (10 pg/mL) removed due to spurious nature, 
error bars omitted.
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Day 4 data was further analysed utilising the PROAST package (Proast 38.9, 
National Institute for Public Health, Netherlands) to derive a Bench mark dose 
(BMD) point o f departure (PoD) metric [212]. The BMD is derived from the 
complete data set by fitting a variety of dose response models, assurance is presented 
as the ratio between the confident intervals around the BMDio (Figure 3.6), with a 
lower ratio presenting greater confidence in the BMD value. The BMDio or CED and 
corresponding CEDLio and CEDUio values were derived as 0.587, 0.439 and 0.881 
respectively (Figure 3.6). The “Nested” set o f  models, utilised to derive the BMDio, 
as well as the log likelihood function, utilised to calculate the upper and lower 
confidence limits, are more fully detailed in the appendix (Appendix Section 3.3.3).
E2-CED:y= a*exp(bx)
version: 38.9
CN
CED- 0 .587
CD
CD
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Figure 3.6. Human lymphoblastoid cells (TK6) Day 4 PIG-A  mutation frequency 
data following 24 hr. low dose EMS exposure, CD59 antigen utilised. Day 4 
frequencies of PIG-A  mutant TK6 cells (Clonally selected) following 24 hr low dose 
EMS exposure (Dose - pg/mL). (N=3) “pig-a” mutants displayed as percentage of 
total single cellular events (0.1% PIG-A Mutants = 1 mutant x 10~3 cells). PROAST 
38.9 modelling; CED, CEDL and CEDU represent the BMDio, BMDLio (Lower 
confidence limit) and BMDUio (Upper Confidence Limit). M ean PIG-A  mutant 
frequencies represented by (o).
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3.3.4 Long-term Cryo-preservation Assessment on CD59 Phenotype Stability
Designing a highly sensitive novel gene mutation assay system is not solely 
adequate; the test system needs to be robust and reproducible to enable inter­
laboratory validation and routine use within industrial settings. The following section 
of data investigates the feasibility to store the pre-enriched, or mutant depleted TK6 
populations over an extended period of time, 6 months, and retaining their 
characteristic growth dynamics and phenotypic cellular surface antigen expression. 
All PIG-A mutant events are phenotypic of CD59 absence, no current genotypic 
assessment available and therefore, are defined as presumptive PIG-A mutants.
Prior to cryopreservation, clonally expanded enriched TK6 cells, for the CD59 
surface antigen, were demonstrated to have an average CD59 expression of 99.85% 
and hence, a spontaneous background PIG-A mutant frequency of 0.15% (Appendix 
Section 3.3.4). All data w ithin this section was defined not normally distributed, 
Shapiro Wilks p<0.05) and therefore, the Dunn’s non-parametric T-tests (1 and 2- 
sided) were utilised for statistical analysis post phenotypic PIG-A  mutant frequency 
assessment to state at what dose, if any, rejection of the Null hypothesis was to be 
assumed (P-value <0.05).
Following liquid nitrogen storage (liquid phase), across the entire 6 month period, all 
samples’ PIG-A mutant frequency rose in comparison to the con-current negative 
control values; DMSO as a major constituent was demonstrated to have a non- 
statistically significant effect on phenotypic PIG-A  mutant frequency, across all time 
points, when compared to the control sample. However, Glycerol based samples 
generated statistically significant increases in phenotypic PIG-A  mutant frequency at 
each time point (Figure 3.7).
Over the entire 6 month cryopreservation period, DMSO was demonstrated to be the 
most consistent major constituent in respect to CD59 surface antigen presence 
stability. DMSO M was the sample which over all three analysis time points 
demonstrated the smallest increase in phenotypic PIG-A  mutant frequency with an 
average of 0.27%, when compared to the negative con-current control value of 
0.15%. Glycerol S was observed to be the sample which generated the highest 
increments in PIG-A mutant frequency, 10.62% - 3 month, this was further apparent
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as the 6 month sample deteriorated and consequently prevented flow cytometric 
analysis (Figure 3.7).
10% sucrose was the additional major constituent assessed, however, was shown to 
be highly detrimental to the TK6 cell cultures and no ensuing analysis was able to be 
undertaken (Appendix Section 3.3.4). Regardless of storage cocktail utilised, PIG-A 
mutant frequencies did appear to increase proportionally with time, however, 
increments were deemed not statistically significant with DMSO based samples.
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Figure 3.7. 1, 3 and 6 Month flow cytometric analysis of TK6 populations post 
cryopreservation. Average phenotypic PIG-A mutant frequency analysed through the 
use of the CD59 cellular surface antigen reporter. (D unn's One-Tailed T-Test (p 
<0.05*), D unn's Two-Tailed T-Test (P<0.05**)) (N=3, Error Bars ±1SD) PIG-A 
mutants displayed as percentage of total Single cellular events (0.1% PIG-A Mutants 
= 1 mutant x 10° cells). DMSO. Dimethyl Sulfoxide; Gly, Glycerol; M, Serum Free 
Media; S, Serum; HiS, Heat In-activated Serum. Gly-S Data omitted from the 6 
Month data set due to poor recovery (Control -  unfrozen clonally expanded cells).
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3.3.5 Introductory Investigations into Potential Non-viable, PIG -A  Mutant 
M imicking Events
In the endeavour to more accurately define putative phenotypic PIG-A  mutant 
events, the following section of work describes advanced FACS Aria I analysis of 
spontaneous presumptive genotypic PIG-A  mutant events within un-treated human 
lymphoblastoid TK6 culture. The inclusion of viability dyes, 7-Aminoactinomycin- 
D (7-AAD) and Annexin V Alexa Fluor 488 were investigated for their ability to 
more accurately define the PIG-A  mutant phenotype during analysis of dose 
response data. Presumptive phenotypic PIG-A  mutant events shown to be non-viable 
will be excluded from future analysis and the effect of this will be evaluated in the 
context of assay sensitivity.
The use of an instrument calibration standard (ICS) was implicitly required for auto­
florescence assessment detection and signal positivity definition across all relevant 
detectors (Figure 3.8); the resultant regions Q4-4 {PIG-A wild type), P2/P4 
(apoptosis positive), Q2-2/Q2-3 (necrotic positive) and P3/P5 (loss of membrane 
integrity) were established. In the context of the PIG-A phenotype assessment, the 
precision of the PE-A gating is critical to accurately defining putative mutant and 
wild type events; the threshold of positivity is set at the auto-florescence maxima as 
outlined in (Section 2.8.2).
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Figure 3.8. Viability Assessment gating strategy for un-stained human TK6 cells 
(Clonally selected) cultures. A) Initial Crude Single Cell Gate B) PIG-A Mutant 
phenotype Assessment C) Viability Dot Plot D) FITC -  channel fluorescence 
histogram measuring Apoptosis E) 7-AAD -  channel fluorescence histogram 
measuring Loss of Membrane Integrity (Cell Death) (-10,000 Single cellular 
events).
Following anti-CD59 R-PE antibody treatment, the phenotypic PIG-A wild type sub­
population was the majority population within the heterogeneous parental population 
(97.6% cells). This was demonstrated to be viable, with only 10.4 and 2.1% of the 
population in apoptosis and losing cellular membrane integrity respectively (Figure 
3.9).
The phenotypic PIG-A mutant defined sub population was much smaller (-2% ) 
when compared to the defined PIG-A wild type population and displayed a 
significant decrease in cellular viability. The frequency of non-viable cells defined 
positive for both apoptosis and loss of cellular membrane integrity was significantly 
higher than the comparable wt statistics at 36.4 and 39.2% respectively.
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During the extended analysis period, >500,000 single cellular events were collected 
to investigate potential analysis bias induced with regards to defined putative PIG-A 
mutant phenotype as well as viability (Figure 3.10).
Dramatically increasing the size of the captured TK6 parental population (50 x fold 
increase) had minimal effects on the population statistics in terms of sub-population 
composition; phenotypic PIG-A mutant frequencies, viability and single cell nature. 
Defined phenotypic PIG-A  wild type cells constituted 96.5% of total single cells and 
displayed respective apoptosis and loss of membrane integrity values of 8.3 and 
4.3% respectively, comparable to the equivalent population figures collected within 
the limited sample size (Figure 3.10). Presumed PIG-A  phenotypic mutant events 
displayed 32.9 and 49.5% values for apoptosis and loss of cellular membrane 
integrity respectively, again mimicking the previous relationship observed within the 
comparable limited sample size figures (Figure 3.9).
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3.4 Discussions and Conclusions
3.4.1 Antibody Optimisation in Conjunction with Cellular Surface Expression  
Analysis - Fluorescein Isothiocyanate vs. Phycoerythrin
Flow cytometry is a high throughput, high precision method for mass data 
acquisition [192]. However, as often is the case with incorporation of modem 
technology, advancements within technology specific to scientific fields often lead to 
a lack of standardisation amongst studies [244]. This observation inclines to lead to 
lack of reproducibility and lowers the integrity of standalone data, until thorough 
validation and subsequent standardisation of data handling has occurred, due to 
increasing subjectivity unknowingly introduced through uneducated novel data 
handling. Recent incorporations of more standardised analysis approaches within 
flow cytometry, as well as genetic toxicology in general, has led to the quality of 
publication being increased [245, 246] However, remnants of the subjectivity, even 
potential bias, within data gating strategies does still remain and can have negative 
implications, especially when developing a desired reproducible assay. Therefore, in 
an endeavour to establish a highly reproducible platform, many assay features were 
investigated with the aim of coordinating an approach to negligate potential sources 
of subjectivity.
Fluorescence staining of this nature is the fundamental technique that was used 
within the in vitro PIG-A  gene mutation assay design, to define and characterise sub­
populations within the heterogeneous population; therefore, antibody-antigen 
binding efficiency is by proxy an essential technique to maintain sensitivity and 
accuracy within subsequent flow cytometric applications.
Flow cytometers much like antibodies often appear generic and therefore, can be 
mistakenly utilised within specific application needs. However, numerous explicit 
features, unique to both flow cytometers (equipment and analysis software) as well 
as antibodies (specificity and sensitivity) highly influence the sensitivity and utility 
o f the subsequently generated data. The initial antibody-fluorophore trials consisted 
o f two main candidates, an IgG k FITC-conjugated anti-CD59 antibody and an 
analogous PE-conjugated antibody, their respective intensity post illumination and
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specificity when coupled to FACS Aria I analysis were unknown. The preliminary 
experimental results, following undiluted antibody treatment (Section 3.3.1) to 
controlled sample sized cultures of TK6 cells, implied there were little differences 
between the two candidates. However, it was noted that the phycoethryin conjugate 
antibody was on average much more intense post illumination, within its specific 
detector, and therefore, was initially favoured for assay incorporation.
Antibody specificity was the next feature under direct investigation, due to the 
potential confounding factor that non-specific antibody binding could have on the 
mutation frequency at the PIG-A gene locus. Events positive for CD59 antigen 
status, could in fact be putative PIG-A mutant events which have a fluorophore- 
conjugate antibody attached via an unspecific mechanism. Immune cells, very 
commonly B-lymphoblast cells, have been demonstrated to have a high number of 
fragment crystallisable (Fc) receptors on their cell surface [247] which are able to 
directly interact and hence bind to Fc regions on the IgG molecule thus, inducing a 
potential for false positivity within the assay design. Additional to this, hydrophobic 
interactions have also been identified as a potential mechanism for un-specific 
interaction and an additional potential confounding factor [248]. Both of these 
characteristics of antibodies have recently been extensively reviewed and 
demonstrated to be resolved via the use of routine fixation, approaches heavily 
utilised within immunohistochemistry applications [249]. However, in order to 
enable live cell analysis, a technique vital to maintain the cells in a state best 
representative o f their natural conditions, the ability o f endogenous Fc receptors to 
bind in an unspecific manor was assessed with the use of isotype controls in the 
absence and presence of Fc block reagent. Fc block reagent is designed specifically 
to block the non-specific FcR-mediated Ig-Fc binding in human samples during flow 
cytometric analysis [250].
W hen compared to isotype controls, both antibodies again produce highly 
comparable data in terms of un-specific binding; the FITC-conjugate isotype 
antibody demonstrated a lower percentage of total non-specific binding when 
compared to the PE-conjugate isotype control. The data suggests that the FITC 
antibody is more specific than the comparable PE antibody (Section 3.3.1), however, 
the PE antibody has lower FcR mediated interactions. The lymphoblastoid nature of
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the cell line, as well as human primary samples, intended on being used within the 
assay biases the decision of antibody candidate towards the PE antibody.
Antibody conjugates destined for research based immunofluorescence applications 
are more expensive than their un-conjugated, purified counterparts [221] and 
therefore, when designing a novel high content assay system, assay practically and 
costly overheads must be taken into account. In an attempt to minimise costs, each 
antibody candidate was investigated for potential antibody titration whilst retaining 
assay sensitivity and integrity. The resultant data suggests that a single dilution 
(0.5X) for both antibody candidates did not significantly decreases the average 
antibody intensity observed. However, additional dilutions resulted in diminishing 
returns in sensitivity as well as signal resolution and subsequent population 
identification. Therefore, to maintain the optimum sensitivity undiluted antibody was 
favoured for assay design.
The undiluted Phycoerythrin conjugated antibody solution was chosen as the 
working concentration of antibody to be incorporated into the in vitro PIG-A  assay 
system. Predominantly, both antibody candidates were very comparable, however, 
even though the FITC conjugate antibody demonstrated to be marginally more 
specific, in the context of the lymphoblastoid based PIG-A assay, this was deemed 
insignificant. The major advantage of the PE-conjugate was the significant increase 
in average fluorescence intensity, as well as the more directly proportional nature of 
the antibody binding metrics (Section 3.3.1). The reason for the increase in 
fluorescence when directly comparing the two antibodies is the actual structure of 
the antibody-conjugate molecules. Fluorescein isothiocyanate (FITC) has a high 
quantum yield, efficiency of energy transfer from absorption to emission 
fluorescence, however only 3-5 molecules on average are present following 
conjugation. W hen comparing this to R-phyocoerythrin (PE), a photosynthetic 
pigment found in red alga, 34 phycoerythrobilin fluorochromes are present per 
molecule, making it a brighter, ideal pigment for flow cytometric applications [251].
Providing a tool to remove ambiguity within sub-population definition was believed 
to be more important in the context of the sensitivity of the mutagenicity assay, this 
can be easily seen within (Section 3.3.1), than a negligible potential increase in false 
negativity within subsequent data analysis. Due to the minimal level of un-specific
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antibody binding observed with BD-Bioscience manufactured primary antibodies, 
the use of isotype controls was believed to be un-necessary for future analogous 
applications.
3.4.2 Enrichment Strategies to Optimise CD59 Expression with the Human 
Lymphoblastoid TK6 Cell Line
Spontaneous background mutant frequency is the occurrence of pre-existing mutant 
events, within a gene mutation assay system, prior to chemical exposure. Assay 
sensitivity is inversely proportional to the spontaneous background mutant frequency 
[252], therefore, the inclusion of a pre-enrichment or comparable mutant depletion 
step is often observed within most validated in vitro gene mutation assays [71, 75]. 
The spontaneous background mutant frequency in-directly defines the number of 
induced mutational events required in order for a chemical dose to be classified as 
statistically mutagenic; therefore, utilising such media as HAT, for the HPRT/TK  
assays, actively removes pre-existing mutants and increases sensitivity.
W ith the potential change in dogma with regards to data analysis, in vivo 
restrictions and modelling, even greater pressure is placed upon the sensitivity of an 
assay system [28, 85, 212]. Programmes such as PROAST calculate their dose 
response matrices with greater emphasis on assay sensitivity, moving away from the 
more traditional NOGEL approach [213]. Therefore, the following section 
endeavours to compare and contrast mutant depletion methodology for inclusion 
within this preliminary in vitro PIG-A  assay design
Dynabead ™  enrichment was shown to generate variable capture efficiency between 
homologous samples and hence the resultant CD59 enrichment showed 
approximately a 10% yield difference (Figure 3.4). The maximum TK6 CD59 
enrichment achieved was in the region of 95% and therefore, an estimated 
spontaneous background mutant frequency of 50,000 x 10'6 cells scored was 
calculated. Paramagnetic positive cell enrichment is a fundamental method used 
within many aspects of cell biology [168, 253, 254], however, even though the
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principles may be rudimentary the actual DSB-X - Dynabead ™ concept relies on a 
number of cellular interactions, antibody conjugations and magnetic enrichment 
steps (diminishing returns) which are potential sources of error and hence, reduce the 
overall process efficiency when compared to the other two methodologies. Dynabead 
™ kits are developed with intended use o f  proteins with relatively large molecular 
weights and therefore, the limited size, -2 0  kDa of the CD59 protein maybe 
retarding the enrichment process. Based on the current efficiency of enrichment and 
no additional immediate methods for optimisation, Dynabead™  enrichment was 
deemed inappropriate for this assay design, however, would be highly cost effective.
FACS is a routinely utilised technique within microbiological research as well as 
clinical medicine [255, 256]. FACS theoretically has the accuracy to isolate and 
capture a single cellular event identified during real-time sample analysis. In order to 
avoid the potential limitations induced following clonal growth expansion, a pooled 
sample approach was initially accepted in which thousands of CD59 defined positive 
homogenous cellular events were collected within a single sample tube and 
subsequently assessed for overall CD59 surface expression. FACS yielded highly 
consistent results, with a comparable maximum enrichment of 96% recorded (Table 
3.5). However, the CD59 expression of recovered samples was directly proportional 
to the viability of the cells post sorting. Operator ability and experience in ensuring 
optimal cellular viability played a critical role in the effectiveness of this technique. 
Due to the relative high operator skill required, potentially FACS would only have 
limited usage within such an assay design; more modem FACS machines are more 
user friendly and stable, generating a more suitable platform and increasing 
reproducibility and robustness.
Clonal expansion methodologies are prevalent within current in vitro gene mutation 
assays, as seen previously within HPRT/TK (MLA) colony scoring [70, 186], 
however, as a method for wild type enrichment/mutant depletion this would appear 
to be novel within the field. Again, this method resulted in a high degree of variation 
between colonies, an approximate 70% difference in surface antigen expression. 
Nevertheless, the technique generated highly effective enrichment for the CD59 
antigen with recorded maxima of 99.8% (Figure 3.4), greater than the comparable 
Dynabead ® and FACS methods, establishing an estimated spontaneous mutant 
frequency of 2,000 xlO"6 cells scored. TK6 cells lend themselves well to clonal
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expansion as a method for mutant depletion due to the primarily CD59 positive 
subpopulation within the heterogeneous parental stock culture. However, as this 
technique requires growth from a single cell into a large enough colony to facilitate 
flow analysis and subsequent cryo-preservation, the additional elongated growth 
period can induce phenotypes characteristic of cellular distress [257]. Induced 
deleterious increases in genomic instability as a direct result o f cellular distress and 
aging have the effect of increasing mutant frequency and hence, indirectly 
decreasing assay sensitivity and robustness.
The enrichment technique which offers most of the beneficial features required 
within a modem in vitro gene mutation assay would be FACS; high throughput, high 
precision and extensive reproducibility without additional overhead expenses [235, 
255]. However, FACS is a highly skill dependent technique requiring experience, as 
well as significant knowledge in sample preparation pre and post sorting [237]. 
Insufficient maintenance, leading to vastly variable performance, limits usage within 
the current assay design (Figure 3.5). However, the selected method for future assay 
design will be clonal expansion, based on the optimal CD59 surface antigen 
enrichment, 99.8 % (Figure 3.4) being significantly greater than the achieved FACS 
yields. Additional investigations into alternative methods for mutant depletion will 
continue, specifically FACS optimisation, to achieve higher assay sensitivity and 
consequently moving away from the known limitations associated with clonal 
expansion and extended cell culture.
3.4.3 Proof of Principle PIG-A  Assessment of TK6 cells Following 24 hr low  
dose Ethyl-methanesulfonate (EMS) Exposure
Following the establishment of a basic in vitro assay design within a human 
lymphoblastoid cellular platform (Section 2.10), coupled with a clonal expansion 
mutant depletion step (Section 3.2.2.2) the assay required initial validation in order 
to assess the direction of further progress and to critically analyse current 
performance to aid future assay refinement. Ethyl Methane Sulfonate was chosen for
121
the initial assay due to the wealth of dose response data utilising validated 
comparable in vitro gene mutation assays [31, 33, 211].
The first three days of analysis generated largely expected data (Section 3.3..3); 
relative cellular viability of the population dramatically decreased at the higher 
doses, following model mutagen exposure, allowing for cytostasis and recovery 
post-treatment. However, no significant change in PIG-A mutant frequency was 
detected (Figure 3.5), when compared to control values. The proposed reason for the 
initial decrease in viability is that following high dose exposure, a large proportion of 
the cells begin to undergo DNA damage and therefore, depending upon a number of 
biological factors, p53 status etc., are halted within the cell cycle and subsequently 
either begin to undergo recovery or alternatively controlled cellular death (apoptosis) 
[258]. Both mechanisms have a common lag period, comparable to cytostasis, in 
which no extracellular phenotypic variation occurs [259]. W hen measuring 
population cell number, techniques solely utilising cellular size descriptors, such as 
the Coulter Principle [260], can be misleading as their data is strictly limited to 
counting particle size. Such measures are unable to correctly identify intracellular or 
surface membrane alterations indicating loss of viability and therefore, can be miss- 
representative o f the overall condition of the population. More advanced 
methodologies such as Vi Cell Series ™ (Beckman Coulter, High Wycombe, UK ) 
as well as integrated flow cytometric viability dye assessment, coupled with counting 
beads [261], could generate much more accurate cellular viability data which more 
accurately describes the population.
The proposed reason for the lack of observed variation in PIG-A mutant frequency is 
based on the idea of mutation fixing as well as phenotypic lag. Assay platform, 
choice of cell line etc., defines a unique time period in which mutagenesis is 
unrepresented and therefore, extended assessment of mutagenesis is required prior to 
standard operating procedure (SOP) drafting. Mutation fixing is generally referred to 
as the amount o f time or number of DNA replications in order to facilitate a 
mutational event, for example, the incorporation of the mismatched base within the 
corresponding DNA strand following an adduct induced point mutation; until DNA 
replication occurs the adducted base has no influence [30]. Phenotypic lag, in the 
context o f the PIG-A  assay, is the period of time in which no measurable phenotypic 
change will occur following a fundamental genotypic alteration. This is best
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illustrated by the following example, suppose that a frame shift mutation within the 
promoter of a constituently expressed gene prevents transcription. However, prior to 
mutation, that specific gene product is present in abundance within the cytoplasm, as 
well as residual functional mRNA available for limited translation. Therefore, for a 
finite number o f generations the cells would continue to have functional proteins 
within the cytoplasm in sufficient quantities to preclude loss of function [262]. 
Assessing both the mutation fixing period as well as the phenotypic lag, the in vitro 
PIG-A assay appears to be insensitive to mutation until 72 hr post mutagenic 
exposure (Figure 3.5), inclusion of more accurate viability measure or cell cycle 
analysis may give an indication of DNA damage at an earlier time point [189].
For the purpose of initially assessing mutagenesis, four consecutive PIG-A  daily 
analyses were undertaken to account for potential mutant lag as well as wild type 
phenotype stability evaluation. 96 hr post mutagenic exposure, EMS generated a 
significant increase in the PIG-A mutant frequency (Figure 3.5) and the BMDio 
metric was comparable to that modelled at the H PRT  endpoint in lymphoblastoid cell 
line following EMS exposure [39, 263]. The day 4 PIG-A  data, as well as day 1, 
were not normally distributed, however, a LOAEL was defined using D unn’s but 
this was nearly 10 fold higher than the comparable statistic defined within AHH-1 
cells with the H PRT  endpoint [39]. Limitations within the dosing regimen must be 
taken into account and a more accurate statement would be the LOAEL was >5 
pg/mL. The assay appears to lack sensitivity at the lower doses, even though 
additional investigation will be required due to discrepancies between the cell lines, 
a critical flaw when considering the strengths of the comparable currently validated 
assays [87, 202, 218].
The current assay background, i.e. spontaneous mutant frequency at the PIG-A  gene 
locus, was 0.117% on Day 4 (Figure 3.5) which extrapolates into the detection of 
approximately 1,170 mutagenic events per 1 x 106 events scored (only 10,000 events 
captured within analysis). Current validated mutation assays, H PRT  for comparison, 
have an average background of 1-50 mutational events per 1 x 106 events scored 
[264] and as such are greatly more sensitive as X-linked reporter systems due to 
requiring lower increments in mutant induction to define statistical significance [75]. 
Therefore, assuming all X-linked genes have an approximate homogenous 
spontaneous mutant frequency, disregarding minor variation due to location and
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length, there is potential for subpopulations of events within the assay being 
incorrectly labelled as PIG-A mutants which do not actually contain a genotypic 
alteration within the PIG-A gene. The human GPI synthesis pathway consists of 
upwards o f 20 human genes [265] and therefore, even though unlikely, due to the 
autosomal nature of the genes involved, excluding PIG-A , potentially any of these 
genes could induce a mutant mimicking event if down regulated. This phenomenon 
was demonstrated recently with a PIG -T  mutation inducing the human PNH disease 
phenotype [146]. Alternatively, there are a number of additional potential causes of 
an observed elevated spontaneous mutant frequency; ineffective mutant purging 
within the wild type enrichment methodology, non-viable cells mimicking PIG-A 
mutant events, antibody marker binding efficiency or loss of marker conjugation and 
clonal expansion of pre-existing PIG-A mutants. Each of the listed potential sources 
o f error will be investigated in more detail within subsequent sections.
3.4.4 Long-Term Cryo-preservation Assessment on CD59 Phenotype Stability
In order to facilitate potential validation of the proposed in vitro PIG-A gene 
mutation assay design, the assay platform in this case pre-enriched TK6 cell culture, 
will need to be distributed amongst a number of genetic toxicology laboratories [166, 
167, 176]. Therefore, due to the variance observed within the yields of CD59 antigen 
expressing TK6 cells, following mutant depletion (Appendix Section 3.3.4, Table
3.1), one potential solution would be the distribution of a pre-enriched cell line as the 
supplied platform. To enable the established distribution of the bespoke cell line, 
cryopreservation will need to be applied; however, initial investigations into the 
effect said cryopreservation has on the PIG-A  phenotype will need to be evaluated 
prior to distribution. For this to be an appropriate solution, the preservation and 
subsequent awakening process cannot be demonstrated to increase the spontaneous 
background mutant frequency, to a point which would facilitate the need for an 
additional mutant depletion step. Additional preparative stages would increase the 
likelihood of genetic variation amongst testing populations as well as introducing a 
key element of variance within ensuing data analysis.
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The results of the long term storage assessment revealed that the routinely used 
cryopreservant DMSO generated the most reproducible results in terms of PIG-A 
mutant frequencies, with respect to stability over time, when compared to glycerol as 
well as 10% sucrose (Section 3.3.4). Glycerol another well-known cryopreservant 
[266] was shown not be a viable candidate when used in conjunction with TK6 cell 
lines; PIG-A mutant frequencies were observed to rise significantly as well as 
distinct decrease in cellular viability over time. Sucrose, often a key constituent 
when freeze drying bacterial cell cultures to preserve extracellular function [266], 
was observed to induce unprecedented levels of cytotoxicity (Appendix Section 
3.3.4, Table 3.2). This strictly deleterious effect was thought to be a direct result of 
the change in osmotic potential and the consequential decrease in turgor within the 
system [267]. Bacterial cells, either gram positive or gram-negative, have distinct 
cell wall structures governed by their peptidoglycan constitution which enables 
cellular resilience to changes in osmotic potential due to the exerted constraining 
force. Cellular integrity is further maintained through the interplay between the 
peptidoglycan cell wall and mechanosensitive (MS) channels that modulate turgor 
[268]. Animal cells, dissimilar from bacterial or plant cells, lack a cell wall structure 
surrounding the cellular membrane and therefore, are less able to tolerate hypertonic 
conditions; specific intracellular solute concentrations rise following an efflux of 
water from the cell via osmosis resulting in plasmolysis, cell shrinkage and eventual 
cell death [269]. Both increases and decreases within osmotic potential can exert 
fatal effects on animal cells, often associated with the movement of K+ ions 
triggering apoptosis [270]. However, even minor alterations within the 
microenvironment can induce cellular stress resulting in reduced viability within the 
cellular population following recovery after cryopreservation [271]; this can 
potentially result in an increased presence o f PIG-A mutant mimicking events and 
hence, decrease assay sensitivity.
The results of this investigation into cellular storage show that long term liquid 
nitrogen preservation o f pre-enriched TK6 cultures is a viable mechanism for mass 
distribution of cell stocks. However, one caveat which must be considered is the 
minor increase in putative PIG-A  mutant frequencies (Figure 3.7) following 
reawakening, as well as the corresponding decrease in cellular viability (recovery) 
(Appendix Section 3.3.4, Table 3.2) following the period of storage. Liquid nitrogen
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cryopreservation, if undertaken correctly, is known to have limited deleterious 
effects on viability, nevertheless still potentially inducing minor increments in 
spontaneous PIG-A mutant frequency and hence desensitising the assay. Further 
investigation into the mechanisms of presumptive mutant generation will need to be 
assessed to more accurately define the potential sensitivity issues as well as solutions 
to exclude such a putative population from subsequent analysis.
3.4.5 Introductory Investigations into Potential Non-viable, PIG -A  Mutant 
M imicking Events
Previous sections within this chapter, have described a number of possible problems 
attributed to the preliminary assay design which could be responsible for the lack of 
observed sensitivity (Sections 3.3.1 -  3.3.4). Features included; potential 
inaccuracies within the reporter mechanism, immunofluorescence staining 
inefficiencies, caveats associated with use of immortalised cell lines, questionable 
viability correlation, robustness and variation concerns. Initial investigations have 
suggested that the frequencies of observed GPI-AP negative events do not 
correspond to the estimated biologically defined spontaneous mutant frequency 
values within human granulocytes [175] and hence, the observed induction of PIG-A 
mutant post mutagenic treatment does not liken to currently validated assays [75]; 
even though the data is not directly comparable, similarities would be expected to be 
observed.
Currently, as there is no evidence, in vivo, to suggest either a positive or negative 
growth bias within the Pig-a mutant sub-population [147]. The current assay design 
would be expected to capture a proportional representation of the clonally expanding 
induced mutant sub-population. The clonal characteristic of the assay post mutagenic 
treatment, offers the beneficial advantage of modest detection of mutants at low 
levels following induced mutagenesis. However, the limited experimental period in 
combination with assay design was implemented to prevent bias during scoring of 
putative PIG-A  mutant events. Therefore, the validity of the early onset presence of
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un-expected high numbers of observed putative mutant events is further questioned 
(Section 3.3.3).
Viability of presumptive mutants was assessed utilising two commercial methods; 7- 
aminoactinomycin-D, a fluorescent intercalating agent which under goes a spectral, 
stokes, shift following association with DNA. 7-AAD is excluded from live cells, 
and therefore, can be utilised as an indicator of cellular membrane integrity as well 
as having limited application as a cell cycle indicating tool [272]. Annexin V Alexa
9 - i -Fluor 488, a calcium (Ca ) dependent phospholipid-binding protein that has high 
affinity for phosphatidyl serine (PS) and therefore, once conjugated to a fluorophore, 
in this case an Alexa Fluor 488 ™ is a sensitive tool for apoptosis detection and 
quantification [273]. Apoptosis is distinguishable by a number of characteristic 
morphological changes, including compaction and fragmentation of the nuclear 
chromatin, shrinkage of the cytoplasm and loss of membrane asymmetry [274]. In 
living cells, phosphatidyl serine (PS) is located on the inner surface of the plasma 
membrane and therefore, cannot be targeting by annexin V molecules. However, 
during apoptosis, PS is trans-located onto the outer surface of the cellular membrane, 
via micro-membrane inversions, thus exposing the PS to the external environment. 
W ithin leukocyte populations, PS is a recognised marker of apoptosis and is 
associated to phagocytosis inducing by macrophage molecules [275].
The results demonstrated that the levels of non-viable cells within the two isolated 
sub populations were fundamentally different. Apoptosis as well as cell death, loss 
of membrane integrity, were significantly higher within the assumed PIG-A mutant 
population than the equivalent wild type populations. During apoptosis the cell 
membrane has been observed to lose symmetry [276] and therefore, during this 
disorganised fluid-like phase potentially the lipid raft rich areas of GPI-associated 
proteins may lose their position upon the outer cellular membrane, causing in­
effective antibody association and hence, false PIG-A  mutant status. Therefore, due 
to the observed increase in cytotoxicity within the presumed PIG-A  mutant 
subpopulation, when compared to the homologous wild type population, both 
apoptosis as well as loss of cellular membrane integrity cannot be disregarded as 
potential mechanisms for the generation of subsequent false positive mutant event 
identification. Apoptosis levels still remained elevated for significant periods of time
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following the typical 30 minute window of identification utilising cell lines of this 
type.
W ith the intention of removing such ambiguity, within the resultant PIG-A  mutation 
data, viability dye inclusion will be an additional feature in future versions of the in 
vitro PIG-A  mutation assay. This development within the assay design potentially 
could increase assay sensitivity significantly, via the removal of ~ 20-50% of non- 
viable presumed PIG-A  mutant events, and subsequently greatly decreasing the 
spontaneous background mutant frequency.
The aim of this chapter was to endeavour to draft a preliminary standard operating 
procedure (SOP), following the identification of a realistic dose response, for a 
quantitative in vitro PIG-A gene mutation assay, comparable to currently validated 
mammalian cell genetic toxicology assays [75, 127, 200]. Initially, human 
lymphoblastoid TK6 cells were chosen as the cellular platform for the PIG-A assay, 
coupling this with phycoerythrin-conjugate CD59 antibodies, demonstrated to 
generate the most specific (non-Fc mediated interaction) and bright fluorescence 
signal post treatment, established a rudimental assay design (Section 2.10). W ith the 
intention of decreasing spontaneous mutant frequency, in line with comparable 
mammalian cell mutation assays, clonal expansion was deemed the most appropriate 
method for wild type enrichment (Section 3.3.2.2). This basic assay design was 
initially tested against acute 24 hr model mutagenic exposure in which EMS was 
demonstrated to induce a significant (P<0.05) increase in putative PIG-A mutant 
events on day 4 (96 hr) of analysis (Section 3.3.3). However, the assay was
observed to be less sensitive than previously predicted and additional techniques 
(Amnis Image Stream ™) were investigated in order to validate current findings, 
review potential limitations as well as potential assay transferability away from strict 
flow cytometric analysis (Appendix Sections 3.5.3.1 -  3.5.3.3). Further 
investigations into the presumptive PIG-A  mutant events alluded to poor viability 
within the subpopulation and additional phenotypic markers were introduced into the 
assay design, facilitating high content analysis (Section 3.3.4). Following 
implementation of enhancements to the assay design, the latest version of this in 
vitro PIG-A gene mutation assay was ready to undergo further investigations into 
potential quantitative dose response modelling.
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Chapter 4: Consideration of Cell Lines in the Further Development of an in 
vitro PIG -A  Gene Mutation Assay
4.1 Introduction
In the previous chapter, the preliminary experimentation established a basic in vitro 
PIG-A gene mutation assay design. The human lymphoblastoid TK6 cell line was 
used in combination with the reporting CD59 cellular surface marker, analogous to 
the in vivo Pig-a gene mutation assay, followed by flow cytometric high content, 
high-throughput and high-precision analysis. However, due to the varied level of 
CD59 expression within the parental TK6 cultures, a physical mutant depletion or 
wild type enrichment strategy was shown to be essential. In order to reduce pre­
existing spontaneous background phenotypic mutant frequencies at the PIG-A  gene 
locus enrichment optimisation was undertaken, and the resultant data demonstrated a 
sensitivity level suitable for qualitative dose response assessment (Section 3.3.2). 
However, further development and refinement is required prior to quantitative 
assessment, as initially predicted.
The initial proof of principle experiments demonstrated an increase in PIG-A  mutant 
frequency in TK6 cells, following model mutagen exposure (Section 3.3.3). 
However, assay sensitivity was shown to be lacking as indicated by the dose 
response metrics, NOGEL (5pg/mL) and LOGEL (lOpg/mL), being significantly 
higher than comparable data generated using a currently validated in vitro gene 
mutation assay [39]. The finalised background at the PIG-A  gene locus was 
established in the region of 0.1-0.2% presumptive phenotypic mutants, which was 
significantly higher (10-20 fold) than the TK  and/or H PRT  gene mutation assays [39, 
75, 264].
Continued review of the preliminary proof of principle experiments lead to further 
investigation into the identity and origins of presumptive PIG-A  mutant events. In 
addition to the potential limitations associated with inefficient mutant purging, 
within the enrichment methodology, potential alternative mechanisms other than 
mutagenesis were identified (Section 3.3.5). Flow cytometric investigation,
131
following immunofluorescence staining, for characteristic markers of apoptosis, 
necrosis and loss of membrane integrity demonstrated a significant sub-population of 
non-viable cells within the presumptive PIG-A  mutant population (Section 3.3.5). 
Therefore, the aim of the following results chapter is to i) further explore assay 
sensitivity issues, ii) provide initial validation o f cell line selection, iii) further 
mechanistic evaluation and iv) exploration into high content screening.
4.1.1 Selecting a Cell Line for use in Genetic Toxicology Applications
Genetic toxicology data are routinely used worldwide in regulatory decision making 
[220], such decision making is often undertaken by large agencies such as the Food 
and Drug Administration (FDA) or Environmental Protect Agency (EPA) and can be 
subdivided into two main categories i) the approval and restrictions of 
pharmaceuticals medical devices and medical use products (including cosmetics) and 
ii) the setting of standards for acceptable exposure levels in water, air and food 
(including pesticides etc.) [277]. Genetic toxicology data are used extensively in the 
hazard identification stage for both of these regulatory decisions and therefore, have 
a pronounced bearing on the outcome of said decisions.
However, advancements within understanding as well as modernisations within the 
field of genetic toxicology [212, 219, 263, 278] have begun to reform the methods in 
which genetic toxicology data are collected. As a direct result of these changes, 
regulatory guidance, which is utilised to provide direction and standardisation within 
the field, is also implementing reform to address how much confidence can be 
attributed to this data. For example, a modem weight of evidence (WOE) approach is 
currently being implemented within regulatory decision making to optimise usage of 
genetic toxicology data within risk assessment decision making and potential human 
health risk assessment [263, 277]. As a direct result o f advancements within the 
field, increasing pressure is now being attributed to gene tox assay design to ensure 
that the resultant data is not only complete, but offers extensive contextual depth and 
biological relevance [100, 187, 278]. Novel reforms are becoming more apparent 
with increasing amount of publications critically reviewing current gene tox data
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[112] and providing advice on limitations as well as re-direction within the field 
away from certain assay types [210]. A specific example of this would be recent 
publications summarising the currently available cell lines for use within genetic 
toxicology testing and their respective beneficial characteristics and/or limitations 
[113, 114,210].
Genetic toxicology testing, in the context of safety assessment, is limited by the cell 
type (platform) in which the test is under taken. The platform in which the system 
operates provides the specific characteristics which the test system utilises in order to 
define risk and hazard; as a direct result o f this many criticisms of test systems fall 
under the initial choice of tissue, cell line or host [208] .Traditionally a substantial 
amount of genetic toxicology data was generated using validated relatively high 
throughput, in vivo rodent gene tox assays often supplemented by inexpensive, often 
based on prokaryotic or rodent platforms, in vitro assays [67, 75, 102, 186, 202]. 
More recently, the latter test systems have been reviewed and shown to demonstrate 
high levels of false positivity and questionable human relevance within subsequent 
generated data [105, 112, 210]. Therefore, individually systems offer limited benefits 
outside of uncompromising sensitivity when reviewed in the context of regulatory 
decision based on a weight of evidence approach; however, still effective at hazard 
identification. As a consequence of this, certain assays have faded out of routine use 
and replaced by more appropriate, high throughput analogous human assay systems 
[279].
Even though the shift away from rodent based to standardised human cell line assay 
systems has removed specificity issues [115], the sheer genotypic variance 
demonstrated within the cell lines, even directly related cell lines, is somewhat 
imposing [75, 124, 127, 201]. However, governmental reforms and initiatives to 
further reduce animal testing within the pharmaceutical industry [85, 86, 203], as 
well as the potential insensitivity to detect genotoxic human carcinogens (-60%  of 
total carcinogens) within pre-existing assay systems, has led to further refinement of 
supplementary testing; in vitro human as well as novel alternative test systems have 
received increasing weight [87, 90, 94, 208]. Human immortalised cell lines as an 
assay platform have a number of caveats associated with routine use [105, 112, 210], 
however, when used in tandem or as part of a hierarchy or test barrage [72, 73] the
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resulting conclusions are effective and are an attractive test barrage representative of 
risk [112, 184].
Variance is an essential characteristic within cell lines routinely utilised in genetic 
toxicology due to the sheer diversity of applications which are explored within the 
field. No single cell line best represents the complexity and diversity observed within 
the human body. Therefore, to account for such natural variety as well as exposure 
mechanisms, a great assortment of representative cell lines, each with specific 
characteristics and traits, must be assayed [34, 73, 87, 89, 93, 94, 104, 108, 150] in 
order to identify those fit for purpose for use within a plethora of varying end point 
assay systems. However, this observation makes assessing data much more complex 
as regulators strive to quantify potential risk based on data collected from a plethora 
of assay systems.
Entirely preventing human exposure to harmful chemicals as well as having a single 
test system defining said risk is un-realistic. Therefore, in order to help facilitate a 
weight of evidence approach to regulatory decision making, increasing attention is 
being placed on explaining statistical analysis that enables derivation of comparable 
PoD metrics [100, 216]. Combining a potential quantitative metric for risk with more 
accuracy and confidence in in-vitro to in vivo data extrapolation, could provide the 
frame work for reformed human health risk assessment [88, 226].
4.1.2 Routinely used Human Lymphoblastoid Cell Lines within Genetic 
Toxicology
Human lymphoblastoid cell lines feature heavily within many validated genetic 
toxicology test systems [124, 126] and often share a number of perceived favourable 
characteristics; short cell cycle times, suspension growth dynamics and well- 
representative of human tissue [113] However, even though morphologically similar, 
some sharing common ancestral derivation [200], many subtle variations are present 
which are often overlooked. For example, TP53 status, cell cycle regulation, 
sensitivity to induced apoptosis and DNA repair are a number of features which are
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well categorised, nevertheless, vary substantially between routinely used cell lines 
[124, 126, 127, 182, 200]. These disparities between analogous cell lines, for 
example p53 status, also appear to be diverse between different sources and hence, 
discrete laboratory assessment is required for individual assessment of practise [124, 
126]. Additional features such as metabolism, cellular receptor expression and 
internalisation, immune cell activation status etc. all contribute as selection criteria 
when deciding upon a cell line for use in human health risk assessment.
W ithin the human lymphoblastoid cell line category there are three cell lines which 
are utilised extensively within the field of genetic toxicology research, TK6, AHH-1 
and MCL-5 cells. TK6 are human B-lymphoblastoid cells, originally derived from 
the WIL-2 cell line, isolated from a 5 year old male suffering from hereditary 
spherocytosis [197]. AHH-1 cells are again human B-lymphoblastoid in nature, 
display high oxidative properties and were isolated from a 33 year old male [199] 
and finally, MCL-5 cells were reportedly derived directly from the AHH-1 cell 
lineage [200]. Collectively, these cell lines constitute the majority of currently 
available in vitro human genetic toxicology data generated in Swansea University 
and will no doubt have continued usage within safety assessment for the near future.
Indistinguishable usage of the fore mentioned human lymphoblastoid cell lines 
within a number of different gene tox end points, for example gene mutation or 
micronucleus assessment, can lead to potential misuse. Each cell line has comparable 
however, unique characteristics which promote optimum use within a specific 
application. The following example illustrates the need for holistic profiling of cell 
lines prior to use in order to provide accurate quantitative assessment. Firstly, TK6 
are heterozygous at the TK  and hemizygous at the H PRT  loci and are sensitive to 
trifluorothymidine (TFT) and 6-thioguanine (6-TG) making them a useful cell line 
for quantitatively detecting mutation as either H PRT  or TK  gene loci [73]. AHH-1 
cells equally are heterozygous at the TK and hemizygous at the H PRT  gene loci and 
therefore, can also be implemented in either the H PRT  or TK  assays. However, what 
distinguishes the two cell lines is AHH-1’s increased oxidative activity, primary 
metabolism (primarily CYP1A1), and can be used within mutagenesis assays for 
substances requiring basic metabolism; AHH-1 are more sensitive to B[a]P exposure 
and other metabolically activated substances [28]. Therefore, when selecting a cell 
line for usage within a particular application, not only are the physical properties
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such as morphology etc. required to be considered, more in-depth analysis of the 
intrinsic properties of the cell line is also required; accurate, precise safety 
assessment is entirely dependent upon the appropriateness and exactness of the 
genetox data. S9 can also be utilised in combination with non-metabolically active 
cell lines to provide some level of metabolism in vitro.
4.1.3 Complexity of Human Cell Lines and their Applications in Genetic 
Toxicology
W ithin the design of this in vitro PIG-A assay, human lymphoblastoid cell lines were 
chosen as the m ost appropriate cell type for many of the same reasons why they 
feature so heavily within the genetic toxicology field [113], as outlined above. 
However, there are a number of specific features which led to the selection over 
analogous lung epithelial (point of contact) [132] as well as metabolically active 
liver cell lines, such as HepG2 [201]. One of the beneficial features within the in 
vivo Pig-a assay which provides a distinctive edge over comparable end points 
would be the un-invasive sample harvesting [77, 166]; similar genetic damage end 
points such as comet [91, 104] require termination in order for tissue harvesting. 
Retaining the origins of the cell line within haemopoetic tissue, maintains the 
advantageous feature, and potentially enables the direct transfer of the assay design 
into primary hum an samples [143, 280]. The suspension nature of the cell line 
facilitates more favourable sample processing with regards to centrifugation and 
predicted trypsin sensitivity of the GPI-AP surface markers [281]. Additionally, the 
hum an origins and nucleated status of the cell line provides both a method for 
mechanistic validation and successive human relevant gene tox data [115, 144, 173, 
222]. Despite the fact that the selection of the parental cell lineage was decisive, the 
specific cell line chosen for the assay had to conform to a number of more particular 
features which were not so absolute.
DNA repair and p53 functionality are two of the features which have larger 
implications on the downstream generated data [22, 39, 45, 48, 51, 118, 264, 282].
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The results of the initial EMS exposure demonstrated insensitivity and hence a 
consequential inability for quantitative dose response analysis and therefore, 
highlighted the necessity of further in-depth investigation; not only to assay design, 
but also to the cellular platform chosen for the assay. DNA can be thought of as a 
substance which is constantly being subjected to assault and sequential repair, and 
thus if damage is not adequately repaired deleterious consequences in the form of 
mutations and chromosome aberrations can occur often leading to disease 
phenotypes [14]. DNA repair is therefore, a fundamental mechanism which 
maintains a homeostatic control over genomic stability [51]; at times of excess 
environmental exposure, DNA repair mechanisms are believed to become saturated 
and the rate of DNA damage increases [283]. Organisms have therefore, evolved a 
complex system of DNA damage repair mechanisms, some associated to p53 status, 
able to firstly detect as well as either repair or remove such lesions [32, 37, 44, 45, 
51, 284, 285]. DNA repair deficient cell lines have been demonstrated to be 
selectively sensitive to specific compound exposures; sensitivity is heavily 
dependent upon the mechanism of action (MOA) and corresponding deficient DNA 
repair mechanism [286]. Subsequently, DNA repair deficient cell types generate 
dose responses with more linear characteristics and subsequently defined PoD dose 
metrics are observed to be more conservative in nature [264]. If a cell line is 
deficient in p53, either heterozygous or homozygous loss-of-function mutations in 
the p53 tum our suppressor gene, an altered response to DNA-damaging agents is 
observed when compared to wild type cells. Included in the mutant p53 phenotype 
are the loss of the Gi/S checkpoint, due to a lack of p21 up-regulation, subsequent 
delayed apoptotic cell death and over sensitivity to genotoxic exposure due to the 
lack of p53 mediated repair; characteristics which have been consistently observed in 
the AHH-1 and TK+/" cell line following exposure to DNA damaging agents [124, 
126].
Human B-lymphoblastoid cell lines have been repeatedly demonstrated to be 
variable at the p53 locus in terms of activity as well as functionality [124, 126, 182]. 
Therefore, prior to preparation of an advanced in vitro standard operating procedure 
(SOP), attaining to quantitative dose response modelling, further consideration of the 
implications such specific features brought was required to be assessed. To further 
emphasise the complexities associated with human cell line usage, the following
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example describes the differences in resultant sensitivity to mutation at specific gene 
loci between two closely related cell lines. MCL-5 cells which were established from 
human lymphoblastoid (AHH-1) TK+/ cells, expressing human cytochrome p450 
CYP1A1 and transfected with two additional separate plasmids containing cDNAs 
of human cytochrome P450s (CYP1A2, CYP2A6, CYP2E1, and CYP3A4) and 
microsomal epoxide hydrolase [200], and therefore, should be more sensitive as 
reporters for mutation for compounds requiring metabolic activation than 
comparable cell lines demonstrating limited metabolism. However, the AHH-1 cell 
line has been demonstrated to exhibit increased sensitivity at the TK  gene loci to 
mutagenic exposure, when directly compared to the daughter MCL-5 cell line. 
Following N-nitrosodimethylamine (NDMA) exposure, the induced mutant 
frequency at the TK  gene loci was shown to be 5 x fold higher in AHH-1 cells than 
MCL-5 [127]. This result would appear to contradict the reasons for the derivation of 
the MCL-5 cell line; providing a superior metabolically active cell line for the use of 
genetox testing applications [200]. This observation was defined to be the result of 
AHH-1’s insensitivity to apoptosis when compared to MCL-5 cells; AHH-1 are 
heterozygous p53 mutants, whereas MCL-5 are homozygous p53 wild type [126, 
127, 182]. Thus the functionality defined by the wild type p53 gene status, facilitates 
a higher frequency of apoptosis in MCL-5 cells post loss of heterozygosity (LOH) 
mutations at the TK  gene loci. AHH-1 cells have a lower frequency of DNA damage 
induced apoptosis and therefore, have a higher recovery of TK7' mutants post LOH 
mutation [127, 182]. Specific features such as metabolic activity, p53 status, 
morphology and DNA repair individually define the application in which a cell line 
can be utilised.
P53 status is a known factor which must be considered when discussing the strength 
o f gene-tox data. p53 deficient cell lines have been showed to have an increased 
sensitivity in MN induction and less of an active G l/S  phase checkpoint following 
genotoxic exposure. Thus impaired p53 functionality is believed to sensitise cells to 
genotoxicants due to its essential role in the DNA damage response [287]. This 
understanding has clear importance for safety assessment of genotoxicity and further 
demonstrates how crucial p53 functionality is [117, 119, 120, 123, 124]. However, 
these features which truly defines the precision and subsequently the usefulness of 
the generated data [210].
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4.1.4 Genetic Profiling of the Cell Lines and the Assessment of the Applied 
M olecular Techniques
Protein quantification via western blotting analysis is a fundamental technique 
extensively utilised in molecular biology; by using western blot the relative presence 
of an unknown quantity of target protein macromolecules can be identified from 
within a heterogeneous mixture [288]. In brief, the entire nuclear or cytoplasmic 
protein fraction, or both, is extracted from the cell or tissue of interest. Following 
extraction, the protein mixture is denatured and separated by size via the use of a 
resolving gel, often acrylamide based gels are utilised. Transfer onto a solid support 
is implemented to facilitate stable immunocytochemical staining for the target 
protein; primary antibody raised against the protein of interest, coupled with a 
reporter secondary antibody matching the species of host organism in which the 
primary was raised. If the protein of interest is present, depending upon the detection 
method, often horse radish peroxidase (HRP) or fluorophore conjugated based 
systems are used as a detection method; a notable emission will be detected.
However, there are a number of limitations to the subsequent data; initially protein 
quantification is generally considered semi-quantitative at best, and not an absolute 
measure o f quantity [288]. Variations in loading and transfer rates between the 
samples in separate lanes, as well as separate blots, prevent direct comparison of 
data. These differences are corrected for via the standardization of assay protocol; 
however, the current technique lacks absolute reproducibility even though it is 
sufficiently robust. Additionally, the signal generated by detection is not linear 
across the concentration range of samples. Advancements within the technique have 
seen the incorporation of fluorophore conjugate secondary antibodies coupled with 
laser excitation and subsequent emission detection. This more m odem  approach to 
western blotting still utilises the analogous preparation steps in which certainty of 
transfer bias cannot be assured and therefore, offers marginal improvements in the 
relationship between detection and quantitation; however, additional 
spectrophotometry or colorimetric methods are available [289].
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Real Time - Quantitative Polymerase Chain Reaction (qRT-PCR) measures PCR 
product accumulation over excess cycles through quantifiable increments within 
fluorescence emission. This method provides precise and reproducible quantitation 
of gene copies and does not require post-PCR sample handling, preventing PCR 
product contamination and results in a much faster and higher throughput assay 
(290). There are two frequently reference methodologies which are commercially 
available; TaqMan ™ and SYBR® Green, each operating via comparable yet unique 
methods (Figure 4.1).
TAQMAN' PROBE-BASED ASSAY CHEMISTRY SYBR' GREEN 1 DYE ASSAY CHEMISTRY
1. Polym erization: A fluorescent reporter IF;' dye 3rd 3 quencher 
IQ> are attached to the 5' and 3' ends of a TaqMan* probe,
1. R eaction setup: The SYBR* Green 1 Dye fluzresces when bound 
to double-stranded DNA.
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Figure 4.1. Representative methodologies for quantitative real time PCR assessment 
utilising both the TaqMan Probe ™ and SYBR® Green nucleic acid dye systems. 
Both methods share equivalent analysis equipment and are distinguished by the use 
o f a fluorogenic TaqMan probe ™ providing assay refinement [291].
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The science behind the reporter system distinguishes the two methodologies; 
SYBR® Green nucleic acid dye is an intercalating agent which binds dsDNA and 
subsequently fluoresces in response to a net increase in PCR product. Whereas, the 
use o f a fluorogenic TaqMan probe ™ provides reproducible increased assay 
sensitivity, lower detection limits, multiplexing opportunities and a greater number 
of applicable downstream applications [291]. Real time detection systems were seen 
to improve following the introduction of fluorogenic-labelled probes that use the 5' 
nuclease activity of Taq DNA polymerase. The availability o f these probes, such as 
Taqman, enabled the development of a real-time method for detecting only specific 
amplification products, however, the limited supply dramatically increase the costs 
and limits the number of applications which can benefit without the initial capital.
W ithin this chapter of work the quantitative PCR analysis was carried out utilising 
the SYBR® Green system, as described in Figure 4.1. However, the SYBR® 
detection system is known to generate potential false positive signals [291]; SYBR® 
dyes binds to any double-stranded DNA, therefore, they are able to bind to 
nonspecific double-stranded DNA sequences. As a result o f this, it is imperative to 
have well-designed primers that do not amplify non-target sequences, and that melt 
curve analysis is performed within each run. An additional aspect of using DNA 
binding dyes is that multiple dye molecules can potentially bind to a single amplified 
DNA molecule; multiple dye binding defines the signal strength to be dependent 
upon the mass o f double-stranded DNA produced in the reaction. Thus, if the 
amplification efficiencies are the same, amplification of an elongated product will 
generate a greater signal than a diminutive one. This is in contrast to the use of a 
fluorogenic probe, in which a single fluorophore is released from quenching for each 
amplified molecule synthesized, regardless of its length and hence has increased 
quantitative properties.
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4.2 Material and Methods
W ithin the following chapter, two different TK6 cellular cultures were utilised; the 
higher passage referred throughout as “Normal” and the lower referred to as “Low 
Passage”, their unique derivation and origins can be found within (Section 2.1.2). 
Initially, the Low Passage TK6 cells were assessed for their ability to be 
incorporated into the in vitro PIG-A assay design along with a corresponding change 
in phenotypic mutant frequency reporting GPI-AP. General cell line viability was 
investigated as well as FACS optimised to produce sufficiently wild type enriched, 
CD55 positive, Low Passage TK6 populations. Assay sensitivity was subsequently 
assessed, following model mutagen exposure, and resultantly additional 
lymphoblastoid cell line and reporting GPI-AP combinations were investigated. 
Validation of selected lymphoblastoid cell lines, focusing on p-53, p-p53 and p21 
status as well as their functional induction following genotoxin exposure followed to 
further develop the assay design.
4.2.1 GPI-AP Expression Assessment within “Low Passage” TK6 Cells
A vial of “Low Passage” TK6 cells were established and maintained as outlined 
within (Section 2.2). Each experimental sample (1 x 106 cells), CD59 (Protectin) 
followed by CD55 (Decay Accelerating Factor), was run in triplicate in conjugation 
with a homologous instrument calibration standard (ICS); cellular cultures were 
treated with either anti-CD59 R-PE antibody or anti-CD55 R-PE (Cat No. 555694, 
BD Biosciences, Hertfordshire, UK) in a comparable manner as outlined (Section
2.8.1). Post incubation, samples were washed, and re-suspended in 1 mL of lx  PBS 
solution, maintained on ice and protected from light, prior to flow cytometric 
analysis.
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4.2.2 CD55 Antigen Optimisation using Fluorescence Activated Cell Sorting
(FACS)
4.2.2.1 Initial Aseptic Sort Evaluation
“Low Passage” TK6 cell cultures were established as outlined in (Section 2.2), 
counted and aliquots equivalent to lx lO 6 cells were transferred into fresh 15 mL 
centrifuge tubes, the parental culture were placed back into incubation. Cellular 
samples were treated with anti-CD55-PE fluorescently labelled antibodies (Section
2.8.1) and analysed on the flow cytometer (Section 2.8.2).
The BD FACS Aria flow cytometer was started up following the procedure outlined 
(Section 2.8), once satisfied with the prerequisite system calibrations, sorting was 
commenced and the recovered presumed homogeneous cells pooled and collected 
within 5 mL polystyrene (12 x 75mm) sorting tubes (BD. Biosciences, Hertfordshire, 
UK) with fresh cell line specific growth medium (1 mL) and consecutively sub­
cultured (Section 2.2.3) within 25 cm2 culture flasks prior to potential long term 
cryopreservation (Section 2.3). Quality assurance (QA) FCM based PIG-A 
phenotype assessment was carried out prior to and 72-96 hr. following enrichment.
4.2.2.2 Preliminary FACS Sample Collection and Volume Asessment
“Low Passage” TK6 cell cultures were established as outlined in (Section 2.2), 
cellular samples, except the ICS, were treated with anti-CD55-PE fluorescently 
labelled antibodies (Section 2.8.1), washed and re-suspended in 1 mL of pre-cooled 
culture media prior to storage on ice, and protected from light. Samples were stored 
for a maximum of 1 hr prior to analysis on the flow cytometer (Section 2.8.2). The 
FACS Aria I was set up and operated in a homologous method to the one outlined in 
the previous optimisation experiment, however, within this experiment the drop 
distance as well as sample collection volume and viscosity were assessed for their 
individual effects on cellular viability post sorting. Eight unique collection tubes
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were prepared for the experiment; a variety of collection media volume (drop 
distance) and constituents (viscosity and protein content) were assessed.
1) 15 mL BD Falcon tube -  containing 10 mL o f Heat inactivated serum (HiS)
2) 15 mL BD Falcon tube -  containing 5 mL o f HIS
3) 15 mL BD Falcon tube -  containing 5 mL o f RPMI 1640 culture media
4) 5 mL Flow tube -  3 mL HiS
5) 5 mL Flow tube -  3 mL Culture media
6) 5 mL Flow tube -  1 mL Culture media
7) 5 mL Flow tube - 0.5 mL HiS)
10-20,000 events (time dependent) were collected within each tube and immediately 
the recovery was assessed for CD55 antigen presence. Post sorting elongated 
recovery and subsequent extended viability was not directly assessed.
4.2.2.3 FACS, Refinement for Optimum Cellular Recovery
“Low Passage” TK6 cell cultures were established, as well as the BD FACS Aria I
started up, and stained in an analogous method to the previous experiment outlined
in (Section 4.2.2.2), however, within this experiment the finer refinements made to 
the collection volum e were assessed for their individual effects on cellular viability 
post sorting. Nine unique collection tubes were prepared for the experiment; three 
separate collection media volumes were assessed in triplicate for potential subtle 
effects associated with marginally different drop distances.
1) 3 x 5  mL Flow tubes -  containing 3 mL of RPM I 1640 media
2) 3 x 5  mL Flow tubes -  containing 1 mL of RPMI 1640 media
3) 3 x 5  mL Flow tubes -  containing 0.2 mL o f RPM I 1640 media
Each initial experimental sample will be analysed in triplicate to generate some 
indication of intra-sample variance within the FACS Aria I platform.
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4.2.3 “Low Passage” TK6 Viability
4.2.3.1 Viability Data for “Low Passage” CD55 enriched TK6 cells
A vial o f CD55 enriched “Low Passage” TK6 cells were established and maintained 
as outlined within (Section 2.2). Three tubes were utilised for sample viability 
assessment, the fourth was an ICS used to set detector voltages and initial population 
gating. Cultures were treated with anti-CD55 PE antibody, in an analogous manner 
to the protocols defined in (Section 4.2.2.2 -  4.2.2.3). Post incubation, cultures were 
washed and re-suspended in 5 mL of 1 X annexin-binding buffer. Binding buffer was 
supplied at 10X concentration and therefore, required a 1 in 10 dilution in dH20 prior 
to usage. Cultures were centrifuged (250 x g for 7 min), supernatant aspirated and re­
suspended in an additional 100 pL  o f 1 X annexin binding buffer. 5 pL  of Alexa 
Fluor® 488 annexin V was added to each culture, excluding the ICS and incubated 
for 20 mins. Post incubation, excess 1 X annexin binding buffer was added, cultures 
centrifuged, supernatant aspirated and re-suspended in 200 pL  of annexin binding 
buffer. 5 pi (0.25 pg) per test (per million cells) o f 7-AAD was added, mixed 
thoroughly and incubated for 5 minutes, protected from light, on ice. Samples were 
maintained on ice protected from light for a maximum of 4 hr prior to analysis. The 
pre-defined compensation matrix (Section 2.8.2.1) was entered into the flow 
cytometry template to prevent potential signal overlap, especially between the Alexa 
Fluor 488® and PE conjugated antibodies; due to the relative proximity of the 
“FITC” and “PE” detectors on the electromagnetic spectrum.
4.2.4 “Low Passage” TK6 preliminary PIG -A  Assessment Utilising the CD55 
Surface Antigen following Exposure to a Model M utagen
“Low Passage” TK6 cell cultures were established and maintained as outlined in 
(Section 2.2) and exposed to EMS for 24 hr under standard chemical treatment as 
described within (Section 2.4.2). Post chemical exposure, cultures were washed,
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counted and seeded ready for initial flow cytometric analysis using anti-human 
CD55 PE conjugate, Alexa Fluor 488® Annexin V and 7-AAD (Section 4.2.3.1). 
Flow cytometric analysis as defined in (Section 2.8) was undertaken within an hour 
of sample preparation, samples were stored on ice, protected from direct light, until 
analysed.
After gating for single cells on a SSC/FSC dot plot and/or counter map, a minimum 
of 10,000 events were analysed for the surface expression of the CD55 surface 
antigen. PIG-A  phenotype was assessed utilising an instrument calibration standard 
(ICS), an unstained sample used to set voltages and mutant gating. During ICS 
analysis, the mutant mimicking sample is utilised to detect auto fluorescence within 
the channel of collection in order to distinguish between a positive event and 
background noise at the channel’s photon multiplier tube (PMT).
EMS dose response data were produced using a FACS Aria I cell-sorter (Section 2.8), 
all fluorescence measurements on the FACSAria were recorded using the “area” 
parameter; annexin V, Alexa Fluor® 488, R-PE and 7-AAD were assessed within 
the pre-specified “FITC”, “PE” and “APC” detectors. FITC, 502LP combined with a 
530/30 band pass filter, PE, 556 LP combined with a 585/42 band pass filter and 
APC, no LP combined with a 660/20 band pass filter. Alexa Fluor 488® and PE 
were excited off the 488nm laser line, and the 7-ADD off the 635 nm laser line, best 
matching their excitation maxima’s.
Following flow cytometric analysis, parental cell cultures were removed from 
incubation every 24 hr for repeated PIG-A  mutagenesis assessment as described in 
an analogous method (Section 2.10).
4.2.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
Fresh vials of low passage number human lymphoblastoid TK6, “Low Passage” 
TK6, MCL-5 and AHH-1 cells were removed from cryopreservation, thawed quickly 
and cultured under standard conditions (Section 2.2). HepG2 required a longer 
growth establishment period and were more sensitive to physical agitation and 
therefore, approximately a week prior to experimentation a fresh vial of HepG2 cells 
were thawed (Section 2.1.5). Samples were prepared and stained in a homologous
146
manner to (Appendix Section 4.2.5) in order to generate comparable metrics for 
FLAER, CD48 and CD55/59 tandem treatment for their relative receptor presence. 
However, due to the adherent nature of the liver immortalised cell line (HepG2), 
different cell line maintenance as well as harvesting protocols were utilised, prior to 
staining, as outlined below.
A fresh vial of HepG2 was removed from liquid nitrogen storage and placed within a 
pre-warmed 37 °C water bath. Once thawed, the contents of the vial were transferred 
to a sterile 25 cm2 culture flask and minimal culture media (Section 2.2) added in 
order to cover the base of the flask and placed within the temperature controlled 
incubator. Routinely, every 12-24 hr the flask was carefully removed, to prevent 
cessation of growth, and microscopically examined for growth. HepG2 cells should 
grow to a uniform monolayer of cells, cells should be passaged to prevent over 
confluency as well as culture medium replaced regularly to aid optimum growth 
dynamic and prevent disruption of the monolayer.
The cells were maintained and sub-cultured as outlined in (Section 2.2.3.2), 
following this, the cells were centrifuged, supernatant aspirated and re-suspended in 
10 m L of fresh culture medium before being counted (Section 2.2.1) and treated with 
the allotted florescence dyes prior to flow cytometric analysis.
All cell lines were monitored regularly, assessed microscopically for signs of 
infection or morphological abnormalities, and sub-cultured once prior to the 
experimental start date to ensure correct growth dynamics.
4.2.5.1 W estern Blotting —Sodium Dodecyl Sulphate -  Poly-Acrylamide Gel 
Electrophoresis (SDS-PAGE)
4.2.5.1.1 Total Protein Extraction
Total protein extractions were undertaken within a class 2 safety cabinet, in a 
temperature controlled environment 2-4 °C, in order to prevent high levels of 
protease enzymatic activity. All centrifugation steps were carried out at 2-4 °C
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within a temperature-controlled Eppendorf 581 OR centrifuge. Cell cultures were 
established as described in (Section 2.2), washed and counted in preparation for the 
protein extraction protocol. The equivalent volume of culture medium to 4-8 x 106 
cells was transferred into a 50 mL centrifuge tube, spun down (-250  x g for 7 min) 
and supernatant aspirated. 5 mL of pre-cooled, 2-4°C, cold pH 7.4 PBS was added to 
the cell pellets, pellets were re-suspended thoroughly, centrifuged and the resultant 
supernatant was discarded. This step was repeated an additional time to ensure 
absence of growth medium. Cellular pellets were re-suspended in 200 pL Radio- 
Immunoprecipitation Assay (RIPA buffer) (R0278, Sigma Aldrich, Gillingham, UK) 
supplemented with 2.5 pL  of (500x) protease inhibitor cocktail (Cat No. ab65621, 
Abeam, Cambridge, UK) and transferred into pre-cooled 1.5 mL micro-centrifuge 
Eppendorf tubes. Post transfer, each culture was incubated for 5 min at 4 °C prior to 
high speed vortexing, confirming cellular lysis. The lysate was centrifuged (10,000 x 
g for 10 min), and the supernatant transferred into new sterile 2 mL Eppendorf tubes. 
The contents o f each tube, a mixture of both cytoplasmic and nuclear protein, was 
labelled accordingly , three 5 pL  aliquots were removed for protein quantification 
and stored at -80 °C until future use.
4.2.5.1.2 Activ M otif Nuclear and Cytoplasmic Protein Extraction
Refined protein extraction was undertaken with the use of the Active M otif Nuclear 
Extract Kit (Cat. No. 40010, Active Motif, La Hulpe, Belgium) all kit components 
were stored at 2-4 °C upon arrival and protected from direct light. Cell cultures were 
establish as outlined in (Section 2.2), counted and washed (Section 2.2.3.1) prior to 
protein extraction protocol, which can be found in (Appendix Section 4.2.5.1.2). In 
brief; firstly, a number of additional solutions were also required to be constructed 
prior to lysis, following this, cellular cultures were treated with phosphatase 
inhibitors, hypotonically lysed and then exposed to detergent. Following incubation, 
cytoplasmic fraction was collected prior to an additional lysis stage, vortexing and 
the collection of the nuclear fraction. All fractions were aliquotted to enable protein 
quantification and stored at -80 °C for long term use.
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4.2.5.1.3 Protein Quantification
All protein quantification within this body o f  work was carried out using the DC ™ 
Protein Assay Kit 1 (Cat No. 500-01111, Bio-Rad, Hertfordshire, UK) and followed 
as outlined within the supplied manufactures protocol (Appendix Section 4.2.5.1.3). 
In brief, bovine serum albumin (BSA) standards were constructed, and with the 
experimental samples loaded in triplicate to the designated 96 well plate (Appendix 
Section 4.2.5.1.3.2). Reagent A and S were mixed and subsequently pipetted onto 
the samples within the plate, followed by the addition of reagent B, and left to 
incubate. Post incubation, protein quantification was undertaken on the FLUOstar 
Omega spectrophotometer (BMG Labtech, Ortenberg, Germany) at 750 nm 
(Appendix Section 4.2.5.1.3.3)
4.2.5.1.4 Western Blotting Buffer Solution Preparations
Prior to the undertaking of any W estern Blott analysis, a combination of long term 
(up to one month storage) and short term buffer solutions (maximum of one week 
storage) were required to be constructed (Appendix Section 4.2.5.1.4.1). Short term 
buffer solutions were made up fresh on the day of experimentation, and used 
immediately (Appendix Section 4.2.5.1.4.2).
4.2.5.1.5 Polyacrylamide Gel Preparation
All western blot analysis was carried out following the procedures outlined in 
(Appendix Section 4.2.5.1), the gels constructed for this body of work were 
polyacrylamide based and the constituent components of each gel were purchased 
and stored according to manufactures guidance (Appendix Section 4.2.5.1.5). The 
addition o f TEMED in combination with Polyacrylamide forms a gel matrix suitable 
for the resolution of macromolecules; percentage composition polyacrylamide 
governs the lattice structure, in conjunction with detergent treatment facilitates a 2- 
dimensional linear separation of proteins. The percentage composition of resolving
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gel was based directly upon the molecular weight of the protein under assay; large 
proteins required lower acrylamide composition. Preparation of gels was undertaken 
in an AFA1000 fume hood due to the hazardous nature of the chemicals used.
4.2.5.1.6 Gel Casting and Electrode Assembly
All western blott apparatus used within this project was purchased from Bio-Rad, 
prior to casting, all plates, spacers, combs and casting stands were washed 
thoroughly allowed to air dry, facilitating correct set up alignment (Appendix 
Section 4.2.5.1.6). In brief; the desired resolving gel was prepared and then applied 
directly to the apparatus, isopropanol, (Cat No. 190764, Sigma Aldrich, Gillingham, 
UK) was applied across the top of the gel and incubated. Post hardening, isopropanol 
was discarded and the stacking gel was applied directly onto of the resolving gel, in 
an analogous method. Following a final assessment for alignment and potential 
retarding bubble formation, the set up was further incubated (Appendix Section
4.2.5.1.6).
Post hardening and gel melding the plate assembly was removed from the casting 
stand, and transferred into a vertical electrophoresis system (Appendix Section
4.2.5.1.6). Protein samples were denatured, loaded along with protein standards and 
the apparatus filled with buffer to enable running. The lid of the electrophoresis 
system was placed onto the chamber, connected and ran. W hen the dye front had 
migrated to within an inch of the base of the gel, the power pack was disconnected 
and the running buffer removed and discarded.
4.2.5.1.7 Protein Transfer
Protein transfer during this thesis project was carried out using the Mini Trans-Blot® 
Electrophoretic Transfer Cell kit contents (Cat. No. 170-3930, Bi-Rad, Hertfordshire, 
UK), operated according to manufacturer’s supplied guidance (Appendix Section
4.2.5.1.7) Unless otherwise stated, all apparatus was supplied within the kit and used 
in conjunction with buffers prepared according to (Appendix Section 4.2.5.1.4).
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In brief; immuno-Blot PVDF membranes (Bio-Rad, Hertfordshire, UK) were 
temporarily dehydrated in 100% methanol, and re-hydrated along with fibre pads and 
thick blott papers in pre-cooled 4 °C transfer buffer (Appendix Section 4.2.5.1.7). 
Post hydration, transfer cassettes were constructed and placed within a Transfer cell, 
cooling unit added and filled with cold transfer buffer. The whole apparatus was 
placed within a polystyrene container filled with ice and moved into the cold room to 
maintain a constant 2-4°C environment. A power pack was attached to the transfer 
cell and ran. Post transfer, the cassette was removed from the transfer cell and the 
membrane was submerged in pre-cooled (2-4 °C) wash buffer (Appendix Section
4.2.5.1.4.2), agitated and cut to correct size.
4.2.5.1.8 M embrane Blocking and Antibody Incubation
Membrane/s were blocked overnight (approximately 8-12 hr) in BSA to prevent non­
specific antibody binding, washed and exposed to primary antibodies within 
blocking buffer. Post treatment, membrane/s were washed several times and 
sequentially incubated in corresponding horse radish peroxidase (HRP)-conjugated 
secondary antibody solution. Post incubation, membranes were washed and analysed 
on the ChemiDoc ™ XRS (Bio-Rad, Hertfordshire, UK), Quantity One (Bio-Rad, 
Hertfordshire, UK) software. Full details described within (Appendix Section
4.2.5.1.8).
4.2.5.1.9 Protein Detection -  ChemiDoc ™  XRS
4.2.5.1.9.1 Protein o f Interest Detection
Protein detection was under taken using the Clarity W estern ECL substrate (Cat No. 
170-5060, Bio-Rad, Hertfordshire, UK) chemilluminescence kit, stored and operated 
as per manufacturers supplied instructions (Appendix Section 4.2.5.1.9.1). Post 
washing, the membrane/s were removed and placed onto the pre-cleaned
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ChemiDoc™  surface, and positioned correctly. The visualising agent was applied 
liberally and visualised according (Appendix Section 4.2.1.5.10). Post probing for 
the protein of interest, the membranes were washed, stripped and treated with the 
anti-house keeper antibody (Appendix Section 4.2.5.1.9.2). The visualisation 
procedure was repeated and data analysed (Appendix Section 4.2.1.5.10).
4.2.5.1.10 Protein Quantification -  Quantity One Software
All protein band detection and estimated quantification were retrospectively 
undertaken using the Quantity One -  Advanced software purchased from Bio-Rad, 
Hertfordshire, UK. Briefly; the relative band intensities were initially standardised 
against the background, following this, each sample band was normalised against the 
corresponding house keeper band, averaged against experimental replicates and 
divided against the con-current negative control generating the average relative fold 
increase in band intensity when compared to un-treated controls (Appendix Section 
4.2.5.1.10).
4.2.5.2 Qualitative Real Time -  Polymerase Chain Reaction Protocol
4.2.5.2.1 Ribonucleic Acid (RNA) Extraction
Total RNA was extracted from the human lymphoblastoid cell lines using the 
Qiagen RNeasy Mini Kit (Qiagen, Sussex, UK) and followed according to the 
manufacturers' instructions (Appendix Section 4.2.5.2.1). Concisely, cell cultures 
were established as outlined in (Section 2.2) and lysed with buffer, precipitated in 
70% ethanol and passed through a centrifugation column. Intracellular contents was 
DNase digested, extensively isolated and washed and finally, the subsequent RNA 
was collected (Appendix Section 4.2.5.2.1) and placed within a -80 °C freezer for 
short term storage.
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4.2.5.2.2 RNA purity Assessment - Nanodrop
Following the RNA extraction (Section 4.2.5.2.1) the RNA yield was measured and 
the purity assessed (260:280 ratio) using a NanoDrop ND-1000 Spectrophotometer 
(Labtech International, Uckfield, UK). Full details of the protocol can be found 
within the (Appendix Section 4.2.5.2.2).
4.2.5.2.3 Double Stranded Complementary DNA (cDNA) Synthesis
Double stranded cDNA synthesis was carried out for all the human lymphoblastoid 
cell lines using the QuantiTect Reverse Transcriptase Kit (Cat No. 2053111, Qiagen, 
Sussex, UK) and followed according to the manufacturers' instructions. The full 
protocol for use is detailed (Appendix Section 4.2.5.2.3), however, In brief; thawed 
RNA was treated with Quantiscript reverse transcriptase, RT primer Mix (Oligo 
DT), gDNA W ipe-out buffer, Quantiscript RT buffer and nuclease-free H 2O and 
placed within a T100 PCR Thermal Cycler (BioRad, Hertfordshire, UK) for 2 min at 
42°C. Following complementary strand synthesis, Quantiscript Reverse 
Transcriptase, RT Primer mix and Quantiscript RT buffer were all added to the 
template cDNA. Each sample was transferred back into the heating block and cycled 
for 15 min. Post incubation, each sample was in-activated for 3 min at 95°C, short 
term stored within a -80 °C freezer.
4.2.5.2.4 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Real-time PCR experiments were undertaken using the QuantiFast™  SYBR® Green 
PCR Kit (Qiagen, Sussex, UK) in combination with synthesised cDNA, full details 
can be found (Appendix Section 4.2.5.2.4). In essence, template cDNA was treated 
with QuantiFast SYBR® Green PCR M ast Mix, forward and reverse primers and 
RNase-free water. All solutions were made in excess and run in triplicate within 
sterile 96-well 0.2 mL PCR plates (Sarstedt, Nuembrecht, Germany). Experimental 
samples, standard serial dilutions as well as non-template negative controls were also
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included for each primer pair. W ithin the negative controls, cDNA was replaced with 
RNase-free water and the inclusion of standard wells allowed post analysis PCR 
efficiency to be calculated. Post plating, each individual 96 well-plate was sealed 
with an Absolute QPCR Seal sheet (Thermo Scientific, Surrey, UK), centrifuged 
briefly before being transferred into the iCycler iQ5 thermal Cycler (BioRad, 
Hertfordshire, UK). The thermal cycler was then programmed and run (Appendix 
Section 4.2.5.2.4.1), following completion the plates were kept for future molecular 
analysis. All retrospective analysis was carried out using the manufacturer supplied 
iCycler iQ5 software version 2.1 (BioRad, Hertfordshire, UK), which full details can 
be found within (Appendix Section 4.2.5.2.4.2 -  4.2.5.2.4.3).
4.2.5.3 P53 Functionality Assessment Following MMC Treatment
4.2.5.3.1 MMC induced p21 qRT-PCR Assessment
Following establishment of human lymphoblastoid cell lines (Section 2.2), cells 
were sub-passaged twice before the start of this experiment in order to assess rate of 
cell division, via RPD assessment. Prior to culture flask preparation, PPE was 
collected and worn in conjunction with collection of suitable vessels for toxic 
chemical disposal. Sterile 25 cm culture flasks, four for each cell line, were seeded 
at 8 x 105 cells/mL and received a 100 pL  dose o f varying M itomycin C (Table 4.1).
Table 4.1. M M C preparations, follow ing establishment o f  stocks “A -  0.05m g/mL” 
and  “B -  0.005m g/m L”, prior to dosing o f  human lymphoblastoid cell lines, TK6, 
AHH-1 and MCL-5.
D ose(pg/m L ) Stock Solution MMC (pL) dH20(pL)
0 N/A 0 100
0.02 “B” 40 60.0
0.08 “A” 16 84.0
0.15 “A ” 30 70.0
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Following acute dosing, in which each culture flask was incubated at 37°C for 4 hr, 
the cultures were transferred into 15 mL sterile BD Falcon tubes and centrifuged 
(250 x g for 7 min). The presumed toxic supernatant was discarded, according to 
local health and safety protocols (Section 2.8.4), and cell pellets washed twice with 
10 mL of lx  PBS. Following extensive washes, the supernatant was aspirated and 
discarded and re-suspended in 10 mL of fresh culture medium; at this point all toxic 
waste and toxic components were stored or discarded as per health and safety 
regime. The cultures were then processed in a homogenous manner to (Section
4.2.5.2) in which qRT-PCR analysis was undertaken to investigate p21 induction 
following genotoxin exposure.
4.2.5.3.2 p-p53 and p21 Western Blot Assessment following MMC treatment
Following establishment of human lymphoblastoid cell lines (Section 2.2); cells 
were sub-passaged twice before the start of this experiment and their growth 
recorded in order to assess rate of cell division to ensure that log phase growth 
dynamics were being exhibited by the cultures. Cultures were prepared and dosed 
with MMC as outlined in (Section 4.2.5.3.1) and subsequently processed as 
described in (Section 4.2.5.1) in order to facilitate p-p53 and p21 protein 
quantification via W estern Blott analysis.
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4.3 Results
4.3.1 GPI-AP Expression Assessment within “Low Passage” TK6 Cells
“Low Passage” Epstein-Barr viral transformed TK6 human B-lymphoblastoid cells, 
originally isolated from the W IL-2 cell line supplied by M asa Honma, National 
Institute of Health Sciences (NIHS); were believed to provide a potential benefit to 
the in vitro PIG-A  assay platform through their assumed increased phenotypic 
stability, lower sensitivity to apoptosis and general increased genomic integrity when 
compared to the normal TK6 cells currently utilised within Swansea University. 
Initially their CD59 GPI-AP surface marker was immuno-fluorescently assessed for 
presence and potential usage, as in-direct reports for mutation at the PIG-A gene 
locus, within the proposed in vitro assay design.
“Low Passage” TK6 cells were demonstrated to exhibit minor protectin 
presence/expression on the cellular surface (0.17-0.58%); the resultant expression 
data, i.e. the positive signal detected within the relevant detector, was even observed 
to  be lower than the un-stained instrument calibration standard in two of the three 
experimental samples (Figure 4.2). This experiment was repeated within an 
additional “Low Passage” TK6 population derived from a different cryo-preserved 
culture and the resultant data mimicked the original findings. The “Low Passage” 
TK6 cell line was demonstrated to be homogenous negative for the CD59 cellular 
surface antigen.
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Sample 1 Sample 2 Sample 3
Figure 4.2. Relative positive expression of the pre-enriched CD59 surface antigen, 
within “Low passage” TK6 cultures following mouse-anti-human anti-CD59 R-PE 
treatment. Specific single cell gating strategies were omitted to provide an unbiased 
assessment on total recorded events, however, FSC-A threshold value was set to 
remove debris. Detector sensitivity was established following instrument calibration 
standard analysis (N =1)
Utilising the unchanged antibody solution, cellular samples of TK6 cells were 
exposed in a homologous manner to primarily provide further functional data for the 
antibody and secondly, provide a direct comparison between the two cell lines. The 
TK6 cells, previously utilised within the first results chapter (Section 3.3), were 
demonstrated to exhibit an approximately 70% distribution of CD59 positive cells 
within the heterogenous parental population (Figure 4.3).
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Figure 4.3. Relative expression of the pre-enriched CD59 surface antigen , within 
“Low passage” and normal TK6 cultures following mouse-anti-human anti-CD59 R- 
PE treatment. Specific single cell gating strategies were omitted to provide an 
unbiased assessment on total recorded events, however, FSC-A threshold value was 
set to remove debris. Detector sensitivity was established following ICS analysis 
(N=3, Error Bars ±1SD)
Cellular GPI-AP assessment continued with the subsequent analysis of the CD55 
(DAF) antigen surface presence assessment. The “Low Passage” TK6 cell line was 
demonstrated to have highly comprehensive CD55 surface antigen presence over the 
majority o f the defined cellular events within the heterogeneous population (Figure 
4.4). An average o f 97.3% of cells within the parental culture were demonstrated to 
display a positive signal in the relevant detector channel following antibody 
treatment. Even though the origins and functions of the two cellular surface antigen 
candidates is highly comparable, the resultant expression data was distinctly 
different and demonstrates no apparent correlation between GPI-AP expression and 
functionality w ithin lymphoblastoid cell lines. Use of the CD59 surface antigen as a 
phenotypic marker for mutation at the PIG-A  gene locus was discontinued within 
further applications utilising the “Low Passage” TK6 cellular populations.
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Figure 4.4. Relative expression of the pre-enriched CD55 surface antigen within 
“Low passage" TK6 cultures following mouse-anti-human anti-CD55 R-PE 
treatment. Specific single cell gating strategies were included; based on FSC-A vs 
SSC-A profile as well as a FSC-A threshold value was set to remove debris. Detector 
sensitivity was established following ICS analysis (N=3, Error Bars ±1SD)
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4.3.2 CD55 Antigen Optimisation using Fluorescence Activated Cell Sorting
(FACS)
From the conclusions drawn from the previous results chapter (Section 3.4), FACS 
was considered to be the enrichment methodology with the most future promise 
(Section 3.4.2). FACS potentially delivers the complete mutant depletion without the 
associated limitations associated to prolonged cell cultures, as observed within clonal 
expansion (Section 3.3.2.2), as well as antigen robustness, heavily featured in para­
magnetic bead enrichment techniques (Section 3.3.2.1). Therefore, in order to fully 
evaluate the technique for incorporation into the assay design, a number of stepwise 
experimental protocols were established, each addressing a slightly different 
potential influencing factor with regards to sort efficiency and cellular viability. The 
data included within this section endeavours to create a finalised protocol, taking on 
board the caveats associated with the technology available and the circumstances of 
use, in which an optimum mutant depletion methodology was established.
4.3.2.1 Initial Aseptic Sort Evaluation
Considering the initial FACS data, utilising the CD55 antigen as the identification 
parameter in which the upper 50 percentile of subsequent cells expressing CD55 
were captured; the initial GPI-AP expression was conservatively estimated at 
80.36% (P2 - Figure 4.5C). The morphology of the cells as well as distribution and 
constitution of debris within the post sort parental sample was distinctly different 
from the ICS as well as pre-sort homologous stained sample. Figure 4.5 A (ICS) and 
B (Pre-sort stained sample) showed distinctly similar parental populations in terms 
o f debris quantity and distribution, their markedly different fluorescence emission 
histograms were attributed to the un-stained nature of the ICS. However, Figure 4.5 
C (post-sort analysis sample) demonstrated increased cellular debris and a resultant 
erratic single cell population following sorting. The partnering histogram for the post 
sort sample (Figure 4.5 C) alluded to a bimodal distribution between CD55 negative 
cells (presumed debris/apoptotic positive) and CD55 positive (presumed viable) cell 
type.
160
■105
PE-AFSC-A
S p ec im en  00 1 -S a m p le  2
(x 1.000)FSC-A
-60
PE-ACx 1,000)FSC-A
Figure 4.5. Immediate CD55 (DAF) surface antigen expression within “Low 
Passage" TK6 cells following initial Fluorescence Activated Cell Sorting (FACS) 
optmisation. Single cell gating strategy “PL ’ omitted within the histograms to 
appreciate the potential detremental effect within GPI-AP expression within the 
parental population following sorting. “P2” the threshold for positivity and “P3” 
visual indication of presumed significantly positve signals. A) Instrument 
Calibration Standard utilised to define positivity within the “PE-A” detector, B) Un­
sorted control sample utilised to establish the basal CD55 expression and C) post- 
FACS enriched sample (N =l).
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4.3.2.2 Preliminery FACS Sample Collection Volume Asessment
The 72 hr recovery optimised FACS data (Table 4.2) demonstrated recovered yields 
o f > 97% o f the total population expressing the CD55 antigen; an increase of -17%  
from previous initial FACS methodologies (Figure 4.5). Subtle variances appeared 
within the recovered yields for the different collection tube set ups, indicating that 
viscosity as well as drop distance both influenced cellular viability post sort and 
subsequent antigen recovery (these trends were seen repeatedly throughout sort 
optimisation). Some evidence for an inversely proportional relationship between 
drop distance and sort purity or yield was observed within the data (Table 4.2), i.e. as 
one decreases the volume of collection medium within the collection vessel the 
respective sort purity post recovery increases. This relationship was particularly 
apparent within the 15 mL BD Falcon tubes (Table 4.2) with the largest volume (10 
mL) and the smallest volume (1 mL) resulting in a 97.4% and 98.3% yield 
respectively.
An additional inversely proportional relationship was also observed when evaluating 
the effect sample viscosity had on sort purity. Medium (RPMI 10% HIS and 1% 
Penstrep) was directly compared to pure heat inactivated serum as a collection 
media, utilising equivalent collection volume and vessel type. Medium demonstrated 
increased CD55 purity post recovery; both 3 mL collection volume within a 5 mL 
vessel and 5 mL collection volume within a 15 mL collection vessel were shown to 
have an increased CD55 expression, post recovery, when utilising medium as the 
collection solution (Table 4.2).
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The data displayed within (Table 4.2) as well as (Figure 4.6) also indicated that the 
collection vessel set up, i.e. either within 15 mL hard plastic tubes or smaller 5 mL 
softer plastic tubes played a role in cellular viability and hence sort purity. The 15 
mL BD Falcon tubes were demonstrated to produce a slightly poorer purity (avg. 
-97% ) following recovery when directly compared to their 5 mL counterparts (avg. 
98%). The optimum cellular viability, sort purity and a corresponding distribution 
analogous to the parental un-sorted cells was observed within the 5 mL collection 
tube containing 3 mL of medium (Figure 4.6). However, 0.5 mL of collection 
medium within the same vessel equally gave comparable sort purity post recovery.
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Figure 4.6. CD55 (DAF) surface antigen expression within “Low Passage"” TK6 cells 
following Fluorescence Activated Cell Sorting (FACS) into a 5 mL FACS tubes 
containing 3 mL of RPMI 1640 culture medium. Single cell gating strategy “P I” 
included to best reflect CD55 expressioin within the context of subsequent PIG-A 
mutant analysis. “P2" is the threshold o f presumed positivity. A) FSC-A vs SSC-A 
contour plot, B) FSC-A vs SSC-A dot plot C) CD55 signal within the “PE-A” 
detector and D) Statistics Summary table (N =l).
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4.3.2.3 FACS Further Refinement for Optimum CD55 +ve Cellular Recovery
The data obtained following the final refinement of the FACS recovery method 
reinforced the subtle differences minor alterations within the set-up have on the 
resultant purity or sort efficiency of the overall process. Based on the previous 
findings, utilising 5 mL collection vessels in combination with varying volumes of 
culture medium as the collection solution generated highly comparable data without 
any specific sample generating profoundly unique results. FACS was observed to 
generate approximately 99% CD55 positive “Low Passage" TK6 cultures following 
72 hr recovery (Figure 4.7). The effect sorting was exerting on the cell cultures in 
terms of cellular viability was deemed tolerable following the refinements to the 
protocol; cellular surface antigen assessment, to calculate sort purity, generated 
population scatter plots which conformed to previously observed untreated cultures. 
The recovered populations displayed minimal debris or cellular abnormalities when 
directly compared to un-treated control samples.
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Figure 4.7. Relative expression of the CD55 (DAF) surface antigen, post 72 hr 
FACS enrichment and varying recovery methods, within “Low Passage'’ TK6 
cultures following mouse-anti-human anti-CD55 R-PE treatment. Specific single cell 
gating strategies were included; based on FSC-A vs SSC-A profile as well as a FSC- 
A threshold value was set to remove debris. Detector sensitivity was established 
following ICS analysis (N=3, Error Bars ±1SD)
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4.3.3 “Low Passage” TK6 Viability
4.3.3.1 Viability Data for “Low Passage” CD55 enriched TK6 cells
In order to assess the relative stability of untreated “Low Passage” TK6 cells, 
following compensation matrix establishment (Section 2.8.2), viability dyes were 
utilised to evaluate the basal levels of cytotoxicity within the populations. A direct 
comparison between unstained and viability dye stained “Low Passage” TK6 cells 
was utilised for investigation.
The results described a generally highly viable population with little evidence for 
elevated cytotoxicity. Subtle differences between the control ICS sample (unstained) 
and the three experimental samples were apparent; apoptosis (0.2%) and necrosis 
(0.113%) remained consistent across the samples, reflecting little cytotoxity. 
However, the percentage of dead cells was estimated at 4.5% within the 
experimental samples, a 9 fold increase over the untreated control. The experimental 
samples had an approximate 95.187% viable population, with no obvious signs of 
elevated levels of basal cytotoxicity, as to be observed within cultures experiencing 
adverse environmental stimuli (Figure 4.8). The described results reflect lower than 
expected levels of cytotoxicity, which were mimicked when microscopically 
assessed for phenotypic signs of damage, cells were demonstrated to be highly viable 
and appeared phenotypic indicator free, i.e. large cell clumps or loss of aspect ratio.
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Figure 4.8. Viability assessment on “Low Passage”, CD55 FACS enriched TK6 
cells. Dead Cells; cellular events which stain positive for 7-AAD, Apoptotic Cells 
events which stain positive for Alexa Fluor 488™  Annexin V, Necrotic Cells; events 
which stain positive for both Annexin V and 7-AAD and finally, Viable Cells; are 
events which are not stained for any of the incorporated viability dyes (N=3, Error 
Bars ±1SD) ICS was utilised form the same homogenous “Low Passage” TK6 
sample - Log y-axis utilised.
4.3.4 “Low Passage” TK6 preliminery PIG -A  Assessment Utilising the CD55 
Surface Antigen following Model Mutagen Exposure
Preliminary dose response experiments were carried out in order to assess the 
potential benefits associated with the refined assay design; novel “Low Passage” 
TK6 cells combined with FACS wild type enrichment, viability dye incorporation 
and CD55 utilised as the in-direct reporter for mutation phenotype. EMS was again 
chosen as the chemical for exposure, for the same reasons as stated previously 
(Section 3.4.3); all “ P/G-A mutants” are events phenotypic o f CD55 absence and 
therefore, are presumptive PIG-A  mutants. Experimental design permitted the initial 
capture of 10,000 cellular events, which were then gated for single cell nature which 
restricted sample numbers to -8 ,000 events.
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All data generated following daily PIG-A  mutation assessment were evaluated for 
normality and variance (P value >0.05) using the Shapiro-W ilk and Bartlett’s Test 
respectively, carried out with DrSmooth within the R-Software Package (R-3.0.2, 
Free Software Foundation’s GNU project). Following assessment, distribution and 
variance were defined in order to facilitate the correct statistical analysis; unique 
assumptions are made about the data within individual parametric and non- 
parametric statistical models, therefore, predisposing specific tests to specific data 
types. Subsequently, data was PRO AST 38.9 modelled in order to define BM Dioand 
BM Dlio values and ensuing statistical analysis was undertaken within the R- 
software. Statistical analysis was implemented to state at what dose, if any, rejection 
of the Null hypothesis was to be assumed (P-value <0.05). At such a dose, variation 
of the viable phenotypic PIG-A mutant frequency was defined as a direct result of a 
significant factor and not as a result of chance.
Low dose EMS treatment of “Low Passage” TK6 cells, FACS enriched for the 
presence o f the CD55 (DAF) cellular surface antigen, resulted in a sub-linear dose 
response for all days o f phenotypic PIG-A  analysis (Figure 4.9 A-D); Day 1 
demonstrated no significant increases or decreases in average viable phenotypic 
PIG-A  mutant frequency across the entire dose range, with an comparable 
relationship observed within the cytotoxicity measure (RPD) (Figure 4.9 A), data 
confirmed to be non-normally distributed (P value = 0.025). Day 2 data 
demonstrated that doses greater than and including the 5 pg/m L resulted in a 
noteworthy increase in the average cytotoxicity, with subsequent RPD values at 64.3 
and 42.3 percent respectively. Variation was observed within the average phenotypic 
PIG-A  mutant frequency across the dose range, however, significance was not 
achieved when compared to con-current negative control values (Figure 4.9 B). Data 
demonstrated to be normal (P = 0.83), with respect to distribution. Day 3 data 
mirrored the relationship observed within the previous daily analysis, with regards to 
average viable phenotypic PIG-A  mutants, however, the cytotoxicity at the 5 pg/mL 
dose appeared to be negligible, with 62.7% RPD at 10 pg/m L (Figure 4.9 C); data 
shown to be non-normally distributed (P = 3.4510 '5)
D ay 4 analysis showed that the top dose (10 pg/mL) appeared to induced an increase 
in the average number of viable putative PIG-A  with respect to con-current negative 
control values, however, was proven to be insignificant (P>0.05). All doses tested
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failed to induce statistically significant increases in the average number of CD55- 
deficient cells, similar to the previous three days of flow cytometry analysis. 
Cytotoxicity was shown to be similar to what was observed on day 2 with both 5 and 
10 pg/m L doses eliciting substantial increases in cytotoxicity, 69.1 and 21.9% 
respectively. Data shown to be not normally distributed (P = 3 .51xl0 '7) and 
excessive intra dose variability was also observed, especially at the top dose (Figure
4.9 D), due to limited sample size.
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Figure 4.9 A,B,C and D - Days 1-4 frequencies of phenotypic PIG-A mutant “Low 
Passage” TK6 cells (FACS enriched) following 24 hr low dose EMS exposure, 
CD55 antigen utilised as reporter o f mutation (Dunn’s Test (p <0.05*)( (N=2, Error 
Bars ±SEM)) PIG-A mutants displayed as percentage of total single cellular events 
(0.1% PIG-A  Mutants = 1 mutant x 10'3 cells) -  A single replicate collected -500 
single cell events -  Day 4 at the top dose.
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4.3.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
Initially, in order to evaluate the potential variability between the different selected 
human B-lymphoblastoid cell lines, terms of surface antigen expression, 
immunofluorescence staining was employed to assess the expression of well 
characterised cellular surface antigens on the extracellular surface. Fluorescence 
Aerolysin (FLAER), B-lymphocyte activation marker ((BLAST-1)/(CD48)) and 
Protectin (CD59) as well as Decay Accelerating Factor (DAF/CD55) were all 
assessed, due to their potential as potential future candidates for in-direct reporters of 
phenotypic PIG-A  mutation.
Primarily, “Low Passage” and normal TK6 cell’s surface antigen expression was 
directly compared to generate a baseline for further surface antigen expression 
investigations as well as potentially identify additional GPI-AP candidates. Briefly, 
“Low Passage” cells were demonstrated to generate very poor staining efficiency 
within all candidates, post antibody exposure, and discontinued from use. Whereas, 
normal TK6 cells exhibited comprehensive average surface staining following 
FLAER -75% , CD48 -73%  and CD55/59 -  78% exposure (Appendix Section 
4.3.5).
The comparable AHH-1 cell line was demonstrated to have more comprehensive 
FLAER staining (75.2%), at the top concentration tested (2.5 pg/mL), significant 
CD48 staining (83.45%) and extensive CD55/59 expression (99.2%) (Figure 4.10). 
M inimal variation was observed within the culture and cells were microscopically 
assessed for signs of distress prior to assessment. The cells demonstrated no signs of 
adverse health, in terms of aspect ratio and agglomeration status and lent themselves 
well to the preparative stages required for staining.
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Figure 4.10. Average cell surface marker expression of the parental control AHH-1 
cell population. FLAER (stock cone) Alexa Fluor 488 ™ conjugate, CD48 
phycoerythrin conjugate and CD55/59 phycoerythrin conjugate fluorescent dyes 
utilised and data captured within their respective detectors. (-10,000 single cellular 
events) (N=3, Error Bars ±1SD).
However, the MCL-5 cells demonstrated the most extensive comprehensive staining, 
approximately 93.5% for FLAER, which facilitated the investigation of a 1:1 
dilution (52.2%). CD48 was shown to be highly promising with an average 
expression of 92.15% and finally, when utilised in tandem CD55/59 were 
demonstrated to show 99.8% surface antigen expression within the cell line (Figure 
4.11).
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Figure 4.11. Average cell surface marker expression of the parental control MCL-5 
parental population. FLAER (stock cone) and FLAER (1:1); Alexa Fluor 488 ™ 
conjugate, CD48; phycoerythrin conjugate and CD55/59; phycoerythrin conjugate 
fluorescent dyes utilised and data captured within their respective detectors. 
(-10,000 single cellular events) (N=3, Error Bars ±1SD).
4.3.5.1 W estern B lotting —Sodium  Dodecyl Sulphate -  Poly-A crylam ide Gel 
E lectrophoresis (SDS-PAGE)
Prior to Western blot analysis and subsequent Chemidoc™  visualisation of the 
protein of interests, specific relevant house keeper proteins were initially screened 
for relevance and suitable localisation and elevated abundance within all cell lines 
tested. Human B-actin, one of six isomers for the constituently expressed protein 
molecules integral in cellular mobility and structural integrity, and Histone H3, one 
of five protein molecules associated with the structure of chromatin molecules, were 
selected as the cytoplasmic and nuclear house keeper proteins respectively, due to 
their abundant and comprehensive expression. B-Actin and Histone H3 were 
therefore, utilised within the subsequent experiments, to maintain data integrity.
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Initially, P21 was demonstrated to be located in both the cytoplasmic and nuclear 
fraction of the protein extracted from each of the cell lines assessed, and deemed to 
be present at suitable quantities to facilitate future detection within any of the 
potential in vitro PIG-A assay cell line platforms (Figure 4.12). However, the relative 
band densities were significantly varied between cell lines, with little intra sample 
variance; AHH-1 demonstrating comprehensive p21 presence, noticeably greater 
than both MCL-5 and TK6 cells (Figure 4.12). TK6 were shown to exhibit the 
smallest amount of the p21 protein constitutively expressed within untreated cells, in 
either cytoplasmic or nuclear fraction, when directly compared to the other cell lines. 
Housekeepers B-actin (cytoplasmic) and Histone H3 (nuclear) were found to be 
extensively abundant across all cell lines, regardless of protein localisation, during 
western blott analysis.
B-Actin
B-Actin
Figure 4.12. Relative protein band densities following primary anti-p21 and 
secondary-HRP conjugate antibody probing and subsequent UV exposure within 
Chemidoc™  imaging; A) Nuclear protein and B) cytoplasmic protein extracted from 
untreated control human lymphoblastoid cell lines. B-Actin (cytoplasmic) and 
Histone H3 (H-H3 (nuclear)) were utilised as housekeeper proteins.
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P53 protein was shown to be present in both cytoplasmic and nuclear MCL-5 protein 
fractions following extraction, however, at noticeably different quantities. Protein 
band density within the nuclear fraction was far greater than the comparable 
cytoplasmic fraction (Figure 4.13), as to be expected with a nuclear transcription 
factor; little variance was apparent between analogous samples.
B-Actin Histone H3
Figure 4.13. Relative protein band densities following primary anti-p53 and 
secondary-HRP conjugate antibody probing and subsequent UV exposure within 
Chemidoc™  imaging; A) Cytoplasmic protein and B) Nuclear protein extracted from 
untreated control MCL-5 cells. B-Actin (cytoplasmic) and Histone H3 (nuclear) 
were utilised as housekeeper proteins.
Following the initial investigation into p21 and p53 localisation, both proteins were 
evaluated across all three potential future cell lines for their respective constitutive 
expression and hence, protein band densities following western blot analysis; data 
was normalised against B-actin and histone H3 respectively for cytoplasmic and 
nuclear fraction derived proteins and displayed relative to the MCL-5 cell line 
protein densities (Figure 4.14). Cytoplasmic p21 expression was demonstrated to be 
present and comparable across the cell lines assessed, however, nuclear p21 
expression was demonstrated to be significantly higher within the AHH-1 cell line, 
exceeding 2 x fold higher than comparable MCL-5 values. P53 protein levels were 
assessed and shown to be highly similar across all three cell lines, however, p-p53 
levels for both TK6 and AHH-1 cells were greater than 2 x fold higher than the 
comparable MCL-5 cells.
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Figure 4.14. Average relative protein band densities, normalised against con-current 
house keeper data, following primary p21, p53 and p-p53 and secondary HRP- 
conjugate antibody probing and subsequent UV exposure and Chemidoc™ imaging. 
Cytoplasmic and nuclear protein extractions are represented by “C” and “N ” 
respectively (N=2, EiTor Bars ±SEM).
In order to better evaluate the assessed cell line's p53 functionality and hence ability 
to react to genotoxin exposure, acute mitomycin C treatment was implemented and 
the normalised as well as relative protein quantities of p21 and p-p53 were detected 
within total protein extracts. TK6 cells demonstrated insignificant variations in the 
relative p-p53 abundancy with respect to MMC dose, however, a significant dose 
dependent relationship was apparent with p21 protein levels (Figure 4.15). AHFI-1 
cells demonstrated comprehensive dose dependent correlations for both p-p53 and 
p21 protein levels over the MMC dose range (Figure 4.15), and finally, MCL-5 cells 
displayed an analogous response to that described within the AFIH-1 cell line, with a 
slight difference in regards to truncated dose response for the p21 expression at the 
top dose tested, 0.15 pg MMC. In respect to the band densities following 
normalisation, each cell line had comparable amounts of house keeper expression; 
the MCL-5 cell line displayed significantly lower quantities of proteins within the 
extract when compared to both TK6 and AFIH-1 cells.
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Figure 4.15. Average relative protein band densities following acute 4hr MMC 
exposure, total protein extraction, and subsequent imaging on the ChemiDoc™ 
platform. p21 and p-p53 proteins were assessed via the use of primary antibodies in 
conjunction with secondary HRP-conjugate and UV exposure; A) data was initially 
normalised against house keeper band densities (H-H3 and B-actin respectively) 
(Error Bars ±SEM) and B) presented as average relative fold change with respect to 
the untreated control for the respective human lymphoblastoid TK6, AHH-1 and 
MCL-5 cell lines.
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4.3.5.2 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Prior to quantitative real time PCR assessment of the target gene, specific relevant 
house keeper genes; comparable constituency expressed genes displaying elevated 
transcription rates, were optimised to ensure their comprehensive expression within 
all cell lines tested. Human receptor like protein-19 (RLP-19) and hypoxanthine 
phosphoribosyltransferase (HPRT) demonstrated the most consistent expression 
across all the cell lines, when compared to common housekeepers B-Actin and 
Histone H3, and therefore, we utilised within the subsequent experiments to ensure 
integrity
Quantitative real time PCR assessment, SYBR© green, was carried out on all three 
cell lines to more accurately determine the relative quantity of p21 constitutive and 
induced gene expression in response to MMC treatment. P21 was shown to 
constituently be transcribed within all three cell lines assessed (Figure 4.16 A), 
however, TK6 was determined to approximately express greater than 3 x fold more 
p21 than the comparable MCL-5 or AHH-1 cell types (Figure 4.16 B).
G e n e  E x p r e s s i o n
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Figure 4.16. The relative expression of the (CIP1/WAF1) p21 gene across the human 
lymphoblastoid AHH-1, TK6 and MCL-5 cell lines; A) Expression data normalised 
against HPRT and RLP19 house keeper genes and B) Displayed as relative fold 
change when compared against the MCL-5 expression data (N=3 technical 
replicates, Error bars ±SD)
Following acute 4 hr MMC exposure, the TK6 cell line was shown to exhibit a 
typically dose dependent relationship, with dose being significantly positively 
correlated to amount of induced p21 expression (Figure 4.17); each increase in 
MMC dose resulted in a corresponding increase in p21 transcription. Both MCL-5 
and AHH-1 were also shown to produce a similar relationship, with a strong 
correlation to dose increment and p21 induction, however, the top dose within AHH- 
1 and the top two doses within the MCL-5 data demonstrated shortened p21 
expression; therefore, the dose responses appeared truncated at the higher doses 
(Figure 4.17).
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Figure 4.17. The normalised and comparable relative expression of the (CIP1AVAF1) 
p21 gene across the human lymphoblastoid AHH-1, TK6 cell lines and MCL-5 cell 
lines following acute 4hr MMC exposure (N=3, technical replicates)(Error bars 
±SD).
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4.4 Discussions and Conclusions
Human B-lymphoblastoid cell lines feature heavily within in vitro genetic toxicology 
assays; they provide sensitivity, apoptosis compatibility, p53 functionality, 
suspension growth characteristics and a variety of additional benefits [75, 113-115]. 
However, due to the nature of cell line distribution and increased risk of genomic 
instability associated to immortalised cell line usage [292], more prominent in 
academic institutes. The lack of standardisation has led to increasing variation, 
especially prominent within variable genetic toxicology end-point backgrounds, 
observed within comparable data sets [293]. To combat this, regulators have put 
forward the proposed use of specific cell lineages in tandem with specific genetic 
toxicology end points [113-115] and tentatively a homogenous cell sample for 
testing has been distributed to ensure inter-laboratory compatibility.
4.4.1 GPI-AP Expression Assessment within “Low Passage” TK6 Cells
“Low Passage” Epstein-Barr virally transformed human B-lymphoblastoid TK 6  
cells, originally isolated from the WIL-2 cell line supplied by M asa Honma, National 
Institute of Health Sciences (NIHS); were believed to provide more stable growth 
dynamics, a characterised reference karyotype and standardisation through trialled 
mass distribution to participating laboratories. Combining genomic stability with 
predicted assumed increased phenotypic stability, lower sensitivity to apoptosis and 
hence, reduced frequency of putative false positive events was believe to increase 
assay predictive ability and sensitivity to detect mutagens. Initially, GPI-AP surface 
markers were immuno-fluorescently assessed for presence and potential usage, as in­
direct reports for mutation at the PIG-A  gene locus, within the proposed in vitro 
assay design.
The resultant immuno-fluorescence flow cytometry data showed negligible CD59 
expression on the surface of the “Low Passage” TK 6  cells, grown under 
recommended culture conditions (Figure 4.2 -  4.3). In order to validate the 
functionality of the utilised antibody, the conventionally used normal TK 6  cell line 
was assessed in a homogenous manner to estimate CD59 expression on the cell
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surface; significant presence of the CD59 antigen was observed (Figure 4.3). In an 
attempt to identify a suitable GPI-AP candidate for the trial usage of the “Low 
Passage” TK 6  cell line within the assay design, an additional marker CD55, 
currently implemented in clinical screening for the human condition PNH [294], was 
utilised and found to be highly expressed within the low passage TK 6  population 
(Figure 4.4).
CD55 (Decay Accelerating Factor (DAF)) and CD59 (Protectin) are complement 
regulatory proteins which provide a vital function within mammalian species [294]; 
in brief, CD55 increases the decay rate of complement proteins and inhibits the 
formation of the C3 convertases which initiates and propagate autolysis of 
haemopoetic tissue [152]. CD59 prevents the terminal polymerization of the 
membrane attack complex (MAC) which facilitates haemolysis and thus, prevents 
uncontrollable autolysis [294]. Therefore, due to their interrelated roles and apparent 
analogous function there is no obvious reason why there should be a significant 
difference in the presence of either solely GPI anchored protein on the surface of a 
specific cell line. To make the situation more complex, the unexpectedly low surface 
antigen presence was observed within the proposed stable “Low Passage” TK 6  cells 
and not the presumed high passage TK 6  cell stock (Figures 4.2 - 4.4).
Human lymphoblastoid cells are not implicitly involved in the transport of oxygen 
around the body and have a much shorter life cycle than erythrocytes [295]. 
Therefore, they do not require the critical presence of either CD55 or CD59 on their 
respective cell surfaces to prevent complement mediated haemolysis [141]. 
However, this data suggests that each cellular antigen potentially has additional roles 
outside of complement mediation and thus, one antigen is more essential than the 
other, reflected in the apparent discrepancies between CD55 and CD59 expression. 
Recent literature has described a novel role for CD55 in granulocyte homeostasis and 
anti-bacterial host defence [296], providing an additional necessity for this specific 
maintained comprehensive surface expression.
Lack of CD59 presence within the “Low Passage” TK 6  cells is very confounding, as 
a higher passage of the identical sample cell type apparently displays the antigen at a 
comprehensive rate within the population (Section 4.3.1). Initially, this data was 
considered erroneous; however, was un-officially re-enforced through the apparent
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lack of expression demonstrated by an additional research laboratory. If the results 
were inverted, i.e. the high passage displayed lack of expression, the most likely 
potential causes of this would be an acquired mutation as a result from prolonged 
culture time [297], reflecting generalised genomic instability within the cell line. 
However, as it is the “Low Passage” showing minimal expression, the potential 
origin of the two cell stocks are questionable, or alternatively the higher passage 
have acquired an up-regulating mutational event within the CD59 gene, quite 
unlikely. The lack of expression does however, fit a lymphoblastoid model due to the 
redundancy of this specific complement mediating surface antigen; further 
investigation into analogous cell lineages and surface antigen expression is required 
to provide a more adequate conclusion about CD59 surface antigen discrepancies 
from the data.
The primary conclusion drawn from this section is that the CD55 antigen 
demonstrated sufficient surface antigen expression to warrant trial with the in vitro 
PIG-A assay design; the expression was borderline to require mutant depletion, 
however, deemed to be satisfactory for preliminary assessment due to the intended 
modifications to the design.
4.4.2 CD55 Antigen Optimisation using Fluorescence Activated Cell Sorting 
(FACS)
Following on from the initial work completed in the first results chapter (Section 
3.3.2), it was clear that FACS had the potential o f delivering a mutant depletion 
method with limited disadvantages. However, when initially optimised, the standard 
able to be obtained w asn’t sufficient in terms of mutant depletion (Section 3.4.2), i.e. 
the remaining number o f presumptive spontaneous phenotypic PIG-A  mutants was 
too large. Estimated spontaneous background mutant frequency at the PIG-A  locus 
was therefore, perceived to be much greater than comparable analogous X-linked 
gene loci [75], due to the presence of this substantial GPI-AP negative 
subpopulation. Consequently, the initial preliminary dose response experimentation 
was undertaken utilising clonal expansion as the foundation for enrichment and
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resulted in qualitative dose response modelling (Section 3.3.3). However, the scope 
of further in-depth investigation was realised and FACS was temporarily suspended 
for evaluation in latter experiments.
FACS in brief, utilises an induced charge on a particle to deflect the trajectory of 
said particle, post analysis, to facilitate isolation and capture (Section 2.8.3). FACS, 
similar to all techniques, is limited to some extent by a number of equipment related 
factors, for example, voltage regulation and systematic pressurisation. As a direct 
result of this, inter-sample variability can be problematic, however, this can be 
minimised with regular maintenance and routine servicing. Additional to these flow 
cytometry specific issues, the perpetual problem associated with FACS is that the 
experimental conditions required for sample processing are unique to that specific 
sample, and are highly changeable [298]. Consequently, the user must be proficient 
in designing a robust protocol taking into account the specific needs of said sample 
type. Primary samples, even though highly inconstant in terms of behaviour, are 
often robust and are able to tolerate inconsistencies within the sorting procedure. 
However, sensitive immortalised human cell lines are much more problematic and 
require much greater attention to detail in order to maintain a high standard of 
sorting efficiency.
The resulting initial optimisation data demonstrated that using a larger drop distance 
within a smaller collection tube, i.e. minimising the collection liquid volume and 
utilising a collection medium with a minimal viscosity i.e. pure RPM I 1640 
(negligible serum proteins) generated the optimum sort purity following recovery 
(>90%). However, in terms of a mutation assay this level of enrichment was still 
significantly sub-standard and therefore, further optimisation and/or protocol 
tweaking was needed. After an additional round of protocol modification, the results 
for the experiment demonstrated that there appears to be no further significant 
increase in FACS efficiency based on the drop, distance, collection medium 
viscosity and/or collection vessel (Section 4.3.2). In brief, increasing the drop 
distance provides additional buffering time for the velocity o f the particle to slow, 
due to air resistance, prior to contact the with collection vessel and/or collection 
medium. In addition to this, decreasing surface tension via limiting the serum 
com position o f the medium, contrary to published literature [299], as well as the 
density of the plastic polymer comprising the collection vessel, have similar positive
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effects on viability. However, what appeared to increase the efficiency to >99% was 
the combination of numerous other additional factors, i.e. the period of time which 
the cells remain in solution, the rate of respiration occurring and hence the apoptosis 
status of the population.
The conclusions able to taken from this section of work are that there is no single or 
small sub group of factors which influence the efficiency of sorting, but a much 
more complex holistic approach is required in order to facilitate the predicted 
optimum yields in terms of mutant depletion/wild type enrichment [300]. However, 
additional factors, which aren’t as apparent as their physical counter parts, which 
appear to maintain and regulate the high end efficiency attained are highly crucial 
and can be thought of as two separate sub groups; i) flow cytometry related, focussed 
on the software and hardware abort rates and ii) tissue type related and reflects 
directly on the sample to be processed, for example pH imbalances inducing 
apoptosis sensitivity (Appendix Section 4.4.2).
Further optimisation is required in order to assess the finalised degree of mutant 
depletion within parental populations. Irrespective of how problematic this appears, 
especially considering the sensitivity of the cell line to apoptosis, the use of 
conditioned medium, medium extracted from a well-established homologous cell 
culture, keeping the pre-sorted cell on ice and maintaining the collected populations 
at 37°C as well as adjusting the collection volume are potential further modification 
which may improve yield further. However, when compared to a chemically driven 
mutant depletion [75] it is unlikely that complete depletion will be obtained, 
however, reducing the pre-existing mutant numbers to a range to facilitate 
quantitative dose response modelling and hence compound screening may be 
applicable. Therefore, currently FACS is able to enrich a population for preliminary 
qualitative dose response modelling; however, low dose quantitative remodelling 
within the current assay design requires a level of sensitivity currently un-obtainable.
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4.4.3 “Low Passage” TK6 Viability
4.4.3.1 Viability Data for “Low Passage” CD55 enriched TK6 cells
Prior to preliminary PIG-A  dose response analysis, the “Low Passage” TK 6  cells 
were assessed for viability following cytometer preparations. The reason for this was 
to look for a robust cell line, not overly sensitive to both intrinsic and extrinsic 
apoptotic induction [8 , 276], which could be a potential future platform for an in 
vitro PIG-A  mutation assay. The data displayed that the “Low Passage” TK 6  cells 
had minor levels of cytotoxicity, typically lower than comparable cell lines, and thus 
generally were presumed very “healthy”, in terms of numbers of cells displaying 
positivity for apoptosis, necrosis or cell death (Section 4.3.3). The number of cells 
displaying positive signals for 7-A AD uptake and hence a direct reflection of loss of 
cellular membrane integrity were the only sub category o f non-viable cells to 
increase when compared to an unstained control samples (Section 4.3.3). Due to the 
absence o f neighbouring fluorophore usage, a compensation matrix was deemed 
unnecessary for use, as well as a comprehensive single stained positive control 
assessment, there was little evidence to suggest that the viability was underestimated. 
Therefore, “Low Passage” TK 6  cells appear to be highly stable pre-treatment, in 
terms of viability and phenotype, as well as consistent in their dose depended 
increase in cytotoxicity when exposed to chemical exposure (Appendix Section
4.5.3.1). Due to the above observations the cell line was deemed appropriate for use 
in conjunction with the CD55 cellular surface antigen within the current in vitro 
PIG-A  assay design.
4.4.4 “Low Passage” TK6 preliminery PIG -A  Assessment Utilising the CD55 
Surface Antigen following Model M utagen Exposure
“Low Passsage” TK 6  cells were demonstated to be highly sensitive and stable 
(Section 4.3.3), via the generation of robust and reproducible dose responses
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following cytotoxic exposure (Appdendix 4.5.3.1). In addition, when assessed for 
GPI-AP expression, the CD55 (DAF) cellular surface antigen was defined to have 
significant conserved expression across the cellular membrane of the parental 
cultures (Figure 4.4). Combining both the relative genomic stability and broad 
expression of a potential in-direct reporter candidate for PIG-A mutation status, as 
well as the incorporation of preliminery viability dyes, this particular combination 
was assessed for refinement of assay design.
The results were comparable, as observed when using the previous assay design, 
with the CD59 antigen as the reporter for mutagenesis. A superficial increase in 
cytotoxicty was observed at the top dose daily following the initial 24 hr recovery 
post treatment (Figure 4.9 A-D). On the final day of analyisis, Day 4, the number of 
viable presumptive PIG-A  mutants at the top dose tested (10 pg/mL) was shown to 
marginally increase, however, due to the limited sample size and excessive 
variability observed between replicates it was deemed not significant 
(P>0.05)(DumTs T-Test). Therefore, no doses across the concentraton range tested 
were demonstrated to significantly increase the number of viable presumed PIG-A 
mutants, as defined by CD55 absence (Figure 4.9 A-D). The background 
spontaneous mutant frequency, or pre-existing number of phenotypic mutant cells, 
was shown to be signficiantly higher utilising this reporter for mutation; as high at 
2% on specific days o f analysis, when compared to the CD59 antigen. Even 
following the addition of preliminary viability dyes, the resulant sensitivity was 
considered unacceptible when compared to validated comparable in vitro 
mammalian cell assays (200 x fold higher). Thus returning to the predicament of 
utilsing an alternative enrichment methodology within the assay design to deplete 
pre-existing phenotypic PIG-A mutants prior to assessment, to enable both 
spontanoeus mutation and induced mutant frequency estimation [301].
The descrepency between the analagous CD55 and CD59 data sets can be attributed 
to a number of different factors and hence, limited conclusions can be taken from 
this preliminery data. However, that being said it does raise the question of the 
origins or identities of the orignal mutants as defined by the CD59 dose response 
data. Following the incorporation of the viability dyes, into the assay design, the 
number o f viable presumed PIG-A mutant events did not increase over the dose 
range tested (Section 4.3.3 -  4.3.4); understandably, the CD55 antigen may be
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defective within this cell line as a reporter, due to the presence of a potential single 
pass membrane isomer [154], as well as the cell line inself not being appropriate for 
assessment, but there is potential for intial miss-classification of presumed mutant 
events within the CD59 assessment (Section 3.4.5). This potential miss-classification 
is re-infored by the intial viability assessment of the presumptive PIG-A mutant 
population (Section 3.3.5). Further clarification of presumed PIG-A mutant event 
will be required prior to further conclusive remarks made, however, the data 
generated does allude towards investigating alternative cell lines and reporter 
combinations in the aid of finding a logical combination, homologous to the CD59 
and erythrocyte combinaiton observed within the in vivo rodent Pig-a assay [91, 161, 
180, 302].
4.4.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
Dose response data thus far has highlighted the critical need for mutant depletion 
prior to PIG-A  assessment; lowering the number of pre-existing spontaneous 
mutants, prior to chemical exposure, facilitates a higher sensitivity to smaller fold 
increments in mutant induction [71]. However, due to the limitations currently 
observed when utilising “Low Passage” TK 6  cells, alternative human cell lines were 
assessed for GPI-AP marker expression, and hence in-direct reporters for mutation. 
The aim o f this section of work was to identify a potential cell line which had a 
sufficiently low pre-existing number of phenotypic PIG-A  mutants and hence, 
spontaneous mutant frequency to enable dose response investigation without the 
required need for mutant depletion; as well as robust qualities lending it well to flow 
cytometry applications.
All cell lines investigated generated appealing results in terms of generalised GPI- 
AP expression (Section 4.3.5), apart from the HepG2 human hepatocellular 
carcinoma cell line which was demonstrated to be unsuitable for this specific 
application [113, 201], due to problems associated with cell growth and cellular 
adhesion, requiring trypsinisation, prior to flow cytometry analysis. The AHH-1 cell 
line was demonstrated to have comprehensive (FLAER), significant CD48 and
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extensive CD55/59 expression (Figure 4.10). M inimal intra-sample variation was 
observed within the culture and cells microscopically showed little signs of distress 
prior to assessment. The MCL-5 cells, derived from the AHH-1 cell stock [126, 
2 0 0 ], demonstrated even more extensive comprehensive staining, and when tandem 
surface marker expression was investigated demonstrated 99.8% surface antigen 
expression within the cell line (Figure 4.11).
FLAER as a marker was expected to generate the most comprehensive expression 
within all cell line assessed; due to its highly unambiguous nature of binding to GPI- 
AP moieties on the cellular surface [303]. FLAER, is the inactivated fluorescence 
form of aerolysin, a cytolytic pore-forming toxin exported by Aeromonas 
hydrophila, a gram-negative bacterium associated with diarrhoeal diseases [304]. 
Consequently, due to its GPI moiety targeting toxicity, it is considered a generic 
selective marker for GPI-AP presence [305]. However, it did not perform to the 
expected levels, as theoretically, unlike monoclonal antibodies which each bind to a 
single GPI anchor protein, FLAER should be sensitive to any single GPI-AP at high 
affinity; enabling subsequent binding and hence, a positive signal. Theoretically 
GPI-APs play a much less critical role within lymphoblastoid cell lines, when 
compared to primary erythrocytes, however, the idea of lymphoblastoid cell not 
having a single GPI-AP on the membrane to be highly improbable, regardless of low 
levels of expression. The most likely reason for this would be protocol limitations, 
GPI-AP shearing and loss of cellular membrane integrity and hence, inaccuracies 
within conditions to allow optimum usage.
Publications outlining the potential short falls o f in vitro genetic toxicology test 
systems have been prevalent within the literature for decades [78, 184, 210, 279], 
however, more recently, a number of publications reporting more specific limitations 
regarding the use of rodent and human immortalised cell lines within in vitro genetic 
toxicology testing [113-115], especially focussing upon the biological features of the 
cell lines and the subsequent effect their respective features have on the integrity of 
the generated data. In brief, p53 competency, false positivity, sensitivity to apoptosis 
and a number of additional features were discussed in the context of highlighting 
current limitations, the extent to which such data can attribute weight o f evidence 
within regulatory decision making, or alternatively, advising definite cell lines for 
future use in conjunction with specific genetic toxicology end points.
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The definitive p53 status of a number of routinely used cell lines within genetic 
toxicology testing, including MCL-5, AHH-1 and TK 6 , are unknown due to the 
publication of contracting evidence as well as the lack of standardisation within cell 
line distribution [124, 126]. Typical.mutational hot spots, codon 282 exon 8 , have 
been assessed and analysed within these cell lines often resulting in contradicting 
opinion over the true p53 status and therefore, questing the potential accuracies 
associated to routine usage of said cell line within future testing [124, 126] 
(Appendix Section 4.4.5).
Due to the nature of the limitations associated with the techniques (Section 4.3.5) 
utilised within the experiments carried out in order to assess the p53 status of the 
TK 6 , MCL-5 and AHH-1 cell lines, no absolute comments on p53 status can be 
made from the preliminary data generated. Limited quantity o f p53 protein was 
isolated from cytoplasmic protein fractions, and comprehensive p53 and p-p53 
presence was demonstrated within the nucleus of all cell lines tested. AHH-1 and 
TK 6  cells were demonstrated to have constitutively more p21 protein (Section
4.3.5.1) as well as p21 gene expression (Section 4.3.5.2) and nuclear p-p53 than the 
MCL-5 cells, indicating the potential homozygous wild type status of the p53 gene.
Following acute MMC exposure, the western blott analysis generally resulted in a 
dose dependent increase in p-p53 as well as p21 protein across all cell lines assessed, 
thus reflecting upon the p53 functionality within the cell lines. However, even 
though all cell lines appear to be p53 functional, MCL-5 again was shown to produce 
much lower quantities of p21 and p-p53 protein when compared to the other cell 
lines following MMC induction; again a potential additional factor eluding at MCL- 
5 cells having reduced p53 activity (less protein does not necessary mean less 
functionality). Finally, acute MMC exposure was once again utilised to assess the 
relative p21 gene expression following MMC induction, as a supplementary 
experiment to generate additional data to come to a conclusion about cell line 
specific p53 status. The results displayed a positive correlation between relative p21 
expression and MMC dose, however, AHH-1 and MCL-5 displayed truncated dose 
responses, in which the top dose or doses were induced a significantly lower than 
expected for induction of p2 1  expression when compared to untreated controls.
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The reason for this is most likely due to the uniqueness within the lymphoblastoid 
cell lines. As discussed previously, (Section 4.1), even though the cell lines chosen 
are highly similar in derivation, with MCL-5 and AHH-1 sharing a common ancestor 
[126, 200, 306], their unique levels of oxidation and/or metabolism have distinct 
impact on their response to specific compounds. W hen a compound which requires 
metabolism is assessed, for example, MMC, subtle pre-existing variations within 
dose response data are magnified. The truncation in the dose response is directly 
proportional to the metabolism status of the cell line; AHH-1 have exceptionally 
high oxidative ability when compared to TK 6  cells which lack any extensive 
metabolism, and MCL-5 cells have additional plasmid derived CYP1A1 p450 
cytochrome metabolism [200]. However, as MMC does not require a CYP-mediated 
metabolism to become active, MCL-5 cells should not receive any more potent dose 
o f the chemical for an extended period of time and subsequently are exposed to a 
similar levels of chemical induced cytotoxicity (Section 4.3.5.2). However, the same 
effect is apparent within protein extraction yields at the higher doses, where 
increased cytotoxicity negatively affects the protein received yields (Section 4.3.5.1) 
alluding to an additional feature present within the MCL-5 and AHH-1 cells but not 
the TK 6  cell line.
Tentatively, the conclusions which can be drawn from this section are that each cell 
line demonstrates some level o f p53 activity and hence, functionality via the 
measurement of p2 1  induction, however, currently, no definitive conclusion can be 
made on the actual TP53 mutational status of the cell lines assessed.
Following sufficient experimentation, the MCL-5 cell line was chosen for on-going 
assessment and further development within the in vitro PIG-A  assay design due to its 
extensive cellular surface marker expression, regardless of enrichment status and 
therefore, has subsequent potential as a reporter for mutation at the PIG-A  locus. 
Tandem reporter marker usage was demonstrated to produce the most 
comprehensive surface antigen expression within the human B-lymphoblastoid cell 
lines, as well as p53 proficiency and functionality. However, TP53 status will be 
required to be more fully validated via sequencing prior to supplement the pre­
existing karyotype before regulatory acceptance.
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variation 
dem
onstrated; protocol adjusted 
to 
account. Scripted 
FCM 
analyses 
able 
to 
be 
generated 
post finalisation 
of PIG-A 
assay 
design.
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Chapter 5: MCL-5 Optimisation, Preliminary Next Generation Sequencing and 
Continued Investigation into the in vitro PIG -A  Gene M utation Assay Platform
5.1 Introduction
Experimentation reported so far has described the progressive optimisation of a basic 
in vitro PIG-A  assay design; commenting on limitations and their potential solutions 
with respect to enabling progressive development. A human lymphoblastoid derived 
cell line was identified with minimal numbers of pre-existing phenotypic PIG-A 
mutant events and was evaluated in terms of p53 functionality in response to 
cytotoxic exposure (Section 4.3). The metabolically active MCL-5 cell line provided 
data alluding to its potential as a novel platform for mutagenicity assessment. MCL- 
5 cells, chosen for further studies, were established from a male donor thus 
harbouring only one X-chromosome and therefore, only one copy of the PIG-A  gene. 
This cell line, similar to the previous described TK 6  and AHH-1 cell stocks, grows 
in suspension which is an important prerequisite to conduct the assay; preventing 
potential limitations associated with trypsinisation or like treatments.
MCL-5 cells constitutively express human cytochrome P-450 CYP1A1 and due to
two unique transfected plasmids, also expresses five transfected human cDNAs
encoding drug-metabolizing enzymes. cDNAs encoding CYP1A2, CYP2A6, and
microsomal epoxide hydrolase (mEH) were introduced by using a vector conferring
hygromycin B resistance, and cDNAs encoding CYP2E1 and CYP3A4 were
introduced by using a second vector conferring resistance to 1 -histidinol [2 0 0 , 306].
As a direct result of this, MCL-5 cells, without incorporated add-ons, have the
proficiency to accurately assess the mutagenic potential of a greater proportion of
compounds listed within the EURL-ECVA [307] or IARC [308] lists than
comparable routinely used genetox cell lines. Promutagens and/or procarcinogens,
such as Benzo-(a)-Pyrene (B[a]P) which require both phase 1 and phase 2
metabolism, in order for the production of mutagenic and/or carcinogenic
metabolites, could potentially be falsely defined as negative within analogous in
vitro gene mutation assays with limited metabolism [67, 70, 75]. B[a]P once
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metabolised forms the highly mutagenic, benzo[a]pyrene-diol epoxide. This large 
bulky adduct molecule intercalates within the DNA, primarily covalently binding to 
the nucleophilic guanine base at the N2 [11, 309]. Consequentially, the DNA 
becomes perturbed and the double-helical DNA structure is disrupted; these 
discrepancies induce errors within DNA replication and hence, result in mutagenic 
events. Human or rodent S9 can be utilised in tandem with pre-existing gene 
mutation assays which lack metabolism [310], in order to mimic in vivo metabolism. 
However, an all-inclusive, highly sensitive, human representative, test system would 
be favourable.
5.1.1 Fluorescence Based Platforms, Signal Capture and Review
Focussing on the fluorescence platforms utilised within this body of work, analogous 
to both flow cytometry and laser scanning confocal imaging is the use of 
photomultiplier tubes (PMT) to convert photons o f light (emitted electromagnetic 
radiation with a discrete wavelength) to an electrical digital signal. PMTs allow even 
the signal from a single photon to be captured and up scaled without excessive 
electrical noise. Alternatively the image stream ™ platform utilises a more 
conventional approach with regards to the field of photography, in which a charge- 
coupled-device (CCD) is utilised to fulfil the same function.
Photomultiplier tubes are small glass envelopes, containing a vacuum inside, which 
houses a photocathode, several dynodes, and a corresponding anode. 
Event photons contact the photocathode metallic material, which is present as a thin 
deposit on the entry window of the device, and subsequently electrons are produced 
as a consequence of the photoelectric effect. These electrons are directed towards the 
consecutive dynodes constituting the electron multiplier, where electrons are 
multiplied by the process of secondary emission; upon striking the first dynode, 
more low energy electrons are emitted, and these electrons in turn are accelerated 
toward the second dynode. The dynode is configured geometrically to facilitate a 
chain cascade with an ever-increasing number of electrons being produced at each
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stage. The resultant large number of electrons finally strike the anode and result in a 
detectable current pulse [311].
Confocal microscopy differentiates itself from typical light microscopy through the 
ability to acquire in-focus images from selected depths, a process known as optical 
sectioning. Images are acquired, through a progressive scanning method; the 
detected light within the specimen represents one pixel in the consequential image. 
As the laser scans over the specimen within the plane of interest, an image is 
obtained pixel-by-pixel, in which the brightness of the resulting image pixel 
corresponds to the relative intensity of detected light. This subsequent image is 
reconstructed within the computer, through the interpreted PMT signal; facilitating 
three-dimensional reconstructions of topologically complex objects (z-stacking). For 
samples in which light cannot penetrate easily (opaque specimens), this is useful 
for surface profiling, while for non-opaque specimens, interior structures can be 
clearly imaged at high resolution [312]. The confocal system therefore, confirms 
itself as a stand out piece of equipment for initial immuno-fluorescence cellular 
membrane surface evaluation and hence, surface reporter marker validation; 
illuminating the underlying mechanisms of the in vitro assay design.
Alternatively, Charge-coupled devices (CCDs) are devices which move electrical 
charges to an area where the charge can be manipulated. One of the most common 
examples of this is the conversion from light into a digital value. The process in 
which the electrical charge is transferred is known as shifting, in which the signal is 
relocated between different stages within the device. CCDs move charge between 
selective bins (capacitors) in the device, with the shifting terminating at the point of 
signal conversion (The last capacitor in the array dumps its charge into a charge 
amplifier, which converts the charge into a voltage.). W hen image acquisition 
begins, the image is projected onto a capacitor array and the incoming photons are 
converted into electron charges at the semiconductor interface; shifting occurs and 
the CCD is utilised to read out the initial charges, the charge being proportion to the 
original intensity of the captured image [313].
The Amnis Image Stream ™  system incorporates the use of CCDs to generate the 
16-bit TIFF images associated with the platform; however, utilising a digital camera 
has some limitations, as well as some great associated advantages when compared to
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similar platforms. Focus, or focal planning issues, is one o f the main recognised 
limitations when imaging “in flow”, attempting to maintain focus within a single 
plane of capture and translate said data to a crisp finalised image is highly complex. 
However, the Amnis Image Stream ™ does have some novel technology to 
implement this, including TDI-CCD facilitating lOOOx faster image detection and 
capture than similar equipment [194, 314]. The benefits associated with this novel 
flow capture system are the high content, sensitivity as well as depth of field 
assessment unique to this platform. The image stream cements itself as a useful tool 
to investigate population distributions, in terms of cell cycle analysis, with respect to 
additional multiplexing fluorescence data capture, i.e. immuno-fluorescence cell 
surface marker status.
5.1.2 Fluorescence Signal Properties and their potential Relationships
Following the initial illumination of the incident particle, the emitted fluorescence 
light under goes pre-amplification, typically facilitated through the PMT, more 
specifically the dynode array, and the subsequent signal generates an electrical pulse 
[192]. This electrical signal (voltage) is processed and responded to if it passes the 
additional tertiary levels of analysis, i.e. the voltage intensity much exceed the 
threshold level to distinguish itself from debris and electrical noise and be 
subsequently sent to the computer. W hen the particle of interest, enters the 
illuminating laser beam and begins to scatter light (FSC or SSC) and/or fluoresce, a 
voltage pulse is created (Figure 5.1). Theoretically, when a particle is bisected 
centrally by the illuminating light, the maximum amount of scatter is achieved, and 
the highest amplitude of the pulse is recorded. However, fluorescence signal, unique 
across all detectors, can be more diverse due to the localisation of the probe and 
hence, is independent o f the excitation plane of the laser, i.e. the fluorescence signal 
is dependent upon the localisation of the fluorescence probe and hence, is not 
necessarily optimal at the centre of the event (Figure 5.2). As the event exits the 
beam  the signal voltage, or amplitude, reduces and the pulse returns to base line.
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Figure 5.1 Representation of a typical fluorescence generated electrical pulse signal 
following PM T stimulation and subsequent electron amplification. The maximal 
amplitude achieved for the electrical signal (voltage) is the descriptor for the pulse 
height (FL-H), the corresponding descriptor for the pulse duration is pulse width 
(FL-W) and the total area or integral of the electrical signal is the referred to as the 
fluorescence area (FL-A).
Pulse shape analysis is based on particle speed, size, and width of the illumination 
beam. W hen referring to fluorescence single generation, distribution of the 
fluorophores within the particle or cell plays a critical role in influencing the 
resultant shape. Different measurements can be taken from the same signal, as 
outlined in the Figure 5.1 above, height, area and width, however, each variable 
gives unique information and characteristics of the cell or population under 
investigation [315].
199
A)
JL
Time
©
I
o> o>
LASER-
B )
«
fo
>
Time
©o>2
o
>
LASER-
D irection o f  F low
Figure 5.2 Fluorescence signal properties and their respective influencing factors. A) 
The generation of a fluorescence electrical signal following laser excitation of a free 
flowing particle and B) the influence fluorophore localisation as well as intensity has 
on electrical signals following PMT amplification. Note the counterintuitive flow of 
the sheath fluid and hence particles, typical of modern flow cytometers. Figure 
adapted from 1315].
Typically within flow cytometry the use of scatter plots to display population or 
event data is common, and generally, the initial data analysis starts with the use of a 
FSC-A vs SSC-A dot scatter plot to differentiate debris from the population of 
interest. This principle relies on the FSC-A being a relative measure of particle size 
and SSC-A representing relative complexity, therefore, small, un-granulated 
particles are subjectively removed. Flowever, due to the diverse nature of biological
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sample, there would be relatively large diversity within cell size, as well as 
complexity, and therefore, gating can be misleading. In order to facilitate more 
accurate gating, the inclusion of additional gating strategies is now common practice, 
including the use of a doublet discrimination scatter plot, FSC-A vs FSC-W  [316]. 
Fluorescence-W , a measure of the time taken for said particle to pass through the 
illumination beam, is independent of area and height and therefore, an additional 
measurement of relative cell size (Figure 5.2). Utilising this allows the user to 
exclude particles which do not conform to the average size of the particles defined as 
single cell in nature, removing both debris as well as cellular agglomerates.
However, utilising additional properties of the signal as specific variables to 
manipulate the data during analysis has specific limitations. One should be aware of 
the relationship of said variable and effects the manipulation could have on the 
subsequent data [317, 318]. For example, when utilising FL-W  measurements as an 
additional gating strategy to remove non-conforming outlier events, the 
corresponding variable must be independent of fluorescence voltage or intensity not 
to  bias the data. I.e. if using a FL1-W  measure for a fluorophore under assay, 
utilising this in combination with a FL1-A or FL1-H measure, would significantly 
increase the risk of data bias due to the additional descriptors being influenced by the 
intensity of the attached fluorophore [318]. Figure 5.2 represents the relationship 
between FL-A and FL-H with respect to fluorophore localisation and intensity; width 
measurements are independent of intensity and therefore, can be used relatively 
freely to add additional levels of outlier exclusion. Overly complex and subsequently 
misleading flow cytometry gating can be as detrimental as no cytometry gating if the 
prejudice within the analysis impacts the finalised data, this is highly problematic 
w ithin the in vitro assay design, in regard to the enumeration of presumptive mutant 
events.
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5.1.3 Potential biasing within PIG-A  data analysis -  Does membrane integrity 
negatively bias data during analysis
Cellular viability has been commented on extensively with in the first two results 
chapters (Sections 3.3 and 4.3); however, limited actual conclusive remarks have 
been made in regards to the physical difference in PIG-A fluorescent intensity with 
respect to viability status. Currently, it is unknown whether or not cells undergoing 
apoptosis or early stage necrosis actually do present a true biasing effect within the 
subsequent in vitro data analysis, as a lack of membrane asymmetry and potential 
lack of membrane integrity [114, 274, 276] could induce inaccuracies in phenotypic 
definition. The initial data generated, demonstrated an extremely apparent 
correlation between phenotypic PIG-A mutant phenotype and loss of membrane 
integrity (Section 3.3.5), however, little could be taken with regards to progressive 
loss of membrane integrity sequentially affecting PIG-A mutant data. Due to this, 
apoptosis, necrosis and complete lack of membrane integrity have all be associated 
with the potential of eliciting false positive results (Section 3.3.5); however, further 
investigation is required to assess the likelihood of phenotypic mutant enumeration 
bias. W ithin the second results chapter’s supplementary work, we demonstrated that 
FL-H, as a measure of phenotypic PIG-A mutant events, was highly variable due to 
its direct correlation to fluorescence intensity and particle shape, and therefore, was 
shown to be sub-optimal as a robust form of measurement (Appendix Section
4.5.3.2). In order to assess the likelihood of additional assay bias, alternative features 
o f the cellular population, momentarily disregarding fluorescence staining, were 
considered for their impact on subsequent analysis.
Apoptosis has been thoroughly researched and well characterised during the latter 
stages of the 20th century [120, 124, 274], and due to this pioneering research the 
field now is better able to understand the triggers, these include; nutrient deprivation, 
infection (viral), hypoxia and increased cellular ion content [319] etc. Intrinsic or 
extrinsic apoptosis terminates with a highly organised mechanism of programmed 
cell death [275], however, even though apoptosis results in the eventual 
fragmentation of the cell, few if any morphological traits are apparent during the 
early stages. Condensation of the chromatin, loss of nuclear membrane integrity,
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cellular membrane budding and the eventual formation of pyknotic bodies, which are 
engulfed via phagocytosis by circulating macrophages, are all characteristic of the 
latter stages which are easily morphologically identified within heterogenous 
populations [274, 276], Apart from nuclear DNA laddering within gel 
electrophoresis, which is not practical single cell basis, only subtle changes within 
the structure of the lipid bi-layer are apparent within the early stages. Loss of 
membrane asymmetry, the migration of negatively charged phospholipids to the 
extracellular surface, is the characteristic which we chose to exploit to enable early 
stage apoptosis detection; the newly acquired negative charge on the cell membrane 
permits Ca2+ mediated fluorophore-conjugated annexin V binding [273, 274]. After 
detecting an un-even distribution of non-viable, annexin V positive, cells within the 
presumptive PIG-A mutant population when compared to the corresponding wild 
type phenotype (Section 3.3.5); tentatively apoptosis was concluded to appear to 
induce an effect which resulted in characteristic loss of GPI-AP binding. However, 
little is known about the extent in which apoptosis, as well as necrosis, have an effect 
on GPI-AP binding, which is a topic which will be assessed within this results 
chapter. Although, GPI-AP deficiency has been alluded to increasing resistance 
against apoptosis and hence, is a potential mechanism describing the expansion in 
numbers o f PIG-A mutants within patients suffering from PNH [320]; this 
mechanistic data conflicts with the data within chapter 2  and further increases the 
need for more detail investigation into the mutant mimicking identity of non-viable 
cells. Theoretically, as cells progress through apoptosis, they accumulate 
significantly more severe membrane alterations, inversions, budding and eventual 
rupture, and therefore, GPI-AP expression or presence may have a negative 
correlation with apoptosis progression, a useful dynamic to correct against during 
subsequent PIG-A analysis.
This progressive loss of membrane integrity, experienced within apoptosis, is 
required to be studied in order to assess the additional requirement of integral 
transmembrane protein immuno-fluorescence labelling inclusion within the assay 
design. If GPI-AP binding is negatively biased by apoptosis progression, then a point 
in which alterations in membrane structure, preventing GPI-AP presence, should be 
identified via the loss of supplementary lipid raft associated membrane proteins 
[321]. HLA-DR or Human Leukocyte Antigen - DR is a specific subtype of a MHC
class II cell surface receptor, encoded by the HLA complex on chromosome 6  [322]. 
HLA were originally defined as cell surface antigens with a critical role in mediation 
between “graft versus host disease” and therefore, play a vital role in rejection or 
acceptance of tissue transplantation [323]. Due to the complex nature of MHC class 
receptors, there are three specific HLA-complexes each with a number of isoforms, 
miss-match can result in fatal rejection o f tissue transplantation in HLA-mismatched 
donors. HLA-DR is also involved in several autoimmune conditions, disease 
susceptibility and disease resistance and therefore, is a vital cellular antigen which is 
constituently expressed at high density within the cellular membrane of most 
leukocyte cell lineages [321, 323-325].
Utilising HLA-DR as a sole progressive marker for membrane integrity loss, or in 
combination with pre-existing measurements as well as maintaining apoptosis 
evaluation should improve assay sensitivity as well as provide more of an identity to 
the resultant flow cytometry data. An additional feature which HLA-DR staining 
provides, unable to be obtained by live or dead cell staining, is the conformation of 
membrane integrity and a generic expression of surface antigens, which is useful 
when commenting on general cellular health and defining the normal phenotype.
5.1.4 Next Generation Sequencing and its Necessity to Validate the Presumptive 
PIG -A  M utant Status to offer Validity within the Test System
The present in vivo Pig-a mutation assay is currently within an extensive validation
in order to assess its likelihood of OECD guidelines drafting and finalised
acceptance within the tiered genetic toxicology standard test battery [77, 143, 166,
169, 176, 196]. The sheer extent of published data supporting the mechanism and
broad steering committee guidance has provided the assay with the best chance of
integration within 28-day tox studies and inclusion within safety assessment [13, 91,
144, 170, 172, 173, 178, 222, 280]. However, due to the nature of erythrocytes, the
true identity of the presumptive mutant events will never be fully validated as they
lack an intact nucleus, and therefore, cannot be sequenced to validate the Pig-a
mechanism. The ideology of the mechanism has been investigated in a number of
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additional haemopoetic tissues and has been reproducibly determined to demonstrate 
extensive PIG-A  mutation as the critical mutational event determining lack of 
phenotype [172, 173], However, more recent publication has demonstrated the 
presumed PIG-A deficient phenotype to be a result of an autosomal double knock out 
mutational event within the PIG -T  gene, re-enforcing the counter argument that even 
though statistically insignificant, additional silencing effects other than the PIG-A  
gene can result in a GPI-AP negative phenotype [146].
Additional to the extensive primary leukocyte sequencing, generally splenocytes 
collected from rodent models, in which the origins of the loss of phenotype were 
investigated [169, 176]. Very little is known about how these outliers could 
potentially impact the assay mechanics, especially due to the extensive sample size 
and subjectivity within flow cytometry gating. Therefore, there is much use in 
producing a flow based assay within equivalent haemopoetic tissue, utilising an 
analogous reporter system in order to in-directly validate the reporter as well as 
evaluate the presence of such non-PIG-A mediated mutant events within the total 
population of phenotypic PIG-A  mutants [181]. Traditionally, sanger sequencing 
utilising chain termination dideoxynucleotides, has been the primary method of 
genomic sequencing [326], however, due to the highly limited read sizes (300-500 
base pairs), as well as other limitations, additional methods based on sequencing 
through synthesis were developed. Pyrosequencing, in which cycled nucleotide 
exposure is correlated to light output, based approaches were developed which 
enable multiplexing sequence analysis, but however, limit reads to 25-100 bp in 
length [326]. Nonetheless, recently, the world of genomics has grown exponentially 
with the invention of the next generation sequencing approaches in which solid state 
sequencing, in combination with Pyrosequencing approaches are miniaturised within 
a single platform to facilitate the sequencing of thousands of DNA molecules at 
once, allowing whole genomes to be sequenced within minutes at an affordable cost 
[327, 328].
The advancements o f Next generation sequencing (NGS) techniques had enabled the 
rapid sequencing o f whole genomes at relatively low costs [329]; this feat has 
brought about numerous benefits to scientific research as well as a number of novel 
challenges to the biomedical research field [330]. W ith costs rapidly falling (the first
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human genome cost $3 billion dollars), the challenge now has evolved from 
physically sequencing the genome (currently ~$ 1-5,000), a feat unable to be 
achieved financially using older sanger methodology [326], but to handle and 
confidently interpret the shear amount of raw data generated during sequencing. As 
the field of NGS rapidly grows and the applications in which NGS can be 
implemented expands due to the removal of financial constraints, the software 
available to be implemented into the analysis pipeline is also rapidly escalating [327, 
328, 330, 331], each version of the software becoming more advanced and 
containing additional algorithms for novel problem solving [332-334]. However, due 
to a lack o f a single standardised approach [335], and the emergence of individual 
fields of research within NGS data analysis, for example metagenomics [336]; 
increasing numbers of possible software packages to complete the same or an 
analogous analysis task are becoming publically available [330, 337, 338]. As a 
direct result of this, leading sequencing institutes can therefore, generating sequence 
data and interpret such data using a unique analysis pipeline constructed by 
themselves, without publishing said pipeline competitive institutes are unable to 
reproduce their data as well as potential critique their analysis flaws, therefore, each 
data analysis has its own unique caveats established through the construction of their 
analysis pipeline.
M etagenomics analysis has begun to make good advancements towards the 
establishment of a single standardised pipeline [327, 336], however due to the 
complexity, sheer volume and plethora of applications for human genome NGS 
analysis, a single pipeline would be too crude for each individual application. 
Therefore, when assessing or interpreting NGS data a very thorough understanding 
of the specific pipeline and individual caveats and variation between the separate 
elements within a pipeline is advised.
Utilising next generation sequencing approaches, in combination with a hetero or 
homogenous population of flow cytometry defined PIG-A mutant phenotype cells, 
could provide data on the error rate within detection, the origins of the m utation 
events, the type of mutation occurring, the synonymy of the mutation and hence, 
functionality of the cell in terms of PIG-A  protein as well as parallel investigation 
into a number of additional genetic causes of the presumed Pig-a deficient
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phenotypic (multiplexing). Obtaining such data could provide supplementary 
information to validate the accuracy of the currently proposed in vivo Pig-a  
mechanism and enable the further optimisation of assay design, including gating 
strategies, to facilitate a more accurate prediction of hazard and risk assessment.
The next generation sequencing (NGS) experiment carried out within the following 
chapter utilised an Illumina™  MiSeq in combination with a heterogenous pooled 
DNA sample, in order to assess the phenotype-genotype relationship within the in 
vitro PIG-A  assay design. Genomic DNA extracted from EMS treated MCL-5 cells 
were FACS, prior to sequencing, to obtain a heterogenous phenotypic PIG-A  mutant 
population, as identified by a characteristic lack o f CD55/59-RPE related 
fluorescence signal. Once isolated, the genomic DNA was amplified, adapter ligated 
and sequenced at a >90% coverage and >3,000 average depth across all genes of 
interest. Four genes were selected for sequencing variant analysis, PIG-A, PIG-T, 
CD55 and CD59\ intrinsic and exonic sequences as well as sizable 5’ and 3’ 
regulatory regions were assessed.
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5.2 Materials and Method
5.2.1 Trialled usage o f HLA-DR Staining to Validate Single M arker PIG -A  Dose 
Response Data within MCL-5 Cells
Low passage (p4) MCL-5 cell cultures were established and maintained as outlined 
in (Section 2.2) and exposed to MNU, ENU, EMS and 2,4 DNP for 24 hr under 
standard chemical treatment as described within (Section 2.4) at Gentronix Ltd. Post 
chemical exposure, cultures were washed, counted and seeded ready for initial flow 
cytometric analysis; 10 pL  anti-human anti-CD59 R-PE, 40 pL  HLA-DR FITC (Cat 
No. 555871, BD Biosciences, Hertfordshire, UK) and 10 pL  7-AAD (Section 4.2.4) 
were used. Flow cytometric analysis as defined in (Section 2.8.2) was undertaken 
within an hour of sample preparation, samples were stored on ice, protect from direct 
light, until analysed. W ork undertaken by Matthew Tate, Jodie Allsop and Sabrina 
Khaliq under the guidance of Prof. Richard Walmsley.
5.2.2 Confocal microscopy GPI-AP expression analysis
5.2.2.1 GPI-AP Expression Analysis on the Surface of 4% PFA fixed MCL-5 
Cells
MCL-5 cells were established as outlined in (Section 2.2) and treated with anti­
hum an anti-CD55 and/or CD59 R-PE antibodies for 30 min according to (Section
2.8.1) before being washed twice in pre-warmed, 37 °C PBS. Briefly, cells were re­
suspended and fixed using 1 mL of 4% PBS buffered paraformaldehyde (Section 
2.7) and incubated for 15 min at 37°C, within the temperature controlled NU-5510 
DHD Auto flow incubator, before being washed twice with excess 1 x PBS. 
Coverslips, Precision 0.17 mm thickness, (Cat No. 474030-9000, Carl-Zeiss,
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Hertfordshire, UK) were then prepared for cellular adhesion on one side; this was 
achieved by placing the attachment side down in a 0.1 mL aliquot of lm g / mL 
aqueous poly-L-lysine (Sigma-Aldrich, Gillingham, UK) on Parafilm. The cover 
slips were allowed to incubate for 1 0  min at room temperature, within a class 2  
safety cabinets, and then washed thoroughly using dH 2 0  and left to air dry. 
Coverslips were then incubated in 1% PBS bovine serum albumin (Sigma-Aldrich, 
Gillingham, UK) for at least 1 hour to prevent subsequent fluorophore conjugates 
binding the cationic poly-L-lysine and causing excessive background fluorescence. 
The fixed cells were centrifuged (-350  x g for 7 min), washed, re-suspended in 3 mL 
o f PBS and then aliquotted into 6 -well plates (Greiner Bio-One, Hertfordshire, UK) 
at a suitable concentration to provide sufficient coverage -1  x 105 - 106 cells/mL. 
Each well received a poly-L-lysine coated cover slip using forceps, adhesion surface 
facing upwards, and was incubated for 10 mins at room temperature. Post 
incubation, the cells were analysed under a light microscope to ensure that 
attachment was successful before begin retrieved and washed thoroughly in a fresh 
6 -well plate containing PBS. Post incubation, cover slips were washed in PBS and 
dried via the touching of filter paper to the outer edge o f the cover slip, to prevent 
damage to the cell surface. Cover slips were then mounted within a medium 
designed to minimise the change in refractive index and limit excessive bleaching - 
l,4-diazabicyclo[2,2,2]octane (DABCO) (Cat No. D27802, Sigma Aldrich, 
Gillingham, UK). The mountant was constructed as follows; 45 mL glycerol (G55- 
16 100 mL, Sigma Aldrich, Gillingham, UK), 2.5 mL Tris-HCL buffer (pH 8 ) and 
2.5 mL dH 2 0 . Polished glass slides (Cat No. 11562203, Fisher Scientific, 
Loughborough, UK) were used in conjunction with autoclave tape in order to 
construct two “mounts” or “posts”, preventing the weight o f the cover slips crushing 
the attached cells. Loaded cover slips were laid attached side down onto 50 pL 
mountant, central between the two posts, within the centre o f the supported glass 
slide. Due to the addition of posts, cells remained in their 3-D conformation and due 
to fixation were stable to be stored protected from light at 2-4 °C for a number of 
days prior to analysis.
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5.2.2.2 Confocal Microscopy Image Analysis
Confocal microscopy was carried out using a LSM -710 laser scanning confocal 
microscope and supplied ZEN software version 2009 in conjunction with either a 
40x or 63x oil immersion DIC objective (Carl Zeiss, Cambridge, UK). All 
fluorochromes/fluorophores were excited using the 405, 488, 594 or 633 nm lines. 
During analysis artifactual data was always referenced against unstained or single 
stain negative controls to ensure consistency, as well as objectives, laser excitation 
intensity and laser gain settings remained consistent to provide comparable data sets. 
For proof of principle experiments, all necessary information was saved associated to 
the file in order to replicate the sample of interest. Retrospective image analysis was 
carried out using the ZEN software, as described within the manufacturers supplied 
information.
5.2.3 Preliminary MCL-5 PIG -A  Assessment; Tandem CD55/CD59 Surface 
Antigens utilised as reporter following M NU Exposure
Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2) and exposed to MNU for 24 hr under standard chemical treatment as 
described within (Section 2.4). Post chemical exposure, cultures were washed, 
counted and seeded ready for initial flow cytometric analysis using anti-human anti- 
CD55 R-PE in tandem with anti-CD59 R-PE conjugate antibodies and 7-AAD 
(Section 2.8.1)). Flow cytometric analysis as defined in (Section 2.8.2) was 
undertaken within an hour of sample preparation, samples were stored on ice, 
protected from direct light, until analysed.
Two different gating strategies were implemented to enable a direct comparison in
method; after gating for single cells on a SSC/FSC dot plot and/or counter map, an
additional doublet discrimination (FSC-A vs FSC-W ) as well as novel FL-2-W  vs
FSC-A scatter pot were implemented to exclude non-single cell events. A minimum
of 1 0 , 0 0 0  single cell events were analysed for the surface expression of the
CD55/CD59 surface antigen. PIG-A phenotype was assessed utilising an instrument
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calibration standard (ICS), an unstained sample used to set voltages and mutant 
gating. During ICS analysis, the mutant mimicking sample is utilised to detect auto 
fluorescence within the channel of collection in order to distinguish between a 
positive event and background noise at the channel’s photon multiplier tube (PMT).
MNU dose response data were produced using a FACSAria I cell-sorter ™ (BD 
Biosciences, Hertfordshire, UK), analogous to the previous work utilising EMS 
induction (Section 3.3.3 and 4.3.4). All fluorescence measurements on the 
FACSAria were recorded using the “area” parameter; R-PE and 7-AAD were 
assessed within the pre-specified “PE” and “APC” detectors. PE, 556 LP combined 
with a 585/42 band pass filter and APC, no LP combined with a 660/20 band pass 
filter. PE was excited off the 488nm laser line, and the 7-ADD off the 633 nm laser 
line, best matching their excitation maxima’s.
Following flow cytometric analysis, parental cell cultures were removed from 
incubation every 24 hr for repeated PIG-A  mutagenesis assessment as described at 
length in (Section 2.10).
5.2.4 Assay Refinement - Gating Strategy Comparison and Apoptotic 
M orphology Investigation
5.2.4.1 Gating Strategy Direct Comparison
Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2) and counted. In an analogous method to previous sections, cells were 
treated with anti-CD55 R-PE antibody and washed prior to being run on the flow 
cytometer (Section 2.8). Within the FACS Diva ™ 6  software, samples were run in 
triplicate utilising different gating strategies, 2-D histograms and 2D-density scatter 
plots, and were assessed utilising the FL-W  measure of the fluorophore channel as 
well as the FSC-W. Gates were drawn subject to -90%  of parental population and 
output was commented in terms of numbers/percentage phenotypic PIG-A  mutant 
single cell events.
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S.2.4.2 Apoptotic Morphology Investigation
Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2) and counted (Section 2.2.1). The equivalent volume containing 4 x 106 
cells was transferred into six fresh 15 mL centrifuge tubes, and the total volume 
adjusted to 10 mL via the additional of culture media. 100 pL aliquots of 1 pM doses 
of Staurosporine solution were added to five o f the culture flasks for the following 
exposure lengths; 30 min, 1 hr, 2 hr, 3 hr , 4 hr and 8  hr. Following Staurosporine 
exposure, all flask contents were transferred into sterile 15 mL falcon tubes, 
centrifuged (-250  x g for 7 mins) and the toxic supernatant carefully discarded. 10 
mL of 1 x PBS was added to re-suspend the cell pellets and remove any excess 
residual chemical (Section 2.4). Samples were centrifuged, supernatant aspirated 
(presumed toxic) and re-suspended in 10 mL of fresh medium. Each sample was 
counted (Section 2.2.1) and three subsequent samples were constructed, each sample 
containing 1 x 106 cells. Subsequently, samples were centrifuged (250 x g for 7 min), 
supernatant aspirated, and re-suspended in 100 pL of pre-warmed media. Each 
sample, excluding the ICS, was treated with 20 pL of anti-human anti-CD55 PE 
antibody in combination with 20 pL of anti CD59 R-PE and incubated at room 
temperature for 30 min, protected from light (Section 2.8.1). Following incubation, 
samples were centrifuged, supernatant aspirated and re-suspended in 5 m L of 1 X 
PBS solution. Samples were re-centrifuged, supernatants discarded, and re­
suspended within 1 mL of 1 X Annexin binding buffer, this step was repeated three 
times. Samples were re-suspended within 100 pL of annexin binding buffer and 
treated with 5 pL of Alexa Fluor 488 nm Annexin V, excluding the ICS sample. All 
samples were incubated for 15 min at room temperature, protected from light. Excess 
1 X Annexin binding buffer was added to each sample, prior to centrifugation, 
supernatant aspiration and re-suspension within 200 pL of 1 X Annexin binding 
buffer. 5 pL of 7-A AD was added, excluding the ICS and incubated for 15 min prior 
to flow cytometry analysis; samples were stored on ice protected from light (Section 
4 .2 .3 -4 .2 .4 ) .
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5.2.5 Next Generation Sequencing
Next generation sequencing performed within this body of work was carried out 
within the Glaxo SmithKline Research and Development centre at Stevenage, UK. 
The sequencing was physically undertaken by Miss Lucy Field, under the 
supervision of Dr Nalini M ehta and group leader David Dow respectively, on an 
Illumina M iSeq platform (San Diego, California, USA) in conjugation with 
SureSelectXT Reagent Kit (Cat No. G9611A, Agilent Technologies, Wokingham, 
UK). All work was carried out according to GLP, regularly inspected, and when 
applicable carried out within class 2  safety cabinets to prevent contamination 
(thorough ethanol cleaning as well as UV sterilisation was undertaken regularly).
Details o f the full methodology used can be found at (Appendix Section 5.2.5), 
however, in brief initially the “Genes o f Interest” target sequences were identified 
{PIG-A,PIG-T, CD55 and CD59), and cross validated across a number of different 
software packages: Berkley Drosophila Genome Project -  Neural Network Promoter 
Prediction [339], Promoter 2.0 Prediction Server [340] and SoftBerry -  FPROM 
[341] (Appendix 5.2.5.1). Following this, SureSelect oligonucleotide primers [342] 
were designed to span across each amplicon (inclusive of the entire coding region as 
well as an additional 1,000 bp 5’ and 3 ’ buffer zone) with sufficient coverage to 
provide confidence and integrity with subsequent next generation sequencing results 
(Appendix Section 5.2.5.2).
Following FACS (Section 2.8.3) phenotypic PIG-A mutant cellular events had their 
DNA extracted and cleaned up using the QIAamp DNA Micro Kit (50) (Cat No. 
56304, Qiagen, Manchester, UK), the resultant isolated DNA was quantified using 
the NanoDrop ND-1000 Spectrophotometer (Appendix Section 5.2.5.3) and Qubit ® 
2.0 Fluorometer (Life ™  Technologies, Paisley, UK) apparatus (Appendix Section 
5.2.5.4).
Following DNA extraction, the genomic DNA was sheared, using the covaris
sonication method (Covaris M220 Focused-ultrasonicator ™ (Covaris,
Massachusetts, USA)) (Appendix Section 5.2.5.6), and quality assured for complete
degradation on a 2100 Bioanalyzer (Agilent Technologies, Wokingham, UK).
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Sequentially, the single stranded DNA (ssDNA) was converted into blunt ended 
double stranded DNA (dsDNA) (Appendix Section 5.2.5.7), additional 5’ adenine 
overhangs constructed (Appendix Section 5.2.5.8 ) and adapter oligonucleotides were 
ligated onto the template DNA sequences (Appendix Section 5.2.5.9) utilising 
components from the SureSelect Library Prep Kit (ILM), SureSelect Target 
Enrichment Kit (ILM) indexing Hyb Module Box #2 and Herculase II Fusion DNA 
Polymerase (Agilent Technologies, Wokingham, UK). The entire library at this point 
was amplified through thermal cycler exposure (T100 thermal cycler (Bio-Rad, 
Hertfordshire, UK)) (Appendix Section 5.2.5.10). Following amplification, 
Agencourt AMPure XP (Cat No. A63882, Beckman Coulter, High Wycombe, UK) 
beads were added to the amplified library in order to wash (ethanol), purify and 
isolate the freshly constructed dsDNA (Appendix Section 5.2.5.11). At this point 
another additional quality assurance (2100 Bioanalyzer) step was utilised to ensure 
that the size of the dsDNA molecules constructed was in the range of 225-250 bp in 
length.
Following on from purification, the dsDNA underwent hybridisation (utilising 
components from the SureSelectXT Reagent Kit)(Appendix 5.2.5.12) prior to 
magnetic bead identification (using Dynabead M yOne Streptavidin T1 and 
corresponding Dynabeads®) and isolation of Target Sequence dsDNA (Appendix 
Section 5.2.5.13). Index tags were now added (Appendix Section 5.2.5.14) following 
hybridisation (SureSelectXT Reagent Kit) and isolation prior to additional rounds of 
speciifc library amplification (Appendix Section 5.2.5.15). Again the dsDNA under 
went purification using magnetic beads and isolation using analgous Agencourt 
magnetic beads (AM Pure XP beads)(Appendix Section 5.2.5.16). Measures were 
taken to assess the homogenous nature of the molecules, ensuring that the dsDNA 
lenghts were in the range of 250-325 bps (2100 Bioanalyzer). Following this, the 
Index Tagged Amplified library was quantiativiely assessed using a SYBR® Green 
QPCR method (QPCR NGS Library Quantification Kit (Illumina) (Cat No. G4880A, 
Agilent Technologies, Wokingham, UK)) - at this point the Illumina adaptor speciifc 
PCR primers were also added to the template dsDNA(Appendix Section 5.2.5.17).
Post quantification and subsequent sample concentration ammendments (Appendix 
5.2.5.18), the Illumina flow cell and MiSeq™  platform were thawed and calibrated
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prior to use. The amplfied illumina adaptor ligated index library was denatured into 
ssDNA, diluted appropraitly and loaded into the MiSeq™  reagent cartridge, 
analgous controls were also constructed at this point. The Illumina MiSeq® was 
loaded, cleaned according to the Illumina MiSeq® system user guide, and the 
ssDNA sequenced (Appendix Section 5.2.5.19). Real time analysis of run efficiency 
and progress was carried out on an adjacent computer running Sequence Analysis 
Viewer software ((SAY) software (Illumina, San Diego, UK)).
5.3 Results
5.3.1 Trialled usage o f HLA-DR Staining to Validate Single M arker PIG -A  Dose 
Response Data within MCL-5 Cells
Dose response experiments were carried out in order to assess the potential benefits 
associated with the refined assay design; low passage MCL-5 cells combined with 
HLA-DR (membrane integrity) staining, limited viability dye incorporation and 
CD59 utilised as the in-direct reporter for mutation phenotype. EMS was 
continuously chosen as one of the chemicals for assay, along with MNU and ENU, 
additional members o f the G4 compounds. 2,4 Dinitrophenol (2,4 DNP), a precursor 
to sulphur dyes extensively used in the manufacturing of cotton products, was also 
selected for its dissimilar properties and mechanism. All events labelled as PIG-A 
mutants are events, phenotypic viable single cells with an apparent absence or 
reduction of CD59 presence on the extracellular surface membrane, and therefore, 
are presumptive PIG-A  mutants. Experimental design, undertaken at Gentronix Ltd., 
permitted the capture of -50,000 defined viable single cell events
All data generated following 4 day PIG-A  mutation assessment were evaluated for 
normality and variance (P value >0.05) using the Shapiro-W ilk and Bartlett’s Test 
respectively, carried out within DrSmooth in the R-Software environment (R-3.0.2, 
Free Software Foundation’s GNU project). Following assessment, data was either 
defined as normally distributed (ENU and 2,4 DNP) or non-normal (MNU and EMS) 
and subsequently, PROAST38.9 modelled in order to define BMDio and BMDlio 
values (Appendix Section 5.3.1). Statistical analysis, Dunns’ or Dunnett’s’ t-tests 
was implemented to state at what dose, if any, rejection o f the Null hypothesis was to 
be assumed (P-value <0.05). At such a dose, variation o f the viable phenotypic PIG- 
A  mutant frequency was a direct result of a significant factor and not as a result of 
chance.
Acute MNU exposure resulted in an apparent sub linear day 4 dose response within 
viable MCL-5 cells (Figure 5.3.A). Doses less than 20 pM  appeared to illicit no
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effect on the relative percentage of phenotypic mutant, when compared to con­
current negative control data. However, as doses increased, a strong positive 
correlation between dose, toxicity and phenotypic PIG-A  mutant number was 
observed, but no doses were demonstrated to be statistically significant (P>0.05). 
Variance was apparent, specifically significant at the higher doses, with much 
greater deviation around the mean displayed; this can highly influence statistical 
analysis and therefore, prevent significance from being derived. BMDio and 
BMDLio values of 4.51 and 3.17 pM  were derived respectively using PROAST 38.9 
(Appendix Section 5.3.1). Cell viability was demonstrated to be dose dependent, 
with doses greater than 5 pM  resulting in excess o f 20% cytotoxicity (Figure 5.3.A). 
RICC was shown to decrease to 20% viability by 40 pM ; larger doses demonstrated 
an analogous result.
Acute 2,4 DNP exposure resulted in a sub linear day 4 dose response within viable 
MCL-5 cells (Figure 5.3.B). All doses tested within the concentration range failed to 
statistically increase the relative average phenotypic mutant frequency, and had very 
little effect on the resultant dose response (P>0.05). Due to the apparent innate 
activity of the chemical as a genotoxicant, and hence, lack of dose response of the 
PROAST modelled data; BMDio and therefore, BM DLio values were unable to be 
derived (Appendix Section 5.3.1). Cytotoxicity again was demonstrated to be highly 
dose dependent, with a generalised decrease apparent over the entire dose range. 
Doses exceeding -125  pM  resulted in an approximate 50% decrease in viability 
(Figure 5.3.B) with greater doses resulting in even more severe cytotoxic effects. 
Little variance in terms of both viability and relative phenotypic PIG-A frequency 
was demonstrated within the data.
Acute 24 hr EMS exposure resulted in a seeming sub linear day 4 dose response 
within viable MCL-5 cells (Figure 5.3.C). There was an apparent dose dependent 
increase in the relative phenotypic PIG-A mutant frequency, when compared to con­
current negative control data, at the top dose of -1 6 0  pM  (equivalent to 20 pg/mL) 
eliciting a statistically significant increase (P<0.05). Limited variance was shown, 
excluding 5 and 120 pM , throughout the dose range with respect to both cytotoxicity 
and PIG-A  mutant frequency. Succeeding PROAST modelling, BM Dio and BMDLio 
values of 11.5 and 8 . 8  pM  were derived respectively (Appendix Section 5.3.1). Cell
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viability was demonstrated to be dose dependent, with doses greater than 40 pM  (5 
pg/mL) resulting in excess of 40% cytotoxicity (Figure 5.3.C). RICC was shown to 
decrease to 20% viability by 100 pM  (12.5pg/ml); larger doses demonstrated an 
analogous result.
Acute ENU exposure resulted in a sub-linear day 4 dose response within viable 
MCL-5 cells (Figure 5.3.D). All doses tested within the concentration range failed to 
statistically increase the relative average phenotypic mutant frequency, and had very 
little effect on the resultant dose response (P>0.05). Due to this, and the lack of 
positive gradient attributed to the data following PROAST modelling, BM Dio and 
BMDLio values were subsequently unable to be derived (Appendix Section 5.3.1). 
Cytotoxicity again appeared to decrease in a dose dependent manner, with a 
generalised decrease apparent over the entire dose range. Doses exceeding 200 pM  
resulted in an approximate 40% decrease in viability (Figure 5.3.D) with greater 
doses resulting in even more severe cytotoxic effects. Significant variance in terms 
o f both viability and relative phenotypic PIG-A frequency was demonstrated 
throughout the entire dose range, and hence, extensive deviation from the mean was 
apparent (Figure 5.3.D).
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Figure 5.3.A Day 4, low passage human lymphoblastoid cells (MCL-5) average 
relative phenotypic PIG-A  mutant frequency following 24 hr MNU exposure, CD59 
antigen utilised as reporter for mutation, inclusion of HLD-DR and 7-AAD staining 
to ensure cellular membrane integrity. (Dunn’s Test (p <0.05*)(N=4)(Error Bars 
±1SD) PIG-A mutant data relative to the percentage of phenotypic PIG-A mutants 
observed within the con-current control (top dose PIG-A data, two replicates 
omitted, N=2).
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Figure 5.3.B Day 4, low passage human lymphoblastoid cells (MCL-5) average 
relative phenotypic PIG-A  mutant frequency following 24 hr 2,4-DNP exposure, 
CD59 antigen utilised as reporter for mutation, inclusion o f HLD-DR and 7-AAD 
staining to ensure cellular membrane integrity. (Dunnett’s Test (p 
<0.05*)(N=3)(Error Bars ±1SD)) PIG-A mutant data relative to the percentage of 
phenotypic PIG-A  mutants observed within the con-current control.
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Figure 5.3.C Day 4, low passage human lymphoblastoid cells (MCL-5) average 
relative phenotypic PIG-A  mutant frequency following 24 hr EMS exposure, CD59 
antigen utilised as reporter for mutation, inclusion of HLD-DR and 7-AAD staining 
to ensure cellular membrane integrity. (Dunn’s Test (p <0.05*)(N=3)(Error Bars 
±1SD)) PIG-A  mutant data relative to the percentage of phenotypic PIG-A mutants 
observed within the con-current control.
7 120
Average RMF Average RICC
6 100
80
60
2
i 2
- 40
-  20
0
0 50 100 150 200 250 300 350
ENU (|lM)
Figure 5.3.D Day 4, low passage human lymphoblastoid cells (MCL-5) average 
relative phenotypic PIG-A  mutant frequency following 24 hr ENU exposure, CD59 
antigen utilised as reporter for mutation, inclusion o f HLD-DR and 7-AAD staining 
to ensure cellular membrane integrity. (Dunnett’s Test (p <0.05*)(N=3)(Error Bars 
±1SD) PIG-A  mutant data relative to the percentage of phenotypic PIG-A  mutants 
observed within the con-current control.
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5.3.2 Confocal Microscopy GPI-AP Expression Analysis
W ithin published in vivo rodent Pig-a and human PIG-A  data, the focus is very 
much directed towards the quantitative dose response analysis following chemical 
exposures. This data serves a vital role within the future of safety assessment, and 
should enable the more apt hazard and risk assessment utilising the assay platform, 
however, little is known in terms of the biological mechanics of the reporter system. 
Due to the highly limited amount of mechanistic data, excluding sequencing of 
additional primary haemopoetic tissues, the purpose of this section was to assess the 
reproducibility of the biology behind the in-direct reporter system and come to a 
preliminary conclusion about the potential limitations associated with such a reporter 
and therefore, the most appropriate method for integration within the assay platform.
In an attempt to better characterise the reporter system utilsed within the PIG-A 
established mutation assays, laser scanning confocal microscopy imaging was 
implemented to more throroughly investigate the surface expression of the selected 
GPI-AP reporter marker as well as potentially evaluate future caveats associated to 
in-direct mutagenesis reporting and subsequent flow cytometry assessment.
The intial CD55 data conveyed that when assessed under a x 40 (Figure 5.4 A) or x 
63 oil (Figure 5.4 B) objective the resultant antibody conjugation was 
comprehensively associated with the extracellular membrane; a distinctive halo was 
apparent within the images reflecting on the presence of preiphery staining. The 
antibody staining appeared to be relatively inclusive in nature, but was not entirely 
surface spanning and appeared to be heavily linked to specific regions along the 
membrane. W hen visualised within a 3D reconstructed image, based on ~ 0.1 pm  z- 
stacked focussed images, the GPI-AP expression was more clearly defined as spartial 
in nature and consisted mainly of smaller dense pockets of expression, consistent 
with the current literature (Figure 5.5). However, an additonal minor internal CD55 
signal was also detected within a central location within a subsection of MCL-5 
cells.
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Figure 5.4. Anti-CD55 R-PE treated 4% PFA fixed MCL-5 cells imaged under A) x 
40 and B) x 63 oil immersion objective utilising the laser scanning confocal 
microscope. Detected, R-PE signal was retrospectively artificially coloured red for 
image clarity and cohesion (Scale bar 50pM).
I I 11III?
III;
i f |H fei&rmmVmm
n pp■
H
jmm
Figure 5.5. Anti-CD55 R-PE treated 4% PFA fixed MCL-5 cells, displayed within a 
3D reconstruction following x 63 oil immersion, 1024 x 1024, z-stack capture 
utilising the laser scanning confocal microscope. Detected, R-PE signal was 
retrospectively artificially coloured red for image clarity and cohesion (Scale bar 
50pM).
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The subsequent CD59 data again demonstrated an analagous relationship in terms of 
the density of surface antigen staining with respect to localisation on the cellular 
membrane (Figure 5.6 A and B); CD59 surface antigen expression was estimated to 
be less comprehensive than the comparable CD55 data, in agreeance with previously 
reported data (Section 4.3.1), but again was localised within distinct pockets of 
expression (Figure 5.6 A and B). When 3D assessed, the density of expression was 
more apparent and the highly sporadic natrure of expression was also more 
prominent, CD55 resulted in a far more encompasing surface expression. The 
presence of intracellular stainng was not detected within the CD59 data, all signals 
were localised to the periphery of the cell.
Figure 5.6. Anti-CD59 R-PE treated 4% PFA fixed MCL-5 cells captured under the 
x 63 oil immersion objective (A) and displayed within a 3D reconstruction following 
1024 x 1024, z-stack capture (B) utilising the laser scanning confocal microscope. 
Detected, R-PE signal was retrospectively artificially coloured red for image clarity 
and cohesion (Scale bar 50pM).
When assessed following tandem exposure, the CD55/59 data generated significantly 
more comprehensive surface expression coverage, as expected, than either single 
stained antigen (Figure 5.7). Regardless of image manipulation, the most stringent 
optical settings resulted in well stained samples, with distinctive surface expression 
(Figure 5.7 A and B). However, even though the extracellualr surface was highly 
dense with CD55 or CD59 antigen presence, the sporadic nature of binding, reflected
223
the uniqueness of each cell within the population and this in it-self was highlighted 
as a potential limitation when utilised in conjuction with laser light excitation 
platforms.
Figure 5.7. Anti-CD59/55 R-PE treated 4% PFA fixed MCL-5 cells captured under 
the x 63 oil immersion objective and displayed within a 3D reconstruction following 
1024 x 1024, z-stack capture utilising the laser scanning confocal microscope. 
Conservative estimation of surface GPI-AP expression (A) and maximal estimation 
of surface expression (B). Detected, R-PE signal was retrospectively artificially 
coloured red for image clarity and cohesion.
224
Tandem marker coverage (Figure 5.7 and 5.8) was far superior to either of the single 
marker surface expression assessed (Figures 5.4 -  5.6). In an attempt to potentially 
relate the nature of surface marker expression with potential physical or 
morphological features on the extracellular membrane the use of transmitted light 
was implemented in conjunction with the detected emitted fluorescence signals. The 
resultant data, clearly showed the diverse variation within surface staining between 
homogeneous cells; no clear association of marker density or expresion was linked to 
any particular morphological feature of the membrane. However, a noteworthy 
correlation between antigen expression and dense localisation within the membrane 
was apparent due to the discrete nature of binding.
Figure 5.8. Anti-CD59/55 R-PE treated 4% PFA fixed MCL-5 cells captured under 
the x 63 oil immersion objective and displayed layer onto a transmitted light image 
(tPMT) utilising the laser scanning confocal microscope. GPI-AP surface expression 
defined clearly too specific regions of the surface membrane, GPI-AP do not entirely 
cover the extra-cellular surface of the cellular membrane. Detected, R-PE signal was 
retrospectively artificially coloured red for image clarity and cohesion (Scale bar 
50pM).
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Finally, the ability of 4% paraformaldehyde to act as a permeabilising agent within 
MCL-5 cell line usage was assessed via the inclusion of a counter stained analagous 
triton-x sample. In the presence of detergent, minor intra-cellular nucleic acid signal 
was identified (Figure 5.9), however, an analagous, but reduced signal was detected 
within the untreated sample, reflecting upon either the limited effectiveness of 
formaldehyde based fixatives on lymphblastoid membrane permeability.
Figure 5.9. Anti-CD55/59 R-PE and 7-AAD treated 4% PFA fixed MCL-5 cells 
captured under the x 63 oil immersion objective (A) in the presence of Triton X and 
B) in the absence of Triton X utilising the laser scanning confocal microscope. 
Detected, R-PE signal was retrospectively artificially coloured red and the 7-AAD 
signal coloured green for image clarity and cohesion (Scale bar 50pM).
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5.3.3 Preliminary M CL-5 PIG -A  Assessment; Tandem CD55/CD59 Surface 
Antigens utilised as reporter following M NU Exposure
Following the dose finding experiments in which a suitable dose range of both EMS 
and MNU were obtained, MNU was chosen as the initial compound to be assessed 
within the revised in vitro PIG-A assay design. MNU is a highly potent alkylating 
agent and induces a well characterised mutagenic lesion, 06 methyl-guanine, 
resulting in GC -> AT transition mutations [264]. Due to the sheer potency of the 
compound, an estimated increase in presumptive phenotypic PIG-A  mutant numbers 
is predicted. The use o f tandem GPI-associated anchor proteins in order to reduce 
false positivity, as well as reduce the resting background mutant numbers in 
conjunction with a novel gating system approach, was trialled to evaluate potential 
sensitivity within the low dose region.
All data generated following daily PIG-A  mutation assessment were evaluated for 
normality and variance (P value >0.05) using the Shapiro-W ilk and Bartlett’s Test 
respectively, carried out within the DrSmooth add-on R-Software Package (R-3.0.2, 
Free Software Foundation’s GNU project). The daily PIG-A  data acquire following 
acute 24 hr MNU exposure was statistically determined to be non-normally 
distributed (p<0.05).
Based on the preliminary MNU dose finding study (Appendix Section 5.5.3.2) the
final PIG-A  analysis was scheduled for 72 hr post treatment (Day 3). The Day 3 data
was retrospectively assessed following acquisition utilising two distinctly different
gating strategies i) the original unrefined gating system and ii) novel exclusive
method. W hen applying the original gating strategy, the background PIG-A mutant
frequency was estimated as high as 80% of the total population, within the control
samples (77.08%). The number of presumptive PIG-A  phenotypic cells did not
display any definite correlation to the applied dose of genotoxicant; however, the
percentage PIG-A  phenotypic viable mutants did appear to reduce as the doses
increased, 46.6% observed at the top dose (Figure 5.10 A). Cytotoxicity was
demonstrated to increase in a dose dependent manner, with a maximum 28% RPD
value obtained at the top dose of M NU tested, 0.1 pg/mL. Even though the data was
limited to a single biological replicate, the relationships observed were inconsistent
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with those previously defined utilising an analogous reporter and cell line (Section
5.3.1).
However, when utilising the novel reformed gating strategy, the same experimental 
data collect at the day 3 analysis showed that the top dose (1 pg/mL) appeared to 
induce an increase in the percentage of viable putative PIG-A  phenotype cells (0.2%) 
with respect to con-current negative control values (0.01%). An approximate 20-fold 
increase over the lowest observed control frequency was observed, however, due to 
replication limitations, i.e. data was a single replicate, cannot be assessed for 
statistical significance (Figure 5.10 B). The data appeared to show a dose dependent 
increase in percentage viable PIG-A  mutants, especially prominent at the top dose, 
with little affect observed at the lower doses; defining a seeming sub linear dose 
response. Doses greater than 0.05 pg/m L seemed to demonstrate a noteworthy 
decrease in cytotox, with the top dose resulting in a 72% decrease in RCC values.
A)
3o
E-
O
'w '
< 3 -s-
w <u
£  °  o3 <D
53 ob
6
a,
a>
•9
CytotoxicityPIG-A90 -I _
so
7 0 ; I
140
60
50
40
30
20
10
0
0 0.2 0.4 0.6 0.8 1
MNU (pg/mL)
228
CytotoxicityPIG-A
r 1400.25 n
120 ^
&nS
- 100 »
0.2
0.15 -
u J2
o  13
1 °  2  4>
3 ? >  
^  ■§
cx
- 40
0.05 I
-  20
0.80.60.40.2
Figure 5.10. Dose response Day 3 PIG-A  data for MCL-5 cellular cultures exposed to acute 
24 hr MNU treatment. Tandem anti-CD55/CD59 R-PE conjugate antibodies utilised as 
reporters for loss of phenotype assessment and membrane integrity dye (7-AAD) 
incorporated. Original Gating System (A) and novel FL-W  based gating system (B) (N =l) 
(>10,000 Single Cell Events acquired).
i
I
5.3.4 Assay Refinement - Gating Strategy Comparison and Apoptotic Morphology
I
Investigation
jWithin the flow cytometry gating strategy, utilised to assess the cellular populations for 
phenotypic PIG-A mutant status, there are multiple stages which can be manipulated and 
hence, are subjective to the operator. Additional to the threshold value, as currently 
determined by the operator following ICS analysis, the mechanism of event exclusion wasf!
‘also investigated to detect potential bias within the subsequent data. W ithin all subsequent
\
data displayed within this section, only a FSC-A threshold was applied, the newly 
incorporated FSC-A vs FSC-W  doublet discriminating gate was removed as well as the use of 
viability dyes, to increase the effect the trialled supplementary gating strategies would have 
on the subsequent data. Utilising tandem CD55/59 markers, the original, novel (FSC-A vs 
PE-W ) and future proposed (PE-A vs PE-W ) additional discriminating gates were evaluated 
for their direct effect on PIG-A  reporting.
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5.3.4.1 Gating Strategy Direct Comparison
^Utilising the original gating system, with no discriminating gates to exclude apoptotic cells, 
doublets or debris -85%  of MCL-5 cells stained positive for CD55/59 presence and hence,
I
w ere defined phenotypic PIG-A wild type. W hen the novel gating system was assessed, the
I
pre-existing number of phenotypic PIG-A  mutants was reduced significantly, from -15%  to 
|~0.005% (Table 5.1), and subsequently increased assay sensitivity considerably. However,
yvhen the potential future additional gating strategy was assessed, the number of pre-existing
i
phenotypic PIG-A  mutants was shown to be completely eliminated from all samples analysed
I
and hence, the gating strategy was shown to demonstrate a significant bias on the subsequent 
PIG-A mutant data (Table 5.1).
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PIG-A 
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data, within 
control untreated 
M
CL-5 
cells, evaluating 
the
W ithin the novel gating strategy, in which doublets are more accurately removed by the 
inclusion of a supplementary doublet and debris discriminator to the pre-existing FSC-A vs
fFSC-W  measure, FSC-A vs PE-W, was accepted as the proposed analysis method to continue
i
assay development. Utilising the novel gating strategy, in the absence of a typical doublet
!
^discriminating plot, the background spontaneous mutants/resting mutant frequency was 
estimated to be 0.005% or 50 phenotypic PIG-A  mutant cells xlO"6 events scored (Figure 
,5.11), analogous to validated genetic toxicology mammalian in vitro gene mutation assays as 
well as recent published literature.
Population ^Events %Parent %Total
B  All Events 48,629 #### 100.0
□  P1 20,391 41.9 41.9
■  FSC-A vs PE-W 18,056 88 5 37.1
H  APC Positive 182 1.0 0.4
□  N0T(APC Positive) 17.87p| 99.0 36.8
L □  CD55/59 Positive 17,8 /b l 100.0 36.8
MCL-5-CD55 A
ARC Positive
-118
APC-A
MCL-5-CD55 A
s3 CD55/59 Positive Cells5
o
PE-A
Figure 5.11. A representation of the current optimal gating strategy, excluding the 
usage of an apoptotic marker, within untreated MCL-5 cells; A) initially an 
estimated single cell population (FSC-A vs SSC-A), followed by the use of B) 
fluorophore specific pulse width measure (PE-W) to remove agglomerates and debris 
prior to C) loss of membrane integrity exclusion (7-AAD) and D) PIG-A phenotype 
assessment (anti-CD55/59 R-PE). (-50,000 Cells were scored for PIG-A phenotype, 
0.005% pre-existing phenotypic PIG-A mutants estimated (-50  x 10'6).
M CL-S-CDSSA
<00
PE-W
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5.3.4.2 Apoptotic Morphology Investigation
Apoptosis is a highly characterised event in terms of the biological processes 
occurring within the cell, reflecting in the sheer number of publications available 
reviewing the mechanistic aspects driving initiation and propagating the removal of 
cells. However, even though microscopy derived images, IHC, and flow based 
platform data are available, very little is published on the ability to track apoptosis 
without the use of fluorescence conjugated dyes. Therefore, in an attempt to better 
characterise apoptotic cells within parental populations, in order to more accurately 
exclude this potential PIG-A mutant phenotype mimicking event, as well as assess its 
impact on the fidelity of the reporter system the following experiments were 
undertaken.
W ithin previous chapters, the data has suggested that the populations of presumed 
PIG-A deficient phenotypic cells, either untreated or following chemical exposure, 
constitutes o f a higher proportion of cells which are non-viable when compared 
directly against the phenotypic wild type cells. Therefore, because of this, there is 
reason to believe that biological pathways shared by non-viable cells, i.e. apoptosis 
or necrosis could be inducing a PIG-A  mutant phenotype, during flow cytometry 
analysis, when there is a lack of mutation at the PIG-A gene locus. In order to 
investigate this phenomenon and theoretically identify novel methods of excluding 
such mutant mimicking events from subsequent flow cytometry analysis, the 
morphology of apoptosis and necrosis, and their effects on cellular surface antigen 
expression were assessed.
Initially, MCL-5 cells undergoing loss of cellular membrane integrity and apoptosis, 
as a result o f 8 hr acute toxic Staurosporine exposure, were assessed in terms of their 
respective light scatter properties. Utilising FSC-A (size) and FSC-W  (time of flight) 
measures, both dead and dying (apoptosis) cells were retrospectively artificially 
coloured, and visualised in terms of the general single cell population. Dead and 
dying (apoptosis) cells did not appear to significantly change in morphology, with 
respect to cellular size, when compared to the general population of viable cells 
(Figure 5.12). However, dead cells did appear to be marginally smaller, as described 
by a lower average FSC-A value. This relationship was again re-enforced by the
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results obtained when FSC-A was compared against PE-W, in which cells which 
lack membrane integrity easily visualised as “smaller" events, especially when 
directly compared to apoptotic cells, with regards to the viable population (Figure 
5.12). The distribution of the dead cell population was distinctly lower within the 
doublet discriminating gate, than the comparable apoptotic data.
MCL-5-8 hr Stauro
Apoptotic Cells
MCL-5-8 hr Stauro MCL-5-8 hr Stauro
Apoptotic Cells
Figure 5.12. Tracking apoptotic and complete loss of membrane integrity within 
phenotypic PIG-A wild type MCL-5 cells; in terms of their physical light scatter 
properties within the context of typical PIG-A gating strategy following acute 8 h 1 
pM Staurosporine exposure (>20,000 acquired and subsequently analysed).
Following Staurosporine (1 pM ) time course exposure, relative percentages of
apoptosis and necrosis cells; categorised by complete loss of membrane integrity as
well as annexin V sensitivity, were demonstrated to increase in a dose dependent
manner, excluding “60 min" necrosis data (Table 5.2). Apoptosis and necrosis were
demonstrated to rise from 2.3 and 27.8 to 46.7 and 76% respectively as the
Staurosporine exposure duration increased from 30 to 480 min (Table 5.2). When the
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data was graphically plotted to establish the nature of the relationship, an ostensibly 
linear correlation was observed; both apoptosis and necrosis revealed a highly 
comparable linear correlation with analogous equation for the line of best fit, the 
comparable R2 values for the slope reflects the positive nature of the correlation 
(Figure 5.13).
It was also apparent that as the exposure time of Staurosporine increased, and 
therefore, the cells were further progressed along their respective death pathways, 
the numbers of cells scoring as phenotypic PIG-A  mutants also increased (Table 5.2). 
At the lower exposure times, and hence, early stages of either apoptosis or necrosis, 
no cells were scored as phenotypic mutants. However, as the exposure time 
increased and the cells were much further established within their respective 
pathways, the number of potential phenotypic PIG-A  mutants was also demonstrated 
to increase (Table 5.2).
Table 5.2. lp M  Staurosporine summary M CL-5 data follow ing a time course 
exposure (0-480 min). Apoptosis was determined by events defined positive fo r  
Annexin V sensitivity , necrosis was defined by events defining positive fo r  both 
complete loss o f  cellular membrane integrity (7-AAD) as well as being apoptotic 
(Annexin V); relative PIG-A data assessed follow ing anti-CD55/59 R-PE tandem  
exposure (>3,000 events captured fo r  each time period).
Sample
Identification
Dead
Cells
Defined
Necrotic
(%)
PIG-A
WT
(%)
PIG-A
Mutant
(%)
Viable Cells 
Defined 
Apoptotic 
(%)
Pig-A
WT
(%)
PIG-A
M utant
(%)
30 min 27.8 100 0 2.3 100 0
60 min 43 100 0 4.4 100 0
120 min 24.9 100 0 5.2 100 0
240 min 61.8 100 0 44.2 99.9 0.061
480 min 76 98.7 1.3 46.7 99.9 0.108
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Figure 5.13. Relative percentage of Necrotic and Apoptotic cells in relation to lpM  
Staurosporine exposure time, within MCL-5 cell cultures. Linear Trend lines 
calculated and R values for both data sets to reflect the correlation within the 
cellular viability and duration of genotoxin exposure (>6,000 events scored for each 
time period).
This observation was more thoroughly investigated through the sequential flow 
cytometry histograms tracking the respective fluorescence intensity signal data 
emitted from specific anti-CD55/59 mediated GPI-AP binding (Figure 5.14). The 
data visually displays the observation that as the length of Staurosporine exposure 
increases, and hence, the progression through the death pathway develops; the 
average fluorescence intensity values corresponding to GPI-AP expression 
decreases. For prolonged exposure, 4 hr or greater, the average fluorescence intensity 
values begin to pass the threshold value, as pre-defined by the ICS, and hence, can 
be classified as phenotypic PIG-A mutant events -  their integrity as mutants is highly 
sceptical as phenotypic expression of GPI-AP loss is estimated as 3-4 days.
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Figure 5.14. Relative phenotypic PIG-A mutant frequency data for MCL-5 cells 
undergoing A) Apoptosis and B) Necrosis following a time course acute 1 pM 
Staurosporine Exposure. 1) 30 min, 2) 60 min, 3) 120 min, 4) 240 min and 5) 480 
min. Relative PE detector signals utilised as the measure for surface GPI-AP 
expression (>3,000 Events analysed in each sample)."P/G-A W T” gate present 
defines threshold for phenotypic PIG-A mutant status.
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5.3.5 Next Generation Sequencing
Using each gene as a reference sequentially, the pooled paired-end reads were 
aligned to the reference using the “mem” command within Burrowers Wheeler 
Alignment (BWA) [343], formatted “mpileup”, SAM tools [344], and variants 
called, VarScan [345]. The parameters required for a variant to be called were as 
follows, read length - >80 bp, minimum coverage - >8 reads, minimum variant 
frequency - 1%, minimum average quality score - Q30. In addition, reads were 
removed from analysis if  the average quality o f  a 4 base “window” or section 
dropped below a score of Q20. Following variant calling, sequential graphical 
outputs were generated describing the relationship between depth and variance, the 
localisation of variants, including insertions or deletions (indels), in regards to the 
coding regions as well as the nature of variants with respect to the open reading 
frame (ORF). Data alignment and variant calling pipeline was constructed under 
guidance and run by Dr. M att Hitchings, and subsequent re-formatting and graphical 
output construction was implemented by Dr. Sion Bayliss.
Unfortunately, the control spontaneously induced phenotypic PIG-A mutant cell 
population failed during sample preparation and therefore, with no control data set in 
order to validate the effects of the chemical, subsequently the integrity of the EMS 
induced data is highly affected. As a direct consequence of this, the conclusions able 
to be taken from this data are speculative and offer little confidence and therefore, 
are available within the Appendix only (Appendix Section 5.3.5).
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5.4 Discussions and Conclusions
5.4.1 Trialled usage of HLA-DR Staining to Validate Single M arker PIG-A  
Dose Response Data within MCL-5 Cells
To date within in vitro PIG-A  assay development, an unceasing point of discussion is 
the impact which cellular viability, cytotoxicity, has on the flow cytometry based 
phenotypic PIG-A  mutant scoring. Previously, comments have been made on the 
required need for inclusion of viability dye incorporation within the assay design; 
due to apparent un-equal distribution of non-viable events between phenotypic wild- 
type and mutant PIG-A populations. Therefore, viability dyes not only appear to be 
needed to be incorporated indefinitely into the assay design, but additional early 
stage detection of such cellular pathways need to be investigated to ensure optimum 
assay sensitivity within the context of false positivity scoring.
Utilising HLA-DR molecules as direct reporters o f membrane integrity may offer an 
initial replacement for the inclusion of highly sensitive, possibly overly sensitive, 
live or dead DNA intercalating fluorescence molecules such as propidium iodide or 
7-AAD [346], as well as provide a more descriptive phenotype of the cellular event. 
The current use of such dyes provides limited biological contextual information, an 
event is simply defined as membrane integrity intact or membrane integrity loss, and 
therefore, there is potential for cells prior to complete loss of membrane integrity to 
suffer from GPI-AP inversion and other such processes which could induce a false 
negative signal.
Following the modified assay design, four chemicals were selected to be assessed for 
in-direct PIG-A  mutant frequency, through the use of anti-CD59 staining in 
conjunction with HLA-DR; these were EMS and MNU for consistency, along with 
ENU and 2,4 Dinitrophenol (2,4 DNP). All compounds were to be assessed to 
concentrations greater than the corresponding L D 50 dose. As previously described, 
EMS, MNU along with ENU are highly mutagenic alkylating agents, which operate 
under both S n l and Sn2 mechanisms [16, 41, 264] which have found limited use as 
chemotherapeutic agents [347]. 2,4 DNP however, was selected not for its mutagenic
Z4U
ability, but more to evaluate the assay design to assess a more complex compound 
(Appendix Section 5.4.1). 2,4 DNP has an essential function as a proton ionophore, 
it therefore, defeats the proton gradient and reduces the efficiency of the electron 
transport chain. For this purpose 2,4 DNP was extensively used in diet pills within 
the 20th century until recalled due to onset of dangerous side effects, however, found 
continued use especially prominent within substance abuse within bodybuilders. 2,4 
DNP is a well-known environmental contaminant, however, has no direct 
mechanism for genotoxicity and offers an interesting case study within the context of 
the in vitro PIG-A  assay development. 2,4-DP has been demonstrated to be highly 
toxic but not genotoxic [348, 349].
Initially reflecting on the EMS and MNU dose response data; previously, EMS 
chemicals had been shown to elicit a sub linear dose response with elevated doses 
displaying statistically significant increments within the frequency of phenotypic 
PIG-A mutant events. Utilising the modified assay design, following HLA-DR 
inclusion, both chemicals demonstrated a comparable sub-linear dose response, with 
the EMS top dose (160 pM ) inducing a statically significant increase in phenotypic 
PIG-A  mutants. A  LOAEL was observed approximately at 20 pg/mL, comparable to 
the previous TK6 data (Sections 3.3.3 and 4.3.4). MNU treatment was not shown to 
generate a statistically significant increase, due to the observed variance between 
replicates, however, was observed to induce a larger relative fold increase in 
phenotypic PIG-A  mutant frequency (data mirrored by PROAST38.9 modelling 
(Appendix Section 5.3.1). These data comply with currently published literature 
describing alkylating ability and potency [39, 167, 264, 350] and offers preliminary 
validation for the sensitivity of the assay design. However, increases in phenotypic 
PIG-A  mutants were potentially associated to increased cytotoxicity, but not within 
the ENU and 2,4 DNP data -  alluding that the method for toxicity measurement 
especially when using highly genotoxic chemicals may be inappropriately over 
estimating toxicity.
However, the resultant data following ENU treatment was not as expected; no doses
(including the LD 50) induced an apparent increase in phenotypic PIG-A  mutant
frequency for this known alkylating agent (Figure 5.3 D). ENU, like MNU, is
another potent mutagenic compound which should have been defined positive within
this assay design and has been demonstrated to be significantly positive within the
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analogous in vivo Pig-a assay [166, 176, 196, 350]. A reason for the lack of apparent 
dose response would be due to the diverse variation observed within dose response 
replicates, due to this, the statistically derived metrics for determining significance, 
which take into account the variance, could be underestimating the response. This is 
more apparent when looking at the PROAST modelled data (Appendix Section 
5.3.1), as the individual replicates are apparent, and the sheer variance can be 
appreciated. 2,4 DNP, the compound believed to be non-genotoxic was demonstrated 
to be negative within the assay design; no significant increments in phenotypic PIG- 
A  mutant frequency were observed across the entire tested dose range.
The data collected from this limited validation ranked the compounds in terms of 
potency, with the exception of ENU, in line with that historically described within 
the literature [39, 350], and the unknown, presumed genotoxic negative compound, 
generated no obvious increase in phenotypic PIG-A  mutant frequency at doses which 
displayed significant toxicity.
Previously, the dose response data could be scrutinised heavily for the apparent 
correlation between increased recorded phenotypic PIG-A  mutant frequency and 
cytotoxicity, especially prominent at doses approaching the LD50 value (Section
3.3.3 and 4.3.4). However, following the implementation of the novel membrane 
integrity marker, the apparent relationship was significantly reduced if not removed; 
2,4 DNP and to some extent the ENU data at doses higher than and including the 
corresponding dose equivalent to the LD 5 0 , no significant variation in mutant 
frequency was detected. This demonstrates a perceived greater level of accuracy 
when reporting the presumptive phenotypic PIG-A mutant frequency utilising this 
design when compared to previous versions.
Incorporating HLA-DR staining, in tandem with anti-CD59 PE in-direct phenotype 
reporting, appears to be an additional viable methodology for assessing, at least 
qualitatively, compounds for mutagenicity. Although due to micro-invaginations or 
inversions of the membrane prior to integrity loss, additional apoptotic marker 
incorporation would also be advised to prevent potential PIG-A  reporting bias. In 
conclusion the MCL-5 cells without enrichment appear to be as sensitive as the 
previous TK 6  platform (dose spacing reliant) for the future development of the in 
vitro PIG-A gene mutation assay. In order to assess quantitative dose response
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modelling, the potential use of tandem marker assessment in conjunction with HLA- 
DR, apoptotic markers and the proposed novel gating systems would be required. 
This planned combination of factors gave the impression to be able to deliver a level 
of sensitivity unobtainable with the use of TK6 cells, which have recently been 
shown to be acceptable under specific technical circumstances [301] or different 
cells.
5.4.2 Confocal Microscopy GPI-AP Expression Analysis
Both the in vitro and in vivo Pig-a gene mutation assay designs rely on the accurate 
reporting of GPI-AP presence as the in-direct reporter for mutational events at the 
PIG-A  gene locus [166, 301, 351]. The in vivo assay is currently a significant way 
through the progressive validatory stage to facilitate OECD guideline drafting [166, 
180]; however, there is a lack of morphological data attributed to both the mutant 
and wild type phenotype. Due to this, the well documented reporter system is still 
un-validated on a biological level and has received criticism due to the lack of 
definitive mechanistic proof. GPI-AP distribution, on the extracellular cell surface, 
has been reported to be highly conserved in nature as well as distinctly localised in 
discrete areas of high lipid density [352]. These areas are termed lipid rafts and have 
an accumulated protein rich density, believed to be the primary binding sight for 
antibodies raised against GPI-AP antigens. M inimalistic distribution on the cell 
membrane actually hinders the reporter system for use in conjunction with laser 
excitation platforms, especially those which favour transverse image capture [240, 
314]. The reason for is the planar bias which corresponds to the distribution of lipid 
rafts across the membrane, each cell may provide a distinctly positive average signal, 
with 95% o f said signal originating from 5% of the surface area. In order to 
investigate the GPI-AP distribution of the selected reporter antigens and their 
subsequent effect on the potential laser excitation platforms within the in vitro 
design, high resolution confocal imaging was utilised in conjunction with 
immunofluorescence staining.
Single stained anti-CD55 and CD59 R-PE PFA 4% fixed MCL-5 cellular samples 
displayed typically comprehensive surface emission profiles when visualised under
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high resolution 1024 x 1024 confocal imaging. Both examples of a transverse section 
demonstrated a distinctly halo like effect, with a comprehensive distribution on the 
extracellular surface of the cellular membrane (Figures 5.4 - 5.6). However, this 
apparent extensive expression was demonstrated to be highly orientation plane 
specific, distinctly sporadic in nature and relatively sparse across the entire surface 
area o f the membrane following 3D reconstructive z-stack imaging. The images 
outlined in Section 5.3.2, reported in detail the limited surface expression and the 
highly restricted distribution, seemingly associated to specific areas of high density 
on the membrane, as outlined by transmitted light composite images (Figure 5.8). 
This lack of true surface abundancy potentially limits the use of such a reporter with 
laser scanning or laser penetrance platforms. The Amnis image stream ™ system, in 
which fluorescence data is displayed within images analogous to transverse light 
microscopy, could falsely report GPI-AP status; an observation which is seen due to 
the focus and plane sensitivity which is apparent within the consequential image 
stream generated Ideas® 5 data (Appendix Sections 3.5 and 5.5). 3-dimensional 
extended depth of field (3D-EDF) imaging is available on the image stream ™ to 
account for this however; it has little impact on the overall relationships displayed.
However, tandem GPI-AP staining was shown to produce a more favourable staining 
efficiency within the parental lymphoblastoid cell lines (Figure 5.7 and 5.8), the 
results appear to further highlight the potential risk o f false positivity within single 
reporting antigen samples. In addition to this, the CD55 antibody reported 
intracellular staining within the z-stacked confocal images collected; a result of 
potential internalisation following limited PFA induced permeability. Triton-X 
treatment appeared to have little effect on membrane permeability and if the use of 
intracellular markers were to be investigated, then in future more optimisation would 
be required.
The confocal imagery within this section provides solid evidence to support a 
biological mechanism of GPI-AP association and density profiling on the 
extracellular surface o f human immortalised cell lines. In conjunction with flow 
cytometry and similar platforms, in which the diameter of the excitatory laser is 
greater than the diameter of the cellular event, there is little evidence to suggest 
potential plane issues. Tandem phenotypic marker staining resulted in a more
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comprehensive surface expression profile, as expected, and would remain the 
advised procedure to limit the risk of plane biasing or false positivity reporting.
5.4.3 Preliminary MCL-5 PIG -A  Assessment; Tandem CD55/CD59 Surface 
Antigens utilised as reporter following M NU Exposure
Prior to any physical or chemical mutant depletion methodology, MCL-5 cells were 
demonstrated to exhibit an optimal comprehensive surface coverage of tandem GPI- 
APs, CD55 and CD59 (99.8%). Following biological assessment, the need for 
tandem antigen reporting was concluded. Therefore, in an attempt to quantify the 
increase in base line increase in assay sensitivity following the incorporation of 
tandem reporting antibody inclusion, HLA-DR staining was omitted. Therefore, the 
proposed in vitro PIG-A  assay protocol was assessed for phenotypic PIG-A mutant 
frequency following acute MNU treatment. However, in addition to assessing the 
chemicals ability to induce genotoxicity, the assay design itself was further tested by 
the trial o f a novel gating strategy aimed to further remove ambiguity within flow 
cytometry data. As previously discussed, misinterpretations of cells based on crude 
light scatter profiles can potentially dramatically increase the number of events 
scoring as presumptive phenotypic PIG-A mutants [318]; therefore, the trialled 
incorporation of pulse width measures to exclude debris and doublets to improve 
assay sensitivity was also assessed.
The MCL-5 cells demonstrated a significant lag period in which limited growth was 
observed, highly similar to that observed within the previously reported dose finding 
study (Appendix Section 5.5.3.2). 24 hr post treatment, a large proportion of the cell 
populations went into apparent cytostasis, but appeared to improve following 1-2 
cell cycles recovery period; some evidence suggesting the immediate cytostatic 
effect o f the genotoxin exposure [353]. Following 72 hr post treatment, phenotypic 
PIG-A mutation data was collected and retrospectively assessed utilising the 
“original” and “novel” gating strategies. In brief, the original strategy purely relied 
on limited viability dye exclusion of non-viable cells and basic FSC vs. SSC scatter 
plots for single cell morphology, whereas the novel strategy utilised a modified
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doublet discrimination plot requiring the pulse width measure of the anti-CD55/59 
fluorophore to define event morphology.
The subsequent MCL-5 PIG-A data generated was significantly different; 72 hr post 
exposure the original gating strategy reported no obvious increase in phenotypic 
PIG-A mutant frequency across the trialled dose range (Figure 5.10 A), with a 
distinctly unsatisfactory background number o f pre-existing phenotypic mutants. 
However, the novel system appeared to substantially increase assay sensitivity, 
background mutant frequency defined as 0.01% with a resultant sub linear dose 
response in which the top dose appeared to increase the relative number of 
phenotypic PIG-A  mutants 8-fold (Figure 5.10 B).
Even with the newly modified increase in assay sensitivity, only the top dose of 1 
pg/m L elicited a significant effect on the phenotypic PIG-A  mutant frequency. This 
LOAEL appears to be significantly higher when compared to analogous data within 
equivalent cell lines [264]. Also, following the omission of HLA-DR staining, the 
continuous association between elevated phenotypic PIG-A mutant frequency and 
increased low level cytotoxicity re-appeared, emphasising the additional measurable 
mechanisms supplementary to mutagenesis within the assay design.
However, utilising the novel gating strategy within the modified pre-existing assay 
design appeared to greatly increase assay sensitivity, and should facilitate the 
generation o f further validatory quantitative dose response data. Assessing the novel 
gating strategy for bias potential will need to be completed prior to more definite 
conclusive remarks, however, elongating the experimental time period, including 
HLA-DR or similar staining as well as comprehensive viability dye assessment 
should facilitate actual quantitative dose response modelling.
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5.4.4 Assay Refinement - Gating Strategy Comparison and Apoptotic
Morphology Investigation
5.4.4.1 Gating Strategy Direct Comparison
Currently, FSC and SSC measurements within flow cytometry analysis are the most 
commonly observed variables in which population statistics are derived [13, 192, 
235, 299, 302, 318, 354, 355]. However, recent reports of inaccuracies as a result of 
over dependence on such crude measures are emerging; FSC values in particular 
have been focussed for their potential misuse due to being particularly sensitive to 
surface area and orientation of the cellular event. Proboscis, micro extensions from a 
cells surface, have been shown to greatly increase a cell’s FSC value; therefore, a 
small dying cell with such proboscis could have a corresponding FSC value of a 
normally distributed single viable cell [356]. The original in vitro gating strategy 
relied solely upon FSC and SSC measures to exclude cellular debris and doublets 
and therefore, could be a significant source of error [318]. In order to investigate this 
more thoroughly, a retrospective parallel analysis was carried out on a shared data 
set, in which the currently trialled novel gating system was directly compared against 
the original strategy and a heavily biasing comparable pulse width measure (Section 
5.3.4); any pre-existing doublet discrimination based on FSC-W  was removed for 
experimental purposes [316, 317].
The results of this experiment demonstrated that the original gating strategy was 
establishing a threshold which resulted in an unacceptable number of defined pre­
existing phenotypic mutants (Section 5.3.3), primarily as a consequence of poor 
classifier identification. The known biasing strategy, in which the fluorescence area 
of the anti-CD55/59 R-PE fluorophore was included as a variable, reported a 0%  
phenotypic PIG-A mutant frequency as expected (Appendix Section 5.4.4.1). 
However, interesting, the novel gating strategy facilitated the detection of phenotypic 
PIG-A  mutants at a frequency comparable to currently validated analogous gene 
mutation assays, providing some confidence in the novel strategy.
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In brief, the inclusion of a variable directly associated to the definition of phenotypic 
PIG-A mutant status, induces a significant bias towards underestimating the number 
of phenotypic mutants (Section 5.3.4). In conclusion, the inclusion of this un-biased 
novel gating system, with a comparable high sensitivity, appears to facilitate the 
assay system to undertake quantitative dose response modelling and allow further 
mechanistic validation.
5.4.4.2 Apoptotic M orphology Investigation
W ithin the first results chapter, it was demonstrated that cellular viability was not 
equally distributed between flow cytometry defined phenotypic PIG-A  mutant and 
wild type populations (Section 3.3.5). Theoretically, this suggested that phenotypic 
PIG-A mutants/GPI-AP deficient cells have a positive association to apoptosis 
and/or necrosis, directly conflicting against recent published in vivo evidence which 
describes the accumulation of such a phenotype, within the bone marrow and 
subsequent peripheral circulation, as a result of resistance to apoptosis [320]. It is 
actually more likely for phenotypic PIG-A mutants, in vitro and in vivo, to be highly 
sensitive to apoptosis, which is currently described within this and the previous 
chapter’s observed results (Sections 4.3.3, 4.3.4 and 5.3.4.2).
Therefore, evaluation whether non-viable cells present a phenotype equivalent to a 
presumptive PIG-A mutant event is required, as the integrity of the in vitro reporter 
system is determined by this; currently unobtainable within in vivo erythrocytic 
assay designs, due to their inability to undergo apoptosis [351]. If such an occurrence 
does transpire within the in vitro assay mechanism, p53 dependent (Appendix 
Section 5.4.4.2), a consequential masking effect, high background of pre-existing 
phenotypic PIG-A  mutant events, would dramatically decrease assay sensitivity and 
therefore, could be the current inhibition of quantitative usage [181].
Relying solely on molecular evaluation of non-viable events may limit the detection 
o f the entire non-viable population. Therefore, investigating additional characteristic 
morphological features of apoptosis could provide a supplementary system for 
exclusion o f non-viable events. The results demonstrated that apoptotic and dead 
cells were equally distributed across the defined single cell population of MCL-5
248
cells, however, when assessed through a doublet discrimination gate, dead cells did 
appear to have a lower average FSC value than comparable apoptotic cells. 
Although, morphological differences were detected, the variation was not solely 
large enough to build a gating strategy around as without molecular viability tagging, 
discrimination from the viable population is impossible. Consequently, the use of 
comprehensive viability dyes is recommended within this lymphoblastoid based 
assay design.
In order to investigate for additional biasing effects apoptotic cells could be inducing 
upon the reporter system, the GPI-AP expression of non-viable cells was tracked 
through apoptosis (PS sensitivity) and necrosis (PS sensitivity combined with lack of 
membrane integrity) respectively. In theory, as cells progress through apoptosis they 
accumulate increased risk of progressive lack of membrane integrity. Subsequently, 
lipid raft GPI-AP distribution is disrupted and the consequential emission profile of 
bound anti-GPI-AP antibody conjugated fluorophores is inhibited. The results 
demonstrated a positive correlation between Staurosporine exposure duration and the 
number of non-viable cells scored, with evidence suggesting that progression 
through apoptosis into necrosis was also exposure correlated, as expected (Section 
5.3.4.2). Staurosporine is a known apoptosis inducing chemical and is frequently 
used as a positive control within scientific experimentation [357]. More 
interestingly, GPI-AP fluorescence emission signal was shown to progressively 
decrease over the exposure duration, with the threshold of signal positivity, defied by 
the ICS, being crossed at the 8hr exposure. Consequently, events would be defined 
as presumptive phenotypic PIG-A mutants with little evidence for a mutational 
origin. Even though as cells progress through the death pathways, their genomic 
instability subsequently rises and therefore, they are more likely to undergo greater 
levels o f genomic mutational activity, however, as they are no longer dividing the 
mutational event isn’t fixed and therefore, would not result in mutational silencing 
events at the PIG-A gene. However, the observed progressive diminishing o f GPI- 
AP signal over the exposure time provides evidence towards a biasing effect elicited 
upon FCM  phenotypic PIG-A  scoring.
In conclusion, apoptosis and cellular death are unable to be excluded purely based on 
a forward or side scatter morphological measure and hence, must be detected
249
through molecular probes [273]. There is preliminary evidence within the section for 
the generation of mutant mimicking events as a result of loss of membrane integrity 
through death pathway progression; however, this can be neutralised by the 
extensive use of viability dyes. Therefore, the continued uses of such dyes are highly 
recommended within any in-direct extracellular protein reporting based within an 
apoptosis sensitive cell platform.
5.4.5 Next Generation Sequencing
Due to the failure o f the control sample during the DNA extraction stage, the 
subsequent purity/integrity of the DNA was not sufficient to enable sequencing, the 
EMS induced results were analysed without the con-current control data; as a direct 
result of this, the proportion of SNPs as a result of the treatment, as opposed to the 
generic background SNPs, cannot be estimated.
Therefore, due to the lack of integrity within the subsequently analysed data 
(Appendix Section 5.3.5), no conclusions can be drawn; however, the experimental 
design along with the complexities of this project offer insight into how to undertake 
such a novel task and are to be discussed.
The goal o f the sequencing data was to investigate the genotypic nature of 
presumptive phenotypic PIG-A mutant events; in addition, known chemical 
treatment was to be utilised to further explore the relationship between mutational 
induction, mutation spectra and genotype. Following FCM, approximately 100,000 
phenotypic PIG-A mutant cells were FACS. The data generated was based on a 
pooled heterogenous population of phenotypic PIG-A  mutant events (CD55 and 
CD59 deficient viable cells), which had been acutely treated with a sufficient dose of 
EMS to expectantly induce enough additional mutants to significantly alter the 
mutational finger print when compared to spontaneous phenotypic PIG-A  mutants. 
However, as the fold increase following EMS treatment within phenotypic PIG-A 
mutants is approximately 2-fold, therefore, only 50% of the population is likely to be 
a result o f EMS exposure. In additional, the primary mutagenic lesion
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(06ethylguanine) approximately constitutes 2% of the total adducts formed following 
treatment [22]. Consequently, observing a visible shift within the adduct spectra of 
the control and EMS induced samples may prove problematic; however the mutation 
spectra should prove more favourable.
Hypothetically, all putative phenotypic PIG-A  mutant events should be statistically 
genotype PIG-A deficient, due to the x-linked nature of the reporter gene [144, 358]. 
Any number of mutational events, point mutations, frameshifts etc. within either the 
coding or non-coding region could induce such a deficient phenotype. Therefore, 
during analysis all mutational events, including insertions and deletions were 
investigated across the entire coding and non-coding regions of the gene of interest. 
The specific amplicons chosen comprised of an approximate basal read depth or 
coverage of 1-2,000 reads across each nucleotide within the gene of interest 
sequence, with an additional 5’ and 3’ buffer zone to look for promoter mutations. 
W ithin the current pig-a  sequence literature, assay designs typically utilised mRNA 
and cDNA synthesis approaches, focus was placed on SNPs within the coding region 
of the pig-a  gene; little or no focus was placed on alternative SNP locations which 
we now know can be as detrimental to phenotype as their coding region counterparts 
[359].
The reference sequence used to call SNPs (hgl9_D N A  [360]), utilised within the 
UCSC genome browser [361] and the NCBI library environments, potentially is not 
an exact reflection of the nuclear DNA sequence within the immortalised MCL-5 
cell lines used. Therefore, there may be some variation which could confound SNP 
variant calling, however, to rationally ensure against this, any SNP variant with a 
corresponding frequency >99% of the pooled read population was excluded from 
analysis. Additionally, one is able to retrospectively construct their own reference 
genome following the sequencing, at sufficient depth and coverage, of control 
samples.
As there is no standard pipeline for a “metagenomics” approach to human amplicon 
NGS data analysis, each programme used within this pipeline has unique caveats and 
restrictions which can be more fully described at their respective developer’s 
websites [344, 345, 362].
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Due to the experimental design, there is no finite way to trace the origins o f the SNP 
variant to any particular cell. Unique oligonucleotides or similar high throughput 
tracking methods can be added to the primers during amplification [363], this 
enables ancestral analysis to be undertaken; in which specific reads can be traced 
back to their parental DNA molecules. This technique provides significantly more 
confidence in the SNP call, however, utilising a heterogenous assay design with 
approximately 100,000 starting DNA molecules did not facilitate much benefit from 
this method, with approximately 1,000 modified primer pairs per experiment adding 
to the cost. In addition to this, as is the nature of amplicon sequencing, primer 
efficiency variation can lead to PCR duplicates; currently there is no standardised 
method to remove primer duplication from amplicon sequencing data, due to the 
common amplification start and stop sites [331]. The SNP variant frequencies can 
therefore, be debated, capping primer duplicate numbers can be a method of 
standardisation; however, often very little difference is apparent within the finalised 
statistics data.
Finally, the hemizygotic properties of the PIG-A  gene mutation facilitate a single 
mutational deactivation to result in a null phenotype; however, the homozygous 
natures o f the additional genes of interest still require a double in-activating event 
within both parental alleles to result in a null phenotype. This observation must be 
taken into account when comparing the four genes of interest, an additional level of 
DNA molecular tracking may have been important for increased ancestral clarity, 
however, highly difficult experimentally to implement utilising the pool extraction 
method. Assuming all these known limiting factors, and what would have been the 
ideal experimental design (homogenous clone approach) the data was collected and 
analysed to the best o f the experimental ability.
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Table 
5.4 
Sum
m
ary 
of 
the 
additional supplem
entary 
data for this 
chapter, contained 
within 
the 
appendix, which 
details 
the 
validation 
and 
additional investigative 
experim
entation 
surrounding 
the 
assay 
developm
ent.
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Chapter 6: Human PIG-A -  A Potential Biomarker Tool for Epidemiology Bio-
Monitoring Studies
6.1 Introduction
The previous chapters have described the progress and advancement of a potential in 
vitro gene mutation assay, which if fully validated could be implemented within 
future tiered genetic toxicology test batteries to improve hazard identification and 
categorization. The assay design fulfils a current niche within safety assessment, 
assessing environmental pollutants or therapeutic drug candidates for potency and 
has limited use within current human health assessment. However, in vitro data is 
currently being assessed for future inclusion within human health risk assessment 
through the ongoing work of the ILSI-HESI jo in t committee. Due to the highly 
conserved nature of the GPI-anchor structure, in combination with an un-invasive 
harvesting method, the fundamentals of the assay system can be exploited within 
humans to enable a potential bio-monitoring tool for epidemiology studies.
Regardless of where we live and to some extent how we live, environmental 
chemicals completely surround us; they are present within the water we drink, air we 
breathe and food we eat. However, most of these substances occur naturally, are well 
categorised, and at low levels of exposure pose little risk. Nevertheless, there are 
others, natural or man-made, which are less well categorised and little is known 
about their presence within the human population (animal populations in general), 
their chemical reactivity and hence, the subsequent interactions they create following 
exposure. This is where human bio monitoring (HBM) as a scientific discipline 
allows access to the data whether or not such chemicals have entered the body and to 
what extent this exposure can harm and how it may change over time [364]. In a 
general sense HBM studies measure the concentration of such natural and synthetic 
compounds in body fluids, and provide the data necessary to contextualise 
environmental exposures and help identify potential health risks [365]. The major 
strength of HBM  is that it provides data, generally highly detailed, on the internal
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exposure of an individual at a precise time, which in combination with a number of 
other methods can be utilised to evaluate a potential health risk [209],
HBM is more than just a potential quantitative measure o f an environmental 
chemical; it can provide route of entry (administration) data and capture key insights 
into the deleterious side effects or consequences of such exposure. Often such a 
study is undertaken in parallel to interview or detailed questionnaires to facilitate 
more specific evaluation of data and interpretation to minimise potential future risk 
[364]. HBM can be thought of as a pipeline to provide additional data to aid 
regulatory decision making, not for NMEs (new molecular entities); the initial frame 
work of planning, budgeting and ethical approving is followed by sampling, analysis 
and interpretation [53, 366]. This stimulates communication, further research and 
additional training, which in turn eventually lead to policy drafting, coordination and 
implementation of decisions [367].
In the case of a specific chemical exposure, HBM can identify trends within the 
population, investigate potential cultural and life style contributing factors and 
isolate groups at increased risk of incident. Two specific examples of HBM studies 
in which the investigations lead to policy changes at a national level were; in 
Germany risk of amalgam fillings, especially within children was identified, and the 
decline of metal contamination via drinking water revision (German Drinking W ater 
Ordinance) and in Belgium (the Flanders bio monitoring programme) the collection 
of pesticide waste was improved, following observed elevated levels of banned 
pesticides in the blood of rural populations [209, 364].
HBM falls into a larger category of epidemiology, the study of patterns, causes and 
effects of health and disease conditions in defined populations [368]. Both HBM and 
epidemiology studies rely on other scientific disciplines in order to better understand 
the disease processes, a biologist is often consultant in parallel with a statistician and 
physical engineer to make a more effective use of the data and draw more accurate 
conclusions. An example of a famous case study was preliminary reported in 1954 
[369] and latter in 1956 [370] in which the published results of a British Doctors 
Study (1951-2001), led by Richard Doll and Austin Hill, provided strong statistical 
support to the suspicion that tobacco smoking was linked to lung cancer, a modem 
relationship which is fundamentally implied. This work was later followed by the
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DNA adduct and mutation spectrum of lung cancers being linked to cigarette smoke 
[371, 372].
6.1.1 Genetic Toxicology’s Impact within Human Bio-M onitoring Studies
Genetic toxicology, as a field is directly involved in the future prevention of human 
risk through rigorous safety assessment within the tier standard battery during novel 
drug formulation/development [373]. However, aside from the potential of drug 
impurities or contamination within drug development, which would stimulate a 
genetic toxicology based assessment within the population affected, there is little 
cross over into potential large scale epidemiology studies. Nevertheless, with 
increased risk associated to naturally occurring environmental compounds, more 
accurately described by their potential exposure within the population, genetic 
toxicology end points are often considered when constructing a decision in order to 
reform, or provide policy on a current issue.
Genetic toxicology data is becoming more prevalent within decision making, 
undertaken by regulatory agencies for risk assessment purposes, especially in regards 
to the backlog of known man-made compounds with the potential to cause risk 
following exposure, for example smoking [370-372] and Asbestos [374], A highly 
relevant example was in 2007 when Roche, the Swizz Pharmaceutical Company, 
recalled the antiviral Viracept (nelfinavir) following identification of contamination 
at the manufacturing stage by ethyl methane sulfonate (EMS) [242, 243]. This lead 
to one of the first example of a known genotoxic compound, previously believed to 
be linear, having a non-linear dose response defined following exposure [241, 350], 
the no-longer currently used Lutz and Lutz hockey stick model [375], showed a clear 
sub-linear response. As well as man-made exposures, natural environmental 
compounds have also been demonstrated, following novel research, to have potential 
deleterious bioaccumulation or damaging mechanisms. These such compounds 
termed persistent, bio accumulative and toxic chemicals (PBTs) are often highly 
lipid soluble [376].
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6.1.1.1 The Micronucleus Assay as a Bio-Monitoring Tool
M icronucleus testing is a well-established assay within the genetic toxicology field 
and is a frequent method utilised within human bio monitoring studies [69, 377, 
378]. The micronucleus assay is thoroughly validated, providing both OECD 
guideline publications for use within in genetic toxicology testing and 
recommendations for its use in HBM [379], The formation and frequencies of 
micronuclei do not necessarily reflect a consistent mode of action within all the 
various test protocols, biological basis of the formation is dependent upon the 
context of chemical exposure [34, 69, 95]. M utation can be thought of a potential 
superior endpoint, due to its recent classification as an apical endpoint, or key event 
within carcinogenesis [380]. The adapted M NT protocol is frequently used for 
monitoring genetic damage in humans; MNT frequencies are monitored across a 
variety o f cell types these include, peripheral leukocytes, erythrocytes and epithelial 
cells [381]. Specific sub-protocols such as the M NT with exfoliated epithelial cells 
(buccal cavity) are used as a minimalistic invasive method for monitoring genotoxic 
damage at the point of contact [382]. However, a more standardised approach is the 
M NT frequency assessment within human cultured leukocytes from human patients 
following exposure or suspected exposure [383]. An additional particular method 
which is gaining favour is the flow cytometry assay, in which the MNT frequency is 
quantified within the RET population of peripheral erythrocytes [383]. M N are 
assessed within the most immature fraction of transferrin receptor positive 
reticulocytes (CD71-positive); cells released by the bone marrow are immuno- 
magnetically isolated before they are removed from circulation by the spleen [384]. 
Therefore, this method fundamentally requires a bone marrow exposure to induce a 
relevant M N response. Chemotherapy and radiotherapy have both been demonstrated 
to induce a statistically significant increase in MN ret formation when com pared to 
un-treated control patients [385]. The limited lifespan of reticulocytes along with the 
limitation in which exposure most occur still limit this method o f HBM  for the 
detection of damage after low-level chronic exposure. Different methods must be 
investigated to ensure a more accurate description of exposure related induction
[379].
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6.1.1.2 The Human PIG-A Assay as a Potential Bio-Monitoring Tool
Potentially there is a niche for a genetic toxicology end point which is easy 
accessible, un-invasive, able to be high throughput and a general description of 
genetic damage following either acute or long term chronic exposure. This method 
of measuring somatic mutation rate is an important biological parameter, as it may 
influence the development and/or the risk of acquiring genetic diseases, particularly 
cancer [386]. The somatic mutation rate can be indicative o f the environmental 
stresses, and hence exposures exhibited onto the general population. The X-linked 
basis o f the PIG-A  gene makes it a prominent candidate for a quantitative somatic 
mutation rate reporter [387] and facilitates the assay design to be able to be 
undertaken within a large plethora of different tissues in theory. However, initially 
focussing on human erythrocytic PIG-A  [351], utilising the rodent Pig-a as a basis 
for finalised design, human peripheral blood erythrocytes can be assessed for genetic 
damage. Again much like the MNT assay, in vivo, the exposure would be required to 
be chronic, and of a highly deleterious nature to induce a significant measurable long 
term end point.
Initial pilot studies exploiting the PIG-A  gene loci have been carried out within the 
FDA, further eluding more data in terms of mechanistic studies as well as potential 
deviation within sexes, species and cell lineages. Initially, the spontaneous somatic 
mutation frequency was calculated within a “normal”, healthy population (average of
5.1 ± 4.9 x 10'6; median of 3.8 x 10'6 and mutant frequency less than 8 x 10'6 for 
75% of subjects). However, a statistically significant difference in median mutant 
frequencies between males and females was detected as well as PIG-A  RBC mutant 
frequency displayed poor correlation with the age and no correlation with the 
smoking status of the subjects. Limited evidence was collected to suggest robustness 
following an additional project failing to measure significant increases in mutant 
frequency following patient exposure to chemotherapeutic treatments [280]. Much 
like peripheral blood reticulocytes being removed via the action of the spleen, 
mature RBC will actively be removed via complement protein mediated haemolysis 
and hence, could result in an underestimation of genetic damage, especially if the 
exposure was acute in nature [152, 153]. The rodent in vivo Pig-a assay is relatively
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unaffected due to the lack of complement system complexity within the species 
[3881.
Therefore, not only investigating erythrocytic lineages as a potential bio monitoring 
tool for systemic exposure, human leukocyte PIG-A offers a more favourable assay 
design to facilitate more accurate risk assessment. Leukocytes, both granulocytes and 
lymphocytes are nucleated and therefore, permit downstream direct sequencing to 
validate the identity of the FCM defined event as well as provide further mechanistic 
evaluation of the nature of exposure. Even though Leukocytes undergo an analogous 
sequential maturation within the bone marrow, their general fixed distribution 
(granulocytes) as well as active gene expression and ability to divide (lymphocytes) 
facilitate accurate reporting of systemic genetic damage [389]. Harvesting leukocytes 
from specific organs or locations around the body would better reflect the 
microenvironment from which they were taken, allowing a more point of contact and 
distribution approach to the exposure to be assessed. However, lymphocytes are 
highly prone to surface antigen expression alterations, especially following 
activation when called into action by the immune system or following the onset of 
disease phenotype [390]. Therefore, utilising an analogous cell type, with a 
homogenous microenvironment, which are less susceptible to activation would 
greatly benefit the bio-monitoring platform. Therefore, monitoring human 
granulocytes, more specifically activated neutrophils, could provide an effective 
platform for the collected of spontaneous, as well as specific chemical exposure 
induced, PIG-A mutant frequency data within localised and peripheral blood of 
donors (see Figure 6.1 for details).
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Rondelli et al., 2013 published data showing a diverse range of spontaneous 
phenotypic PIG-A mutant granulocytes within a normal population. Further 
development from the same group showed robustness within the approach and 
defined a “normal” range of mutant granulocytes (lx lO  6 - 37.5xl0~6, with a median 
of 4 .9 x l0 -6) [175]. Unlike other techniques commonly employed in population 
studies, such as comet assay, this method can detect any kind of mutation, as long as 
the PIG-A  gene is functionally inactivated [79, 392]. A t the end o f  2014, Litron ™ 
published a development paper on human erythrocytic PIG -A , analogous to the paper 
presented by the FDA a few years earlier, with the extension of mutant RET 
measurement [351]. The spontaneous mutant frequency was estimated from the 
analysis from 52 -  non-smoking self-reported healthy normal volunteers (mean 
frequency of RETCD59/CD55‘ and RBCCD59'/CD55'w ere  6.0 x 10'6 and 2.9 x 10'6, 
respectively). The difference, demonstrates the “modest selective pressure against 
mutant phenotype mature erythrocytes in the circulation”, and suggests the major 
advantage of reticulocyte measurement utilising the modernised methodology, 
immuno-paramagnetic mutant enrichment. Thus this publication demonstrated the 
ability to feasibly collect PIG-A mutant data, utilising a highly un-invasive sample 
harvesting method, which could be utilised as a potential HBM assay.
6.1.1.3 Genetic Data: The Future of Toxic Tort Legislation
Currently one of the biggest obstacles to overcome during toxic tort cases is 
establishing, with adequate proof that exposure to a potential toxin resulted in the 
proposed injury. Currently, in a general sense causation is determined through a 
complex overview based on multiple witnesses, each putting forward an expert 
opinion either for or against the proposed mechanism of injury. However, through 
recent advances in gene sequencing, biomarker identification and generalised more 
comprehensive understanding of pathogenesis markers some plaintiffs have begun to 
use genetic information in order to more solidly put forward the case of exposure 
related toxicity, which more likely than not induced damage [393]. Biomarkers in 
this case can be used as directly measurable molecular changes in the blood, 
sometimes even unique moieties directly related to a specific compound interaction,
2 6 4
which can indicate abnormalities or disease. Currently, the most important 
biomarkers in terms of damage estimates are those which demonstrate chromosomal 
rearrangements (both aberrations as well as aneuploidy) or specific gene mutations. 
These genetic biomarkers in combination with sufficiently high sensitivity 
assessment are beginning to more accurately estimate duration and potency of 
exposure. Equally, genetic information can also be used by a defendant providing a 
case for pre-disposition to a genetic condition or disease phenotype; a gene 
expression which is atypically of exposure can provide strong evidence to disregard 
a proposed exposure related illness. Ideally, utilising more genetic information and 
providing a sufficiently details comprehensive assessment should enable a more 
objective, pure approach to these cases, minimalising the need for personal opinions 
from experts in the field [394].
Even though in principle the ideology of utilising extensive genetic information 
regarding gene expression and biomarker study provides a more objective view point 
to a decision making process. The complexities and understanding in order to come 
to an objective opinion following data interpretation in my opinion is still 
fundamentally lacking. The sheer complexity of human biological nature requires 
extensive validation and the presence of anomalies or spurious data cannot be 
disregarding as within this specific context could immensely damage a company’s 
reputation or individuals life style. Additionally, high expense and time consuming 
protocols are associated with genetic testing. However, advances in modem 
technology and medicine especially in the fields of biomarker or bio-monitoring, 
which in essence should provide more holistic objective data, can provide data in 
less than a few days at a relatively low cost [393].
6.1.2 Cancers and additional Genetic Diseases
The PIG-A  mechanism in-directly reports the mutation frequency observed at the 
PIG-A  gene locus [387], and therefore, is fundamentally a non-specific measure of 
mutation; although potential assay revisions into more specific tissue types has 
endeavoured to provide localisation data for m utation frequency (Appendix Section
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5.5.3.4). Mutation has recently been elevated as a genetic toxicology end point, 
defined as an apical end point of carcinogenesis, and therefore, is increasingly a 
critical measure for the detection of genetic damage and potential carcinogenesis
[380]. Cancer appears to be the most topical genetic disease which affects humans, 
of which there a numerous unique sub-types. Research has shown the progressive 
stages in which a tissue generally undergoes prior to the adoption of the cancer 
phenotype; these include, alterations in gene expression (down regulation of tumour 
suppressor genes (p53), up regulation of pro-oncogenic genes (RAS), over 
expression of growth factors, resistance to hypoxia through the recruitment of 
angiogenesis regulators and increased genomic instability [395]. These so called hall 
marks of cancer are commonly found within the vast majority of cancer phenotypes; 
there are also additional unique features which further categorise the cancer 
phenotype and often provide identity and localisation to the cancer. Tissues, 
therefore, in some respect undergo a progressive cancer development, which if 
identified at an early stage can be effectively treated with therapeutic agents, 
however, as the cancer develops the amount of genomic instability increases which 
facilitates the further development of the phenotype. As the phenotype reaches its 
latter stages, often the condition is untreatable, due to the systemic affect the cancer 
has on the patient following node penetration, i.e. metastatic expansion often 
associated with very poor prognosis [396].
However, mutational events are either directly present or as of a consequence of a 
number of further disease phenotypes. For example, inflammation is common to 
rheumatoid arthritis [397] and is highly associated to reactive oxygen species (ROS) 
activity [398], which in turn have been demonstrated to induce mutational damage 
[399]. Therefore, via localised PIG-A mutation frequency assessment, tissues 
potentially affected by ROS activity and therefore, a potential risk of disease 
development could be detected. However, without a viable physical phenotype 
alluding to preliminary ROS mediated damage, it is highly difficult to detect the 
onset of the disease phenotype prior to initial symptoms.
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6.1.3 Additional Purposes of Developing a Human PIG-A Bio-Monitoring Tool
The aim o f this chapter was to develop a suitable human PIG-A bio-monitoring 
platform, able to sensitivity measure mutation. As previously mentioned, there is a 
number of pre-existing published studies which were undertaken with this common 
aim [175, 351, 358, 387]. Utilising such models as smoking exposure, limited 
convincing data has been generated demonstrating any correlation [351] to date. 
However, the lack of obvious correlation may be as a result of limited assay 
protocol, focussing heavily on RET and/or RBC data potentially could limit the 
observed response due to the required chronic systemic nature of exposure. 
Therefore, more recent analogous studies were published focussing more heavily on 
the establishment of a robust WBC (granulocyte) assay platform to enable more 
localised PIG-A assessment [175].
Developing a Human Granulocyte assay platform in combination with the more 
traditional erythrocytic versions of the PIG-A  assay, offers additional benefits 
specifically poignant within the current in vivo Pig-a  validation. Each cell type 
offers a particular advantage in the context o f data acquisition; periphery 
erythrocytes would have limited sensitivity to tissue specific exposure, due to their 
limited gene expression. However, any potential accumulation of damage whilst 
within the bone marrow is easily detected due to the -100  day maturation within the 
circulatory system. Alternatively, white blood cells, even though less prevalent in 
terms o f numbers, are more robust, sensitive to environmental stimuli and are 
sensitive to DNA damage, as well as are nucleated to permit direct sequencing. 
Direct sequencing validation of the presumed phenotypic PIG-A  mutant events 
would, in a homologous manner to the in vitro PIG-A  assay, enable some level of 
validation to the putative PIG-A deficient phenotype, as observed within the 
erythrocytic assay designs. Lacking complete validation of the presumptive mutant 
phenotype is still a retarding data gap potentially preventing OECD guideline 
drafting. Therefore, granulocytes could provide a generic biomarker for chronic 
exposures, including such disease phenotypes as smoking, obesity and aging, as well 
as a potential platform to validate the assay set up in regards to direct sequencing.
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6.2 Materials and Method
6.2.1 Human Haematocyte PIG-A Exposure Assay
This body of work was constantly progressing to improve three separate PIG-A 
exposure assays. In order to achieve this, numerous progressive developmental 
stages were undertaken often assessing similar reagents for performance. Throughout 
this section, unless otherwise stated, human blood was collected directly into a 
heparin coated vaccutainer succeeding venipuncture within the median cubital vein, 
following verbal consent. All blood was stored blind within a biohazard cool bag 
within a 2-4 °C temperature controlled environment, protected from light. All human 
blood work was carried out within Scan Lab class 2 safety cabinets, with extensive 
70% ethanol cleaning and additional use of detergents to prevent contamination or 
biohazard. Sample often were “racked” which is a process similar to vortexing which 
breaks down agglomerates without the excessive shear forces associated.
6.2.1.1 Human Erythrocyte (RBC) PIG-A  Exposure Assay
4 mL o f venous blood was removed via venipuncture, most commonly bled from the 
M edian Cubital Vein located on the ventral surface of the forearm; into 4 mL heparin 
(60 USP) coated vaccutainers (Cat No. 367 884, BD Biosciences, Oxford, UK). 
Vaccutainers were stored protected from light at room temperature to prevent photo­
degradation. Vaccutainers were de-capped, 5 pL  of heparinised whole blood 
removed and aliquotted directly into the base of a 1.5 mL eppendorf tube containing 
95 pL  of filter (0.2 pM ) sterilised PBS supplemented with 0.2% BSA (1:20 dilution). 
The diluted blood was pipetted up and down a number of times to prevent 
undesirable agglomerates and aid clotting cessation. The entire contents of the 
eppendorf tube were transferred into a sterile 15 mL falcon tube, taking additional 
care to prevent any blood from touching the side of the tubes, this step ensures 
against artifactual PIG-A  mutants during analysis. 20 pL  o f hum an anti-CD55 R-PE
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antibody (IgG 2ak) (Cat. No. 555694, BD Biosciences, Oxford, UK), 20 pL  o f human 
anti-CD59 R-PE (IgG 2ak) (Cat No. 555764, BD Biosciences, Oxford, UK) as well as 
5 pL  of human anti-CD235a APC (IgG 2bk) (Cat No. 551336, BD Biosciences, 
Oxford, UK) (1:10 dilution within 0.1 % BSA/ 0.05% NaN 3/PBS) antibody were 
added in unison to the 15 mL falcon tube, pipetted a minimum of 5 times and 
incubated at room temperature (22 °C ± 2 °C), protected from light for 30 min. Post 
incubation, the samples were centrifuged (500 x g for 5 min), supernatant aspirated 
and discarded. 5 mL of 1 x PBS was added re-suspending the cellular pellets, 
centrifuged at 500 x g for 5 minutes. The supernatant was aspirated and discarded. 
An additional 5 mL volume of 1 x PBS was added, centrifuged (500 x g for 5 min) 
and supernatant discarded. Cellular pellets were re-suspended in 1 mL 1 X  PBS 
solution, racked extensively and stored up to an hour on ice protect from light prior 
to flow cytometric analysis. Instrument calibration standards (unstained) as well as 
single stained sample controls were also prepared for calibration and compensation 
respectively.
6.2.1.2 Human Reticulocyte (RET) PIG-A  Exposure Assay
6.2.1.2.1 Erythrocytic Depletion: Haemolysis Variant
Versalyse (Cat No. 41116015, Beckman Coulter, High Wycombe, UK) was stored as 
outlined within the manufacturer’s guidelines at 18 -  25 °C and was used within a 90 
day period starting the day of first use. Blood was collected from a healthy control 
donor as outlined in (Section 6.2.1.1); 100 pL  of heparinised un-diluted whole blood 
was transferred into a fresh 15 mL falcon tube, taking great care to expel the contents 
of the pipette directly into the base of the tube. The whole blood was treated with 
erythrocyte specific antibodies as outlined in (Section 6.2.1.1) and incubated at room 
temperature, protected from light for 30 min. Following incubation, 1 mL of 
VersaLyse solution (IX ) was added, vortexed immediately (1 sec) and allowed to 
incubate at room temperature, protected from light, for 10 min. Immediately 
following incubation, the lysed sample was centrifuged (150 x g for 5 min), 
supernatant aspirated and re-suspended in 3 mL of 1 X PBS solution. Due to mass
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lysis, take great care when discarding supernatant not to remove cells of interest. The 
sample was centrifuged, supernatant aspirated, treated with 1 mL o f 0.1 % Retie 
Count diluted within PBS/BSA (2%) and allowed to incubate at room temperature 
for 1 hr protected from light. Post incubation, the sample was gently mixed, racked 
extensively and stored on ice for up to an hour prior to flow cytometric analysis. 
Instrument calibration standards (unstained) as well as single stained sample controls 
were also prepared for calibration and compensation respectively.
6.2.1.2.2 Erythrocytic Depletion: Concentration Gradient Variant
Versalyse was stored as outlined within the manufacturer’s guidelines at 18 -  25 °C 
and was used within a 90 day period starting the day o f first use. Blood was collected 
from a healthy control donor as outlined in (Section 6.2.1.1). However, 10 mL 
heparin coated vaccutainers (Cat No. 367 980, BD Biosciences, Oxford, UK) were 
used and loaded with 9 mL of venous blood. 5 mL of heparinised blood was 
transferred using a sterile 10 mL pipette in conjunction with a pipette controller onto 
5 mL of histopaque ® 1077 (Cat No. 1077-100mL, Sigma Aldrich, Gillingham, UK) 
within a 15 mL Falcon tube. Samples were centrifuged (-300  x g for 30 min) at 
room temperature, forming a distinctly reproducible layered blood sample. Starting 
with the least dense, the plasma layer was removed, “buffy white coat” presumed 
lymphocytes, followed by the histopaque ® 1077, and very carefully the layer of 
reticulocytes/polymorphonuclear white blood cells removed and aliquotted into a 
fresh 15 mL centrifuge tube (-100  pL  volume). The erythrocyte dominated cellular 
pellet as well as the additional layers, excluding the reticulocyte layer were discarded 
and disposed of according to health and safety protocol. Excess (-1 0  mL) of pre­
warmed RPM I 1640 medium was added to the minimal volume of suspected 
reticulocytes and centrifuged at (-280  x g for 10 min) room temperature. Post 
centrifugation, supernatant was aspirated and the cell pellets initially re-suspended in 
a minimal volume of RPM I 1640 medium, before additional excess was added. 
Cellular sample was centrifuged (-280  x g for 7 min), supernatant aspirated and 
discarded, and washed with excess RPMI medium -  this step was repeated an 
additional two times. Cell pellets were re-suspended in 0.5 - 1 mL o f 1 x PBS
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solution and treated with antibodies in an analogous fashion was outlined in (Section 
6.2.1.1). Following incubation, 1 mL of VersaLyse solution (IX ) was added, 
vortexed immediately (1 sec) and incubated for 10 min at room temperature, 
protected from light. Post incubation, cells were centrifuged (150 x g for 5 min), 
supernatant aspirated and re-suspended in 3 mL of 1 X PBS solution. Due to mass 
cell lysis, great care was taken when discarding supernatant not to remove cells of 
interest. The sample was centrifuged, supernatant aspirated, treated with 1 mL of 0.1 
% Retie Count diluted within PBS/BSA (2%) and allowed to incubate at room 
temperature for 1 hr protected from light. Post incubation, the sample was gently 
mixed, racked extensively and stored on ice for up to an hour prior to flow 
cytometric analysis. Instrument calibration standards (unstained) as well as single 
stained sample controls were also prepared for calibration and compensation 
respectively.
6.2.1.3 Human Granulocyte PIG-A  Exposure Assay
6.2.1.3.1 Erythrocytic Depletion: Haemolysis Variant
Versalyse was stored as outlined within the manufacturer’s guidelines at 18 -  25 °C 
and was used within a 90 day period starting the day of first use. Fluorescence 
aerolysin (FLAER) was purchased from VH Bio Ltd, Gates-head, UK and 
reconstituted within 1 mL of 1 x PBS solution, constructing a 50 pg/m L stock which 
was aliquotted and stored at -20 °C protected from light until further use. Blood was 
collected from a healthy control donor as outlined in (Section 6.2.1.1). 100 pL  of 
heparinised un-diluted whole blood was transferred into a fresh 15 mL falcon tube, 
taking great care to expel the contents of the pipette directly into the base of the tube. 
The whole blood was treated with granulocyte specific antibodies, 20 pL  of human 
anti-CD 15 APC (IgM k) (Cat No. 551376, BD Biosciences, Oxford, UK), pipetted up 
and down at least five times and incubated at room temperature for 30 min, protected 
from  light. 15 min within to the incubation, the cells were treated with pre-warmed 
(37°C) 5 pL  FLAER and incubated for the remaining 15 min from the previous
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incubation. Post incubation, 1 mL of VersaLyse solution (IX ) was added, vortex 
immediately (1 sec) and incubated at room temperature for 10 min, protected from 
light. Following this, the cells were centrifuged (150 x g for 5 min), supernatant 
carefully aspirated and washed a minimum of twice with 3-5 mL of (0.2% 
BSA/PBS) wash buffer. The cellular pellets were re-suspended in 1 mL of lx  PBS, 
treated with 5 pL  of propidium iodide solution (lm g/m L) (Cat No. P-3566, Life ™ 
Technologies, Paisley, UK) and incubated on ice protected from light for a minimum 
of 5 min. Samples were stored once for up to an hour prior to flow cytometric 
analysis. Instrument calibration standards (unstained) as well as single stained 
sample controls were also prepared for calibration and compensation respectively.
6.2.1.3.2 Erythrocytic Depletion: Concentration Gradient Variant
Versalyse was stored as outlined within the manufacturer’s guidelines at 18 -  25 °C 
and was used within a 90 day period starting the day of first use. Blood was collected 
from a healthy control donor as outlined in (6.2.1.1). However, 10 mL heparin 
coated vaccutainers (Cat No. 367 980, BD Biosciences, Oxford, UK) were used and 
loaded with 9 mL of venous blood. 5 mL of heparinised blood was transferred using 
a sterile 10 mL pipette in conjunction with a pipette controller onto 5 mL of 
histopaque ® 1077 (Cat No. 1077-100mL, Sigma Aldrich, Gillingham, UK) resting 
upon 5 mL histopaque @ 1113 (Cat No. 1113-100mL, Sigma Aldrich, Gillingham, 
UK) within a 15 mL Falcon tube. Samples were centrifuged (-300  x g for 30 min) at 
room temperature, forming a distinctly reproducible layered blood sample. Starting 
with the least dense, the plasma layer was removed, “buffy white coat” presumed 
lymphocytes, followed by the histopaque ® 1077, and very carefully the layer of 
polymorphonuclear white blood cells removed and aliquotted into a fresh 15 mL 
centrifuge tube (-100  pL  volume). The erythrocyte dominated cellular pellet as well 
as the additional layers, excluding the granulocyte layer were discarded and disposed 
of according to health and safety protocol. Excess (-1 0  mL) of pre-warmed RPMI 
1640 medium was added to the minimal volume of suspected reticulocytes and 
centrifuged at (-280  x g for 10 min) room temperature. Post centrifugation, 
supernatant was aspirated and the cell pellets initially re-suspended in a minimal
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volume of RPMI 1640 medium, before additional excess was added. Cellular 
samples were centrifuged (-280  x g for 7 min), supernatant aspirated and discarded, 
and washed with excess RPMI medium -  this step was repeated an additional two 
times. Cell pellets were re-suspended in 0.5 - 1 mL o f 1 x PBS solution and treated 
with antibodies in an analogous fashion was outlined in (Section 6.2.1.1). Following 
incubation, 1 mL of VersaLyse solution (IX ) was added, vortexed immediately (1 
sec) and incubated for 10 min at room temperature, protected from light. Post 
incubation, cells were centrifuged (150 x g for 5 min), supernatant aspirated and re­
suspended in 3 mL of 1 X PBS solution. The sample was centrifuged, supernatant 
aspirated, re-suspended in 1 mL of 1 x PBS solution and treated with 5 pL  of 
propidium iodide solution (1 mg/mL) and incubated on ice protected from light for a 
m inimum of 5 min. Samples were stored once for up to an hour prior to flow 
cytometric analysis. Instrument calibration standards (unstained) as well as single 
stained sample controls were also prepared for calibration and compensation 
respectively.
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6.3 Results
All work carried out within this section was undertaken in direct collaboration with 
Dr Hasan Haboubi, who personally over saw the collection of the blood samples and 
contributed towards the undertaking of the optimisation/developmental experiments.
6.3.1 Human Erythrocyte (RBC) PIG -A  Assay Platform Optimisation
In order to evaluate the potential of developing a sensitive and accurate bio­
monitoring platform, initially an estimation of the spontaneous background 
frequency is required. In this specific context, the pre-existing frequency of 
phenotypic PIG-A  mutants within “healthy” human patients is essential. Patients 
(healthy volunteers) were identified as “healthy” based on their own self­
proclamation, adhering to a number of limited criteria, and the subsequently 
generated data would provide an estimation of the expected sensitivity, as well as 
any obvious pit falls within the current preliminary protocol. However, in addition to 
this, a number of additional experimental variables must be evaluated prior to 
generate confidence and primarily validate assay robustness. Preliminary 
investigations into antibody sensitivity, blood agglomeration status, viability and 
phenotypic marker selection were undertaken to assess the likelihood of establishing 
an assay platform with adequate robustness and reproducibility to facilitate long term 
bio-monitoring. If the platform was unable to establish a spontaneous mutant 
frequency, at the PIG-A gene locus, in-line with current publications, as well as 
showing some degree of reproducibility, there would be limited use within human 
health assessment. Future potential investigations should firstly; i) enable an 
extended validation of the test platforms and ii) correlate any measurable increases 
or decreases in patient phenotypic PIG-A mutant frequency with potential exposure 
acuteness or duration etc. The following body of work, all PIG-A mutant frequencies 
stated are phenotypic mutant frequencies; displaying a loss or partial loss o f GPI-AP 
associated surface antigens, no sequencing validation has been undertaken to defined 
genotype.
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6.3.1.1 Introductory Antibody Investigation
Due to the nature of fluorescent probes and the risks associated with photo 
bleaching, experimental incubation conditions were investigated to ensure optimum 
conditions were adhered to; promoting accuracy and validity within subsequent data.
Prior to detailed data analysis a crude gating strategy, based on size and granularity 
of presumed cellular events, was implemented. This enabled the subsequent 
investigation to comment on any observed generalised trends following 
experimentation. In addition, data was tested for normality utilising the Shapiro- 
Wilks Test to facilitate supplementary statistical analysis, if required. The 
experimental data was demonstrated to be normally distributed (P = 0.452), with 
direct protection from polarising light, minimised photo-bleaching, shown to result 
in a significantly (P = 0.048) higher average staining efficiency (99.96%) than 
parallel samples exposed to work bench light (99.91%). Furthermore, extending the 
incubation period was shown not to have a significant effect on the efficiency of 
sequential antibody staining, once optimal exposure had been reached (30 min 
incubation period (P>0.05)) (Figure 6.2).
Figure 6.2. The frequency of defined single cell RBCs staining positive for the GPI- 
AP CD55 and/or CD59, following extended incubation and protection from direct 
polarising light, when compared to the generic incubation conditions. Data was 
demonstrated to be normally distributed, Shapiro Wilks, P = 0.452 (D unnett's 2- 
sided T-test, P<0.05*, <0.01 **) (Error Bars ±SD) (N=3, from same donor)( 10,000 
cells scored).
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Whole blood was used as the generic sample type with no prior sample separation 
implemented; therefore, cellular identity was based on crude FSC and SSC profiles 
generated during initial FCM analysis. In order to increase confidence within 
reported data, the practice of incorporating an erythrocyte sensitive antibody probe 
was employed; this provided further validity of the identity of presumptive RBC or 
RETs events scored on the flow cytometer. Anti-CD235a (Glycophorin A) was 
trialled for its use as a selective marker for erythrocytes, the smaller volumes of 5 
and 10 pL  (-99.5% ) were shown to produce the most favourable results when 
compared to the larger 50 pL  (97%) volume (Figure 6.3 A). 10 pL  loading volumes 
generated the highest sequential staining efficiency and hence identification of an 
erythrocyte population (99.75%). As well as loading volume, the length of 
incubation was also assessed; little difference was shown between the analogous 30 
m in or 60 min incubation tim e’s staining efficiency. However, 60 min on average 
generated the highest staining efficacy (99.75%) (Figure 6.4 A). Due to the presence 
of significant agglomeration following antibody treatment, sample racking was 
investigated to quantitate the effect “racking” had on agglomerations status. Two 
identical samples were constructed and a single sample vigorously physically 
agitated. The “un-racked “sample displayed a substantial presence of a second major 
population within the anti-CD235a fluorescence emission channel, indicative of 
doublets, or larger agglomerates (Figure 6.3 B). The “racked” sample was shown to 
exhibit a significantly smaller agglomerate population (Figure 6.4 C), and more
i
| highly resembled a mono-particle suspension of cultured cells.
|
t
i
2 7 6
06/12/11 -60  m in 10 (racking)
Loading Volum e (pL)
Figure 6.3. The frequency of defined single cell RBCs staining positive for the 
Glycophorin A sensitive CD235a primary antibody following variable incubation 
times and treatment concentrations (A). The effect that vigorous sample racking has 
on the distribution and frequency of RBC agglomerates (Pre-racking (B) and Post- 
racking (C)) (>10,000 cells analysed).
Finally, the effect of whole blood concentration and increased flow cytometry 
sample running rate were evaluated with respect to PIG-A mutant phenotype 
assessment. Typically a 1:20 blood dilution factor is used to generate RBC data, 
however, a second 1:10 dilution was set up to directly compare the effect a more 
concentrated sample could have on phenotypic mutant frequency. The results 
showed that the average background PIG-A mutant frequency was significantly 
lower (P = 0.0007) for the 1:20 sample (0.01%) when compared to the more 
concentrated 1:10 sample (0.08%). The background mutant frequency appeared to 
shown a positive correlation with sample concentration, i.e. as the concentration 
increased, so did the background mutant frequency (Figure 6.4).
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■ 1:20 Dilution ■ 1:10 Dilution
£  0 1 0  “
^  0 .0 9U
Figure 6.4. The average RBC PIG-A mutant phenotype frequency following anti- 
CD235a identification in conjunction with tandem PIG-A reporting, anti-CD55/59 
R-PE antibody staining of whole blood. The effect of greater event capture through 
whole blood sample concentration and increased flow rate was investigated (~ lx l0 6 
events scored) ((Dunnett’s2 sided T-Test (p <0.05*)(N=3, Error Bars ±1SD))
6.3.1.2 H um an E ry th rocy te  (RBC) PIG-A  Assessm ent -  Spontaneous M utan t 
F requency  D erivation
Taking into account the initial antibody evaluation and optimisation, the crude assay 
platform was utilised to collect the data for the first “healthy" control patient, in 
order to assess enumeration of RBC and preliminary RET events, and their 
respective PIG-A status (Figure 6.5). The sample was run in triplicate and 
demonstrated an average spontaneous background mutant frequency as 0.013%, 
which correlated in the range of 100-200 PIG-A mutant phenotype cells per 1 x 106 
events scored (Table 6.1); showing good correlation to published literature [280, 
351). The samples took on average 8-10 min to run, which facilitated the capture of 
>1 x 106 mature RBC and estimated >10,000 RET events; insufficient RET events 
would be able to be captured to provide sufficient statistical strength in mutation 
frequency estimation.
278
0 6 /1 2 /1 1 - S a m p l e  1
i 111in|— i i 111111| 
10" 10* 10s
SSC-A
0 6 /1 2 /1 1 -S a m p le  1
N u c le a te d  Cell
i i n n ri|— i i n  irri]— r
10“
FITC-A
£  ___________ 0 6 /1 2 /1 1 -S a m p le  1
£
wt Pig-A
I I III r r r m n — r  
10“  10s
D
o - 
2~-
0 6 /12 /1 1 -S a m p le  1
£
rh15O Oj
o % - -
Erythrocyte
o -
1
S i J
" I ‘I 1 1 1 M il
CD59PE-A
10 “
APC-A
06/12/11-Sample 1
Leukoc
1
0 6 / 1 2 / 1 1 - S a m p l e  1
|  i  i m in ]— i 1 1 i i i i i |— i i  i m i i | — i 1 1 1 1 r n | — r
101 102 103 10* 10s 
APC-A
Q1 RETS
Q3 4 K
10 10 
APC-A
<6< w 2~
06/12/11-Sam p le 1
Mutant R :Ts WT RETs
10 10 
C D 59 PE-A
H 0 6 /1 2 /1 1 -S a m p le  1
Mutant R 3Cs W T R B C s
10 10 
C D 59 PE-A
Figure 6.5. Flow cytometry analysis work flow, showing the progressive labelling, 
identification and sub-population derivation in order to obtain phenotypic PIG-A 
mutant frequency assessment. A) Crude FSC vs SSC dot plot indicative of 
morphology and cell size. B),C) and D) Relative fluorescence intensity for lineage 
specific markers; B) DNA content C), GPI-AP status and D) Glycophorin A 
presence. E) Leukocyte specific gating, F) RET and mature RBC identification and 
separation, G) GPI-AP assessment of RETs and H) GPI-AP assessment of RBCs 
(10,000 events shown for ease of visualisation from ‘"'healthy” patients).
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Table 
6.1. Sum
m
ary 
of 
the 
initial PIG-A 
m
utant phenotype Assessm
ent within 
M
ature 
RBCs 
(Lim
ited 
Capture 
~1,000,000 
events
6.3.2 Initial Human Erythrocyte (RET) and Granulocyte PIG-A  Assay Platform
Optimisation
6.3.2.1 H um an E ry th rocy te  (RET) PIG-A  Assay P latfo rm
6.3.2.1.1 P relim inary  A ntibody Investigation -  R E T IC  C ount™
Based on the relative success of the preliminary RBC assay design, RET events were 
evaluated for their potential as a platform for PIG-A reporting. In order to capture, 
with confidence, sufficient RET events for phenotypic PIG-A assessment, to estimate 
background mutant frequency, specific antibody optimisation was required. The 
RETIC Count™ reagent was shown to be highly affected by the incubation 
temperature as well as the length, with 30 min on ice (~ 0-2 °C) generating the 
lowest identification of RET numbers within the whole blood sample. Both 30 and 
60 min room temperature incubations displayed significantly higher numbers of RET 
identification (P<0.01), when directly compared to the 30 min ice incubated sample. 
60 min RT generated the most reproducible, maximum identification of putative 
RET events within the whole blood sample and was selected for incorporation into 
the human erythrocyte RET assay design (Figure 6.6).
Figure 6.6. The average number o f events displaying RETIC Count ™ positive 
staining, following varied incubation time and direct polarizing light exposure. Data 
was demonstrated to be normally distributed. Shapiro Wilks, P = 0.384 (D unnett's 2- 
sided T-test, P<0.05*, <0.01 **)(Error Bars ±SD) (N=3) (RT - Room temperature, 
ICE- ~2°C).
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6.3.2.1.2 Preliminary Human Erythrocyte (RET) PIG-A Assessment -
Spontaneous Mutant Frequency Derivation
Following incorporation o f  the RETIC Count™  reagent into the erythrocyte RET 
assay design, preliminary phenotypic PIG-A  assessment was undertaken in order to 
quantify the spontaneous background mutant frequency at the specific gene loci. The 
results were obtained from measuring the relative phenotypic PIG-A  mutant 
frequency within whole blood taken from a “healthy” donor (Figure 6.7 and Table 
6.2). Utilising a highly inclusive gating strategy, analogous to that within the initial 
developmental stages of the in vitro PIG-A  assay design, approximately 10,000 
defined RET events were able to be captured (staining positive for both RETIC 
Count™  and CD253a) in less than 20 minutes per sample. The average spontaneous 
PIG-A mutant frequency within the RET population was estimated to be 0.03% 
(Table 6.2), approximately 3 fold higher than the corresponding mutant PIG-A RBC 
frequency; this relationship is supported by the recently published literature [351, 
358, 387]
Table 6.2. Summary o f  the preliminary relative phenotypic PIG-A mutant frequency 
within the RBC and R E T  population. Whole blood was exposed to anti-CD235a, 
tandem CD55/59 R-PE antibody exposure and REITC Count™; RETs were 
identified on their double positive nucleic acid staining and erythrocyte specific 
m arker presence and assessed fo r  GPI-associated PIG-A status. 10,000 RE T  
defined events were captured in 10-20 min sample running time).
Sample
Identification
Total
Number
of
Defined
RRCs
Number
of
defined
mutant
RRCs
Percentage
PIG-A
phenotypic
M utant
RRCs
Total
Number
of
Defined
RETs
Number
of
defined
mutant
RETs
Percentage
PIG-A
phenotypic
M utant
RETs
Sample 1 702307 47 0.007 12475 0 0
Sample 2 654304 11 0.002 7626 2 0.026
Sample 3 778524 74 0.01 8544 6 0.07
Average 711712 44 0.01 9548.3 2.67 0.03
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(controls) 106/12/11 -Non Lysed (controls) 1 06/12/11-Non
Erythrocytes
Ttrr
A P C -AAPC-A
-34
CD59 PE-ACD59 PE-A
Figure 6.7. The preliminary RET PIG-A mutant frequency assessment within whole 
blood samples; A) Nucleic acid content, as defined by RETIC Count™ staining, B) 
GPI-AP status following anti CD55/59 R-PE tandem staining, C) Erythrocyte 
specific marker, anti-CD235a staining, D) Population distribution following 
advanced staining, E) Phenotypic PIG-A assessment within mature RBCs and F) 
Phenotypic PIG-A assessment within RETs (-10,000 RETs scored).
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6.3.2.2 Human Granulocyte PIG-A Assay Platform Optimisation
6.3.2.2.1 Preliminary Enrichment Evaluation - Ammonium Chloride
Prior to the utilisation of enrichment methodology, the enumeration o f sufficient 
granulocyte events had proven impossible within the tight experimental sample time 
constraints. The employment o f an ammonium chloride solution was investigated to 
determine the possibility of FCM scoring >10,000 granulocyte events within an 
approximate 10-20 min analysis period; greater analysis periods could potentially 
elicit deleterious effects on the population viability. The results of lysis were 
demonstrated to have a distinct effect on the percentage constitution of different 
populations within the whole blood sample (Figure 6.8). Prior to lysis, 100,000 cells 
were captured without a single defined granulocyte event, CD 15 positive, identified 
(Figure 6.8 A). However, following lysis, the granulocyte population was shown to 
increase to -10%  of the total sample constitution (Figure 6.8 B). During analysis it 
was shown to be possible to score 10,000 granulocyte events for sequential PIG-A 
phenotypic mutation status, within the allotted 10-20 min analysis time period. 
However, utilising this specific method of enrichment, there was little scope to 
increase the enumeration of events to the desire 1 x 106 within such limited time 
constraints.
2 8 4
Tube: Whole Blood 1 A
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■  All Events 100,000 100.0
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Figure 6.8. Overview of FCM data following capture of an un-treated, 1:10 diluted, 
whole blood sample (A) run in parallel with a ammonium chloride treated 1:10 
diluted whole blood sample (B). An anti-CD 15 APC-conjugated antibody was 
utilised as a granulocyte, activated neutrophil, specific antibody selective marker and 
was solely utilised to provide identity to the cells. FSC vs SSC dot plots (cytograms) 
were used to display the generic population data, C D -15 positive cells were painted 
Red for ease of visualisation retrospectively.
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63 .2 .2 .2  Preliminary Human Granulocyte PIG -A  Assessment -  Spontaneous 
Mutant Frequency Derivation
Following incorporation of a preliminary optimised ammonium chloride lysis step 
(Section 6.3.3.2.1), initial PIG-A mutant frequency assessment was undertaken in 
order to quantify the spontaneous background mutant frequency at the gene loci. The 
subsequent results initially mirrored the previous enrichment of the leukocyte 
population (Figure 6.8), as well as defined the spontaneous phenotypic PIG-A 
m utant frequency, within whole blood taken from a self-proclaimed “healthy” donor, 
utilising FLAER as the reporter mechanism (Figure 6.9). Applying an inclusive 
gating strategy, events were included based on their FSC vs SSC profiles in 
combination with CD 15 positive staining, approximately 5,000-10,000 defined 
granulocyte events were able to be captured in less than 20 min per sample. The 
optimal average spontaneous phenotypic PIG-A  mutant frequency within the 
granulocyte population was estimated to be 0.2% (Figure 6.9), utilising an undiluted 
FLAER treatment within an undiluted blood sample. An inversely proportional 
correlation was observed as decreasing concentrations of FLAER resulted in 
increasing background mutant frequencies. The current granulocyte assay platform is 
operating under a sensitivity levels approximately 20 fold lower than the 
corresponding mutant PIG-A  RBC frequency, which in turn is 3 times more sensitive 
than the mutant RET platform. Insufficient numbers of defined granulocyte events 
could be scored to provide the assay with sufficient power to be a standalone 
assessment of PIG-A  mutant frequency.
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Figure 6.9. Average spontaneous background phenotypic mutant PIG-A frequency 
within CD 15 labelled neutrophils (Granulocytes) utilising FLAER as the reporter for 
mutation; the effect of FLAER dilution as well as blood concentration was assessed 
within the content of PIG-A mutant frequency (Error Bars ±SD) (N=3).
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| 6.3.3 Human PIG -A  Assay Platform Supplementary Investigations
6.3.3.1 Lysis Buffer Evaluation
After completion of a retrospective compensation analysis (Section 2.8), the subsequent
i
i  matrix was applied to the original lysis buffer optimisation FCM data and re-analysed 
j  thoroughly. The resultant populations were defined through simplistic FSC and SSC profiling
j
I with the combined usage of lineage specific markers (CD235a). It is apparent from the data
[
j that the concentration o f the different buffer solutions did not have any significant influence
i
| on leukocyte enrichment. However, there were significant differences in leukocytes
i
I enrichment efficiency between the different types of buffer solutions; BD FACS lyse resulted 
; in a significantly sub-optimal, approximately 20%, leukocyte composition. Easylyse and 
Versalyse were shown to produce very comparable results, -80-90%  relative enrichment, 
which appears to be independent of the concentration of the buffer used (Figure 6.10 A).
j During reticulocyte enrichment, events defined as both RETIC Count™  and CD235a 
| positive, both type of lysis buffer as well as relative concentration appeared to highly effect 
! the consequential yield. Initally, both Easylyse and Versalyse solutions generated higher
i
| reticulocyte yields than the comprabale BD Facs lyse, across the concentration range
| investigated, with optimal yields being observed when using the most dilute (1/10 X) solution
i
j (~2.5-3.5%), for all buffers analysed. This appears to reinforce the intial observated 
I relationship which separated BD FACS lyse from the comparable Easylyse and Versalyse 
: solutions during leukocyte enrichment (Figure 6.9). Versalyse was shown to generate the 
optimum reticulocyte enrichment (3.867%) utilising the 1/10 X concentration, with the 
relative final reticulocyte consistuent frequency of the population being defined significantly 
smaller than the leukocyte population, following RBC lysis.
W hen analysing the data in terms of relative PIG-A  mutant frequency; both Easylyse and 
Versalyse buffer solutions demonstrated analgous enrichment efficiency, superior to the BD 
FACS lyse data for leukocyte capture (concentration independent). However, their respective 
phenotypic PIG-A  mutant status, post enrichment, were considerably different. Versalyse, 
using an undiluted or 1/10 X diluted sample, generated the most favourable data with respect
2 8 8
to the presence of GPI-AP on the cell surface (0.243% phenotypic PIG-A mutant frequency) 
(Figure 6.10 A and B). Subsequently, Versalyse was chosen to be implemented to enrich for 
leukocytes during the next stage of assay optimisation (FLAER analysis).
Reticulocyte PIG-A status was more complex in nature; Versalyse (1/10X) generated the 
optimal results in comparison to alternative buffer solutions in terms of RET enrichment. 
However, the phenotypic PIG-A  mutant frequnecy was highly variable using either BD FACs 
or the Versalyse solution. Therefore, even though Easylyse was not the optimum buffer for 
enrichment, conforming to all additional needs o f the platform, Easylyse was chosen as the 
buffer for reticulocyte enrichment. Using either undiluted or IX  concentrations favoured the 
populations with respect to PIG-A status (0.0 14-0.07%).
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6.3.3.2 Cellular Viability during prolonged Human PIG-A Assessment
The results for the experiment were divided into the specific cell lineages present 
within peripheral human whole blood; when assessing the minor populations, RBC 
lysis was utilised in order to obtain sufficient sample cell number. Identification of 
the subgroups was mainly attributed to their unique FSC and SSC profiles, however, 
some lineage specific markers were also implemented during flow cytometry 
assessment. The results revealed that there was a significant presence of apoptotic 
cells within both the leukocyte (-10%) and reticulocyte (-0.5%) sub-populations 
(Figures 6.11 B and C respectively), when compared to unstained controls. However, 
the monitored levels of apoptosis, observed over the experimental time period, were 
surprisingly consistent within both populations. No significant variation in apoptosis 
was detected over the experimental time period when compared to con-current 
control samples (fresh whole blood sample). Apoptosis was not observed within the 
non-nucleated sub lineage (mature RBC) which supports the lack of intrinsic and 
extrinsic biological mechanisms (Figure 6.11 A).
Loss of membrane integrity (Cell Death) was apparent within all sub lineages across 
the whole blood sample (Figure 6.11). Within the erythrocytic cell lineages, the level 
of cell death remained consistently around the 5% figure, with no significant 
variations across the experimental time period. The percentage of dead cells present 
within the leukocyte sub-population was elevated (-20%) when compared to the 
comparable cell types, however, again it remained consistent across the extended 
experimental time (Figure 6.11 B). There was no obvious correlation between 
variance in cell death or apoptosis with respect to the experimental period; loss of 
cellular viability appeared independent of time.
Necrosis was defined as a morphological state in which the cells were presenting as 
annexin V positive as well as having a significant loss in membrane integrity, as 
depicted by propidium iodide positivity. Again, the results showed that necrosis was 
only observed within the nucleated sub-populations, and that relative levels remained 
consistent across the time course. Leukocytes again were shown to exhibit slightly 
elevated levels of necrosis than RETs, -3%  compared to 0.1%, similar to their 
relative levels of apoptosis. This result again appeared to show an analogous trend, 
the independence of cellular viability in regards to experimental time period. The
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levels of apoptosis, necrosis and cell death were demonstrated to be cell lineage 
specific; however, they remained at a consistent level during the extended 
experiment with no significant variation detected.
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Figure 6.11. Summary of relative viability of the three sub-types of haemopoetic 
cells within human peripheral blood, over an extended experimental period (up to 6 
hr). Cell death, i.e. membrane integrity, was assessed utilising Propidium Iodide 
nucleic acid dye presence; apoptosis was assessed using a phosphatidyl serine 
sensitive Alexa Fluor 488nm Annexin V conjugate antibody and finally, necrosis 
was monitored through combined assessment of membrane integrity and PS 
presence on the extracellular surface (>100,000 RBC (A) and >5,000 leukocyte (B) 
and RET (C) events scored.)
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6.3.3.3 Cellular Enrichment Investigation
6.3.3.3.1 Centrifugation as the Sole Granulocyte Enrichment Tool and the effect 
FLAER Titration has on Spontaneous PIG-A background Mutant Frequency
Initially considering the population statistics following sole high speed 
centrifugation when compared to the more typical lysis method, approximately 7- 
10% of the resultant population post centrifugation were leukocyte in nature (based 
on FSC and/or SSC profiles). However, of the presumed leukocyte population, only 
-10% were CD15 positive in nature (Table 6.3), highly dissimilar from the greater 
than 95% CD 15 populations associated with RBC lysis optimisation (Section 
6.3.3.1). Centrifugation demonstrated an apparent preferential enrichment for 
leukocytes in general, not specifically the CD 15 activated neutrophil sub-population; 
this had a diluting general effect on granulocyte enrichment. FLAER titration 
generated results which were to be as expected, showing a general trend of 
increasing dilution leading to a greater spontaneous background frequency (Table 
6.3). The optimum results were observed when using either un-diluted or a single 1:1 
dilution within 2% BSA/PBS, resulting in an average 0.17 and 0.1% phenotypic 
PIG-A mutant frequency respectively. Larger dilution factors resulted in significantly 
higher spontaneous background mutant frequencies at the PIG-A locus, as 
demonstrated by the observed average 1.17% PIG-A mutant frequency following a 
1:10 dilution.
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Table 
6.3. Sum
m
ary 
of 
the 
affect centrifugation 
and 
FLAER 
titration 
have on prelim
inary 
PIG-A 
mutant frequency 
assessm
ent.
6.3.3.3.1.1 The Possible Effects on Cellular Viability as induced via High Speed 
Centrifugation
The potential effect on viability was assessed through the direct comparison of two 
analogous human peripheral blood samples, one exposed to high speed 
centrifugation separation and the second RBC lysis buffer (Versalyse) followed by 
viability dye staining. The resultant data demonstrated that lysis resulted in a 
significantly lower percentage of single cell events (-1%  and 10% respectively), 
greater relative numbers of cells which have lost membrane integrity (-10% to 1%), 
and a greater population constitution of CD 15 positive cells (->95% to 25%) when 
compared to high speed centrifugation (Table 6.4). The only variable which 
remained constant between the two methods was the relative amount of apoptosis 
detected within the subsequent CD 15 populations (-0.5%). As well as comparing the 
affect the separation/enrichment method had on the resultant viability of the 
population, extended experimental incubations were also evaluated for their effect on 
viability. The results demonstrated that apart from a marginal increase in the relative 
amount of loss of membrane integrity within the CD 15 sub-population, all other 
measurable viability endpoints were consistent when compared to the immediate 
analysis and the pro-longed 6 hr delay period on ice and/or at room temperature 
(~22°C). Full experimental method can be found at (Appendix Section 6.2.3.3.2.1).
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Table 
6.4. Sum
m
ary 
of 
the 
effect high 
speed 
centrifugation 
has on 
granulocyte viability 
and 
capture 
efficiency, when 
compared 
to 
lysed 
whole 
blood 
sam
ples. (Sample ID 
la 
= 
Ice 
6hr, lb 
= 
Room 
Tem
perature 
6hr and 
2a 
= 
Room 
Temperature 
Ohr) 
ICS 
- Instrum
ent Calibration 
Standard.
6.3.3.3.2 Investigations into Histopaque® Enrichment
Based on an average healthy adult’s peripheral blood constituting 1-2% of immature 
red blood cells (RETs), the use of histopaque® was investigated to assess the 
feasibility of RET and Granulocyte sub-population enrichment in excess of previous 
methods and hence, subsequent FCM scoring in regards to PIG-A mutant frequency 
assessment. Following histopaque® enrichment, there were two obvious layers with 
characteristics corresponding to peripheral blood mononuclear cells (PBMCs) and 
poly-nuclear cells (PNCs) granulocytes with retrospective densities less than that of 
the mature RBC pellet. Each WBC layer was extracted, stained and FCM assessed 
for phenotypic PIG-A mutant status. In terms of enrichment, the results were not as 
comprehensive as previously described methods (RBC lysis buffer) only facilitating 
the enrichment of RETs to 2.9% of the total population when compared to between 
5-10% with VersaLyse (Section 6.3.2). The distal layer, in terms of erythrocyte 
pellet, demonstrated highly minimal (<0.1 %) CD235a staining, eluding at highly 
comprehensive separation of the differential cell lineages.
“Layer 1”, the layer corresponding to the lower density, constituted o f -90%  
morphological leukocytes, which was significantly higher than “layer 2”, the 
proximal layer to the erythrocyte pellet (<1%). However, even though defined 
leukocyte by their FSC/SSC profiles, approximately only 1.3% of the population 
were CD 15 positive in nature, of which their respective PIG-A mutant frequency was 
on average 2% (Table 6.5). Although, “layer 2” generated a relatively small 
population of CD 15 positive granulocytes (0.7%), the corresponding background 
mutant frequency at the PIG-A locus of an average 0.03%, which is the highest 
granulocyte sensitivity recorded within assay development. The lack of neutrophil 
enrichment in terms of fold change only facilitated the capture of approximately 
2,000-5,000 granulocyte positive events and therefore, would require further 
optimisation in order to obtain the number of granulocytes required for strong 
statistical analysis.
The results in terms of population location within the histopaque ® centrifugation 
tube indicated that the granulocyte population was being split between the two layers 
flanking the histopaque ® layer and therefore, could be the reason for such poor
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6.3.3.3.2.1 The Finalised Optimisation of Histopaque®
This experimental design was utilised to assess the potential robustness of the usage 
of two distinct histopaque ® layers to capture and isolate (PNC) granulocytes 
(Figure 6.12). The design of this experiment took into account the affect that 
temperature has on the enrichment protocol and also allowed the granulocytes and 
potentially reticulocytes layers to be isolated and harvested efficiently.
Within both samples the results generated were quite dissimilar, clear presumed 
granulocytes (PNC) layers were present and located above the erythrocytic pellet. 
The layers themselves were slightly pink in colour, eluding at the indication of 
potential RET isolation due to the spiking effect of erythrocyte presence; the colour 
change was more apparent as you proceeded down the layer. Both samples were 
subsequently stained for RET and granulocyte presence and were showed to generate 
significantly large granulocyte sub-populations. Following FCM analysis, the EDTA 
sample was observed to provide marginally better yields (granulocytes) however; the 
difference wasn’t significant and did not affect the sample’s ability to score 
granulocyte presence for an extended period of time (Table 6.6).
From averaging the running time for both EDTA and Heparin samples, to collect 
approximately 1 x 106 granulocyte events, the estimated acquisition time would 
approximately be 20-30 min per sample acquisition. The resultant phenotypic PIG-A 
mutant frequencies observed within both the EDTA (0.08%) and heparin (0.11%) 
samples were highly similar, approximately 0.1% spontaneous background mutant 
frequency (Table 6.6). The RET sub-population within both samples was 
demonstrated to comprise very few RET events and prevented full analysis; the 
subsequent data generated was not of particularly good quality and the spontaneous 
background phenotypic PIG-A mutant frequency was >10% PIG-A mutants. The 
exact reason for this discrepancy in data is not fully understood, however both 
temperature and technical ability highly influence the use of histopaque® solutions 
within assay protocols. EDTA generated the most appropriate results in terms of 
viability, phenotypic PIG-A mutant frequency as well as harvesting efficiency and 
will be utilised in the future as the granulocyte specific PIG-A assessment platform. 
Further investigations can been located within the appendix.
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Table 6.6. Summary of the average preliminary phenotypic PIG-A mutant frequency 
assessment following the optimisation of the combined use Histopaque ®  1077 and 
1119 solutions.
Sample
ID
Number 
of 
Events 
Defined 
CD 15 
Positive
Number
of
Single
Cell
Events
Number
of
Viable
Cells
Number of 
Viable Cells 
which meet 
"refined" 
gating
Number of 
phenotypic 
PIG-A 
Wild type 
Cells
Number of 
phenotypic 
PIG-A 
Mutant 
Cells
Percentage 
phenotypic 
Mutant Cells 
of Refined 
Population
EDTA 112218 1049076 209063 197001 196836 165 0.08
Heparin 402576 385900 102729 97139 97035 104 0.11
6.3.4 Finalised Human Erythrocyte (RET) and Granulocyte PIG-A Assessment 
-  Spontaneous Mutant Frequency Derivation
6.3.4.1 Human Erythrocyte (RET) PIG-A Assessment
Using analogous stains to the previously described protocol for mature red blood cell 
(RBC) capture (Section 6.2.1) in combination with VersaLyse RBC lysis and 
implementation of a more sophisticated gating strategy the finalised spontaneous 
background mutant frequency within RETs was investigated. Prior to this, utilising a 
updated compensation matrix it was apparent that the RETIC Count ™, FL1 
fluorescence dye, used to measure residual RNA/DNA presence, was saturating the 
cells and causing additional spectral overlap into neighbouring fluorescent regions 
(data not shown).
Utilising a titration of RETIC Count™ reagent in combination with the protocol 
listed above the sub population of RETIC Count™ positive (RNA positive), CD235a 
positive (erythrocyte specific lineage) RETs were showed that irrespective of the 
concentration o f RETIC Count ™ used, ranging from a 1:1 to 1:10 dilution, the 
channel compensation required was fixed at approximately 30% reduction. The 
resultant phenotypic PIG-A mutant frequencies observed across the concentration 
range were consistent at 0.05, 0.03 and 0.04% respectively (-5,000 events 
scored)(Figure 6.13). These background values are higher than the reported
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corresponding mature RBC PIG-A mutant background frequencies (0.01%); 
however, the number of events scored and assessed is much fewer than the RBC 
platform and therefore, these figures provide robust estimates, but still remain under 
the 0.1 % figure for sensitivity.
■ 1:1 Retie Count 1:2 Retie Count ■ 1:10 Retie Count
Figure 6.13. The average phenotypic PIG-A mutant frequency within the RET sub­
population following titration of the RETIC Count ™ reagent. Tandem anti-CD55 
and CD59 R-PE conjugates utilised as in-direct PIG-A reporters in conjunction with 
anti-CD235a - APC lineage specific marker (Error Bars ±SD) (N=3)(~5,000 events 
analysed).
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6.3.4.2 Human Granulocyte PIG-A Assessment
FLAER staining was demonstrated to be superior to the analgous anti-CD59 R-PE 
antibody staining in terms of granulocyte reporter sensitivity. Following lysis, 
FLAER resulted in an approximate background spontaneous phenotypic PIG-A 
mutant frequency for a healthy control of 0.009%; significantly lower than the 
comparable 68% generated following anti-CD59 PE treatment (Figure 6.14). The 
results demonstrated comparable control metrics as previously defined in recent 
human PIG-A publications [ 175, 351, 358, 3871.
■ FLAER Assessment ■ CD59 Assessment
Figure 6.14. Average spontaneous background phenotypic mutant PIG-A frequency 
within CD 15 labelled neutrophils (Granulocytes) utilising FLAER or anti-CD59 as 
the reporter for mutation; the effect of reporter sensitivity was assessed within the 
content of PIG-A mutant frequency analysis (Error Bars ±SD) (N=3).
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6.4 Discussions and Conclusions
6.4.1 Human Erythrocyte (RBC) PIG-A Assay Platform - Preliminary Antibody
Optimisation
The reporting system within the proposed human PIG-A gene mutation assay relies 
upon the principle usage of fluorescently conjugated antibodies. Therefore, this 
relatively simple reporter system must deliver on sensitivity and specificity to enable 
the accurate quantitative assessment of phenotypic mutant numbers. Therefore, there 
is a critical need to optimise the reagents utilised within the test system to enable 
their optimal performance to generate a holistic sensitive system. Fluorescently 
labelled antibodies are recommended to be kept protected from direct-light during 
the preparative stages prior to analysis, the results shown reflect the negative impact 
that polarising light has on the efficiency of antibody reporting during analysis 
(Section 6.3.1). The reason for this is due to the nature of fluorescence conjugates, 
once exposed to a suitable excitation source, the low energy electrons (ground state) 
within the system are promoted to a higher energy state, become unstable and release 
a quantum of energy at a detectable wavelength prior to falling to their original 
energy level [403]. This energy release has a specific wavelength which facilitates 
the capture of a signal. However, each dye has a unique number of emittable photos 
and therefore, a unique life span with regards to photo bleaching [404], the 
photochemical destruction of a dye by the light exposure necessary to stimulate them 
into fluorescing [405]. Therefore, if exposed to light prior to analysis, the resultant 
efficiency of a fluoresce dye to emit a detectable emission post FCM illumination 
can be severely reduced if not inhibited. The duration of antibody treatment, 
regardless of light exposure conditions, was demonstrated to have limited impact on 
the efficiency of staining; most likely as the minimal incubation time (30 min) is an 
approximate of the manufactures published optimised protocol. However, 
significantly extended incubation times can have a negative impact on the staining 
efficiency due to the formation of agglomerates within the cell sample.
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Anti-CD235a is a commercially available antibody selectively raised against the 
glycophorin A protein on the surface of erythrocytes [406]. Glycophorin A is 
conservatively expressed across the red blood cell lineage and is highly expressed 
exclusively on the cell surface [254, 407]. Therefore, using a relatively small amount 
of antibody will suffice to produce a suitable signal to detect erythrocytes; however, 
over saturation of the blood sample, due to either excessive antibody exposure or 
incubation length can result in severe agglomeration. The antibody can cross link 
between the surfaces of neighbouring erythrocytes, acting like biological glue, 
forming large impenetrable agglomerates. This has the overall effect of causing mass 
agglomeration within the sample, reducing staining efficiency, inducing flow 
cytometry stream blockages and massively increasing the difficulty of re-suspending 
the cell pellet during preparations. The results demonstrated the optimum 
concentration of CD235a to use, within this setting, to provide adequate staining 
profiles whilst maintaining limited agglomeration. Incubation length did not appear 
to affect the staining efficiency, however, as expected a significant deleterious effect 
was observed when increasing the volume of anti-CD235a used (Section 6.3.1).
Therefore, to minimise any possible deleterious effects associated to C235a usage, 
racking was investigated. Racking is a physical force exerted onto the cells in order 
to dislodge loose agglomerates though mechanical shearing, which is less abrasive 
than sonication or vortexing based approaches [408]. The results demonstrated that 
the combined usage of the optimum amount of anti-CD235a with sufficient racking 
generated a sufficiently viable cellular population for FCM analysis, controlled 
racking had no deleterious effects on PIG-A mutant frequency within the assessed 
cell types.
Finally, in an effort to assess the estimated time taken to collect greater than 1 x 106 
events in order to generate PIG-A assessment data with sufficient statistical strength, 
the initial concentration of the whole blood sample was investigated. Whole blood 
can be run directly through the FCM, when using the lowest possible flow rate; 
however, the resultant accuracy is reduced due to the sheer number of events 
analysed per second. Therefore, an appropriate dilution factor was investigated; the 
optimal results were obtained using the 1:20 dilution, with an observed negative 
correlation between more concentrated blood samples and relative PIG-A mutant 
frequency. The proposed reasons for this correlation are firstly, the finite amount of
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antibody being exposed to the cellular sample. As the cell numbers increase, 
especially by factors of 10, in order to maintain antibody saturation to result in 
optimal sample signal, the resultant amount of antibody is also required to 
significantly increase. This regulates the number of events which are able to come 
into contact with the desired antibody molecules. Secondly, the slower the sample 
runs the higher the sensitivity and hence, the greater time within the laser light and 
subsequent detector regions; decreasing the software abort rate [409].
This human erythrocyte RBC assay platform has been demonstrated to perform at a 
sensitivity level comparable to current published studies [143, 351], and hence, 
suitable for both preliminary qualitative and quantitative assessment. Utilising the 
optimised protocol (Section 6.2.1.1) the spontaneous background mutant frequency 
at the PIG-A gene locus was estimated at 130 mutant RBCs per 1 x 106 total RBC 
events scored, enabling the undertaking of future HBM trials within peripheral blood 
haemopoetic cells. Work by Dr Haboubi, based on this preliminary protocol, has 
shown good initial progress into establishing a HBM platform [400-402].
6.4.2 Initial Human Erythrocyte (RET) and Granulocyte PIG-A Assay Platform 
Optimisation
6.4.2.1 Human Erythrocyte (RET) PIG-A Assay Platform
Reticulocytes are immature red blood cells, differentiated in the bone marrow from 
haemopoetic stem cells, which still have a relatively high RNA content when first 
exposed to the peripheral blood circulation [410]; during maturation (5-7 days) the 
cells eventually excrete their RNA content and adopt the characteristics of mature 
RBCs and continue to persist in the circulation for approximately 100 days [295, 
411]. Reticulocytes are therefore, more functionally active, have limited exposure to 
complement protein activity [351] and are less differentiated than mature RBCs. As 
a result of this, RETs are more similar to the progenitor or stem cells, in which the 
original mutational event occurred, and are typically referred to as a more sensitive
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reporter for this measurable end point [143, 167, 302]. Even though RET events are 
much more sparse within the peripheral circulatory system [410], when compared to 
mature RBCs, having an additional directly comparable analogous end point within 
homogenous samples provides increased strength and confidence within generated 
data, especially when a proposed known correlation should be apparent [160, 280, 
351].
The RETIC Count™ reagent [412], a fluorescent SYTOX™ [413] like dye which 
intercalates nucleic acids and used to define residual RNA content was shown to be 
highly affected by the incubation temperature as well as the length (Section 6.3.2.1). 
RETIC Count™ highly analogous to the additional commercially available RET 
specific nucleic acid dye, thiazol orange, freely permeates the cells and intercalates 
between adjacent nucleotides within the DNA double helix structure. When excited 
by a suitable high energy light source, a corresponding measurable fluorescence 
emission is detected [412].
Utilising an elongated exposure time (60 min) as well as the highest assessed 
temperature (-22 °C), the most reproducible highest identification of putative RET 
events within the whole blood sample was generated; and subsequently selected for 
incorporation into the human erythrocyte RET assay design. Providing additional 
temperature during the fluorescence reagent incubation, as with any reaction, offers 
additional kinetic energy to the molecules which facilitates added collisions. 
Increasing the rate of collisions as well as the success by enabling the molecule to 
exceed the activation energy [414]. However, certain antibodies, under raised 
temperature conditions, often have reduced binding efficiencies due to the 
internalisation of the cellular surface receptors [415, 416], and hence, why antibody 
staining is generally undertaken at 2-4 degrees Celsius. Due to RETs being 
erythrocytes in nature and therefore, having limited gene expression; their sensitivity 
to environmental stimuli is decreased, which permits the use of a higher temperature 
to provide sufficient molecular interactions [295]. Similar to temperature, incubation 
length can be detrimental during elongated exposure due to the deleterious effects 
onto cellular gene expression, as well as photo bleaching of specific fluorophores 
[405]. However, adhering to good laboratory training [417], i.e. preventing the 
exposure of the fluorophore to plane polarising light permits the use of an extended
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incubation period, in combination with the unique characteristics of RETs produces 
optimum results.
The results of the initial RET PIG-A assessment were encouraging in regards to the 
potential sensitivity of the RET assay platform, demonstrating a spontaneous back 
ground mutant frequency of 0.03% (Section 6.3.2.1.2 ), this is in-line with the stated 
RBC phenotypic PIG-A mutant frequency (Section 6.3.1.2). However, during the 
acquisition, 20 min, only 10,000 RET positive events were identified; insufficient 
numbers of RETs were able to be scored within a realistic time period to provide the 
assay with sufficient power to be a standalone assessment of PIG-A mutant 
frequency. Therefore, the current protocol will be used as a platform for additional 
optimisation, focussing on sub-population enrichment and statistical power 
calculations.
6.4.2.2 Human Granulocyte PIG-A Assay Platform Optimisation
Granulocytes, more specifically activated neutrophils were chosen as an additional 
parallel PIG-A assessment platform due to a number of distinct advantages they 
possess. Neutrophils are polymorphonuclear leukocytes (PMNs) [418], a critical 
component of the innate immune system, having an anti-infectious (phagocytosis) 
and a pro-inflammatory function (cytokine release) [419]. Neutrophils are amongst 
the first responders of the innate immune system to migrate towards the site of 
inflammation, penetrating tissues and removing microbial infection [420].
During activation, not only are extracellular pathogens affected but the surrounding 
cells and tissues of the host are also damaged. Therefore, neutrophils are quickly and 
efficiently removed from an inflammatory site by macrophage phagocytosis. 
However, they serve as a direct marker for environmental changes and hence, 
systemic damage. Neutrophils have a relatively limited lifespan, estimated between 5 
hr -  5 days, and therefore, the bone marrow harbours a large constantly active 
granulopoiesis compartment [148, 418, 420]. Granulocytes are nucleated which 
permits direct sequencing to validate the presumed PIG-A deficient genotype, and
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unlike analogous lymphocytes they are less morphogenic, and have a more stable 
cellular surface antigen expression throughout their lifespan [229].
Utilising fluorescent aerolysin (FLAER) as the generic marker for mutation at the 
PIG-A gene locus in combination with anti-CD 15, an activated neutrophil marker 
[421, 422] and a crude RBC lysis through an ammonium chloride based mechanism 
preliminary PIG-A mutant frequency assessment was undertaken (Section 6.3.2.2). 
The results displayed demonstrate the relative enrichment of the leukocyte 
population (Figure 6.8) as well as the phenotypic PIG-A mutant frequency within 
whole blood taken from a self-proclaimed healthy donor; approximately 5,000- 
10,000 defined granulocyte events were able to be captured in less than 20 min per 
sample. The optimal average spontaneous PIG-A mutant frequency within the 
granulocyte population was estimated to be 0.2% (Figure 6.9), significantly higher 
than the comparable RET or RBC frequencies (Section 6.3.1.2 and 6.3.2.1). 
Theoretically, the granulocyte mutant frequency may be significantly higher due to 
its systemic role and close proximity to deleterious microenvironments, high 
concentrations of ROS contributing to potential deletion or abasic site formation 
[423]. Nevertheless, due to the lack of mutation fixation and hence, development of a 
null phenotype, granulocytes would only be microenvironment sensitive following 
direct exposure to limited sources of immediate DNA damage or epigenetic factors. 
Recent publications provide evidence to suggest that the current granulocyte assay 
platform is operating under a poor reporting sensitivity level [175], approximately 20 
fold lower than the corresponding mutant PIG-A RBC frequency. Further 
optimisation of the enrichment protocol, especially to aid the capture of 1 x 106 
events which is the pre-defined benchmark for statistical robustness [166, 175, 280, 
301, 351], is required to facilitate routine patient granulocyte PIG-A assessment.
6.4.3 Human PIG-A Assay Platform Supplementary Investigations
6.4.3.1 Lysis Buffer Evaluation
RETs have a different intracellular environment than their comparable mature 
counterparts; due to the presence of differing quantities of residual RNA. Therefore,
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the lysis protocols should not ultimately lyse the RET event but could have a 
deleterious effect (Section 6.3.3.1). Granulocytes, simialr to the RETs are nucleated 
and therefore, have limited suseptibility against changes in osmotic pressure and 
potential.
Following the completion of a retrospective compensation matrix, the results of the 
RBC lysis buffer evaluation were suitable for analysis and conclusions were drawn. 
The data demonstrated (Section 6.3.3.1), initially from a leukocyte enrichment point 
of view, that enrichment was independent of buffer concentration, and that no 
significance increases or decreases had particular impact on the subsequent 
enrichment figures (Figure 6.10). However, there were significant differences in the 
respective yield of leukocyte enrichment when compared between the different 
buffer solutions. This can primarily be attributed to the different constituents within 
the buffer solutions and therefore, their common or dissimilar mechanisms for lysis. 
BD FACS Lyse displayed dissimilar results to the previous optimisation work 
carried out utilising an ammonium chloride based solution [424, 425], the typical 
mechanism often exploited when depleting whole blood samples of RBCs [426]; this 
lysis buffer is believed to operate under a different mechanism, or alternatively an 
analogous mechanism utilising a difference salt solution [427]. BD FACS lyse was 
shown to result in suboptimum enrichment with some evidence suggesting leukocyte 
activation, which can potentially alter physical characteristics; however, the degree 
of alteration is somewhat unknown in the context of FSC vs SSC profiles [427-429]. 
Easylyse and Versalyse were similar in terms of results, showing robust comparisons 
and limited variability within the data sets; any effect lysis buffer concentration was 
to play, apart from speed of haemolysis, was mitigated by the exaggerated lysis 
incubation period.
The most concentrated whole blood samples would acquire more events per second 
during acqusitions and therefore, provide more robustness during statisical 
evaluation. With this in mind, Easylyse or Versalyse were put forward as potential 
candidates for granulocyte enrichment, the corresponding PIG-A assessment data 
demonstrated that Versalyse generated the most unaffected population with respect 
to the presence of GPI-AP on the cell surface (Figure 6.10). Therefore, Versalyse can 
be concluded as to have the least affect on the PIG-A status in the whole blood 
sample (leukocyte specific). Henceforth, Versalyse will be used to enrich for
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granulocyte (CD 15 positve) leukocytes during the next stage of assay optimisation 
(FLAER analysis).
RET enrichment data was shown to demonstrate that both lysis buffer concentration 
and buffer type, significantly affected the respective reticulocyte enriched 
population. Easylyse and Versalyse generated higher reticulocyte yields than BD 
FACS lyse, across the concentration range tested, providing additonal evidence to 
support the intial hypothesis that BD FACS lyse utilises a different method for lysis 
when compared to the two additonal buffer solutions. Versalyse generated the 
optimum results in terms of RET capture, but then again both concentration and 
incubation were demonstrated to be significant factors in the general health of this 
sub-population. Sensitivity of the PIG-A reporter, the most critical in terms of assay 
devlopment, was required to be assessed in conjunction with enrichment efficiency 
prior to drawing any permanent conclusions.
Providing a single protocol for reticlucyte enrichment was intricate, as the optimum 
buffer interms of enrichment generated highly variable effects on PIG-A mutant 
frquency (Figure 6.10). For that reason, even though Easylyse was not the optimum 
buffer for event enrichment, in general conforming to the specific needs of the assay 
secured the lysis buffer for future optimisation.
6.4.3.2 Cellular Viability during prolonged Human PIG-A Assessment
Apoptosis was a critical source of error within the in vitro PIG-A assay development, 
relatively regardless of methodology used [181, 301]. All versions of the PIG-A 
reporter system currently rely on the indirect measurement of the mutant frequency 
at the PIG-A gene locus via a physical measurement of a GPI-associated cell line 
specific epitope [77, 196]. However, many viability associated pathways and 
processes, such as apoptosis, membrane invaginations, blebbing and/or necrosis have 
been shown to influence cell membrane integrity (Sections 3.3.5, 4.3.3 and 5.3.4.2) 
and hence could potentially generate putative PIG-A mutant mimicking phenotypes 
which subsequently could be scored as false positive events [8, 274, 276].
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Within future applications of this PIG-A assessment, blood is likely to be harvested 
off site and transported to the laboratory. In worse case scenarios, the blood may take 
as long as 6 hr or longer to be processed prior to FCM acquisition. Consequently, in 
order to better estimate the potential deleterious affect prolonged out of host blood 
incubation has on mutant PIG-A frequency, as well as to optimise the best storage 
method, cellular viability was investigated.
The results were subdivided into the specific cell lineages present within whole 
blood, based on their FSC vs SSC profiles. RBC lysis was utilised in order to enrich 
for the minor populations; RETs, leukocytes and nucleated cells. Apoptosis was 
recorded within the leukocyte and nucleated cell populations, the levels of apoptosis 
observed over the time course were highly consistent. Loss of membrane integrity (a 
characteristic of cell death) was apparent within all sub lineages across the whole 
blood spectra; the level of cell death (-5%  within all samples) remained consistent 
across the experimental time period. Necrosis was characterised as late stage 
apoptosis in which cells were annexin V positive as well as having a significant loss 
in membrane integrity [274, 276, 353]. Necrosis was only observed within the 
nucleated sub lineages, and levels remained consistent across the time course (Figure 
6.11).
The conclusions are as follows; i) viability appears to be independent of time within 
the context of sample storage, ii) each cell type has its own unique levels of viability, 
iii) viability appears to remain consistent across the prolonged incubation period 
(Figure 6.11). Temperature of storage equally does not seem to have any significant 
effect on the viability status of the blood (RBCs, RETs and generic leukocytes). 
Therefore, this evaluation provides further validity to the current experimental 
protocol and provides additional strength to the subsequently generated data.
A particular fear for the human ex vivo assay was the occurrence of FCM defined 
leukocyte positive cells undergoing apoptosis following prolonged storage; 
resultantly these events would generate potential false positive PIG-A assessments. 
However, viability was demonstrated to be independent of both storage time and 
temperature. Naturally, the concerns about erythrocytic lineages undergoing 
apoptosis were limited due to their apparent restricted functional RNA and hence, 
insensitivity to apoptosis [295, 411], GPI-AP deficient acquired insensitivity to
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apoptosis [320] and the sheer quantity of published erythrocyte in vivo Pig-a data. 
However, leukocytes are highly different in terms of their sensitivity to external 
stimuli [230, 427], adaptiveness, GPI-AP expression profiles [229] and life span. 
The results showed no obvious decrease in viability, compared to base levels, over 
the time period. Conversely, a generic nucleated leukocyte population was 
monitored, based on FSC vs SSC profiles. A more specific identification of sub­
populations, for example CD 15 activated neutrophils, being required to provide more 
definitive conclusions.
6.4.3.3 Cellular Enrichment Investigation
6.4.3.3.1 Centrifugation as the Sole Granulocyte Enrichment Tool and the effect 
FLAER Titration has on Spontaneous PIG-A background Mutant Frequency
The aims of this project was to develop a combined system platform in which human 
bio-monitoring could be possible, however, within that scope assay robustness, 
reproducibility as well as cost were all influential sub-goals. Utilising FLAER as a 
generic marker for phenotypic GPI-AP absence is expensive, making large cohort 
studies problematic; only facilitating limited number of patients and therefore, 
potentially jeopardising data integrity. Additionally, subpopulation enrichment, 
utilising RBC lysis buffer, again potentially offers a source of error regarding 
phenotypic PIG-A mutant scoring, as well as an additional overhead cost. 
Consequently, in an aid to reduce assay costs whilst maintaining sensitivity and 
accuracy during PIG-A assessment, high speed centrifugation as well as FLAER 
titration were investigated for their potential enrichment and phenotypic reporting 
possibilities.
An issue with granulocytes is that they have relatively short life spans (5 hr to 5 
days) [418, 419, 429], are moderately easily damaged, highly sensitive, 
communicative, especially in an in vivo environment, and demonstrate sensitivity to 
apoptosis. Combining these factors as well as the penetrance and systemic nature of 
exposure, granulocytes are likely to have a raised spontaneous PIG-A mutant
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background frequency, either as a result from false positive inclusion or just greater 
exposure to potential sources of GPI-AP deficiency. Therefore, in order to account 
for the sensitive nature of the cell choice, removal of a potentially deleterious RBC 
lysis buffer exposure in favour for a less abrasive centrifugation may offer an 
alternative methodology for enrichment as well as reduce potential sources of error. 
However, centrifugation, especially at high speed is known to shear cellular surface 
antigens [430, 431], can alter cellular morphology [432] and potentially result in 
fewer captured cells post enrichment.
The enrichment yield following centrifugation was demonstrated to be encouraging, 
indicating an approximate 10% constitution of leukocytes within the sample; in 
which around 10% were CD15 positive (Section 6.3.3.3). This facilitated the 
collection of >10,000 CD 15 positive events within a few minutes of relatively high 
speed FCM acquisition. The results were also shown to indicate the comprehensive 
presence of GPI-APs on the cellular surface within the CD 15 positive granulocyte 
population; comprehensive FLAER binding (Figure 6.12) was observed within most 
of the concentrations trialled within the titration. The two highest concentrations of 
FLAER tested, undiluted and a single 1:1 dilution within PBS/BSA 0.2%, generated 
highly analogous results with respect to FLAER binding efficiency and therefore, 
produced an approximate 0.1% (0.1 and 0.17 % respectively) spontaneous PIG-A 
background mutant frequency. The lower dilution of 1:10 failed to generate such a 
background frequency compatible with a sensitive endpoint; however, the resultant 
mutant frequency was still < 5% (1.6%).
Therefore, with the achieved enrichment and subsequent phenotypic PIG-A 
background mutant frequencies falling in-line with previous reported RBC lysis 
optimisation experiments (Section 6.3.3.1), centrifugation appears to be a viable 
technique to incorporate within assay design. Further investigations into the potential 
effect on cellular viability, including GPI-AP loss as well as cell activation and 
apoptosis status is required to comprehensively assess the methodology. Currently, 
RBC lysis buffer appears to generate the most erythrocytic depleted population but 
also has specific subsequent unwanted effects on cellular viability which are not yet 
associated with centrifugation (Section 6.3.3.3).
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6.4.3.3.1.1 The Possible Effects on Cellular Viability as induced via High Speed 
Centrifugation
With the intention of assessing the impact centrifugation has on cellular viability, the 
experimental design directly compared the subsequent effects to RBC lysis buffer 
exposure, as a benchmark for performance. As well as this, the samples were all 
collected simultaneously, with one being processed immediately, and the other two 
stored for 6 hours at room temperature and on ice respectively. The general aim was 
to come to a more conclusive decision with respect to the methodology for 
granulocyte enrichment, as well as re-assess the impact prolonged storage, under 
different conditions, can have on sample integrity.
For the RBC lysed samples, there was a distinct relationship observed between 
cellular viability and incubation time. As predicted, the most typical “normal” 
population of cells, in regards to viability, were observed within the immediately 
processed blood samples (5.3% apoptosis and 7.5% loss of cellular membrane 
integrity respectively). The two samples which were stored for 6 hr prior to 
acquisition displayed significantly higher levels of cytotoxity, especially prominent 
within the sample stored on ice with (98.6% apoptosis and 10.7% loss of cellular 
membrane integrity) (Table 6.4). Immediately, this was attributed to the limited life 
span of the specific cell lineage assessed; activated neutrophils are estimated to have 
a life span approximately between 5 hrs and 5 days [418, 419, 422] dependent upon 
their specific role at the time of activation. As the exposure period was in excess of 
the conservative estimate of life span, the expected loss of viability was assumed to 
be in the region of >50%. However, the sample stored for 6 hr at room temperature, 
which was expected to perform worse than the sample stored on ice considerably 
lower figures than those stored on ice (13.7% apoptosis and 8.6% loss of cellular 
membrane integrity) (Table 6.4). As a result of this, storage at temperatures below 5 
°C appeared to have a significant deleterious effect on the neutrophil population’s 
vitality, an observed effect which was highly dissimilar from the prolonged viability 
assessment within the morphological “leukocyte” population (Section 6.3.3.2).
The same general relationship was observed within the centrifuged sample, however, 
the levels of cellular viability were much greater and minimal cytoxicity was
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observed; the highest apoptosis and loss of cellular membrane percentages were 
observed when stored for 6 hr on ice but only reached 1.1 and 1.4% of the total 
population respectively (Table 6.4). Therefore, centrifugation appears to have a 
much more subtle effect on cellular viability and in terms of a proposed 
methodology for enrichment, looks favourable to the general aims of the assay 
development. Obviously, during either method, the entire activated neutrophil 
population may or may not have been captured, which could have a specific effect 
on the cytotoxity figures, with centrifugation having a much greater risk of event loss 
due to density alterations when compared to lysis buffer exposure. The general 
conclusions taken from this are; if possible blood samples should always be 
immediately processed and analysed to avoid any increases in loss of viability, 
however, if they are to be stored, within a breathable box, protected from light at 
~22°C.
Centrifugation does appear to be a viable methodology with respect to sub­
population enrichment with obvious advantages over comparable lysis methods 
[175]. However, the resultant sample post centrifugation was contaminated with a 
much greater percentage of erythrocytes (obvious within the “FSC vs. SSC” density 
plot). This was re-enforced by the observed decrease in percentage of CD 15 positive 
cells within the total population of recorded events. Further optimisation will be 
required in order to reach optimum levels of cellular enrichment, in respect to the 
granulocyte population. In addition to enrichment optimisation, additional practice 
using this technique is required; the protocol is more technically challenging in order 
to separate whole blood in this manor, especially during the harvesting of the 
specific sub lineages without excessive contamination.
6.4.3.3.2 Investigations into Histopaque® Enrichment
The initial high speed centrifuge method relied purely on the separation of the cell 
types based on their densities within a whole blood sample; however, the combined 
use of high speed centrifugation within a density gradient to aid separation/resolution 
would potentially enable more accurate layer isolation and ease the technique for 
harvesting. The net results should enable a greater more specific enrichment with
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again, minimal effects on the cellular viability. The chosen commercially available 
density gradient was histopaque® 1077, due to its relative density approximately in 
the range of that of a normal granulocyte, as well as published use in literature [175]. 
With the addition of a layer with a corresponding density highly similar to that of an 
average granulocyte, the population of interest should residue either within the layer 
or fractionally above to ease identification and harvesting.
The resultant centrifugation generated a distinctly separated whole blood sample, 
working from the top down; plasma layer, leukocyte (MNC), histopaque ® 1077 and 
then finally a red blood cell pellet. RETs were believed to residue within the surface 
layer of the RBC pellet, however, as the direct location of the granulocyte population 
was not defined; both the initial presumed MNC leukocytes as well as the minor 
fraction at the top of the RBC pellet were harvested. The results generated displayed 
a relatively poor enrichment; RETs were enriched to approximately 2.9% of the 
population when directly compared to previous lysis figures of 5-10% using 
Versalyse (Section 6.3.3.1). Equally CD15 positive granulocytes were demonstrated 
to constitute approximately 1% from either isolated layer, a poor yield. However, a 
positive outcome of this initial trial was the measurable spontaneous phenotypic 
PIG-A mutant frequency when assessed with FLAER exposure (in the region of 
0.03%, layer 2, and 1.93%, layer 1) (Table 6.5). The conclusions able to be drawn 
from this are that from a purely enrichment point of view, the recovered yields of 
initially RET and granulocyte populations were significantly lower than expected, 
and what has been observed with alternative methods.
However, the fact that CD 15 positive granulocytes are present within both 
presumptive layers does suggest that in-fact the specific density of the histopaque® 
solution utilised is within the expected density range of a normal granulocyte. There 
has been recent publications commenting on the differences between low and high 
density granulocytes [433, 434] and their distinctive roles within innate immunity, 
and therefore, to overcome this, further investigation utilising two specific flanking 
histopaque ® layers may provide more efficient sub type capture. Using a 
combination of two distinct histopaque ® solutions may permit the capture of the 
entire granulocyte population and drastically aid enrichment.
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6.4.3.3.2.1 The Finalised Optimisation of Histopaque®
In an effort to generate a high throughput human granulocyte PIG-A assessment 
platform, tandem histopaque® enrichment was further investigated. The 
experimental design again utilised two discrete histopaque ® layers with densities 
1.077 and 1.119 g/mL to evaluate any potential in the capture of the PNC cells 
within the confines of the flanking layers. The time, speed and temperature of the 
centrifugation separation were all adjusted to bring the protocol more in line with an 
analogous recent publications [175]; an additional inclusion of a loss of cellular 
membrane integrity dye was also implemented for viability monitoring.
The results of this experiment were dissimilar to the previous tandem histopaque ® 
solution trial, both samples (EDTA and Heparin) generated clearly defined 
presumptive granulocytes layers, located slightly above the erythrocyte pellet. 
Within the presumptive granulocyte layer, there was minor indication of potential 
RET presence due to a colour discrepancy as you travelled through the layer towards 
the RBC pellet. Both samples resulted in significant CD 15 positive granulocyte 
populations; the consequential phenotypic PIG-A mutant frequencies observed 
within both the EDTA (0.08%) and heparin (0.11%) samples were comparable, 
approximately 0.1% spontaneous background mutant frequency respectively (Table 
6.6). The RET sub-population within both samples was demonstrated to comprise 
very few RET events and prevented full analysis (data not shown).
EDTA generated the most favourable results in terms of viability, phenotypic PIG-A 
mutant frequency as well as harvesting efficiency and contrary to the current 
protocol should be considered as the anti-coagulant of choice for future bleeds 
(Appendix Section 6.3.3.3.2.2).
However, throughout the use of histopaque ® as an enrichment method to increase 
the numbers of CD 15 positive events scored, the matching phenotypic PIG-A mutant 
frequencies have been elevated when compared to the previous RBC lysis protocols. 
The aim of assay development was reproducibility, a feature easily obtained through 
lysis, and robustness, fundamentally demonstrated by commercially bought lysis 
buffer and finally cost, which is again in favour of RBC lysis.
318
Therefore, even though through the use of histopaque® the numbers of cells scored 
for PIG-A assessment are increases, the resultant corresponding mutant frequency 
has yet to be shown to be competitive to either other published protocols [175] or 
alternatively analogous RBC lysis protocols. Therefore, due to the demonstrated 
stability of the cell types over time, this enables the combined use of RBC lysis and 
extended periods of sample acquisition (-45 mins) to generate patient data. In the 
confines of a minimalistic validatory study, running 2-3 parallel samples per session 
should not result in any significant assay complications. However, assay protocol 
could be further optimised to facilitate the use of this assay system as a popular 
screening system; with a favoured higher throughput methodology. Alternatively, 
wild type depletion can be undertaken with the use of either anti-FITC (granulocyte) 
or anti-PE (RET and RBC) para-magnetic beads in combination with an external 
magnetic field. A commercial set up utilising a pre-establish protocol such as 
Miltenyi [435] analogous to that used within the high throughput version of the 
erythrocyte in vivo Pig-a assay could also be used.
6.4.4 Finalised Human Erythrocyte (RET) and Granulocyte PIG -A  Assessment 
-  Spontaneous M utant Frequency Derivation
6.4.4.1 Human Erythrocyte (RET) PIG -A  Assessment
The aim of this final section was to come to a conclusion on a finalised protocol for a 
human RET PIG-A assay, in order to facilitate both high sensitivity and adequate 
samples size capture. Following the incorporation of the novel gating strategy 
(Section 5.3.4), and using an equivalent protocol as defined in (Section 6.3.2), the 
last variable to be assessed was the potential spectral overlap as a result of RETIC 
Count™ exposure. Spectral overlap can be a problem within any fluorescence 
application and therefore, it must be accounted for. Previously to this experiment, the 
compensation matrix was established utilising positively controlled spiked 
populations, however, the compensation required for the RETIC Count ™ reagent in
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particular was very high. Generally any compensation >30% required a significant 
loss of signal and therefore, a corresponding sensitivity decrease. The previous level 
of compensation was -80% signal reduction, and therefore, there was a noteworthy 
chance of a potential source of error within the subsequently generated data.
The subsequent results following RETIC count™ titration showed that irrespective 
o f the concentration of RETIC Count ™ used, the compensation required was fixed 
at approximately 30% reduction in the FL1/FL2 overlap. This was lower than 
previously assessed, and resulted in corresponding phenotypic PIG-A mutant 
frequencies in the range of 0.03 - 0.05% (Figure 6.13). These background values are 
analogous to the previous values recorded (Section 6.3.2.1.2) and maintain the 
reported relationship between RET and RBC PIG-A mutant frequencies.
This human RET PIG-A assay platform was demonstrated to show a limited sample 
size capture, with a highly sensitive endpoint. This assay design can now be utilised 
to begin to gather human patient data, however, the limited sample size may be 
detrimental to the statistical significance of observed variation in mutant frequency. 
Apart from high content immunomagnetic bead separation to deplete wild type cells 
in combination with counting beads, no other immediate feasible options remain to 
continue protocol optimisation.
6.4.4.2 Human Granulocyte PIG -A  Assessment
Utilising Versalyse, the erythrocyte population was heavily depleted, resulting in an 
enrichment of the leukocyte sub-population from -0.0001 to between 2 and 3% 
(Section 6.3.3.1). This enrichment facilitated the capture of approximately 100,000 
CD 15 positive neutrophil events, within 10-20 min per sample acquisition. However, 
it was still unknown whether the more conventional anti-CD59/55 surface antigens 
[152, 229, 294, 387], commercially available and utilised heavily within the in vivo 
(Litron ™) [77, 143, 196] and in vitro PIG-A [181, 301] assay designs, were 
practical in this specific assay set up. FLAER [305] and CD59 staining were both 
utilised in parallel to produce comparative phenotypic marker scoring and scrutinised 
on sensitivity and accuracy of PIG-A mutant detection.
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Based on the results generated from this experiment, CD59 was initially ruled out as 
a phenotypic granulocyte specific GPI-AP marker due to the varying expression 
demonstrated on the extra cellular surface membrane within the peripheral blood 
samples (Figure 6.14); neutrophils (CD15 positive) demonstrated an average, 30% 
expression of the CD59 antigen on the cellular membrane. The critical role played by 
CD59 in terms of complement protein mediation, via the preventing of the MAC or 
TTC formation, within erythrocyte was not shadowed by an analogous role within 
the neutrophil population [152, 153]. Due to the numbers of phenotypic PIG-A 
mutants constituting close to 70% of the total population, the marker was deemed 
insensitive as a reporter in this setting.
FLAER however, was demonstrated to be a highly sensitive marker for mutation as 
the PIG-A locus; the spontaneous background mutant frequency was shown to be in 
the region of 0.01%, and due to nature of FLAER binding, the accuracy of mutant 
calling is well validated [305] (Figure 6.14). By utilising Versalyse in combination 
with FLAER, an assay platform able to in-directly measure the PIG-A gene mutant 
frequency at an adequate sensitivity was developed. A cell surface GPI-AP specific 
marker could therefore, be implemented into the assay design instead of the more 
expensive FLAER, however, its use could be limited by the functional role such a 
marker would play within granulocyte specific lineages. For example, CD55 may 
generate a more comprehensive phenotypic wild type population due to an additional 
functional role within granulocytes [296] when compared to the analogous CD59 
surface antigen.
The establishment of this preliminary protocol enables further investigation into the 
possible relationships between genomic instability and phenotypic PIG-A mutant 
frequency [175, 351].
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Chapter 7: General Discussions and Conclusions
Throughout this thesis, the goal has been to develop an in vitro PIG-A assay. The 
assay was intended to share the endogenous reporter system as exploited within the 
in vivo rodent Pig-a gene mutation assay, and would hopefully enable the 
preliminary development of an additional human bio-monitoring assay. The reason 
for such an undertaking is primarily driven by the evolving regulatory guidance 
[219, 277] as well as the ethical and financial situation currently facing the cosmetics 
as well as the pharmaceutical industry. Modernising the current tiered battery of test 
systems, via the inclusion of high content, multiplex analysis within genetic 
toxicology safety assessment, will assist the future inclusion of an in vitro gene 
mutation assay within drug development. As well as securing future use, 
modernising reforms would potentially increase global effectiveness in terms of 
sensitivity, specificity and cost of hazard and risk assessment. Recent policy 
alterations, specifically targeting the field of scientific research, have seen ever 
increasing limitations placed on the use of animal models and in specific examples 
there has been a ban on animal testing; for example, the cosmetics industry [86, 
203]. Consequently, with the new restrictions placed within the field, reforming and 
optimising the currently available in vivo [180, 219, 220, 277] and in vitro based test 
systems [112, 125, 208], as well as developing novel platforms, should result in 
advancing the ability of hazard and risk identification within genetic toxicology. 
Subsequently, the field of safety assessment, focussing on the manner in which data 
analysis and hazard identification is undertaken [63, 88, 103, 219, 263] will advance 
and hence, change the current regulatory decision making procedure.
Under the scope of the general aim, investigations were undertaken around the 
debated topic within the in vivo equivalent assay; the genotype to phenotype 
relationship [144, 161, 172, 173]. Incomplete validity with the identification of 
presumptive phenotypic Pig-a mutants, with no direct method of validation, has 
proven to be a potential drawback in the overall speed in advancements of the in 
vivo assay design and subsequent OECD guideline drafting. No conclusive evidence 
has been published to date demonstrating, within the actual assay platform and not 
an analogous system, complete proof of principle. As well as this, a broader thesis
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aim was to investigate assay transferability; expansion of the in vitro PIG-A 
mechanism into additional tissues (Appendix Section 5.5.3.4) as well as 
investigating the potential of expanding the assay system into a human bio­
monitoring context [175, 180, 351, 358, 387]. The former aim was specifically 
investigated to deliver more systemic genetic toxicology safety assessment data 
through the incorporation of point of contact and metabolism simulating tissue types 
[87, 89, 90, 92, 93, 310]. The latter was utilised to propose a preliminary assay 
design which could be used as a basis for future clinical trials [400-402]. Therefore, 
in addition to the developing and optimising of an in vitro assay design, multiple 
additional ex-vivo assay systems were to be analogously developed, in parallel, to 
potentially facilitate the undertaking of validatory human clinical trials. Each 
standalone assay platform adhered to a number of specific criteria; high precision, 
high content, high throughput and finally high sensitivity, in order to generate 
reproducible, robust standalone bio monitoring data.
The initial starting point of the thesis was to design an in vitro equivalent assay, 
retaining the reporter system as well as the haemopoetic and high throughput nature 
of the current in vivo rodent pig-a assay [160], whilst introducing a number of 
additional beneficial features, including nucleated properties of the cell platform and 
high content multiplexed analysis [208, 278]. Therefore, prior to the under taking of 
any additional goals, assay development was the fundamental pinnacle of the project. 
Initially the preconceived design went under a number of validatory/optimisation 
stages, prior to any real proof of principle experimentation; antibodies (Section
3.3.1), enrichment strategies (Section 3.3.2), cryopreservation enabling long term 
storage (Section 3.3.4), additional acquisition/analysis platform usage (Amnis Image 
Stream ™ or Laser Scanning Confocal) (Appendix Section 3.5.3), as well as many 
other additional topics covered within the first results chapter were investigated, with 
the overall aim to establish a central assay platform.
Antibody optimisation was of high priority, the basis of the reporter system 
fundamentally utilises fluorescently conjugated antibodies to report on the phenotype 
of the cellular population [160, 196], utilising such an in-direct mechanism has the 
potential of incorporating a number of sources of error. Therefore, any additional 
sources of error, or known error at such a critical early stage of analysis would have 
a significant impact on overall sensitivity and quantitative risk assessment [158,
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263]. Both trialled antibody conjugates generated comparable low levels of error, 
(Section 3.3.1), however, the PE conjugate demonstrated a fluorescence profile much 
more suited to the assay design, in terms of phenotype separation as well as lower 
levels of Fc mediated un-specific binding. There was no scope for antibody titration, 
in terms of cost effectiveness, due to the observed loss of signal coverage as well as 
negatively correlated increases in difficulty to distinguish between phenotypic PIG-A 
wild type and putative mutant events. Due to the non-essential nature of the roles 
facilitated by the selected GPI-AP surface markers on the extracellular surface of the 
chosen lymphoblastoid cell lines [229], an additional enrichment or putative mutant 
depletion step was shown to be a necessity in order to deplete pre-existing mutants 
and subsequently lower the spontaneous background mutant frequency at the PIG-A 
gene locus. Mutant depletion or wild type enrichment steps are currently 
implemented within the validated HPRT/MLA assays [70, 75, 144, 183, 186]; HAT 
medium and 6-thioguannine (6-TG) or trifluorothymidine (TFT) are used 
respectively. OECD and similar regulatory acceptance would hinge on whether the 
assay could provide sufficient levels of sensitivity and robust detection of putative 
mutant events [73]. Even though clonal expansion was not the optimum method for 
mutant depletion; clonal expansion potentially introduces a source of error due to 
extending the assay period which in turn brings elevated passage number and genetic 
instability within the cell stock. No suitable alternative was able to be found, and 
therefore, was the most sensitive method for mutant depletion at the time (Section 
3.3.2).
Providing the most sensitive assay system, would enable accurate, high precision, 
detection of putative PIG-A mutant events which in turn could enable the system to 
be used for quantitative dose response modelling [214, 226, 263, 277]. Quantitative 
modelling is an essential practice in toxicology [436], and is becoming more heavily 
utilised during hazard and risk assessment. An application which is now seeing 
further use within in-vitro potency assessment [88, 213, 227, 437], with approaches 
being investigated in the context of in vitro to in vivo, and in vitro to human 
extrapolation for risk assessment [88]. Therefore, by developing a system able to 
facilitate this, as well as function as a high throughput genetic toxicology assay, this 
could potentially greatly benefit the safety assessment field and genetic toxicology in 
general [100, 208, 226, 278]. In conjunction with such a system development, an
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endeavour was made to establish a complete assay system that did not suffer from 
the current problems facing the genetic toxicology community; i) inter-laboratory 
variation, ii) lack of robustness between analogous cell lines and iii) discrepancies in 
analysis methodology. Providing a cellular platform, as well as an all in one analysis 
software package (Appendix Section 4.5.3.3), would enable a single method of data 
generation and again move the project in line with the global aims of harmonisation 
and standardisation across the field of scientific research [65, 73, 82].
Using the preliminary assay design, Ethyl Methane Sulfonate (EMS) was chosen as a 
model mutagen to initially evaluate the sensitivity of the assay system, as well as 
potentially provide some validation with the reporter system [181]. At the time, there 
was a plethora of published mutation spectra available for EMS, with a well 
characterised mode of action and significant additional published in vitro and in vivo 
genetic toxicology data [20, 39, 241-243, 350]. Within the proof of principle 
experiment, 24 hr acute dosing, extended assessment was implemented to enable 
phenotypic lag estimation as well as providing a sufficient mutational fixing period 
(Section 3.3.3); initially the data looked promising, it was apparently non-linear, 
most obvious at the day 4 (96 hr) time point and demonstrated the concept of a high 
throughput assay system. However, cytotoxicity issues were apparent from the start, 
potentially caused by overly sensitive toxicity measures, and the relatively high pre­
existing numbers of putative phenotypic PIG-A mutant events resulted in higher dose 
response metrics than comparable HPRT data [350]. The assay demonstrated a 
correlation with respect to putative PIG-A mutants and cytotoxic events (Section 
3.3.5), as expected to some degree; however, an additional insensitivity prevented 
quantitative dose response analysis, limiting the system to enable qualitative 
modelling.
Providing a high throughout, high content, human relevant in vitro assay system 
which enables qualitative dose response analysis provides very little benefit to the 
current field of drug development. Qualitative assessment lacks the refinement to 
ensure conservative, safe assessment, and can often result in a highly complex data 
set with evidence of cytotoxicity. Less critical safety assessment studies could make 
use of such an assay system, especially when regulatory decisions are made based on 
a whole host of data from in vitro and in vivo sources. However, to avoid adverse 
health effects, safety assessment without adequate sensitivity is fundamentally
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floored. In vitro test systems have been criticised for being overly sensitive [105, 
210]; high sensitivity enables highly accurate identification of the vast majority of 
human carcinogens, with increasing false positive rates as a direct consequence. 
Within this specific niche, airing on the side of caution has been historically accepted 
and has resulted in test systems (especially at the lower tiers) with very high 
sensitivity and specificity. However, as drug development becomes increasingly 
expensive, modem reforms have begun to trying to account for this potential 
problem [113-115]. Early stage drug attrition, based on a positive test result, within a 
known overly sensitive test system can retard or even inhibit drug development of a 
potential candidate due to misleading results; a practice which is finically 
uneconomical for pharmaceutical companies [217]. Exposure driven test systems 
could alleviate the potential of false positivity, current test systems often dose at non- 
therapeutic concentrations.
If this in vitro assay system cannot reach the basal level of sensitivity outlined by 
predecessor assays, then irrespective of the additional benefits the novel design may 
bring, the assay will have little scope in a hazard and risk assessment setting. 
Therefore, the aims of the second results chapter were slightly different, using the 
basic established assay design and initial data set collected; the chapter was intended 
to more accurately investigate the identity of putative PIG-A mutant events as well 
as investigate the most suitable cellular platform in terms of sensitivity and 
molecular benefits and further the assay design to facilitate assay distribution. The 
most logical place to start in respect to this particular assay would be the pre-existing 
(background) number of phenotypic PIG-A mutant events within the parental TK6 
cell line; initially, additional TK6 cell lineages were to be assessed for potential 
inclusion within the in vitro PIG-A assay design.
There are problems faced by genetic toxicologists regarding the integrity and identity 
of the cell lines used within experimentation. Genetic drift cause through poor 
maintenance or inappropriate distribution leads to cell lines that do not conform to 
their pre-determined characteristics. Consequently, constructing a complete assay 
system able to be implemented into any laboratory primarily overcomes some of the 
problems associated to independent cell line maintenance and improper distribution. 
Therefore, the earliest “Low Passage” lineage of the TK6 cell line was obtained from 
the ILSI-HESI, NIHS (Masa Honma) and these cells were assessed for GPI-AP
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expression as well as general morphological and physical characteristics (Section
4.3.1). The aim of this sub-study was to find a GPI-AP surface reporter marker 
candidate to be used in combination with the “Low Passage” cell line which 
facilitated highly sensitive mutation analysis without the need for a pre-enrichment 
step. However, prior to any PIG-A phenotypic assessment, obvious differences were 
detected between the normal and “Low Passage” cell lines; ranging from dissimilar 
morphology to unique responses following mutagen exposure.
Clonal expansion is a technique which has been utilised for decades within 
microbiology; however, in the context of genetic toxicology assays, it often has 
associated complications. Within current validated in vitro gene mutation assays, 
clonal expansion is utilised to provide sufficient cellular growth to enable visual 
identification of colonies post chemical exposure to enable scoring [70, 71, 112]. 
However, the cell lines used within testing contexts are often immortalised, some 
cancer, cell lines with abnormally high levels of genomic instability; this feature 
often provides increased sensitivity which again helps contribute to the overly 
sensitive stereotype [113-115, 210]. Therefore, extended experimental time periods 
can facilitate the accumulation of abnormal spontaneous mutation frequencies, often 
within non-human cell lines, which propagate additional genomic damage 
independent of chemical exposure. In order to move the field of in vitro genetic 
toxicology testing forward; human cell lineages, with representative functionality, as 
well as novel molecular techniques, which do not emphasise known technical issues, 
are required. Flow cytometry is a high throughput platform in which such an assay 
system can be developed, with potential to provide accuracy and sensitivity as well 
as additional high content features to enable multiplex analysis [235, 246]. 
Following the technological advances of the last decade, most bench top flow 
cytometers now have the ability to sort events of interest, using a technique known 
as FACS. This is a potential method to enable highly effective high-throughput 
mutant phenotype depletion prior to distribution and subsequent PIG-A assessment, 
eliminating the required need for a clonal expansion step. However, much like most 
modem technology, FACS is incredibly susceptible to loss of sensitivity, through 
poor event characterisation as well as machine error, following less than impeccable 
maintenance. Often the highly impressive numbers associated with potential FACS 
purity sorts can be obtained routinely by specialised FACS labs, but more general
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laboratories would not be able to routinely reach the stated figures. Therefore, it 
comes at no great surprise that FACS was demonstrated to be highly effective; 
however, unable to obtain the required level of sensitivity to secure integration into 
the long term assay design (Section 4.3.2).
The assay system appeared to be subsiding below the required standards of 
sensitivity even prior to mutagenic exposure and therefore, the reporter system itself 
was fundamentally assessed for error. The preliminary experiments had quantified 
the sensitivity of the antibodies used in the assay; however, the additional proof of 
principle experiment had also highlighted the existence of a subset of putative PIG-A 
mutant events which were non-viable. This issue has been discussed previously, and 
is also an associated concern to the in vivo Pig-a assay due to the lack of the means 
to fully test and validate the genotype of the proposed mutant events. Having 
identified a relationship between cytotoxity and a corresponding increase in mutant 
frequency, as well as successfully identifying a sub population of non-viable putative 
in vitro PIG-A mutants (Section 3.3.5), alternative mechanisms were investigated for 
in vitro phenotypic mutant mimicking event induction. The “Low Passage” TK6 
cells were assessed for viability pre-exposure to attempt to bring the system in-line 
with current validated levels of sensitivity, however, following only minor levels of 
detected apoptosis and cell death, the system still appeared to fundamentally lack the 
ability to differentiate induced from pre-existing phenotypic PIG-A mutant events 
(Section 4.3.3). This was mirrored within the preliminary EMS data utilising FACS 
enrichment, CD55 as the reporter for mutation and viability assessment within the 
PIG-A assay design. The resultant data again demonstrated a similar dose response 
with comparable defined metrics to the previous EMS exposure (Section 4.3.4). 
Highly varied GPI-AP expression, with seemingly no obvious correlation to surface 
distribution or expression was shown to be the critical sensitivity limiting factor in 
preventing the inclusion of the “Low Passage”, apparently more stable, cell line 
within the assay design. Therefore, in order to fulfil the initial goals of constructing a 
standardised assay system, enabling mass reproducibility as well as data robustness, 
additional features as well as cellular platforms were to be assessed.
Cell lines utilised within genetic toxicology testing are generally quite similar in 
terms of physical characteristics and applicable uses, this is re-enforced by the 
common ancestry shared by a number of routine use cell lines [124, 126, 127, 182,
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200]. However, genetic and phenotypic differences are often apparent and therefore, 
different cell lines are used for different genetic toxicology applications; for 
example, AHH-1 and MCL-5 cells have increased metabolic function than other 
analogous suspension cell lines and can be used when metabolic activation of the 
genotoxicant is required [28, 126, 182, 200, 306, 350]. However, in order to put 
forward a self-contained assay system with most, if not all, of the features currently 
desirable within the field, i.e. p53 functionality, apoptosis sensitivity and human 
relevance etc., assay optimisation as well as cell line characterisation is required 
[113]. To facilitate the automation and hence standardisation of the FCM in vitro 
PIG-A assessment, a number of different mathematical gating strategies were 
investigated to find a reproducible and accurate system for defining phenotypic 
status (Appendix Section 4.5.3.3). All gating strategies were shown to be robust and 
reproducible, and following further development of a graphical user interface (GUI) 
within a suitable programming environment, a simple automated statistical analysis 
package can be constructed. This would provide standardisation as well as a non- 
subjective method for analysing in vitro PIG-A mutation data; removing any 
potential inaccuracies as well as subjectivity and increasing data integrity.
Investigating alternative cell lines and GPI-AP combinations was shown to identify 
potential candidates for the in vitro assay design (Section 4.3.5), with the aim of 
identifying a cell line with a constituently expressed critical GPI-attached surface 
antigen, removing the need of any additional preparative stages (mutant depletion). 
In addition a brief validation of the candidate cell lines was undertaken to 
demonstrated potential p53 expression as well as functionality. All cell lines 
assessed demonstrated p53 presence, and some level of functionality which 
facilitated their inclusion in further experimentation and potential assay integration. 
MCL-5 cells were concluded as the most appropriate cellular platform for the assay 
for a number of reasons; their p53 competency, suspension growth dynamics, 
metabolism capability and general robustness were all suitable (Section 4.3.5).
By the end of the second results chapter the assay design had moved into the MCL-5 
cell line, optimised the gating strategy, demonstrated feasible p53 competency and 
apoptosis capability, isolated a potential flaw in the current assay protocol with 
regards to non-viable putative PIG-A mutant mimicking events and identified a 
number of suitable GPI-AP to act as in-direct reporters for mutation. The assay was
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beginning to coincide with the goals initially outlined by the project. However, the 
assay still lacked any real hard evidence for dose response data at a sensitivity level 
comparable to validated assay systems. A number of additional mechanistic 
problems were also investigated, FCM scoring bias as well as assay robustness 
(Appendix Section 4.5.3) and therefore, the ensuing chapter, was aimed to generate 
proof of principle data. As well as investigate in greater detail issues regarding GPI- 
AP coverage, imaging platform compatibility and potential sources of bias, including 
the cell cycle.
Conforming to the modernisation of the genetox field is critical to ensure the 
longevity of the assay test system. With ever increasing economic reforms applying 
increasing pressure on the restrictions with animal usage [86] and the desired 
application of the data [88], in vitro test systems are required to deliver on both cost 
efficiency and strength of subsequent data. No longer has it appeared to be sufficient 
to generate a test system with immense sensitivity, it also must ensure high content, 
toxicity assessment, high through put and often associated to a parental or analogous 
test system sharing a well validated mechanism. The pre-existing validated in vitro 
gene mutation assays have recently come under criticism for a number of reasons 
aforementioned [113-115], especially the test systems which offer little human 
relevance as well as limited strength. As a consequence of this, their future inclusion 
within safety assessment batteries, is not definite, especially with the development of 
novel high throughput analogous test systems [301]. Therefore, not only is there a 
current requirement for the development of novel test systems to meet demands of 
the evolving field, but also a strong supplementary feature which heavily favours this 
particular developing test system. The additional benefits the field would receive if 
an in vitro PIG-A platform could be validated not only could provide the high 
throughput, high precision nature of a gene mutation test system, but more 
importantly a stage for the further validation of the in vivo mechanism, a current 
limitation for OECD guideline drafting. By facilitating direct sequencing validation 
of the phenotypic PIG-A mutants, an in vitro PIG-A assay, meeting all the predefined 
criteria, guarantees inclusion within the near future of genetic toxicology. There are a 
number of currently published studies which have begun to investigate the 
relationship between phenotypic Pig-a mutant events and their respective genotypes, 
however, experimental design has prevented true representation. Experimental
333
designs are yet to truly reflect the reporter mechanism without any potential bias; 
however, data collected has shown some correlation between phenotype and 
genotype [144, 172, 438, 439]. This presumptive guarantee within the near future 
inclusion of toxicology research makes the assay unique, as well as additional 
quantitatively dose response modelling, providing human relevance, and a potential 
correlation to current in vivo data as well as human health potency assessments. The 
design and development of a suitable assay system exploiting the in vivo mechanism 
could provide a significant benefit to the genetic toxicology community and aid 
future regulatory decision making, human health risk assessment and field 
progression.
A complex relationship exists between toxicity and genotoxicity within the field of 
genetic toxicology. Following compound exposure and the saturation of homeostatic 
defence mechanisms, including DNA repair, induced lesions or mutational events are 
not repaired and subsequently, the cell begins to accumulate irreparable damage [8, 
14, 118]. Each cell is unique in terms of the exact amount of tolerated damage, but 
once the threshold is met the cell either undergoes apoptosis, necrosis or has 
accumulated such genomic damage that it is unable to undergo a death pathway and 
results in the cancer phenotype. As a result of this, genotoxicity testing often does 
not exceed 40-50% cytotoxicity, to avoid falsely underestimating genotoxic potential 
of a compound. In addition and to further complicate the relationship, in vitro, 
toxicity can lead to genotoxicity through the release of ROS from dying cells [440]. 
However, minor physiological differences within either pathway progression are able 
to be exploited to define the subsequent results of genotoxic exposure. For example, 
cells undergoing genotoxic damage do not often have morphological alterations 
within the extracellular membrane; damage is often confined to the nucleus or other 
mechanism specific organelles [275, 276, 441].
Therefore, there is a great need for accurate viability assessment within safety 
assessment testing to ensure correct definition of damage and to prevent either 
grossly over or under exaggerating a compounds effect. Genetic toxicology has 
moved over the past decade into more high content multiplex analysis with specific 
focus placed on more accurate viability assessment. Previously, scoring viability has 
been based on the size of the cell, and traditionally RPD or RICC assessment has 
been the gold standard in cytotoxicity, cytostasis and mitotic arrest assessment [133,
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357]. However, utilising the coulter principle and operating under the current 
standards, there is a high potential of cells being miss-incorporated into analysis as a 
result of poor viability assessment and subsequent definition. Molecular markers for 
apoptosis for example generally provide a much more accurate measure of the actual 
health of a cell however; such methods are more expensive and often have rate 
limiting associating properties. With the introduction of such platforms as FCM, the 
incorporation of viability dyes within the staining cocktail allows either monoclonal 
antibodies, or nucleic acid dyes to more accurately assess the health of the cellular 
population. The in vitro PIG-A assay designed to this point demonstrated some 
correlation between genotoxic potency and cytotoxicity, an unfortunate relationship 
adding to the complexities observed within such assay systems [65]. However, by 
utilising more modem methods along with additional viability assessment and a 
more complex gating strategy, this correlation should be removed. These efforts will 
provide help to establish a solid foundation from which to work on in the future 
developments, to allow this test system to be integrated in the in vitro test battery in 
future years.
The third results chapter focussed heavily on two separate aims; firstly to generate 
suitable qualitative MCL-5 dose response data, for proof of principle as well as 
showing potential applications of the assay (Section 5.3.1). Secondly, the 
undertaking of an apparent successful preliminary novel heterogeneous sequencing 
experiment, in which a direct assessment of phenotype to genotype relationship 
could be made, was investigated to potentially increase validation of the in vivo 
mechanism (Section 5.3.5). The novel approach utilised a metagenomics style in 
which heterogeneous populations were assessed for mutational spectra shift, 
following model mutagen induction, at multiple PIG-A related gene loci.
Initially, model mutagen exposure was utilised again to demonstrate proof of 
concept, with EMS, MNU and ENU being used as well characterised alkylating 
agents. However, the addition of a non-genotoxic 2,4 DNP compound as an 
assessment for false positivity and assay ability to detect mutagens and pro-mutagens 
from toxic, non-genotoxic compounds. In an attempt to demonstrate that the current 
reformed assay was free from cytotoxicity bias, 2-4 DNP was tested as well as a 
trans-membranous antigen marker, HLA-DR, included. HLA-DR inclusion, much 
like CD 19 or equivalent antigens, is as an additional viability and phenotype validity
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assessment. HLA-DR constituently present within the extracellular surface of 
lymphoblastoids, serves as a “se lf’ marker for membrane integrity, which in turn 
increases phenotype validity by ensuring that cells with aberrant membranes are not 
scored as presumptive PIG-A mutant cells. The data generated looked promising, 
and all compounds exhibited non-linear dose responses, admittedly corresponding 
toxicity was often observed at the high doses, and were ranked in terms of potency 
by their respective fold increases in phenotypic PIG-A mutant frequencies (Section
5.3.1). Good specificity in identifying known model mutagenic compounds was 
apparent, in addition to this; the non-mutagenic compound was demonstrated not to 
increase phenotypic PIG-A mutant frequency. More importantly, the previous 
observed correlation between cytotoxicity and increase in mutant PIG-A frequencies 
was no longer apparent. This point in particular is of importance within the 
continued debate about the identity of putative Pig-a mutant events within the rodent 
Pig-a assay. However, the assay was unable to deliver on the sensitivity; the pre­
existing background mutant frequency was elevated and hence, lacked the ability to 
detect minimal phenotypic PIG-A mutant induction. A feature required to bring the 
assay design in-line with the HPRT or MLA/TK assays and a continued problem 
requiring further optimisation prior to any chemical validation step. Flow cytometry 
gating improvements could be utilised (Section 5.3.4), especially in terms of false 
positivity refinement, tandem antibody GPI-AP marker stains can be used to increase 
validity of phenotype (Section 5.3.2), a technique recently exploited within the 
development of an analogous TK6 based in vitro PIG-A testing platform [301].
In addition to the lack of definitive sequencing evidence, which would provide 
comprehensive support for the in vivo pig-a mechanism, there also appears to be a 
data gap in regards to additional molecular derived supplementary data. The 
continued development of the in vivo pig-a assay, i.e. OECD guideline drafting, is 
currently being retarded by the lack of complete mechanistic validation. However, 
supplementary supporting molecular data could be used to strengthen the case of 
phenotype validity without excessive sequencing. For example, lipid raft associated 
sporadic cellular surface marker distribution, visualised following confocal imaging, 
is one of the reasons why tandem reporting surface markers should be incorporated 
into assay design. In addition to providing a physical image depicting a strong 
positive phenotype, the data also highlights potential flaws in the potential future
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imaging platforms able to analyse the data correctly (Section 5.3.2). Utilising FCM 
based approaches would be appropriate as the diameter of the laser light used to 
excite the cellular events is greater than the average diameter of a MCL-5 cell, 
however, other platforms utilised alternative excitation approaches could induce 
significant bias within analysis. Identification of such technical issues provides 
insight into the future development of imaging technology as well as enables more 
accurate research. As well as this, exploiting more complex features within flow 
cytometry analysis could also provide additional sensitivity to the assay. Unlike the 
proposed in vitro assay designs, the rodent erythrocyte assay is pretty robust in terms 
of mutant identity. Erythrocytes lack the ability to apoptose and are heavily 
determined in terms of their fate and therefore, quite unresponsive post release into 
the circulatory system. However, although this cell type is idealistic for scoring 
purposes, they are less than ideal for validation. Moving the assay into a nucleated 
cell line for validatory reasons, splenocyte etc., potentially can introduce a number of 
associated cytoxicity problems. Utilising novel pulse width measurements, time of 
flight, as an additional in-direct method for phenotypic identification, could provide 
the assay with an increase in sensitivity, as well as enable the analyser to have 
increased confidence in the resultant data (Section 5.3.3). This modification 
improved the sensitivity through a decrease in spontaneous background mutant 
frequency that became in line with current validated test systems [301]. This 
preliminary data displayed within the chapter critically highlights the potential of 
this modified assay, as well as provides some level of confidence for future 
qualitative use, as sensitivity issues were mostly resolved.
The latter half of the chapter was focused on the investigations into the phenotype, 
genotype relationship. Flow cytometry defined putative phenotypic PIG-A mutant 
events were to be assessed through next generation sequencing approaches to 
validate their genomic identity (Section 5.3.5). The experimental design was free 
from biasing techniques and involved sequentially inducing phenotypic PIG-A 
mutant events, FACS isolating and capturing said events, and immediately 
sequencing the resultant heterogeneous pooled putative phenotypic mutant 
population. The genotype of the collected events were analysed at multiple gene loci, 
selected for their implicit relevance in assay design, which facilitated the calculation 
of the frequency of actual PIG-A' mutational events within the pooled population.
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Contrary to current published data, all mutational events potentially resulting in a 
GPI-AP deficient phenotype were studied which enabled some comment on the 
validity of the Pig-a reporting mechanism. The main aim of this section was to 
potentially validate the proposed Pig-a mechanism and solidify the potential future 
use of the in vitro platform for future applications. The chapter showed good 
evidence to suggest that the current developmental process had reached a point to 
facilitate further advancement of the test system and to enable the potential 
fulfilment of larger more validatory goals.
Ethyl Methane Sulfonate (EMS) exposure appeared to result in an apparent 
correlation between presumptive mutant events and identified non-synonymous 
mutations within the coding region of the PIG-A gene. Exon 6 was preliminary 
identified as an area of high activity in terms of mutational events. However, 
mutational events were also preliminary defined within the CD59 and PIG-T, at a 
lesser frequency within the coding region than the comparable PIG-A data. Resultant 
proposed EMS induced mutants, across all the amplicons investigated, displayed 
higher frequencies of GC->AT transition mutations, when compared to any other 
form of mutational event. Therefore, the subsequent generated proposed mutation 
spectra were in-line with the published mechanism of the alkylating agent. However, 
the con-current control data failing within the DNA extraction stage of sample 
preparation prevented any conclusions being able to be associated with the data and 
therefore, the lack of direct sequencing data for the in vivo Pig-a mechanism is also 
still apparent. Recently, a number of additional Pig-a sequence papers have been 
published which show a mixture of findings. Data generated from the FDA 
laboratory utilising rodents (Rats) treated with both DMBA and ENU show strong 
correlation and evidence for PIG-A mutational events resulting in the GPI-AP 
deficiency. However, no additional genes were investigated other than the PIG-A 
gene loci, which is a potential limiting factor for OECD acceptance [438, 439]. 
Interestingly, two additional publications have put forward data demonstrating 
further PIG gene mutations inducing firstly, the PNH phenotype within human 
patients [146] as well as the GPI-AP deficient phenotype within human cell lines 
[442]. These publications provide some evidence for the validity of the mechanisms, 
as well as quite strong confounding evidence for additional, currently un-measured, 
genetic alterations resulting in the defined “PIG-A mutant” population. Therefore,
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phenotypic scoring, data analysis and subsequent interpretation become more 
complex until future assay refinement. Without further investigation, and more direct 
sequencing data it is unclear whether these recent publications will further retard the 
development of the in vivo assay. However, their presence does generate further 
need for an in vitro test system utilising the mechanism to facilitate direct 
sequencing. The field requires the presence of conclusive data and therefore, further 
investigations are required. Potentially, within the upcoming IWGT work group 
specific data gaps will be focussed which should more readily move the community 
to a decision on the assay design.
As briefly discussed earlier, a test system is more likely to have a role in hazard and 
risk assessment if it is able to combine with a number of additional supplementary 
end points (multiplexing) or directly correlates to an in vivo genetox assay. The 
reason for this is the nature of the current regulatory decision making. Due to the 
holistic approach utilised when coming to a decision on safety assessment [226, 
277]; often data is highly varied and can be quite unconnected and therefore, difficult 
to rank its potential strength. Consequently, if data can be directly compared to an 
analogous end point or partnering in vivo data set, and positive correlations 
observed, the strength of the data set is considerably increased. Accrediting more 
strength to an assay platform facilitates increases usage and longevity within safety 
assessment. Currently in vitro potency does not relate to human health assessment, 
and therefore, does not play a significant role in decision making. However, further 
developmental work within this specific field may demonstrate potency correlations 
which could enable more weight of evidence being placed on in vitro data sets. Due 
to the transferability derived from the comprehensive and conserved nature of the 
GPI-AP structure [163, 165, 174, 320, 352]; the potential scope for usage of the 
PIG-A mechanism is broader than a purely safety assessment role [180] (Appendix 
Section 5.5.3). Human biomarkers are rapidly being investigated in order to better 
characterise, diagnose and treat a number of human health conditions; however, 
many known disease phenotypes have no currently identified biomarkers associated 
with progression. Consequentially, miss-diagnosis or alternatively late stage 
diagnosis are more common which often complicate identification and can have life 
threatening complications and a more severe prognosis.
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Rarely genetic toxicology end points have made the transition into the wider world 
of human bio monitoring; the micronucleus assay in its own right has been used in 
broader epidemiology studies for the past two decades [69, 382, 383]. However, the 
typical MN assay protocol is only sensitivity to environmental exposures which 
penetrate the bone marrow and result in subsequent DNA damage within peripheral 
blood cells; thus, having an un-invasive protocol, however, limiting the ability to 
detect acute exposures [46, 378, 379]. As well as this, few genetox end points are 
versatile enough to be used as a potential biomarker within HBM studies [144]. 
Additional MN assay platforms are available, for example buccal cells are targeted 
to investigate oral routes of exposure [382], however, these studies are less robust 
and often have additional costs (cheaper than current pig-a assessment) and invasive 
procedures associated. Therefore, development of a novel test system which equally 
enables high precision, highly sample volume and rapid sampling with a more 
systemic exposure metric as well as a specific tissue specific metric is highly 
attractive.
Over the past decade, the possibility to generate a robust human ex vivo PIG-A gene 
mutation assay has repeatedly been described [175, 351, 358, 387]; however, little 
correlation has ever been demonstrated between elevated PIG-A mutation 
frequencies and adverse phenotypes within such studies [175, 280]. The recent 
advances within the basic Pig-A assay design potentially now could be utilised to 
readdress the assay design and subsequently produce a more accurate reporting 
platform for human bio monitoring. The conserved GPI-AP structure enables the 
PIG-A mechanism to theoretically be undertaken within any cell type/tissue type as 
long as a suitable GPI-anchored surface protein can be identified to act as an in­
direct reporter for mutagenesis. Similarly to the human MN studies, exposure would 
have to be systemic if haemopoetic cell lineages were to be utilised, similar to the 
traditional erythrocytic pig-a assay platform. However, utilising a more active cell 
lineage for example granulocytes or liver hepatocytes, would provide better models 
for comprehensive selective exposure to be measured, nevertheless, a number of 
confounding factors would also be introduced; including highly invasive biopsies, 
trypsinisation issues during sample homogenisation as well as metabolic instability 
and sample degradation.
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A supplementary study was carried out in which an intracellular in vitro PIG-A assay 
design, with the ability to act as an organ/tissue specific platform, was put forward 
and investigated. Even though the data generated was purely proof of principle 
preliminary experimentation, the concept was demonstrated to be achievable 
(Appendix Section 5.5.3). The study was undertaken purely to demonstrate the 
transferability of the mechanism, an assay design which potentially could work for 
any X-linked gene which encoded a known constitutively expressed protein. 
Providing such a model is of great benefit to the genetic toxicology community as it 
offers the ability to measure genetox end point within any organ or tissue within the 
body. It also provides a slightly refined reporter mechanism, as it no longer 
introduces the potential complexities of the additional genes within the GPI-AP 
synthesis pathway, a recent contested point within the in vivo Pig-a development 
[442]. By directly measuring PIG-A protein presence, only a single gene locus is 
actively involved in the formation of the phenotype and hence, the genotype is more 
simply deduced. However additional investigations into the sample preparative 
procedure would be required prior to further validation, the current human cell line 
models provide little resistance in terms of sample preparation prior to high 
throughput analysis.
The results described in the fourth results chapter, outline the initial optimisation and 
development of a potential human RBC, RET and Granulocyte PIG-A assay, taking 
influence from a number of assay designs published over the past decade [175, 358, 
387]. The finalised assay protocols were able to meet the desired sensitivity level to 
facilitate the further validation of a potential bio monitoring platform (Sections 6.2 -  
6.4). The limitations still present within the use of erythrocytic cell lineages 
threatened the strength of the platform and again introduced scepticism into 
phenotypic classification. Therefore, granulocytes were chosen, because of existing 
fundamental protocols [175] as well as the potential for sequencing validation. 
Granulocytes were chosen over lymphocytes for a number of reasons, specifically 
their role in the innate immunity and hence, localisation to areas of chronic or acute 
exposure to deleterious micro environments throughout the body. This feature would 
be highly beneficial if localised blood sampling was to be undertaken, however 
utilising peripheral blood means that exposure should be bone marrow penetrating to 
enable response measuring. Granulocytes do not divide as such, and therefore have a
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fixed lifespan ~5hr - 5days, similar to RBCs and should model bone marrow 
exposure accurately. However, they are also nucleated and are subjected to 
deleterious microenvironments following infection and/or inflammation [433, 434]. 
Both environments have been associated to cancer progression and are especially 
prominent in ROS, which can induce mutational events [148, 232, 443]. Due to lack 
of mutational fixing, neutrophils would theoretically have limited specificity to all 
mutational events, however, still could provide a more point of contact or systemic 
reflection of genomic health. Lymphocytes present a difficult situation as their 
characteristics make them both highly beneficial and inappropriate for drug 
screening. Their nucleated status, their un-invasive means of extraction make them 
an ideal cell lineage, however, their ability to alter surface antigen expression, 
especially at times of activation make them too heterogenous and subsequently 
errorous for routine assessment [198, 233, 292, 390].
Within traditional erythrocytic Pig-a research there is an abundance of red blood 
cells able to be phenotypically assessed. However, the nucleated leukocytes 
comprise a much smaller percentage constitution of blood and therefore, require 
extensive enrichment prior to assessment. The introduction of immunomagnetic 
[168] or differential gradients [175] as means of enrichment were key turning points 
in the relative development of their respective Pig-a protocols. The purpose of this 
study was to attempt to develop a platform able to be utilised in future validatory 
clinical trials associating the PIG-A deficient phenotype with genomic instability and 
specific disease phenotypes. Preliminary data, utilising this developing platform as a 
basis, has been presented demonstrating promise [400-402]. However, major 
limitations were also apparent during development; highly extended sample 
collection periods, frequently greater than an hour per sample in order to collect the 
number of events required to generate statistical significance. The problem stems 
back from the enumeration of the minor populations, RET and granulocytes, even 
following enrichment occupied less than 10% of the total blood population. Further 
optimisation into the proposed finalised protocols would have been preferential 
utilising immuno-enrichment approaches.
The potential benefits of developing such a bio monitoring platform, as a result of 
further assay platform refinement, could enable identification of exposure correlated 
mutation driven disease predisposition. During early stages, cancer is most treatable;
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it is often contained and yet to metastasise and often responds well to chemo, radio 
therapy and/or novel treatments. Prognosis following early diagnosis is often very 
positive, especially within bowl cancer where the 5 year survival rate is >90% if 
detected early [444]. However, as the cancer phenotype progresses, the genetic as 
well as biological alterations begin to fester; subsequently allowing the cancer to 
develop further, switching off biological failsafe’s and moving out o f infancy [6, 66, 
138, 205]. At this stage in progression cancer can become highly aggressive, 
completely self-sufficient and mobile, in which metastases are able to systemically 
attack other tissues within the host. Once the cancer has become well established its 
ability to respond to therapies is highly reduced and often becomes highly 
symptomatic [395, 443]. Therefore, deep tissue cancers once presenting symptoms 
are often untreatable and are highly associated to poor prognosis, Pancreatic cancers 
have a comparable 5 year survival rate of <10% [444]. One of the reasons for this is 
the dormant nature of the developing cancer which potentially been present 
asymptomatically for a number of years whilst it facilitates self-sufficiency and 
growth. Treatment in general is expensive, however, as the treatment becomes more 
novel and/or more critical the price tag escalated. Consequently, the associated costs 
of supplementing this treatment to the general public can be exorbitant, and 
therefore, as a financial model, treating cancer at an early stage is much more 
appealing; not only does it increase prognosis but is generally more effective. In 
addition to cancer, potentially obesity, diabetes, inflammatory diseases could all be 
monitored for progression, following the comprehensive refinement, validation of 
the test system platforms and the incorporation of localised blood 
harvesting/sampling, via this relatively un-invasive preliminary test system.
Identifying a novel approach of detecting a pre-disease phenotype, identified by an 
elevated level of genomic instability, through a cost effective, relatively un-invasive 
method would be highly financially and clinically beneficial. This supplementary 
project was able to generate three standalone preliminary assay protocols for high 
throughput, high precision human PIG-A assessment. However, apart from the RBC 
protocol, each assay fell short of the levels of sensitivity and robustness required to 
be highly comparative to currently published protocols or analogous in vivo assay 
designs [175, 351]. Further development is required to facilitate the complete usage 
of this preliminary test system as a standalone biomonitoring assay.
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7.1 Thesis Summary and Proposed Future Work
Throughout the undertaking of this thesis project the in vitro PIG-A assay design has 
undergone a number of revisions, refinements and general modifications. The 
finalised assay protocol, within the time constraints of the thesis, was established 
within the metabolically active, genetically modified, human MCL-5 cell line. Using 
this assay design, proofs of principle experimentations were able to show the 
potential for future work, and that the general approach was promising. A number of 
assay refinements are still required, generally focussing on two separate areas, i) 
toxicity issues and ii) the genotype to phenotype relationship. Toxicity was 
demonstrated to be a continuous problem associated with the miss-identification of 
the putative PIG-A deficient phenotype; however, following much work, the problem 
was removed following the inclusion of membrane integrity markers such as HLA- 
DR or CD19 (highlighted by the 2,4-DNP case study)(Section 5.3.1). Interestingly, 
the previous versions of the assay design may also prove to be useful following a 
retrospective validation of the toxicity measures currently used within the assay 
design. RICC, RPD and RCC are all measures which were frequently used however, 
may be best suited with their initially intended usage within the MN assay. Shifting 
the toxicity measure more in-line with analogous test systems, such as HPRT and/or 
MLA, will potentially alleviate miss interpretation of phenotype, and more 
accurately report in-direct mutation status.
The genotype/phenotype relationship validation is still on-going, especially 
following the preliminary work presented (Section 5.3.5), as well as recent 
publications of additional confounding data [146, 442]. Potentially, due to the 
identification of additional genes active within the current phenotypic PIG-A scoring 
mechanism, challenging the current reporting with a more generic phenotypic for 
example, “GPI-AP deficiency” may provide a more accurate description o f mutation. 
However, currently it looks promising that further investigation and refinement will 
lead to the establishment of a high content, high-throughput assay system with the 
potential to be used within a hazard and risk assessment environment.
The supplementary ex-vivo Human bio monitoring design development equally was 
shown to have a number of limitations (Section 6.3). However, the approach showed
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good promise for actual future usage, especially within preliminary bio monitoring 
studies. Further refinement of the assay protocols is required to make use of the 
additional cell lineages within assessment, RETs and Granulocytes as currently they 
lack sensitivity and robustness. Making use of an analogous immunomagnetic 
column enrichment [168] may provide the increased enrichment required, and hence, 
enable the system to obtain the required level of sensitivity as well as specificity. 
However, if completed, the potential benefits the assay designs would offer to the 
field would be significant; an additional bio-monitoring platform with sufficient 
sensitivity to investigate the correlation between genomic instability and disease 
phenotype [175, 351, 358, 387]. This may be able to help early stage diagnosis and 
prevent un-necessity increased financial costs of treatment.
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Table 7.1 -  Summary o f the thesis project major developments - described within the 
chapter contents, as well as the additional most important data presented within the 
appendix.
In vitro PIG-A gene mutation assay
S  MCL-5 Cells (p53 Competent, Apoptosis sensitive, Metabolically active)
S  Suspension Human Cell Line (No enrichment required, Biologically relevant)
S  Novel FCM Gating Approach (Utilising FL-W measures)
S  Viability and integrity markers (Apoptosis, cell death and membrane integrity)
•7 Tandem GPI-AP assessment (CD55 and CD59)
S  Preliminary work demonstrated promising sensitivity and specificity
In vitro PIG-A platform Supplementary Investigations
S  Cell line characterisation (TK6, AHH-1 and MCL-5)
S  Proteomic validation (p53 status; p21, p-p53 and PIG-A protein)
S  Cross platform validation (FCM, ImageStream ™ and laser scanning Confocal)
S  Viability Assessment
S  Preliminary Next Generation Sequencing analysis of phenotypic PIG-A mutants 
Intracellular PIG-A gene mutation assay
S  Standardised protocol for most tissue types
S  Preliminary MCL-5 data to show intracellular localisation of PIG-A protein 
S  Proof of principle house keeper protein data 
S  Positive future for additional tissue validation
Development of ex vivo Human PIG-A bio monitoring assays
•7 Human RBC, RET and Granulocyte assay protocol development 
'T RBC assay in-line with currently published data
^  RET and Granulocyte assay platforms show good promise, but require further work 
S  Assay protocols show great promise for potential future clinical trials
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Appendix
All cellular cultures utilised during the undertaking of this Ph.D. were established 
and subsequent work undertaken in an aseptic manor; fluorescence staining was 
carried out in the absence of direct light, all antibody incubations were undertaken in 
a temperature controlled environment, preventing internalisation of cellular 
receptors, and thorough decontamination protocols were in place to prevent 
contamination. Unless otherwise stated, all culture work was carried out within a 
class 2 safety cabinet and all necessary safety precautions were taken with regards to 
the work embodied within this chapter. Initially, antibody optimisation was 
undertaken to increase confidence in the ensuring data generated utilising the in vitro 
PIG-A assay platform, enrichment methodologies were investigated to improve assay 
sensitivity, and model mutagen exposure followed for preliminary assay assessment. 
Following establishment of a functioning assay design, validation of putative PIG-A 
mutant events ensued in which additional high throughput techniques such as Amnis 
Image Stream ™ were implored to facilitate investigation.
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Chapter 3: The Concept and Development o f an early stage in vitro PIG -A  gene 
mutation assay
3.2 Materials and M ethods
3.2.2 Enrichment Strategies to Optimise CD59 Expression with the Human 
Lymphoblastoid TK6 Cell Line
3.2.2.1 Dynabead ® Enrichment and Subsequent M agnetic Bead Retrieval o f  
the TK6 cells Expressing the CD59 Cellular Surface Antigen
DSB-X™ Biotin Protein Labelling Kit (Cat No. D-20655, Molecular Probes, Life™ 
Technologies, Paisley, UK) was utilised in order to fully biotinylate an anti-human 
anti-GPI-AP fluorescently labelled antibody. Prior to biotinylation, kit contents were 
stored at 2-4°C as well as fresh PBS pH 7.2 as well as 1M sodium bicarbonate were 
prepared as follows. PBS; 0.36 g of NaH2PO4*H20, 1.02 g of Na2HP0 4 and 8.77 g of 
NaCl were dissolved in 750 mL of deionized water. pH was initially measured and 
adjusted to 7.2 using 1M NaOH and/or 1M HCL stock solutions, final volume 
adjusted to 1 L with dH20. 1M sodium bicarbonate; 8.4 g of NaHCC>3 (molecular 
mass 84 g) was dissolved in 100 mL of dH20.
200 pL of a 0.5mg/mL antibody solution along with 20 pL of freshly prepared 1M 
sodium bicarbonate were added to a 2 mL reaction tube containing a small metallic 
stir bar (Component C). Simultaneously 40 pL of DMSO (Component B) was added 
to a vial of DSB-X biotin succinimidyl ester (Component A), critically completely 
dissolving the contents of the vial. 2 pL of the DSB-X biotin solution was then 
added to the anti-human purified CD59, clone P282 (H I9) Mouse IgG2a k antibodies 
purchased from BD Biosciences (Cat No. 555761, BD Pharmingen™, San Jose CA, 
USA), whilst being stirred, mixed thoroughly, ensuring that 3-8 DSB-X molecules 
covalently bound per antibody molecule and incubated for 1-1.5 hr at room 
temperature. A spin column (Component E) was then placed within a glass tube and
3
subsequently a 1 mL volume of purification resin (Component D) was added and 
allowed to settle. Additional suspension was added until the volume was 
approximately 1.5 mL, the column was allowed to drain by gravity initially and then 
centrifuged for 3 min at 1100 x g. Post incubation, the antibody-DSB-X conjugate 
(-220 pL) was added to the centre of the prepared spin column, allowed to absorb 
into the gel and centrifuged for a further 5 min within a new collection tube. Post 
centrifugation the newly conjugated DSB-X biotinylated antibody was eluted within 
the collection tube, retaining the excess free DSB-X biotin within the spin column. 
Using the following equation, extracted from Life ™ guidance documentation [1], 
concentration of the newly synthesised conjugate was calculated, due to a potential 
loss of 15% recovery.
Equation 1
Initial mg of protein x 0.85 
mg/mL DSB-X biotin-labelled protein = ..............................................................
mL in collection tube
As the final concentration of the purified antibody conjugate was less than 1 mg/mL, 
bovine serum albumin (BSA) was added to a concentration of 1-10 mg/mL, the 
conjugate was stored at 2-4°C for future usage.
Dynabeads ® Flow Comp™ Flexi Kit (Cat No. 1106ID, Molecular Probes, Life™ 
Technologies, Paisley, UK) was utilised to purify the phenotypic PIG-A wild type 
cells. 10 mL of isolation buffer was initially prepared (Ca2+,Mg2+ free PBS, 
supplemented with 2% Foetal Bovine Serum (FBS) and 2 mM 
Ethylenediaminetetraacetic acid (EDTA)). Cell cultures were established as outlined 
in (Section 2.2), centrifuged and re-suspended in 500 pL of pre-cooled (2-8°C) 
isolation buffer. 25 pL of DSB-X ™ biotin labelled antibody was added to the 
solution, mixed well, incubated at 2-8°C (protected from light) for 30 min. 2 mL of
4
cold isolation buffer was added, cells were collected by centrifugation (8 min at 350 
x g), supernatants carefully aspirated and re-suspended in 1 mL of cold isolation 
buffer. 75 pL o f vortexed Flow Comp ™ Dynabeads ® were added mixed 
thoroughly and incubated for 15 min (2-8°C rolling and tilting). The tube contents 
were then transferred into a 2 mL micro centrifuge tube (MCT), placed within the 
12-tube magnetic rack (Cat No. 36912, Qiagen, Manchester, UK) for 2 min, prior to 
removing (and discarding) the supernatant. Prior to re-suspension in 1 mL cold 
isolation buffer, the tube was removed from the magnet, this step was repeated once. 
1 mL of Flow Comp ™ release buffer was added to the bead bound cells, mixed 
thoroughly and incubated for 10 min (25°C under rolling and tilting). Post 
incubation, the suspension was mixed thoroughly, via inversion, and the tube placed 
into the magnet rack for 2 min. The supernatant, containing the bead free cells, was 
transferred into a new MCT, placed back into the rack for an additional 2 min, 
ensuring removal of residual Dynabeads ®. The suspension was transferred into a 
new centrifuge tube and centrifuged (350 x g) for 8 min, supernatant aspired and 
placed within a 25 cm2 cell culture flask.
Following magnetic enrichment, quality assurance (QA) FCM based PIG-A 
phenotype assessment was carried out following enrichment, the recovered TK6 
cells were centrifuged (-250 x g for 7 min) and re-suspended in long term storage 
media, as outlined within (Section 2.3) and cryo-preserved within liquid nitrogen for 
future use in conjunction with model genotoxin exposure and the in vitro PIG-A 
gene mutation assay.
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3.3 Results
3.3.3 Proof o f Principle Evaluation Utilising CD59 as a Phenotypic Reporter for  
Mutation at the PIG -A  Locus within the TK6 cell line following EMS Exposure
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Figure 3.1 Human lymphoblastoid cells (TK6) Day 4 PIG-A mutation frequency data 
following 24 hr. low dose EMS exposure, CD59 antigen utilised. Day 4 frequencies 
of PIG-A mutant TK6 cells (Clonally selected) following 24 hr low dose EMS 
exposure. (n=3) PIG-A mutants displayed as percentage of total single cellular 
events (0.1% PIG-A Mutants = 1 mutant x 10' cells). A) Graphical output of the 
Nested set of models utilised to derive the CEDio (BMDio) value, B) PRO AST 
modelling; CED, CEDL and CEDU represent the BMDio, BMDLjo (Lower 
confidence limit) and BMDUio (Upper Confidence Limit) respectively and C) 
Calculation of Confidence Intervals (CEDL10 and CEDU10) based on likelihood 
function (in this case log-likelihood).
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3.3.4 
Long-term
 
C
ryo-preservation 
A
ssessm
ent on 
CD59 
Phenotype 
Stability
Table 3.2. Summary o f  Human TK6 cellular viability follow ing 72 hr recovery 
period post liquid nitrogen cryo-preservation. The viability data below are relative 
to the growth o f  DMSO M  human TK6 cells follow ing 72 hr recovery post 
awakening, cell counts were undertaken on a Z1 Coulter Counter (Beckman Coulter) 
with 5-17pm size classifier.
Relative Cell Counts (RCC) Following 72 hr Culture (%)
Medium
Constituents
Month 1 Month 3 Month 6
DM SO M 100.00 100.00 100.00
DM SO S 131.71 125.87 102.82
DM SO HiS 145.42 124.56 91.28
G lyM 38.40 63.99 63.31
G lyS 41.70 34.12 0.06
Gly HiS 44.84 85.29 67.27
Sue M 2.15 1.60 0.78
S u cS 1.16 4.94 0.32
Sue HiS 0.41 6.75 0.42
The data recorded, 72 hr post cryo-preservation awakening, showed that the samples 
within DMSO or Glycerol generally appeared to remain stable and consistent in 
terms o f viability over the experimental period. However, in the specific example of 
Glycerol supplemented with serum, the recovery potential of the culture appeared to 
decrease periodically over the experimental period, 41.7, 34.12 and 0.06%, highly 
apparent at the 6 month awakening time period. This data potentially was as a result 
o f human error and therefore, cannot be attributed excessive weight as evidence for 
this observed relationship.
Each major constituent was demonstrated to produce reproducible viability data 
irrespective of the minor constituent within the storage cocktail. Taking DM SO as an 
example, the 1 month RCC following 72 hr incubation/recovery was 100, 131.71 and 
145.42 % for M, S and HiS samples respectively. DMSO was shown to generate
8
increased yields in terms of cell numbers post awakening when directly compared to 
the other two major constituents.
Sucrose (10%) was demonstrated to be highly deleterious to the cells in terms of 
recovery potential post cryopreservation. All samples containing sucrose as a major 
constitutive demonstrated insufficient numbers of single cells remaining post 
awakening to extract a lx lO 6 cell sample for ensuing immunofluorescence staining 
and flow cytometric analysis.
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3.5 Supplementary Work
3.5.1 Introduction
In an endeavour to identify the most appropriate novel high content, high through­
put and highly sensitive platform for the recording of the phenotypic identification of 
putative PIG-A  mutant events, as well as further PIG-A mechanisms evaluation, a 
number of additional technologies other than FCM we also deliberated. FCM 
provides the majority of the features required for the development of the assay 
however, it does not provide any insight into the validity of identity of the 
presumptive PIG-A  mutant events. Therefore, in an endeavour to provide 
significantly more confidence and thus attributing a greater weight of evidence to the 
subsequently generated data, additional microscopic based platforms were 
investigated for use. Traditional confocal or fluorescent microscope based 
applications were tested, however, the preparation work associated and highly 
exaggerated analysis times were proven detrimental to the scoring o f phenotypic 
PIG-A mutations, especially when using live cells. Therefore, the more recent 
establishment o f the Amnis Image Stream ™ range o f  high throughput, imaging, 
flow cytometers potentially brought a solution to the assessment of the presumptive 
mutant events whilst maintaining all the associated benefits of flow cytometry. The 
following section of work comments on the versatility of the Amnis Image Stream 
™  platform and its potential use in conjunction with the in vitro PIG-A  reporter 
system.
10
3.5.2 Materials and Methods
t
3.5.2.1 Preliminary Evaluation of the Amnis ImageStream ™  as a Potential 
Qualitative Platform for the in vitro PIG -A  Gene Mutation Assay
A vial of pre-enriched TK6 cells, clonally expanded for the CD59 antigen, were 
awoken (Section 2.2) and RPD monitored (Section 2.2.1) prior to treatment with an 
anti-CD59 human R-PE conjugated antibody in an analogous method as outlined in 
(Section 2.8.1).
Following antibody treatment, all samples were washed twice with 1 X PBS pH 7.4 
solution and either; re-suspended in 1 mL of BD Cell Fix or 4% paraformaldehyde 
solution (Section 2.7), incubated for 1 hr at 4°C or alternatively re-suspended in 50 
pL  of sterile PBS solution and transferred into a 750 pL  micro centrifuge eppendorf 
tube for immediate flow cytometric analysis on the Amnis platform.
The cells which were fixed, post incubation were centrifuged (250 x g for 7 mins), 
supernatant aspirated carefully, and re-suspended in 50 pL  of 1 x PBS in the 
identical manner as above. Fixed samples were able to be stored in a temperature 
controlled environment, 2-4°C, protected from light for a period of up to 7 days prior 
to analysis. Immediately before analysis, samples were re-suspended by thorough 
flicking, preventing blockages during sample input.
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3.5.2.2 Amnis Image Stream ™  Assessment on Physical Agitation and 
Corresponding Antibody-Antigen Shearing
Pre-enriched TK6 cells were treated with an anti-CD59 human R-PE conjugated 
antibody in an analogous method as outlined in the previous (Section 2.8.1).
Following antibody treatment, all samples were washed and either fixed in BD Cell 
Fix ™ or 4% paraformaldehyde (Section 2.7) or re-suspended in PBS, as described 
in section (Appendix 3.5.2.1) and stored on ice, protected from light, until ready to 
be analysed. Each sample was prepared in duplicate to facilitate one sample being 
vigorously flicked prior to analysis, and one sample being minimally re-suspended to 
prevent blockages. Immediately before analysis, both samples were re-suspended by 
moderate flicking, preventing blockages during sample input.
3.5.2.3 Critical Amnis Image Stream ™  Assessment on Cellular Characteristics 
of High Resolution Imaging and Incorporation within the in vitro PIG -A  assay
Pre-enriched TK6 cells were treated with antibodies in an analogous manner as 
described in detail (Section 2.8.1).
Following antibody treatment samples were either re-suspended in 1 mL o f BD Cell 
Fix™, 4%  Paraformaldehyde (Gibco ® PBS base), Dulbecco’s 4%
'j, 'j,
paraformaldehyde solution (with Mg and Ca ions) or Dulbecco’s 4%
9 i
paraformaldehyde solution (without Mg or Ca ions). Each culture was incubated, 
protected from light, for 1 hr at 2-4°C. Additionally, a single sample was not fixed, 
and therefore, immediately processed and analysed on the Amnis Image Stream™ 
platform within 1 hr post antibody treatment. Post incubation, samples were 
centrifuged (250 x g for 7 mins), supernatant aspirated and washed twice with 1 x 
PBS solution.
Following the wash steps the samples were re-suspended in 50 pL  of 1 x PBS in an 
analogous protocol as outlined in the previous sections. Fixed samples are much 
more stable and can be re-fridgerated (2-4°C) for up to and including 7 days prior to
12
I
! analysis. Once intended to be analysed, all samples were gently re-suspended to
i
[ prevent blockages within the sample inlet system.
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3.5.3 Results
3.5.3.1 Preliminary Evaluation o f the Amnis ImageStream ™  as a Potential 
Qualitative Platform for the in vitro PIG -A  Gene Mutation Assay
The Amnis Image Stream ™ is a highly sophisticated imaging flow cytometer, 
combining the high-content, high-throughput, high precision and fluorescence 
sensitivity of a conventional flow cytometer with the functionality of high resolution 
light microscopy. Incorporation o f Image Stream ™  technology into the PIG-A  assay 
design potentially could provide insight into the true identity of putative PIG-A  
mutant events; visual descriptors could be applied to each event allowing validation 
of generated data. High content analysis could also provide the ability to add further 
fluorescence detection of noteworthy characteristics, including cellular viability as 
well as cell cycle information, facilitating a more holistic approach to measuring 
mutagenesis.
14
Figure 3.5.1. Image Stream ™ generated images o f live TK6 cells treated with anti- 
CD59 PE Ab. A single cell population was defined, aspect ratio >0.75 and an area o f 
100-500, each single cell was evaluated for focus, gradient RMS (Root mean square 
of the rate o f change o f the image intensity profile) score >40-60 prior to still capture 
of high resolution images displaying anti-CD59 PE binding on the extracellular 
surface membrane. “Ch04" detected anti-CD59 PE fluorescence, “Ch05" brightfield 
images and “Bf/Fluoro" composite combined images.
The results of the initial live cell capture images, as well as the additional fixed cell 
images showed the extracellular location of the bound anti-CD59 R-PE antibody 
(Appendix Figure 3.5.1); binding was sporadic in nature and appeared solely 
confined to the extracellular surface. The multiple fixatives utilised within this 
section of work were shown to have no effect on the location of antibody binding.
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Table 3.5.1. Summary o f  Image Stream  ™  dose response data follow ing EMS 
treatment o f  TK6 cells, the CD59 surface antigen was used as a reporter fo r  mutant 
frequency. Data displayed in the table below was collected using a standardised 
approach (Appendix Section 3.5.2); A  single cell population was defined, aspect 
ratio >0.75 and an area o f  100-500, each single cell was evaluated fo r  focus, 
gradient RM S (Root mean square o f  the rate o f  change o f  the image intensity profile) 
score >40-60 prior to fluorescence intensity data acquisition. >10,000 focussed, 
single cellular events were collected fo r  each sample analysed (PFA = 
Paraformaldehyde).
Ir
Dose of 
EM S 
(Hg/mL)
A verage
C ellu lar
A rea
A verage 
C ellu lar A rea 
R ange
A verage
Fluorescence
In tensity
Un-fixed 0 205.43 104 - 452.25 29732.39
Un-fixed 10 208.96 104 - 455 29322.52
PFA  (4% ) 0 233.04 108.5 - 455 30915.30
PFA  (4% ) 10 245.59 104-456 .75 29521.72
BD Cell Fix ™ 0 257.15 106.5 - 455.5 33335.63
BD Cell Fix ™ 10 264.51 105 - 457 32323.99
I
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Initially, each fixation method was run in duplicate with a single replicate being 
exposed to a high dose of EMS (10 pg/m L) and the other un-treated. All three 
methodologies investigated were demonstrated to have an apparent decrease in their 
respective relative fluorescence intensity values recorded within the corresponding 
channel to the PE signal, when comparing acute high dose EMS treatment with 
untreated samples. Live cells demonstrated the lowest difference in fluorescence 
intensity values, with paraformaldehyde (4%) and BD Cell Fix ™  having 
significantly larger intensity differences, 1393.58 and 1011.64 units respectively. 
The data appeared to correlate an increased average decrease in fluorescence 
intensity post EMS treatment with the method o f sample fixation; difference was 
significantly higher in fixed samples when compared to un-fixed analogous control 
samples (Appendix Figure 3.5.2).
Following compartmentalisation of the x-axis, relative fluorescence intensity within 
channel 4, and all EMS treated samples showed an increase in the percentage of the 
total population of focussed single cells residing within the lowest fluorescence 
compartment, R l, when compared to their un-treated control samples. This 
relationship was observed within all test samples un-fixed (Figure 3.5.2.A), 
paraformaldehyde (4%) (Figure 3.5.2.B) and BD Cell Fix ™  (Figure 3.5.2.C), 
however, population statistics within the higher fluorescence compartments appeared 
to stay relatively stable in comparison.
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Fixation methods were demonstrated to elicit a distinct effect on the integrity of the 
antibody-antigen conjugate; this affect was observed within the average fluorescence 
intensities o f the samples post vigorous physical agitation (flicking) when compared 
to their relative controls. Un-fixed samples were shown to have a substantial 
decrease, 6189 arbitrary units, in fluorescence value (26057), post flicking when 
compared to their con-current control sample, (32246.85) (Appendix Table 3.5.2). 
This relationship was mirrored in the 4% paraformaldehyde samples, however, the 
decrease was less apparent, 3021.89 arbitrary units. Alternatively, BD Cell Fix™  
was demonstrated to increase the average fluorescence intensity of the sample 
following flicking, 768.35 arbitrary units.
Un-fixed samples were observed to have a significant increase in the percentage of 
single focussed events falling within the R1 compartment, following physical 
agitation when compared to control values 54.2, to 67.1% respectively (Appendix 
Figure 3.5.3.A). This increase was visualised within the adjacent histogram via the 
presence o f a sharp peak within the R1 compartment within the agitated sample 
which was not mirrored within the un-fixed control. Fixed samples, 4% 
paraformaldehyde and BD Cell Fix ™ were shown to be less affected by physical 
agitation and therefore, displayed lower corresponding increases in the percentage 
R1 population, and no novel observed peak was present within the R1 region within 
the gated histograms (Appendix Figure 3.5.3.B and C).
The results appear to suggest that fixation can prevent the loss of signal 
differentiation associated with physical agitation, and even in specific examples 
improve the efficiency of fluorescence conjugate antigen tagging during such 
agitation. The affect physical agitation had on the samples was again more easily 
envisaged within corresponding 2-D fluorescence intensity histograms (Appendix 
Figures 3.5.3.A, B and C).
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The results indicate that fixation in general was demonstrated to increase the average 
area of the samples when compared to their un-fixed negative controls (Appendix 
Table 3.5.3); un-fixed samples had an average area o f 188.25 units, which was lower 
when compared to all fixation methodologies, 4% paraformaldehyde 223.04, D-Para 
4 (Ion +ve) 229.63, D-Para 4 (Ion -ve) 217.87 and BD Cell Fix ™ 239.89. The
f
I fluorescence maxima values, corresponding to auto-fluorescence within the channel,
|
j were observed to decrease within fixed samples; un-fixed 32707.49 compared to D-
! Para 4 (Ion -ve) 22551.74 arbitrary units.
i
i
W ithin all experimental samples, including the un-fixed treated control, the number 
of CD59 negative events, as defined by any event scoring a value greater than the 
fluorescence maxima of the ICS, was meaningfully higher than comparable flow 
| cytometric data (Appendix Section 3.3.3). CD59 negative frequencies were observed
at a maxima value of 89.7% of the total, focused, single cell population within un-
i
! treated controls (Appendix Table 3.5.4).
The result appear to reflect the lack of signal separation and hence, indirect
sensitivity observed within the technology when compared to an equivalent flow
| cytometer as a result o f insufficient signal filtering technology within the Amnis ™
i
| Image Stream Platform.
I
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3.5.4 Discussions and Conclusions
3.5.4.1 Am nis® Image Stream ™  Evaluation
Incorporating high-content, high-throughput and high-precision technology is an 
assured way to advance the field of genetic toxicology. Undertaking a more holistic 
approach to data acquisition, analogous to systems biology [2], has the ability to 
provide a greater degree of relevance as well as context. Providing such data at 
earlier stages within drug discovery/development should facilitate a more precise and 
cost effective safety assessment [3, 4]. The Amnis Image Stream ™ is a platform 
which enables the combination of high resolution imaging in combination with flow 
cytometric analysis [5]. In the context o f the in vitro PIG-A  gene mutation assay, the 
Image Stream ™ potentially can more dependably confirm the identity o f  currently 
debated putative mutants events however, had a higher than expected background 
mutant frequency (Appendix Table 3.5.4). Currently, presumptive PIG-A mutant 
events are thought to possible include non-viable cells, cells within Go/G], cells 
stripped of the surface antigen marker or GPI anchor and additional inaccuracies 
associated with flow cytometry sample preparation including aggregation or cellular 
debris.
GPI anchors are attached to the membrane in clusters associated with areas of dense 
lipid concentration, known as lipid rafts, to monitor functionality, and therefore, 
have highly limited and cholesterol sensitive expression on the outer surface of the 
cellular membrane [6]. Unfortunately, this association does not lend itself well to 
laser illuminating assays with single image capture due to the precise path of 
illumination. Laser light must transverse the cell in the correct orientation to 
correctly detect stained GPI-AP clusters. Initial antibody location assessment (Figure 
3.5.1), in which the extracellular membrane was experimentally demonstrated to be 
sporadically covered with comprehensive CD59 expression, confirmed this initial 
concern. However, the extent in which this limitation would impact the subsequent 
data analysis was unknown and therefore, the Image Stream ™  was assessed for the
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ability to detect significant differences following model mutagenic exposure within 
the TK6 population.
Average fluorescence intensity, area and basic morphology were evaluated, the 
results indicated that even though there were defined differences between the con­
current negative control and the EMS treated samples, in terms o f area and 
morphology, the differences, were in-sufficient to be utilised as potential markers for 
exposure. However, the number of cells falling within the lowest fluorescence value 
region was confirmed to increase following EMS exposure (Figure 3.5.2.A, B and 
C); potentially this reflects the induction of novel putative PIG-A  mutant events 
following mutagenesis. Acute mutagenic exposure, at the doses tested, would 
potentially only induce an additional few hundred mutant events within the allotted 
experimental time period [7-9] and therefore supports the generated data. However, 
due to the high level of auto-fluorescence detected within the un-stained control 
sample, a potential weakness associated with the Image Stream’s ™ lack o f band 
pass filters and mirrors as well as imaging system, this method is currently limited to 
basic qualitative dose response analysis.
Following EMS exposure, fixation did appear to increase the difference in average 
fluorescence between the top dose and the untreated samples (Table 3.5.1). The 
reason for this was thought to be the increased stability of the antibody-antigen 
binding complex following protein-aldehyde crosslinking [10] and hence, 
subsequent more precise identification of wild type and PIG-A  mutant events. The 
GPI anchor structure within white blood cells (WBC) is known to be less 
comprehensive than the erythroid counterpart [11-13]; WBC have two fatty acid 
chains/tails protruding into the membrane, compared to three within RBC and 
therefore, could be susceptible to dislodgement or shearing following physical 
agitation
To further investigate the effect of physical agitation on PIG-A  mutant frequencies, 
within flow prepared samples, a variety of aldehyde based fixatives were assessed. 
The results confirmed that heavily “flicking” the tubes prior to analysis induced a 
significant decrease in average fluorescence within the R-PE channel (Appendix 
Table 3.5.2); re-enforcing that the current spontaneous background mutant frequency 
at the PIG-A  locus may constitute additional mimicking events not solely PIG-A
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mutants. This observation was in the best way observed with the generation of a 
novel sub population of GPI-AP deficient cells within the R1 gated region o f the un­
fixed control (Appendix Figure 3.5.3.A, B and C).
However, fixation was observed to greatly limit the decrease in average fluorescence 
value and therefore, could potentially be a viable inclusion into the assay design to 
prevent the induction of novel PIG-A  mutant mimicking events through sample 
processing. Fixation was also demonstrated to have a beneficial effect on the 
physical morphology o f cells, with the average area observed to increase 
substantially when compared to un-fixed negative control samples (Appendix Table 
3.5.3). This observation was attributed to the variance in pH value between the 
buffered fixatives, and hence the corresponding change in osmotic pressures applied 
onto the cells following submergence. Increasing or decreasing the pH can have a 
distinct effect on the solubility o f previously bound reactive groups, generally 
located within protein macro-molecules, resulting in an increase or decrease in 
osmotic potential [14, 15]. Creating a uniform population in terms of area would be 
valuable in several ways; initially the cells would be easier to image due to a 
common focal plane and secondly, more accurate size descriptors could be 
implemented into assay design to further precisely define the critical sub population 
under assessment.
W ithin this section o f work the Image Stream ™ platform was assessed for the 
ability to accurately define PIG-A mutant events post mutagenic exposure. Although 
the ImageStream ™ has distinctive features which potentially could enhancement the 
basic PIG-A assay design; for example, generation of high resolution images, 
providing validation of antibody binding specificity as well as PIG-A  phenotype 
(Appendix Figure 3.5.1), high content analysis, providing insights into cell cycle and 
a highly intuitive analysis software package. The technique was considered 
inappropriate for assay incorporation due to the overwhelming number of associated 
limitations, but would be utilised in a supplementary role for high content validatory 
mechanistic image analysis.
In brief, the spontaneous background PIG-A  mutant frequency, following antibody 
treatment, was approximately 80%. Elucidating that 800,000 cells were presumptive 
PIG-A  mutants per 1 x 106 cells scored. This was directly compared to the more
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realistic presumed 0.1-0.2% PIG-A  mutant population using the flow cytometer [7]. 
Fluorescent outliers within the instrument calibration standard, generated as a result 
o f “focal smearing” were the reason for this spiked the maximum auto-fluorescence 
value, resulting in inconsistent gating strategies. “Focal smearing” describes the 
occurrence of an artificially saturated pixel, and hence false positive resultant signal 
as a direct result of a fluorescing event passing the camera out of focus. Unlike the 
flow cytometer the ImageStream™ utilising 8-bit image capture, not PMT photon 
capture, and relative intensity is measured through pixel saturation. This problem can 
be potentially over come via the use of extended depth of field capture, a 3-D render 
of the cellular events, more accurately displaying the location of the bound anti- 
CD59 R-PE conjugate antibody. However, accounting for the potential focussing 
issues, the Image Stream ™ platform is inferior to the FACS Aria 1 in terms o f 
precision and sample throughput and therefore, was not included in future 
quantitative PIG-A  assessment.
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Chapter 4: Consideration of Cell Lines in the Further Development of an in 
vitro PIG -A  Gene Mutation Assay
4.2 M aterials and Methods
4.2.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
“Low Passage” TK6 and Normal TK6 cell cultures were established and maintained 
as outlined in (Sections 2.1 - 2.2). Cultures were washed, counted (Section 2.2.1) and 
equivalent volumes containing lx lO 6 cells aliquotted into sterile 15 mL BD Falcon 
tubes. Samples were prepared in triplicate in order to generate comparable metrics 
for direct comparison between both cell lines; FLAER, CD48 and CD55/59 tandem 
treatment were all assessed for their relative receptor presence. Each cell line had a 
unique ICS to facilitate accurate flow cytometric analysis.
Fluorescent Aerolysin (FLAER) Staining Protocol
Prior to use, 1 mL of 1 X PBS was added to 25 pg of powdered (lyophilised) 
FLAER in order to construct a stock solution. The stock solution was diluted 1 in 10 
within dFLO and aliquotted into 50 pL  volumes within 0.5 mL eppendorf tubes to 
facilitate long term storage. Each individual tube or vial was wrapped in aluminium 
foil and stored at -20°C, protected from  direct light.
Twelve samples for each cell line, containing lx lO 6 cells, were transferred into 
sterile 15 m L falcon tubes, centrifuged (250 x g for 7 min), supernatant aspirated 
and re-suspended in 100 pL of fresh pre-warmed culture medium. Cell pellets were 
carefully re-dispersed, minimalizing cellular agitation, and treated with 5 pL  of 
various concentrations, in triplicate, o f FLAER; FLAER (IX ) -  undiluted FLAER 
taken directly from the pre-aliquotted vials, FLAER (0.5X) requiring a single 1 in 2 
dilution using 2% BSA/PBS and finally FLAER (O.lx) requiring a 1 in 10 dilution 
using 2%  BSA/PBS. Each tube was incubated for 15 min at room  temperature, 
protected from direct light. Post incubation, samples were centrifuged, supernatant 
aspirated, and re-suspended within 10 mL of 1 X PBS. Samples were returned to the
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centrifuge, spun down, supernatant aspirated carefully and re-suspended within 1 mL 
of lx  PBS. All samples were placed on ice, protected from light; to maintain the 
stability of the suspensions and the fluorophores used, prior to flow cytometer 
analysis.
CD48 - p-Lymphocyte Activation M arker 1 (BLAST-1) Staining Protocol
Four lx lO 6 cellular samples were transferred into separate sterile 15 mL BD falcon 
tubes, centrifuged (250 x g for 7 min), supernatant aspirated and re-suspended in 
100 pL  of fresh pre-warmed culture medium. Cell pellets were carefully re- 
dispersed, minimalizing cellular agitation, and treated with 20 pL  of mouse anti­
human anti-CD48 R-PE antibody (Cat No. 552855, BD Biosciences, Hertfordshire, 
UK) and incubated at room temperature, protected from direct light, for 30 min. Post 
incubation, samples were centrifuged, supernatant aspirated, and re-suspended 
within 10 mL o f 1 X PBS. Samples were returned to the centrifuge, spun down, 
supernatant aspirated carefully and re-suspended within 1 mL of lx  PBS. All 
samples were placed on ice, protected from light; to maintain the stability of the 
suspensions and the fluorophores used, prior to flow cytometer analysis.
CD55 and CD59 Tandem Staining Protocol
Four lx lO 6 cellular samples were transferred into separate sterile 15 mL BD falcon 
tubes, centrifuged (250 x g for 7 min), supernatant aspirated and re-suspended in 100 
pL  of fresh pre-warmed culture medium. Cell pellets were carefully re-dispersed, 
minimalizing cellular agitation, and treated with 20 pL of mouse anti-human anti- 
CD55 R-PE antibody and 20 pL  o f mouse-anti-human anti-CD59 R-PE antibody, 
and incubated at room temperature, protected from direct light, for 30 min. Post 
incubation, samples were centrifuged, supernatant aspirated, and re-suspended 
within 10 mL o f 1 X PBS. Samples were returned to the centrifuge, spun down, 
supernatant aspirated carefully and re-suspended within 1 mL o f lx  PBS. All
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samples were placed on ice, protected from light; to maintain the stability of the 
suspensions and the fluorophores used, prior to flow cytometer analysis.
4.2.5.1 W estern Blotting --Sodium  Dodecyl Sulphate -  Poly-Acrylamide Gel 
Electrophoresis (SDS-PAGE)
4.2.5.1.2 Activ M otif Nuclear and Cytoplasmic Protein Extraction
Refined protein extraction was undertaken with the use of the Active Motif Nuclear 
Extract Kit (Cat. No. 40010, Active Motif, La Hulpe, Belgium) all kit components 
were stored at 2-4°C upon arrival and protected from direct light. Cell cultures were 
establish as outlined in (Section 2.2), counted and washed (Sections 2.2) prior to 
protein extraction protocol. Additionally, the following solutions were also required 
to be constructed prior to lysis.
4.2.5.1.2.1 Quick Chart for Preparing Buffers
All buffers containing biological components were made fresh at the start of the 
protein extraction protocol, stored on ice, and protected from direct light. 
Phosphatase and protease inhibitor cocktails progressively lose activity, 
approximately 2 hr post thawing, and therefore, cannot be stored long term as ready­
made solutions. Following construction and subsequent short term storage, 2-4 °C, of 
the PBS/Phosphatase inhibitor solution, if precipitation occurs and the solution 
becomes turbid, heat at 50 °C for 10 min to dissolve precipitate. The DTT solution 
provided within the kit comes supplied as a 1M solution, prior to buffer construction 
the solution is required to be diluted with filter prepared dFLO to a 10 mM solution; 
this solution can be stored at -20 °C for up to a year.
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Table 4.1. Buffer components and their respective quantities in respect to the volume 
o f starting material.
Size of Plate or Equivalent Number of Cells 
(Starting material)
60 mm plate 
(or 3.2xl06 
cells)
100 mm plate 
(or 8.8 x 106 
cells)
150 mm plate 
(or 2 x 107 
cells)
PBS/Phosphatase Inhibitors(rnL)
10X PBS 0.4 0.8 1.6
Distilled water 3.4 6.8 13.6
20X Phosphatase 
Inhibitors
0.2 0.4 0.8
TOTAL REQUIRED 4 8 16
IX  Hypotonic Buffer (uL)
10X Hypotonic Buffer 25 50 100
Distilled water 225 450 900
TOTAL REQUIRED 250 500 1000
Complete Lysis Buffer 10 mM (uL)
DTT (lOmM) 2.5 5 10
Lysis Buffer AMI 22. 25 44.5 89
Protease Inhibitor 
Cocktail
0.25 0.5 1
TOTAL REQUIRED 27.25 50 100
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4.2.5.1.2.2 Cellular Lysis and Protein Extraction
The following method is based on the manufacturers supplied protocol for 3.2 x 106 
cells, which accompanies purchase of the protein extraction kit. Cellular pellets were 
re-suspended and subsequently washed with 3 mL of pre-cooled, ice-cold, 
PBS/Phosphatase inhibitor solution, centrifuged (-250 x g for 7 min) and the 
supernatant discarded. Following centrifugation, an additional 1 mL volume of ice- 
cold PBS/phosphatase inhibitors was added, ensuring complete re-suspension, 
centrifuged and then the resultant supernatant aspirated. Cell pellets were stored 
immediately on ice throughout the entire protocol. Cellular pellets were re­
suspended in 250 pL IX hypotonic buffer solution, ensuring that the pellets were re­
suspended thoroughly via pipetting the mixture several times. Post mixing, the cells 
were transferred to pre-chilled micro-centrifuge tubes (1.5 mL Eppendorfs), and 
incubated for 15 min on ice. Post incubation, 12.5 pL of detergent was added, the 
samples vortexed for 10 seconds at high speed and subsequently centrifuged (14,000 
x g for 30 sec). The supernatant, containing the cytoplasmic protein fraction, was 
transferred into pre-chilled 1.5 mL micro centrifuge tubes as well as three 5 pL 
aliquots were removed for protein quantification. The cytoplasmic protein fractions 
were stored at -80°C ready for future use.
The residual cellular pellet was re-suspended in 25 pL complete lysis buffer (10 
mM), via pipette agitation/mixing. Immediately, the samples were vortexed for 10 
sec at high speed prior to 30 min incubation on ice within a rocking platform (150 
rpm). Post incubation, samples were vortexed for an additional 30 sec at high speed, 
centrifuged (14,000 x g for 10 min) and the resultant supernatant, nuclear protein 
fraction, transferred into additional pre-cooled micro centrifuge tubes. Analogous to 
the cytoplasmic fraction, three 5 pL aliquots were removed for protein quantification 
and the larger volume stored at -80°C.
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4.2.5.1.3 Protein Quantification
All protein quantification within this body of work was carried out using the DC ™ 
Protein Assay Kit 1 (Cat No. 500-01111, Bio-Rad, Hertfordshire, UK) as outlined 
within the supplied manufactures protocol. Prior to protein quantification, bovine 
serum albumin (BSA) (Cat No. A9418, Sigma Aldrich, Gillingham, UK) powder 
was purchased and dissolved in dH20 in order to construct excess 2.5 mg/mL 
solution, the solution was aliquotted into 0.75 mL eppendorf tubes and immediately 
frozen within a -20°C freezer for long term storage. A single aliquot of (2.5 mg/mL) 
BSA was removed from the freezer and thawed over ice; the following BSA 
standards were constructed.
4.2.5.1.3.1 Bovine Serum Albumin (BSA) Protein Standards
For each protein quantification plate, five protein (BSA) standards, with known 
concentration, were constructed, facilitating the use of the stand curve approach to 
estimate unknown protein quantification. BSA was either diluted in AMI lysis 
buffer or lx  hypotonic buffer solution for use with nuclear and cytoplasmic refined, 
Active Motif ™, protein extraction respectively or alternatively RIPA buffer for use 
with crude protein extraction methodology.
Table 4.2. BSA standard construction.
Concentration of 
BSA Standard (mg/mL)
Volume of BSA 
component (pL)
Volume of Buffer 
component (pL)
0 0 20
0.5 4 16
1 8 12
1.5 12 8
2 16 4
2.5 20 0
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4.2.5.1.3.2 Protein Quantification - Microplate Reader
30 pL of reagent S was added to 1.5 mL of reagent A, in the ratio of 1:50, this 
amount is adequate for approximately 60 wells, thoroughly mixed via a pipette and 
placed on ice. Each experimental sample was loaded in triplicate within a 96-well 
microtiter plate (96-W ell Standard Microplate, Thermo Scientific, Hampshire, UK) 
as well as corresponding protein standards, using the correct diluent for optimum 
results.
Each 96-well plate was constructed as outlined below; note that the number of 
samples under assay is highly variable between experiments.
( 1 2 3 4 5 6 7 8 9 10 11 12^
A • o o o o o o o o o o o
B • o ©o o o o
C O C ) ©o o o o o Calibration Standard
D • o o o o o o o Experimental Sample
E o o o o o o o o 2.5 mg/ml BSA
F o o o o o o o oo 2.0 mg/ml BSA 1.5 mg/ml BSAG o o o o o o o o 1.0 mg/ml BSA
HV. o o o o o o o o 0.5 mg/ml BSA J
Figure 4.1. Overview o f the 96 well plates used for protein quantification prior to 
incubation pre-plate reader analysis. Colour coding included, highlighting the 
decrease in protein standard concentrations as one moves horizontally across the 
plate.
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5 pL of each protein (BSA) standard solution was pipetted directly into a clean, dry, 
96-well microtiter plate, repeated in triplicate, enabling sequential protein 
quantification. Nuclear and cytoplasmic protein fractions were analysed separately 
using different standard solutions on separate plates. Following experimental and 
standard plating, 25 pL of working reagent A was pipetted directly into each well, 
200 pL of reagent B, supplied within the purchased kit, was added sequentially and 
each plate was incubated for 15 min at room temperature under rolling (150 rpm) 
conditions. During the incubation, the reagents were able to mix thoroughly; in the 
event of bubble formation within the well, using a needle (21G) each bubble was 
individually dispersed. Post incubation, each well was examined for the 
characteristic colour change as well as assessed for the absence of bubbles. The 
plates were transferred and read on the FLUOstar Omega spectrophotometer (BMG 
Labtech, Ortenberg, Germany) at 750 nm, and their respective protein quantities 
estimated. If plates were unable to be read immediately, they were placed on ice and 
protected from direct light for a maximum of an hour prior to analysis.
4.2.5.1.3.3 FLUOstar Omega Protein Quantification Data Analysis
All retrospective data analysis carried out, post protein extraction, was undertaken 
utilising the FLUOstar plate reader and corresponding MARS Data Analysis 
Software (BMG Labtech, Ortenberg, Germany). The instrument was directed to 
measure the absorbance at 750 nm of the well contents in turn and utilising the 
protein standards, of known concentration construct, a standard/calibration curve 
was calculated. Utilising a common approach to data analysis, a linear regression fit 
function was chosen and the model was assessed for “Goodness o f fit”. Spurious 
results were omitted in order to achieve an r2 value of >0.99, however, only a 
maximum of a single data point was removed within each triplicate to retain 
statistical integrity. Each run took approximately 1-30 mins depending upon the 
number of empty wells on each plate, omitted from data analysis. Using the derived 
standard curve, the concentration of the unknown experimental protein samples was 
estimated. Plates were discarded post analysis and disposed of according to health 
and safety regulations.
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4.2.5.1.4 Western Blotting Buffer Solution Preparations
Prior to the undertaking of any Western Blott analysis, a combination of long term 
(up to one month storage) and short term buffer solutions (maximum of one week 
storage) were required to be constructed. Short term buffer solutions were made up 
fresh on the day of experimentation, and used immediately.
4.2.5.1.4.1 Preparation of Long Term Buffer Solutions
10% (w/v) Ammonium Persulphate (APS) -  1 g of Ammonium Persulphate (Cat 
No. GE17-1311-01, Sigma Aldrich, Gillingham, UK), weighed accurately on a 
Sartorius LA120S Analytical Balance, was transferred into a fresh 250 mL glass 
McCartney bottle. 5 mL of filter prepared dt^O was added to dissolve the solute, 
prior to the final volume being adjusted to a 10 mL total volume, the solution was 
stored at 2-4°C protected from direct light.
Laemmli Buffer (2X concentrate) was purchased from Bio-Rad (Cat No. 161- 
0737, Bio-Rad, Hertfordshire, UK), stored at room temperature on the bench top, 
protected from direct light. Prior to use the buffer was activated via the addition of 
B-mercaptoethanol (BME) (Cat. No 161-0710, Bio-Rad, Hertfordshire, UK); 50 pL 
(BME) was added to 950 pL of (2X) Laemmli buffer within the AFA1000 fume 
cupboard, mixed thoroughly and stored on ice prior to immediate use.
Alternatively Laemmli buffer could have been constructed using the following recipe 
(62.5 mM Tris (pH 6.8), 2% (w/v) Sodium Dodecyl sulphate (SDS), 10% (v/v) 
Glycerol, 0.02% (w/v) Bromophenol blue (store at -80°C as 245pL aliquots). Add 
5pL (2% v/v) B-mercaptoethanol before use.
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10% (w/v) Sodium Dodecyl Sulphate (SDS) -  25 g of SDS (Cat No. 151-21-3, 
Sigma Aldrich, Gillingham, UK) was weighed accurately and transferred into a 500 
mL glass McCartney bottle. 100 mL of double distilled filter prepared H 2O was 
initially added to dissolve the solute, with an additional volume of H2O added in 
order to construct a final volume of 250 mL. Solution was stored on the bench top at 
room temperature protected from direct light.
1.5M Tris (pH  8.8) -  45.4 g of Tris Base (Cat No. 77-86-2, Sigma Aldrich, 
Gillingham, UK) was weighed accurately and transferred into a 1 L glass McCartney 
bottle. 250 mL ddH20 was added, mixed thoroughly and the solute dissolved. Using 
a Jenway 3510 pH meter, the pH was initially measured and adjusted to 8.8 via the 
drop wise addition of Hydrochloric Acid (1M). Excess dH20 was added in order to 
construct a total volume of 1 L (molecular weight of Tris is 121.14g/Mol). Solution 
was stored on the bench top at room temperature protected from direct light.
1M Tris (pH 6.8) - 30.3 g of Tris Base, weighed out accurately, was added to 250 
mL of ddH20 within a glass McCartney bottle. Using a pH meter, the pH was 
adjusted via the drop wise addition of 1M HCL solution and total volume adjusted to 
1 L via the addition of excess dH20. Solution was stored on the bench top at room 
temperature protected from direct light.
Tris/GIycine/SDS 10X -  30.3g of Tris Base was weighed accurately and transferred 
into a glass McCartney bottle containing 500 mL of ddH20, mixed thoroughly and 
dissolved. 144. lg  of glycine (Cat No. G8898, Sigma Aldrich, Gillingham, UK) and 
100 mL of 10% (w/v) SDS were also added sequentially, and excess ddH20 was used 
to adjust the total volume to 1 L. Solution was stored on the bench top at room 
temperature protected from direct light. (250nM Tris (pH 8.3), 1.92 M Glycine and 
1% (w/v) SDS).
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TBS 10 X -  24.2 g of Tris Base and 80.lg  of Sodium Chloride (NaCl) (Cat No. 
S7653, Sigma Aldrich, Gillingham, UK) were weighed separately and accurately 
prior to being transferred into a 11 glass McCartney bottle. 800 mL of ddtUO was 
added, mixed thoroughly and solutes diluted, pH measured and adjusted to prevent 
acidic properties, and the final volume was adjusted to 1 L via the addition of excess 
dH20. (200mM Tris (pH 7.6) and 1.37 M NaCl). Solution was stored on the bench 
top at room temperature protected from direct light.
4.2.5.1.4.2 Preparation of Short Term Buffer Solutions
Running Buffer -  100 mL of Tris/GIycine/SDS 10X (Appendix 4.2.5.1.4.1) 
solution was transferred into a fresh 1 L McCartney bottle, 900 mL of ddH20 was 
added, the bottle inverted several times and labelled according to GLP. Once suitably 
mixed, the bottle was placed on the bench top, protected from direct light and used 
with 24-48 h. (25mM Tris (pH 8.3), 192 mM Glycine, 0.1% (w/v) SDS)
TBS/T Wash Buffer -  100 mL of TBS 10X (Appendix 4.2.5.1.4.1) was measured 
out and transferred into glass 1 L McCartney bottle, to this 10 mL of 10% (v/v) 
Tween 20 (Cat No. P9416-50 mL, Sigma Aldrich, Gillingham, UK) was added and 
the contents of the bottle inverted several times. Prior to refrigeration, the final 
volume of the solution was adjusted to 1 L via the addition of ddH20. (20mM Tris 
(pH 7.6), 125 mM NaCl, 0.1% (v/v) Tween20)
Bovine Serum Albumin (BSA) blocking buffer -  12.5 g of BSA powder was 
weighed accurately and transferred into a 500 mL glass McCartney bottle. To this, 
TBS/T was added to achieve a final volume of 250 mL, flee added and the solution 
mixed thoroughly at room temperature until the BSA had dissolved producing a 
distinct colour change. (20mM Tris (pH 7.6), 137 mM NaCl, 5% (w/v) BSA) 0.1% 
(v/v) Tween20)
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Stripping Buffer -  3.8g of glycine was weighed, transferred into a 500mL glass 
McCartney bottle followed by the sequential addition of 2.5 mL 10% (w/v) SDS 
(Appendix 4.2.5.1.4.1) and 2.5 mL 10% (v/v) Tween20. Prior to addition of ddtLO, 
the pH was measured and adjusted via drop wise addition of HCL (lm ) solution and 
the final volume adjusted to 250 mL. (200mM Glycine (pH 2.2), 0.1% (w/v) SDS, 
1% (v/v) Tween 20). Alternatively, Restore Western Blott Stripping Buffer (Cat No. 
21059, Thermo Scientific, Hampshire, UK)
Transfer Buffer -  200 mL of absolute methanol (34860 -  2L, Sigma Aldrich, 
Gillingham, UK) was measured out within an AFA1000 fume cupboard, and 
decanted into a 1 L glass McCartney bottle. 100 mL Tris/Glycine, SDS 10X 
(Appendix 4.2.5.1.4.1) was added and the total volume adjusted to 1 L via the 
addition of ddH20. (20mM Tris (pH 8.3), 192 mM Glycine, 20% (v/v) Methanol, 
0.1% (w/v) SDS)
4.2.5.1.5 Polyacrylamide Gel Preparation
All western blot analysis was carried out following the procedures outlined in 
(Appendix 4.2.5.1), the gels constructed for this body of work were polyacrylamide 
based and the constituent components of each gel were purchased and stored 
according to manufactures guidance; 30% Acrylamide/Bis solution, 19:1 dilution 
ratio (Cat No. 161-0154, Bio-Rad, Hertfordshire, UK) and TEMED (Cat No. T- 
9281-50 mL, Sigma Aldrich, Gillingham, UK) were stored at 2-4°C protected from 
light and further information about the buffers used can be found in (Appendix
4.2.5.1.4.1 -  4.2.5.1.4.2). The addition of TEMED in combination with 
Polyacrylamide forms a gels matrix suitable for the resolution of macromolecules; 
percentage composition polyacrylamide governs the lattice structure, in conjunction 
with detergent treatment facilitates a 2-dimensional linear separation of proteins. The 
percentage composition of resolving gel was based directly upon the molecular
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weight of the protein under assay; large proteins required lower acrylamide 
composition. Preparation of gels was undertaken in an AFA1000 fume hood due to 
the environmental pollutant nature of the chemicals used.
Table 4.3. Gel constituents, 
Stacking Gel Resolving Gels
4% 6% 8% 10% 12%
2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4 Gels 2 Gels 4Gels
30% Acryl 0.65 1.3 3 6 4 8 5 10 6 12
ddH20 3 6 8 16 7 14 6 12 5 10
1.5M Tris 
(pH 8.8)
3.75 7.5 3.75 7 .5 3.75 7.5 3.75 7.5
1M Tris 
(pH 6.8)
1.25 2.5
10% SDS 
(pL)
50 100 150 300 150 300 150 300 150 300
10% APS 25 50 75 150 75 150 75 150 75 150
TEMED
(pL)
5 10 15 30 15 30 15 30 15 30
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4.2.5.1.6 Gel Casting and Electrode Assembly
All western blott apparatus used within this project was purchased from Bio-Rad; 
however, many of the Kits have been discontinued in recent years, therefore, where 
appropriate the currently available kit will be referenced. Be aware that the current 
kit may contain newer versions of the apparatus used; however, their basic design 
and features are analogous to the apparatus used when casting and running the 
Western Blott gels and subsequent analysis.
Prior to casting, all plates, spacers, combs and casting stands (Mini-PROTEAN Tetra 
Cell #165-8007, Bio-Rad, Hertfordshire, UK) were washed thoroughly with 70% 
ethanol and allowed to air dry, facilitating correct set up alignment. 1.5 mm glass 
plate assemblies were fitted together, the larger plate at the rear, assembled into the 
casting stand and the whole set up was checked for integrity..
The desired resolving gel recipe was prepared and then applied directly to the cast 
via 5 mL pipette and pipette gun (MACROMAN ™ Pipette Controller, Gilson, 
Middleton, USA), leaving approximately 2-3 cm for the stacking gel. Isopropanol, 
(Cat No. 190764, Sigma Aldrich, Gillingham, UK) minimal volume, was applied 
across the top of the gel and incubated at room temperature for 30-60 minutes. Post 
incubation, the gel was assessed for hardening and the entire rack inverted and 
isopropanol discarded. The stacking gel was applied directly onto of the resolving 
gel, in an analogous method, and the corresponding (1.5mm) 10 well comb was 
inserted evenly into the resolving gel. Following a final assessment for alignment 
and potential retarding bubble formation, the set up was incubated for a further 30-60 
min at room temperature.
Post hardening and gel melding the plate assembly was removed from the casting 
stand, comb removed and transferred into central chamber of the 2-gel vertical 
electrophoresis system. 20-40 jig of protein sample was added to equal volumes of 
activated (addition of BME) Laemmli buffer (1:1), vortexed for 30 sec at high power 
and heated at 95-100°C for 5 min. Dual colour (Precision Plus Protein ™ Dual 
colour standards #161-0374, Bio-Rad, Hertfordshire, UK) and biotinylated
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molecular weight ladder (Cat No. B2487, Sigma Aldrich, Gillingham, UK) were 
thawed during the incubation.
Post incubation, the central chamber was placed within the 2-gel electrophoresis 
system and partially filled with running buffer (Appendix 4.2.5.1.4.2). Running 
buffer was poured directly into the wells to facilitate loading as well as covering the 
electrode at the base of the chamber sufficiently. 10 pL of the protein standards, 
Dual colour and biotinylated were pipetted into the first two wells respectively 
followed by the protein-Laemmli samples into the corresponding remaining wells. 
When pipetting samples the pipette tip was placed firmly within the centre of the 
well and removed prior to full discharge preventing bubble formation. The lid of the 
electrophoresis system was placed onto the chamber, connected via colour coded 
leads to the power pack (PowerPack Basic Power Supply, Cat No. 164-5050, Bio- 
Rad, Hertfordshire, UK) and the whole assembly was run at 120 V for approximately 
60 min. When the dye front had migrated to within an inch of the base of the gel, the 
power pack was disconnected and the running buffer removed and discarded.
Each assembly was run at 120 v until the dye front had reached the bottom of the gel 
which took approximately 60 mins.
4.2.5.1.7 Protein Transfer
Protein transfer during this thesis project was carried out using the Mini Trans-Blot® 
Electrophoretic Transfer Cell kit contents (Cat. No. 170-3930, Bi-Rad, Hertfordshire, 
UK), operated according to manufacturer’s supplied guidance. Unless otherwise 
stated, all apparatus was supplied within the kit and used in conjunction with buffers 
prepared according to (Appendix 4.2.5.1.4.1 -  4.2.5.1.4.2).
Immuno-Blot PVDF membranes (Bio-Rad, Hertfordshire, UK), one per protein gel, 
were submerged in 100% methanol, performed within an AF1000 fume hood, until 
the membrane became translucent (-10-30 sec). Simultaneously to this, two fibre 
pads, extra thick blott papers (cat No. 170-3965, Bio-Rad, Hertfordshire, UK) were 
incubated in pre-cooled 4°C transfer buffer (Appendix 4.2.5.1.4.2). Post incubation,
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transfer cassettes were constructed ready to house the freshly ran protein gels. 
Transfer cassettes were opened, placed flat on a drainable work surface and loaded 
with a single fibre pad and filter paper. Protein gels were removed from their glass­
ware, washed in transfer buffer, and placed faced down (standard on the right hand 
side) onto the filter paper. A re-hydrated PVDF membrane was positioned on top of 
the gel, ensuring full coverage, and the cassette was completed via the addition of an 
additional filter paper and fibre pad. Before the cassettes were finalised, a small 
rolling pin was used to flatten the membrane against the gel to ensure an effective 
protein transfer. The cassette was lock and placed within a Transfer cell, prior to the 
sequential addition of cooling unit (containing frozen transfer buffer) and filled with 
cold transfer buffer. The whole apparatus was placed within a polystyrene container 
filled with ice and moved into the cold room to maintain a constant 2-4°C 
environment. A power pack was attached to the transfer cell and ran at 400 mA for
1.5 hr.
Post transfer, the cassette was removed from the transfer cell and unlocked; all 
contents except for the membranes were discarded according to laboratory health 
and safety protocols. The membrane was submerged in pre-cooled (2-4°C) TBS/T 
wash buffer (Appendix 4.2.5.1.4.2), agitated and cut via a scalpel to ensure 
separation of the protein samples and the biotinylated ladder, preventing any 
potential contamination issues. A small notch was cut in the lower left comer of each 
membrane piece to facilitate correct orientation during Western Blott analysis.
4.2.5.1.8 Membrane Blocking and Antibody Incubation
Membrane/s were incubated overnight (approximately 8-12 hr) in approximately 5- 
10 mL of pre-cooled blocking buffer (Appendix 4.2.5.1.4.2) at 2-4°C. The 
membrane/s was placed on a rocking/shaking platform (-200 rpm) for the duration. 
As a precaution, to minimise detection of endogenous biotin carrier proteins, 
approximately 50 pg/mL of avidin was added to the biotinylated protein standards 
blocking buffer/solution. Post incubation, blocking buffer was removed and the 
membranes washed; wash steps were achieved via the addition of 5-10 mL of TBS/T
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buffer (Appendix 4.2.5.1.4.1) and placed on a rotating platform (-1500 rpm) for 5-7 
min.
Generally, primary antibodies raised against the protein of interest within that 
specific blott were rabbit monoclonal antibodies and diluted within 10 mL of 
blocking buffer. Post dilution, membrane/s were treated with the primary antibody 
solution (10 pL primary antibody solution diluted 1:1000 within BSA blocking 
buffer) for 1 hr at room temperature under shaking conditions (-200 rpm), washed 
several times (a minimum of 4) and sequentially incubated in corresponding horse 
radish peroxidase (HRP)-conjugated secondary antibody solution (10 pL HRP- 
antibody diluted 1:1000 within BSA blocking buffer) for an additional 1 hr. The 
biotinylated protein standards were incubated in the Streptavidin HRP-conjugate 
(Bio-Rad, Hertfordshire, UK) BSA blocking buffer (1:1000) solution for an 
analogous incubation period. Post incubation, membranes were washed five times 
and during this period o f time the ChemiDoc ™ XRS (Bio-Rad, Hertfordshire, UK) 
was switched on and the supplied Quantity One (Bio-Rad, Hertfordshire, UK) 
software loaded.
4.2.5.1.9 Protein Detection -  ChemiDoc ™ XRS
4.2.5.1.9.1 Protein of Interest Detection
Protein detection was under taken using the Clarity Western ECL substrate (Cat No. 
170-5060, Bio-Rad, Hertfordshire, UK) chemilluminescence kit, stored and operated 
as per manufacturers supplied instructions. Prior to visualisation, the “luminol” 
enhancer and peroxide buffer solutions were mixed, 1:1 and stored protected from 
light until ready for use. Post washing, the membranes were removed and placed 
onto the pre-cleaned ChemiDoc™ surface.70% ethanol and professional care tissues 
were used to clean the surface thoroughly without causing damage. Using stainless 
steel straight forceps the membrane was moved into position and aligned with its 
corresponding biotinylated standards under epi-white light. Once in position, the
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white light was switched off, and the pre-made visualising agents was applied 
liberally to the membrane, concentrating on regions of interest, the ChemiDoc™ was 
closed and the membrane incubated for 5 min. Post incubation the camera was 
adjusted within the Quantity One software to a high focus and the membranes were 
exposed to trans-UV light for a minimum of 10-30 sec, exposure length was highly 
variable depending upon abundance and the protein bands visualised and captured 
via the incorporated digital camera.
4.2.5.1.9.2 Stripping Membranes and House Keeper Detection
Post probing for the protein of interest, the membranes were removed, washed 
(Appendix 4.2.5.1.8) and treated with Restore Western Blott Stripping Buffer. 
Membranes were exposed twice to 5-10 mL of striping buffer for a period of 10-15 
min, washed extensively and re-hydrated in 100% methanol. Following re-hydration, 
membranes were washed and treated with the anti-house keeper antibody as outlined 
in (Appendix 4.2.5.1.8). Succeeding secondary conjugation, washing and placement 
in the ChemiDoc ™, the membrane was aligned and treated with the 
illuminator/enhancer solution (Appendix 4.2.5.1.9.1) and incubated prior to protein 
band detection (Appendix 4.2.5.1.9.1).
4.2.5.1.10 Protein Quantification -  Quantity One Software
All protein band detection and estimated quantification were retrospectively 
undertaken using the Quantity One -  Advanced software purchased from Bio-Rad, 
Hertfordshire, UK. During protein band visualisation the Quantity One software was 
loaded, save directory chosen and used initially to capture a still image of the 
western blott membrane post UV exposure (Appendix 4.2.5.1.9). The image was 
cropped, aligned correctly and each band was distinctly classified, including an 
additional band for background. The relative band intensities were initially 
standardised against the background, following this, each sample band was
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normalised against the corresponding house keeper band, averaged against 
experimental replicates and divided against the con-current negative control 
generating the average relative fold increase in band intensity when compared to un­
treated controls. Western Blott analysis for proof of principle experimentation was 
carried out in experimental replicates, Standard error of the Mean (SEM) error bars 
included, however, within experiments requiring a greater level of confidence, 
biological replicates from individual cell cultures were utilised.
4.2.5.2 Qualitative Real Time -  Polymerase Chain Reaction Protocol
4.2.5.2.1 Ribonucleic Acid (RNA) Extraction
Total RNA was extracted from the human lymphoblastoid cell lines using the 
Qiagen RNeasy Mini Kit (Qiagen, Sussex, UK) and followed according to the 
manufacturers' instructions. Cell cultures were established as outlined in (Section 
2.2), counted and washed prior to the extraction. The volume of cells equivalent to 8 
x 106 cells was extracted from the cultures, transferred into 50 mL centrifuge tubes, 
centrifuged (250 x g for 7 min) and supernatant was aspirated. Cellular pellets were 
re-suspended in 600 pL of RLT buffer, homogenized (passing the lysate through a 
needle (21G) a minimum of 3 times) and then diluted in 600 pL of 70% ethanol. 
Following ethanol addition, solutions were mixed thoroughly using a 1000 pL 
pipette and the contents (-700 pL) was applied to the supplied columns within the 
kit. The column was then placed within a 5424 24 Place Eppendorf Micro centrifuge 
(Eppendorf, Hamburg, Germany), centrifuged (>8000g for 15 sec) and diluent 
discarded. This step was repeated in order to load the total -1200 pL volume of 
starting solution into the column. Post centrifugation, DNase digestion followed; 
DNase I stock solution was added to 70 pL RDD buffer - RNase-Free DNase Set 
(Qiagen, Sussex, UK) -  350 pL RW1 buffer was added to the column and 
centrifuged (as above). Post centrifugation, the DNase I incubation mix (80 pL) was 
directly applied to the centre of the column membrane and incubated at room 
temperature for 15 min. Following incubation, the column was washed with 350 pL
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RW1 buffer, centrifuged (as above) and washed again with a 500 pL volume of RPE 
buffer. Following centrifugation (as above) another 500 pL of RPE buffer was added 
to the column and centrifuged (>8000 x g for 2 min). The column was carefully 
removed, and then transferred to a fresh collection tube and centrifuged at full speed 
for 1 min to ensure complete dryness. The column was transferred to a fresh 
collection tube, 33 pL Nuclease-free water was added to the column membrane and 
incubated for 3 min at room temperature, prior to being centrifuged (>8000 x g for 1 
min). The contents of the collection tube was labelled according to GLP protocol, 3 
pL aliquot removed for purity assessment and placed within a -80°C freezer for short 
term storage.
4.2.5.2.2 RNA purity Assessment - Nanodrop
Following the RNA extraction (Appendix 4.2.5.2.1) the RNA yield was measured 
and the purity assessed (260:280 ratio) using a NanoDrop ND-1000 
Spectrophotometer (Labtech International, Uckfield, UK). The NanoDrop was 
switched on and the supplied software loaded, prior to being directed to assess 
“Nucleic Acids”, in which “RNA” was selected, for purity and content. 1 pL o f 
sterile, nuclease-free, dfUO was pipetted directly onto the detector plate, the machine 
was calibrated and the water wiped off using professional care wipes (Kimberly 
Clark ®, Kent, UK).l pL volumes of the extracted RNA were pipetted sequentially 
onto the detector, a wash step using nuclease-free water was implemented between 
each assessment, (260:280), (260:230) and content were recorded for each sample; 
excess RNA was stored at -80 °C until further use.
4.2.5.2.3 Double Stranded Copy DNA (cDNA) Synthesis
Double stranded cDNA synthesis was carried out for all the human lymphoblastoid 
cell lines using the QuantiTect Reverse Transcriptase Kit (Cat No. 2053111, Qiagen, 
Sussex, UK) and followed according to the manufacturers' instructions. The protocol 
is for use with 10 pg to 1 pg RNA, therefore, reaction volumes can be scaled up to 
enable > 1 pg RNA starting material. All stages of cDNA synthesis were carried out
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within the PCR hoods, thorough 70% ethanol cleaning followed by RNase 
decontamination (RNase ZAP™, Life Technologies ™, Paisley, UK) and extensive 
UV sanitization were under taken prior to any work. Previous to thawing the total 
RNA, all precipitates within the gDNA Wipe-out buffer were dissolved by 
vortexing, no precipitates required warming (37°C) to dissolve. Template RNA, 
Quantiscript reverse transcriptase, RT primer Mix, gDNA Wipe-out buffer, 
Quantiscript RT buffer and nuclease-free H2O were all thawed over ice for 30 min, 
flicked to enable mixing and centrifuged briefly to collect the liquid from the sides of 
the tubes. For the duration of the protocol all solutions were kept on ice and 
protected from direct light. The initial stage within the protocol was to establish a 
genomic DNA elimination reaction as follows; 2 pL of gDNA Wipe-out Buffer (7x) 
was added to a variable volume of RNA template, equivalent to 1 pg within a 0.75 
mL eppendorf, and RNase-free water was added to create a final reaction volume of 
14 pL. Each sample was incubated at 42°C for 2 min within a T100 PCR Thermal 
Cycler (BioRad, Hertfordshire, UK) and immediately placed on ice post incubation. 
The second stage of the protocol was to enable first strand synthesis and subsequent 
amplification of the newly formed genomic cDNA. 1 pL of Quantiscript Reverse 
Transcriptase, 1 pL RT Primer mix and 4 pL of Quantiscript RT buffer (5X) were 
aliquotted into a fresh 0.75 mL eppendorf, these components when mixed made up 
the reverse-transcriptase master mix. To the master mix, 14 pL of newly prepared 
template RNA was added and placed on ice prior to incubation. Each sample was 
transferred back into the heating block of theTlOO PCR thermal cycler and incubated 
at 42 °C for 15 min. Incubation time can be increased to a maximum of 30 min, if the 
RT-PCR product is longer than 200 bp, in order to maximise yields. Post incubation, 
each sample was in-activated for 3 min at 95°C, within the thermal cycler, and 
immediately labelled according to GLP prior to short term storage within a -80 °C 
freezer.
4.2.5.2.4 Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
Real-time PCR experiments were undertaken using the QuantiFast™ SYBR® Green 
PCR Kit (Qiagen, Sussex, UK) in combination with synthesised cDNA following the
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protocols outlined in (Appendix 4.2.5.2.3). The reactions were set up in the PCR 
hood using sterile equipment, as described in (Appendix 4.2.5.2.3) and all stock 
solutions kept on ice protected from light. Master mixes, prepared in triplicate, were 
initially constructed consisting of the following; 50 pL (2X) QuantiFast SYBR 
Green PCR Mast Mix, 1 pL Primer A, 1 pL Primer B, 6 pL of template cDNA 
(genomic DNA can be used) and 42 pL of RNase-free water, constructing a total 
reaction volume of 100 pL (4 x 25 pL). All solutions were made in excess within 
0.75 mL Eppendorf s, as each sample was run in triplicate and thawed over ice, 
protected from light prior to experimentation. 25 pL of each resultant master mix 
was aliquotted separate adjacent wells of a sterile 96-well 0.2 mL PCR plate 
(Sarstedt, Nuembrecht, Germany). Experimental samples, standard serial dilutions as 
well as non-template negative controls were also included for each primer pair. 
Within the negative controls, cDNA was replaced with RNase-free water and the 
inclusion of standard wells allowed post analysis PCR efficiency to be calculated. 
Post plating, each individual 96 well-plate was sealed with an Absolute QPCR Seal 
sheet (Thermo Scientific, Surrey, UK), any air pockets disrupted and centrifuged 
briefly before being transferred into the iCycler iQ5 thermal Cycler (BioRad, 
Hertfordshire, UK). The thermal cycler was then programmed with the following 
schedule which took approximately 1.5 hr per plate.
4.2.5.2.4.1 iCycler iQ5 thermal Cycler Programme Breakdown
Step 1 - 95°C for 5min
Step 2 - 95°C for lOsec 
Step 3 - 60°C for 30sec
X 4 0
Step 4 - 95°C for lm in
Step 5 - 55°C for lm in
Step 6 - 0.5°C increments in temperature starting from 55°C to 95°C - melt curve 
analysis
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Step 1 is included to activate the HotStarTaq Plus DNA polymerase, with subsequent 
steps 2 and 3 representing the PCR reaction (denaturation and annealing/elongation). 
Steps 4, 5 and 6 are included in order for the software to generate an accurate melt 
curve. Data was collected at step 3 as well as step 6 for PCR amplification and melt 
curve respectively and analysed in real time. Retrospective analysis was carried out 
following the completion of the entire plates, cross plate comparisons were also 
under taken utilising the on-board software to create a “gene study”.
4.2.5.2.4.2 iCycler iQ5 Data Analysis
All retrospective analysis was carried out using the manufacturer supplied iCycler 
iQ5 software version 2.1 (BioRad, Hertfordshire, UK). Melt curve analysis was 
undertaken; specificity of PCR products as well as the efficiency of the plate was 
defined. Any discrepancies found within the melting temperature (Tm) of the PCR 
product, or the PCR efficiency, resulted in that specific wellbeing omitted from 
analysis. Relative quantitation of gene expression was achieved using the standard 
curve method [16]. Standard samples, non-template controls as well experimental 
samples were all defined within the “sample setup” view. Stock cDNA samples were 
constructed (10-fold serial dilutions with the dilution values: 1, 10, 100 and 1000). 
The standard wells were utilised to construct a standard curve, omitting errorous
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wells non-conforming to an r figure of 0.99 or greater, i.e. the data fell outside of 
the acceptable criteria for a “good fit”. The threshold points or crossing points (Cjs) 
were plotted against the log of the template amount, resulting in a straight line. 
Threshold cycle (Cj) values for the experimental samples were then used with the 
standard curve to estimate the amount of starting template in each well. All samples 
were normalised by their respective endogenous control genes selected with 
homogenous high expression across all tissue or cell lines under assay, and the 
resultant normalised target value used to calculate the fold-difference in target when 
compared to con-current negative or un-treated samples.
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4.2.5.2.4.3 Equations Used During iCycler iQ5 Data Analysis
4.2.5.2.4.3.1 Normalised Target (Well Specific)
Normalized target = Target/Endogenous control
The normalized target values were then divided by one another (concurrent or un­
treated sample) to calculate the fold-difference in target quantity.
4.2.5.2.4.3.2 Fold Difference (Treatment Specific)
Fold difference = Normalized target (treated sample)/ Normalized target (un-treated 
sample)
4.2.5.3 P53 Functionality Assessment Following MMC Treatment
Mitomycin C (MMC) (Cat No. M4287-2MG, Sigma Aldrich, Gillingham, UK) came 
supplied as a 2 mg powder, stabilised within 48 mg of NaCl to enable minimum 
effort dissolving and distribution. 4 mL of dlUO was added to the powder and re­
constituted at the final concentration of 0.5 mg/mL (0.5g/L). The solution was 
aliquotted into 0.5 m L eppendorf tubes and stored, sealed in a separate box, and 
placed within a -20 °C freezer. Prior to usage within the experiment, a serial dilution 
was undertaken, utilising dH^O as the diluent generating a 0.05 mg/mL stock defined 
as “A” and a further 0.005 mg/mL stock “B”.
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4.3 Results
4.3.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
In order to evaluate the potential variability between the low passage and normal 
TK6 cell cultures, in terms of surface antigen expression, immunofluorescence 
staining was employed to assess the expression of well characterised cellular surface 
antigens as well as their diverse nature of functionality within the cell line. CD55 
and CD59 are typical cellular surface antigens found within haemopoetic lineages, 
FLAER is a bacterial toxin able to bind to the GPI anchor moiety which attaches a 
whole plethora of cellular surface markers to the membrane and CD48 is a cell line 
specific marker for activation. Evaluation of the generated results would be an 
indication of how comparable the cell lines are outside of the context of dose 
sensitivity and recovery to genotoxic exposure.
■ FLAER DCD48 BC D 55/59
Figure 4.2. Relative average cell surface marker expression, with respect to parental 
control parental population, within 4*Low Passage’’ TK6 cells. FLAER (stock cone) -  
Alexa Fluor 488 ™ conjugate, CD48 phycoerythrin conjugate and CD55/59 
phycoerythrin conjugate fluorescent dyes utilised and data captured within their 
respective detectors. (-10,000 single cellular events) (N=3, Error Bars ±1SD).
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■ FLAER n C D 48 B C D 55/59
Figure 4.3. Relative average cell surface marker expression, with respect to parental 
control parental population, within ‘‘Normal" TK6 cells. FLAER (stock cone) -  
Alexa Fluor 488 ™ conjugate, CD48 phycoerythrin conjugate and CD55/59 
phycoerythrin conjugate fluorescent dyes utilised and data captured within their 
respective detectors. (-10,000 single cellular events) (N=3, Error Bars ±1SD).
The “Low Passage” TK6 cells were shown to have minimal FLAER staining (5.9%), 
even at the top concentration tested (top concentration (2.5 pg/mL), negligible CD48 
staining (2.2%) and marginal CD55/59 expression (62.6%) (Appendix Figure 4.2). 
Relatively little variation was observed within the culture and cells were 
microscopically assessed for signs o f distress prior to assessment. The “Normal” 
TK6 cells demonstrated comprehensive staining, approximately 75% for all markers 
challenged within the scope of this experiment; CD48 (73.3%), CD55/59 (78.4%) 
and finally top concentration FLAER (75.4%) (Appendix Figure 4.3). The “Normal” 
TK6 population demonstrated extensively greater average expression values when 
compared to the “Low Passage" cell stock.
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4.4 Discussions and Conclusions
4.4.2 CD55 Antigen Optimisation using Fluorescence Activated Cell Sorting
(FACS)
As a particle passes through the nozzle the fluorescence illumination data is 
acquired, following excitation and subsequent emission and said particle is assigned 
an identity. The user is able to directly charge the nozzle and apply a unique voltage 
to a cell or sub population of interest. As the stream reaches its break off point and 
forms successive droplets of sheath fluid, each potentially containing a single or 
multiple events, it passes through two charged deflector plates. The droplets fall 
through said plates, and the pre-determined carried charge facilitates repulsion and 
hence, re-direction from the parental stream, into a side stream which is able to be 
captured for further passage and analysis [17]. Immunofluorescence staining is often 
utilised in tandem with FACS to identify and isolate sub populations of cells from 
heterogenous parental populations; applications within clinical medicine [18], 
disease diagnosis as well as scientific research [19] are common.
The initial rounds of sorting took approximately 2-5 hrs, the various set up stages 
were time consuming and often required minor alterations which were highly tedious 
and prolonged set up. The side-stream intensity, as measured by diode laser 
intersection, and hence stability was the major perturbing factor, especially 
prominent during the accudrop drop delay calibration and hence directly affected 
sorting efficiency. Following, the initial sorting methodology (Section 2.8.3), the cell 
population was visually separated into viable and non-viable fragmented cells. The 
viable population, the right quadrant on a bi-modal distribution, had a fluorescence 
profile matching the 50% upper percentile of the pre-enriched sample. However, 
severe viability problems immediately post sort predestined that the recovered cells 
often displayed expression profiles consistent with debris or fragmented cells and 
following further propagation cultures displayed noteworthy PIG-A mutant 
populations (Figure 4.5). Additional rounds of investigation and protocol amendment 
were utilised to assess the impact collection vessel size, constituency in terms of
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density and collection liquid viscosity had on viability and hence sort efficiency 
(Section 4.3.2).
Apart from the physical properties of the flow cytometer set up an additional 
software level of regulation is built in, referring to the stringency of the sort process. 
This in turn can be broken down into two separate issues, i) drop count (yield and 
purity masking) and ii) phase masking which both have a similar effect of the 
efficiency. Drop count refers to the stringency of the sort process to determine how 
many drops the system will deflect when a target particle is detected (sort event). 
When a particle is expected to be close to the edge of a drop it is beneficial to sort 
the adjacent drop, depending upon stringency, one or two drops can be sorted. Purity 
masks prevent the drop from being deflected if no particle of interest is actually 
present within the droplet. Finally, phase masking, only applicable with purity 
masks, govern the effects the presence of additional particles within a close 
proximity to the droplet of interest, and defines the conditions in-which software 
aborts occur. The more stringent the control of the sort process the more frequent the 
cytometer will abort the sort to prevent potential contamination (software aborts), 
and therefore, increase sort purity, not yield [20].
Cell viability pre and post sorting, particularly prominent in this instance due to the 
potential of non-viable single cell events mimicking presumptive PIG-A mutants, is 
critical in aiding recovery as well as yield. Cell lines are highly sensitive to changes 
in pH and buffer constituency and often as a result fail to recover post sorting [15, 
21], intense attention to detail in terms of cell wellbeing is essential for optimum 
results; the time in which the process occurs to prevent apoptotic triggers [22], the 
aseptic nature of the entire process, the respiration rate and maintained temperature 
post sort all impact the purity results.
4.4.5 Normal TK6, AHH-1 and MCL-5 Cell Line Characterisation
In order to come to a final decision whether to incorporate “Low Passage” TK6 cells 
into the in vitro PIG-A assay design, an additional comparison of potential GPI-AP 
reporter markers was investigated. The “Low Passage” TK6 cells were shown to 
have consistently reduced GPI-AP or FLAER staining (Appendix Figure 4.2) when
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compared to the normal TK6 cell lineage (Appendix Figure 4.3). As FLAER is a 
generalised marker for a plethora of GPI anchored protein ligands, the resultant 
percentage expression was uncharacteristically low and therefore, in conjunction 
with no obvious potential future surface anchor candidate to select as an in-direct 
reporter the decision was made to cease usage of the cell line. Without more detailed 
genomic information, there are no further conclusive remarks to be made about the 
discrepancies observed during staining.
Prior to the selection of a new cell line platform for the current in vitro PIG-A assay 
design, the functionality as well as constitutive TP53 gene status within the current 
cell line candidates must be evaluated. P53 is a nuclear transcription factor, which 
when inactive is often bound to MDM2 and shuttled into the cytoplasm distal to any 
potential nuclear targets. In response to oxidative stress, DNA damage, hypoxia etc., 
p53 is returned to the nucleus, activated through a conformational change via a 
phosphorylation at the n-terminal (serine 15) and dissociated from MDM2 (dramatic 
half-life increase). Once active, p53 has a prominent role in cell cycle regulation, 
more specifically the up-regulation of p21 (WAF1/CIP1) and the inhibition of CDk2 
activity, resulting in a maintained G 1/2 arrest (cell cycle check point). At this point 
DNA damage can either be repaired or alternatively, the cell is directed towards 
programmed cell death (apoptosis) if repair is deemed inefficient [23-26].
Tentatively, the conclusions which can be drawn from this section are that each cell 
line demonstrates some level of p53 activity and hence, functionality via the 
measurement of p21 induction, however, currently, no definitive conclusion can be 
made on the actual tp53 mutational status of the cell lines assessed. Further 
molecular analysis and potential sequencing is required to reveal the actual stats of 
the tp53 gene within the tested cell lines. Due to the unsurpassable GPI-AP presence 
and subsequent comparable p53 assessment, the MCL-5 cell line was chosen as the 
novel cell line to facilitate in vitro PIG-A assay development.
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4.5 Supplementary Work
4.5.1 Introduction
The work embodied within chapter 4, explores the prospect of optimising the 
sensitivity of the current in vitro PIG-A gene mutation assay by incorporating a 
number of modifications; a novel in-direct reporter of mutation, CD55 GPI-AP, as 
well as the use of a proclaimed superior cell line, “Low Passage” TK6, viability 
dyes, Annexin V and 7-AAD and an optimised phenotypic wild type enrichment 
methodology, FACS. Following the evaluation of the protocol modifications, 
additional human cell lines were assessed in terms of molecular characterisation i.e. 
p53 status and functionality, as novel candidates for the assay platform.
However, in addition to the work described within the results chapter a number of 
further investigative directions were also taken to provide additional validation as 
well as look into specific topics which were fundamental to the future development 
of the in vitro PIG-A assay system. Therefore, the following work describes the 
subtle molecular and physiological differences between the “Low Passage” TK6 
cells and the pre-existing normal TK6 cell stocks, utilised here at Swansea 
University, in terms of their strengths and weaknesses within the content of the in 
vitro PIG-A assay system. The work also focusses heavily on FCM, in specific, the 
novel gating strategies devised and trialled to increase assay sensitivity, as well as 
explore the potential bias induced through analysis. In addition to this statistically 
derived FCM analysis protocols, which could help to greatly remove bias within 
subjective flow cytometry scoring, were also devised and assessed for their potential 
future inclusion as a supplied standalone test system.
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4.5.2 Materials and Methods
4.5.2.1 “Low Passage” TK6 Cell Line Stability and Viability, Following 
Genotoxic Exposure
A vial of Low Passage TK6 cells as well as Normal TK6 cells were established and 
maintained as outlined within (Section 2.2) and assessed for cytotoxicity profile 
following EMS exposure. Following sufficient growth to certify population fitness 
cells were counted using a Haemocytometer as well as a Coulter Counter (Section 
2.2.1) and the equivalent volume housing lxlO 6 cells were transferred into sterile 25 
cm2 pre-labelled culture flasks (9 per TK6 culture). The final volume of each culture 
flask was adjusted to 10 mL via the addition of fresh culture media (Section 2.4) 
constructing a final concentration of lxlO 5 cells/mL. Prior to genotoxic handling, 
suitable PPE was collected, worn and appropriate disposal vessels collected. Ethyl 
methanesulfonate was collected from storage and diluted within an apt vehicle, to 
enable dissolving under minimal effort and stock concentration establishment 
(Section 2.4). Serial dilutions within DMSO were utilised to construct the required 
stock solutions and subsequent doses (0, vehicle, 0.1, 0.2, 0.4, 1, 2, 5 and 10 pg/pL). 
Cellular cultures were treated with 100 pL volume doses of EMS and incubated, 
under controlled environment, for 24 hr. Following treatment, cultures were washed 
(excess 1 X PBS) and re-suspended in 10 mL fresh culture media and counted 
(Section 2.2.1). Cultures were incubated for an additional 24 hr and counted to 
provide population statistics for a total of 48 hr post chemical treatment. Relative 
population doubling (RPD), relative cell counts (RCC) and estimated mean 
generation time (EMGT) were calculated from the produced cell counts in order to 
facilitate direct cell line comparisons in terms of stability and sensitivity post 
genotoxicant exposure.
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4.5.2.1.1 Compensation Matrix and General Viability (Positive Control 
Samples)
A vial of CD55 enriched Low Passage TK6 cells were established and maintained as 
outlined within (Section 2.2). Following sufficient growth to certify population 
fitness cells were counted using a Haemocytometer as well as a Coulter Counter 
(Section 2.2.1) and the equivalent volume housing lxlO 6 cells were transferred into 
four sterile 25 cm2 pre-labelled culture flasks. Each flask was diluted with fresh 
culture media to a final volume of 10 mL and received a different treatment: i) 4 hr 
10 pm Ionomycin, ii) 30 min 10pm Staurosporine, iii) Combined 10pm 
Staurosporine (30 min) and 4 hr Ionomycin and iv) no treatment. Following 
treatment, cultures were transferred into 15 mL BD Falcon tubes and washed with 
IX  PBS (Section 2.8.1). Cellular pellets were re-suspended in 50 pL of pre-warmed 
fresh medium and exposed to antibody treatment; however, ICS samples remained 
untreated throughout. 20 pL of anti-CD55 PE antibody solution was added in an 
analogous manner to the protocol defined in (Section 2.8.1). Post incubation, 
cultures were washed in excess 1 X PBS and re-suspended in 1 mL of 1 X annexin- 
binding buffer. Binding buffer was supplied at 10X concentration and therefore, 
required a simple 1 in 10 dilution in dH20 prior to usage. Cultures were centrifuged 
(1100 rpm for 7 min), supernatant aspirated and re-suspended in an additional 100 
pL of 1 X annexin binding buffer. 5 pL of Alexa Fluor® 488 annexin V was added 
to each culture, excluding the ICS and incubated in an equivalent manner to the 
protocol defined in (Section 4.2.3.1). Post incubation, excess 1 X annexin binding 
buffer was added, cultures centrifuged, supernatant aspirated and re-suspended in 
200 pL of annexin binding buffer. 5 pi (0.25 pg) per test (per million cells) of 7- 
AAD was added, mixed thoroughly and incubated for 5 minutes, protected from 
light, on ice. Samples were maintained on ice protected from light for a maximum of 
4 hr prior to flow cytometric analysis.
Based on the staining method above, seven samples were created in order to 
construct a comprehensive compensation matrix:
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Single Stained (“FITC-A” positive) -  30 min Staurosporine treatment culture
Single Stained (“PE-A” positive) -  Untreated ICS culture
Single Stained (“APC-A” positive) -  4 hr Ionomycin treatment culture
Double Stained (“PE-A” and “APC-A” positive) -  4 hr Ionomycin treatment culture
Double Stained (“FITC-A” and “APC-A” positive) -  4 hr Ionomycin and 30 min 
Staurosporine treatment culture
Double Stained (“PE-A” and “FITC-A” positive) -  30 min Staurosporine treatment 
culture
Combined Staining (“PE-A”, “FITC-A” and “APC-A” positive) -  4 hr Ionomycin 
and 30 min Staurosporine treatment culture
Each sample was assessed on the flow cytometer in which the respective signal 
intensities of the specific fluorophore were reduced in order to prevent signal 
detection in neighbouring channels. Following this, the dual stained samples were 
analysed in order to evaluate the effect the proposed matrix had on resultant signal 
detection. Finally, the combined signal was assessed for signal detection, solidifying 
the utility of the compensation matrix.
4.5.2.2 Preliminery Linear Dose Response Capture Utilsing both Fluorescence- 
Area and FIuoresence-Height as Potential Descriptors
Low passage TK6 cell cultures were established and maintained as outlined in 
(Section 2.2) and exposed to EMS for 24 hr under standard chemical treatment as 
described within (Section 2.4). Post chemical exposure, cultures were washed, 
counted and seeded ready for initial flow cytometric analysis using anti-human 
CD55 PE conjugate, Alexa Fluor 488® Annexin V and 7-AAD (Section 3.2.5). Flow 
cytometric analysis as defined in (Section 2.8.2) was undertaken within an hour of 
sample preparation, samples were stored on ice, protect from direct light, until 
analysed.
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After gating for single cells on a SSC/FSC dot plot and/or counter map, a minimum 
of 10,000 events were analysed for the surface expression of the CD55 surface 
antigen. PIG-A phenotype was assessed utilising an instrument calibration standard 
(ICS), an unstained sample used to set voltages and mutant gating. During ICS 
analysis, the mutant mimicking sample is utilised to detect auto fluorescence within 
the channel of collection in order to distinguish between a positive event and 
background noise at the channel’s photon multiplier tube (PMT).
EMS dose response data were produced using a FACSAria I cell-sorter ™ (BD 
Biosciences, Hertfordshire, UK) equipped with the standard three, 405 nm 
ultraviolet, 488 nm blue and 635 nm red lasers and the default filter wheel set-up. All 
analyses within this section of work were performed using a standard 70 pm nozzle 
at the manufactures suggested 70 psi pressure. FACS Diva 6.0 software (BD 
Biosciences) was used for operating the cytometer and for data analysis. All 
fluorescence measurements on the FACSAria were recorded using the “FL-Area” as 
well as the “FL-H” parameter; R-PE was assessed within the pre-specified “PE” 
detector, 556 LP combined with a 585/42 band pass filter. PE was excited off the 
488nm laser line, best matching its excitation maxima.
Following flow cytometric analysis, parental cell cultures were removed from 
incubation every 24 hr for repeated PIG-A mutagenesis assessment as described at 
length in (Section 2.10).
4.5.2.3 Gating Strategy Assessment -  Statistical Approach
A number of unstained ICS samples as well as untreated control samples were 
acquired on the flow cytometer and Amnis Image Stream ™ over a period of 14 
days. Untreated samples were stained with anti-CD59 PE antibody and subsequent 
PE emission data was captured following typical 488 nm laser light excitation. 
During flow cytometry acquisition of the ICS, a number of additional data was 
collected including emission data for forward (FSC) and side scatter (SSC), Green 
light emission (FITC) and Orange Light emission (PE) following 488 nm laser 
excitation, Red light emission (APC) post 635 nm laser light excitation and Blue 
light emission (eFluor450) corresponding to 405 nm laser light excitation. Auto
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fluorescence signals within a number of widely distributed detectors were collected 
to facilitate automated robust gating strategy evaluation. Flow cytometry data was 
exported from the BD FACS Aria I in the typical FCS 2.0 or 3.0 (flow cytometry 
standard) format and into tabulated data able to be read by excel using the 
“FCSExtract.app” [27]. A number of statistical approaches were employed within 
the R-software (R-3.0.2, Free Software Foundation’s GNU project) to initially 
evaluate the inter sample variance on the FACS Aria flow cytometer (day 0, 7 and 
14) as well as to generate a number of potential automated gating strategies which 
could be implemented into the in vitro assay design to produce the most reliable, 
reproducible PIG-A mutation data. The graphical outputs were coded by Sion 
Bayliss.
4.5.2.3.1 Methods for Deriving Threshold Values during Reproducible Gating 
Strategy Assessment
Method 1: Mean and Standard Deviation
The threshold value is set at 2* the standard deviation (SD) of the mean for the ICS 
sample, assumes threshold to be 97.5 % of the distribution.
SD = Square root of the average of the squared differences of the values from their 
average value.
Method 2 : Outlier Exclusion
The threshold is set at the maximum value which is determined not to be an outlier, 
as defined by the equation below.
Threshold Value = Quartile 3 + (Interquartile Range * 1.5)
c11 C!2 C13
25% 25% 25% 25%
Interquartile Range = Q3-Q1
Figure 4.5.1. A summary of the quartiles and where they sit in relation to the defined 
data set, figure adapted from [28]
Method 3 : Upper Quartile
The threshold value is set at the 95 % upper quartile of the ICS sample.
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4.5.3 Results
4.5.3.1 “Low Passage” TK6 Cell Line Stability post Genotoxic Exposure and
General Viability
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Figure 4.5.2 Relative Cell Counts (RCC) for Normal (A) and Low Passage (B) TK6 
cellular cultures following 24 hr acute EMS treatment. Vehicle control data (DMSO) 
labelled as “0”, and true untreated controls omitted from graph (N=l).
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Figure 4.5.3. Relative Population Doubling (RPD) for Normal (A) and Low Passage 
(B) TK6 cellular cultures following 24 hr acute EMS treatment. Data displayed as a 
bar chart to emphasize the variations or similarities between recovery periods (N=l).
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Figure 4.5.4. Relative Estimated Generation Time (EGT) for Normal (A) and Low 
Passage (B) TK6 cellular cultures following 24 hr acute EMS treatment. Vehicle 
control data (DMSO) labelled as “0”, and true untreated controls omitted from graph 
(N=l).
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“Low Passage” Epstein-Barr viral transformed TK6 human B-lymphoblastoid cells, 
were further investigated to assess the likelihood of potential beneficial qualities 
including insensitivity to apoptosis when compared to the original “normal” TK6 
stock culture. Initially, simultaneously, parental cultures of both TK6 cell types were 
exposed to acute model mutagen treatment and monitored in terms of cell recovery 
and cell doubling time over the following experimental time period. Particular 
attention was placed on reproducibility and robustness of dose response, both intra 
and inter sample comparable, with a finalised aim to come to a preliminary 
conclusion about potential usage of low passage TK6 cells within the developing in 
vitro PIG-A assay design. However, the variation observed both intra and inter 
sample would be subtle and therefore, limited conclusions can be drawn from the 
data outside of the context of PIG-A assay incorporation.
Initially considering the data from a holistic point of view the generalised trend 
mutually observed within both TK6 cell cultures was a dose dependent decrease in 
cellular viability across the EMS dose range (Appendix 4.5.3.1). The relative cell 
counts (RCC) data demonstrates the overall trend observed within both cultures; 
nevertheless, there is a discrepancy with regards to the cell line recovery from the 
genotoxic treatment. The “Low passage” TK6 culture appear to be more sensitive 
and responded faster than the normal TK6 cultures (Appendix Figures 4.5.2 -  4.5.4) 
as represented by the low dose effect on cytotoxicity and the exaggerated early 
observation of viability concerns, observed at the 24 hr time period, respectively. 
The “Low Passage” TK6 cells display sparse evidence for a lag period immediately 
following genotoxic exposure, compared to the normal TK6 cultures which appear 
unaffected until 48 hr post treatment. An analogous dose response was observed 
within the normal TK6 cultures at the 48 hr time period (Appendix Figure 4.5.2), the 
24 hr sample time appeared to reflect an extended lag period associated with 
genotoxic exposure as illustrated by limited effect on cytotoxicity values. Lower 
doses of EMS appeared to illicit an effect within the “Low Passage” TK6 cells when 
compared to their normal TK6 counterparts, minimal effect was observed with doses 
less than 0.4 |ig/mL within the normal TK6 cells.
The relative population doubling (RPD) data again displayed a generalised 
association between data sets and mimicking the overall trend of the data. However, 
the Low passage TK6 data appeared to be more consistent between dose in terms of
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reproducibility as well as overall trend. The data reflects the early significant 
decrease in cellular doubling times over the initial 24 hr time point, followed by an 
accelerated doubling time, as demonstrated with the rapid increase in population 
doublings between the 24 and 48 hrs (Appendix Figure 4.5.3). Re-establishing the 
typical doubling time of the cell line appears to exceed two cell cycles and additional 
extended time points would be required for more precise definition. The normal TK6 
data is less reproducible in terms of intra dose trends, though still mimics the 
| generalised decrease in population doublings across the dose range. The top doses
I appear to be more highly affected that the low passage TK6 cells, with the top dose
I
observed to display negative growth figures for the 24- 48 hr period. Similarly to the 
I RCC data, the normal TK6 cells population doubling reflects the observed trend in
which they appear relatively unaffected over the initial 24 hr period, where as a dose 
dependent decrease in doubling is observed within the low passage TK6 cells. Doses 
greater than 0.4 pg/mL appeared to decrease population doubling within the normal 
TK6 cultures, as apparent within the 24 -  48 hr experimental period (Appendix 
Figure 4.5.3). However, lower doses appeared to illicit an adverse effect on doubling 
times within the low passage cultures.
I
| The estimated generation time data demonstrated that the top dose (10 pg/mL) illicit
a significant effect on the normal TK6 population in which the cell culture did not 
double over the 24-48 hr period, this is also apparent within the RPD data. As 
previously reported, the low passage TK6 data is more reproducible across the dose 
range, as well as the experimental time period, and clearly demonstrates a correlation 
between extended generation time and increase dose of genotoxin. The normal TK6 
data again reflects this general trend, as apparent within both RCC and RPD data 
sets; however, the data is more variable between experimental time points (Appendix 
Figure 4.5.4).
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Fluorophore emission spectra were assessed for potential spectral overlap to prevent 
ambiguity within the subsequent results. Spectral overlap is the phenomenon in 
which fluorophores, regardless of their excitation frequency, emit subsequent light of 
varying wavelengths which may happen to be of an analogous nature and therefore, 
detected within a single detector. As a result of this, the PMT is unable to clarify the 
origins of the detected photons and the resultant signals become merged within the 
detector as an ambiguous trace. In order to assess the basal viability of low passage 
TK6 cells, viability dyes will be incorporated into the staining protocol to better 
characterise the cells, as previously described in chapter (Section 3.3.5).
The preceding data displays the flow cytometry outputs following the construction of 
a compensation matrix based on single stained cell populations. The use of the dual 
stained sample was to evaluate the successful nature of the matrix, preventing over 
compensation and loss of induced signal detection.
Specimen A displays the flow cytometry data following CD55 R-PE in combination 
with Alexa Fluor 488 ™ Annexin V exposure. The data suggests that limited 
apoptosis was detected within the” FITC” detector and a significant “PE” signal was 
identified reflecting the majority PIG-A wild type population status. Specimen B 
resultant output shows an apparent signal detected within both the “7-AAD” as well 
as “FITC” detectors, corresponding to the dual Staurosporine and ionomycin 
treatments. Specimen C displays positivity within the “7-AAD” and “PE” detectors, 
and defines the limited amount of cell death observed within the nearly exclusively 
PIG-A wild type population. Finally, specimen D was observed to display positivity 
within all three assessed detectors. The compensation matrix generated from the 
single stained experimental samples; PE/FITC 47.5%, FITC/PE 0.4%, APC/PE 0.1% 
and PE/APC 11.7% was evaluated within these results and deemed acceptable for 
use within cell line viability assessment (Appendix Figure 4.5.5).
The establishment of a typical calibration matrix, which fundamentally was utilised 
in the initial preliminary viability assessment (Section 4.3.2), was implemented from 
this point on within the project due to the simultaneous use of similar fluorophores.
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4.5.3.2 Preliminery Linear Dose Response Capture Utilsing both Fluorescence- 
Area and Fluoresence-Height as Potential Descriptors
Simplistic dose response experiments were carried out in order to investigate the 
potential effect logarithmic capture as well as fluorescence area (FL-A) as the 
descriptor for emitted signal has on PIG-A mutant frequencies. Low passage TK6 
cells were treated with EMS and assessed daily for PIG-A mutant frequency utilising 
both the FL-A as well as fluorescence height (FL-H) descriptors. The flow cytometry 
data was initially captured in a linear amplification manner, and descriptors directly 
compared for variance. “PIG-A mutants” are events phenotypic of CD55 absence 
and therefore, are presumptive PIG-A mutants. Experimental design permitted the 
initial capture of 10,000 cellular events, and utilised the FLW measure as an 
additional size descriptor.
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Figure 4.5.6. A,B,C,D and E -  Days 0-4, low passage human lymphoblastoid cells 
(TK6) PIG-A wild type frequency following 24 hr low dose EMS exposure, CD55 
antigen utilised as reporter for mutation. Fluorescence data amplified linearly, 
integration of additional size parameter (FL-W) and a direct comparison between 
FL-A and FL-H sensitivity. (N=l) PIG-A wild type displayed as percentage of total 
single cellular events (99.9% PIG-A wild type = 1 mutant x 10'3 cells).
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Figure 4.5.7 Day 4 FL-A (A) and FL-H (B) PROAST 38.9 modelled low passage 
human lymphoblastoid cells (TK6) PIG-A mutant frequency following 24 hr low 
dose EMS exposure, CD55 antigen utilised as reporter for mutation. Data amplified 
linearly, integration of additional size parameter (FL-W). (N=l) PIG-A mutant 
displayed as percentage of total single cellular events (0.1% PIG-A mutant = 1 
mutant x 10'3 cells).
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Considering the day 0 data, both descriptors (FL-A and FL-H) generate a distinctly 
comparable relationship between the two dose responses. There are no apparent 
significant increases or decreases in the percentage PIG-A wild type with respect to 
dose of EMS, although there is a definite discrepancy between the background PIG- 
A mutant frequencies utilising both methods. FL-A as a descriptor generated an 
approximate spontaneous PIG-A mutant frequency of 0.2%, however, FL-H defined 
a much greater background of approximately 1%, which translates into an 8,000 
difference in number of defined PIG-A mutant events (Appendix Figure 4.5.6). 
Linear amplification capture appears to have little impact on the subsequent flow 
cytometry data as background appears in line with the previously generated data 
utilising CD59 as the reporter for PIG-A mutation (Section 3.3.3).
The day 1 data shows no apparent dose dependent relationship in terms of viable 
PIG-A mutants, however, does mimic the overall trend of FL-H data being more 
variable and having a much greater spontaneous background mutant frequency than 
the comparable FL-A data. The background mutant frequency in general was higher 
than the previous day of analysis and the FL-H background mutant PIG-A frequency 
approached 2.5% with respect to the total single cell population (Appendix Figure 
4.5.6). Day 2 and Day 3 data both display analogous dose responses for both 
descriptors. FL-A is very consistent with respect to the percentage of viable PIG-A 
mutant phenotype cells across the entire dose range, whereas FL-H data is more 
variable and has an increased background mutant frequency (approaching 2.5 and 
2% respectively for days 2 and 3).
Day 4 data is dissimilar in terms of both dose response relationships displayed and 
the background mutant frequency utilising the comparable detectors. FL-A again as 
demonstrated to have a seemingly low background mutant frequency within the 
region of 0.1-0.5%, comparable to the previous preliminary experiments (Section 
3.3.3), however, FL-H also was demonstrated to produce an analogous background 
mutant frequency. FL-A displayed again a consistent non-dose dependent 
relationship in terms of viable PIG-A mutants, but the FL-H data displayed a 
significant increase in the frequency of viable PIG-A mutant phenotype cells at the 
top dose. 10 pg/mL was demonstrated to increase mutant PIG-A frequency by 
approximately xl9  with respect to con-current control values. Significant differences
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were observed between the data generated as a result of descriptor choice, in terms 
of dose response as well as variability.
A direct comparison was made following PRO AST 38.9 modelling of both the final 
day’s analysis data. Even though the data was in singlet and thus the data set highly 
limited, the results reflect the potential variation in subsequent generated BMD value 
due to variance within the background of the collection method. The FL-A descriptorif
I generated a lower background mutant frequency and therefore, a lower BMDio value
1
I (Appendix Figure 4.5.7).
|
Iij
4.5.3.3 Gating Strategy Assessment -  Statistical Approach
During flow cytometry analysis, the maximal auto-fluorescence, or back ground 
noise, is estimated in the detector of interest via the use of an unstained ICS, and is 
subsequently utilised as the limit or definition of positivity. Any signal with a
i
fluorescence emission value greater than the maximum observed ICS value for that 
specific detector is defined as positive. However, due to the variable nature of 
biological data, specific outlying presumed cellular events often have an emission 
value significantly higher than the mean value for the analysed population and 
therefore, result in a skewed non Poisson distributed data set. In order to assess 
potential machine variability, both same day acquisition as well as time course 
assessment was carried out, and evaluate the potential limitations in current gating 
strategy; more specifically its impact on reproducibility, initial preliminary statistical 
investigation was undertaken. All data sets unless otherwise describes consisted of 
>10,000 events presumed single cell in nature.
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Figure 4.5.8.A Average maximum fluorescence emission signal recorded within the 
Phycoerythrin specific detector during unstained, normal TK6, instrument calibration 
standard flow cytometry acquisition at the same time point (Day 0) (>10,000 single 
I cellular events) (Error Bars ±1SD, (-) Average Maximum Fluorescence value
i recorded across all samples) Trend line and equation of the line include on graph.
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Figure 4.5.8.B Average maximum fluorescence emission signal recorded within the 
Phycoerythrin specific detector during unstained, normal TK6, instrument calibration 
standard flow cytometry acquisition at multiple different time points (day 0,7 and 
14) (>10,000 single cellular events) (Error Bars ±1SD, (-) Average Maximum 
Fluorescence value recorded across all samples).
82
Same day acquisition data demonstrated that the variance observed within each 
sample was minimal as illustrated by the relative small standard deviation around the 
means, although the variance between each of the five samples was larger than 
expected. The lowest mean maximum fluorescence value recorded was 347.2, and 
the largest 564.2 with a range of 217 arbitrary units. The average mean fluorescence 
maxima value for this sample set was 490 arbitrary units. A correlation was observed 
between time and arbitrary maximum fluorescence value, as sequential samples 
average value was demonstrated to rise (Appendix Figure 4.5.8.A). Each sample 
was acquired using the identical protocol as well as BD FACS Aria I configurations, 
therefore, preventing unwanted bias within the data.
Time course assessment generated data re-enforced the results taken from the 
previous experiment (Appendix Figure 4.5.8.A). There was a reduced range of 
average mean maximum fluorescence values 84.4 in comparison to 217 arbitrary 
units, and comparable variance between samples collected on different experimental 
days (Appendix Figure 4.5.8.B). Although there was less variance observed between 
data acquired on different days than consecutive acquisition, there was no definite 
consistency to the data. The fluorescence values for the consecutive collection of 
data were much lower when compared to the time course acquisition and the 
previously mentioned increase in average fluorescence value with time appeared to 
be apparent within these data.
4.5.3.3.1 Methods for Deriving Threshold Values during Reproducible Gating 
Strategy Assessment
Fluorescence  In tensity
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Figure 4.5.9. Mean and Standard Deviation (Mean + (2* STD)) (A) Statistical 
Outlier Exclusion (B) and Upper quartile (95%) (C) approaches for evaluating a 
reproducible gating strategy. Data generated using normal untreated TK6 cells; ICS 
sample ([H i) and stained, anti CD59 PE antibody, sample ([ | )  (>10,000 cells 
analysed)(Red vertical line represents the derived threshold value).
Figure 
4.5.11. 
N
orm
al 
TK.6 
unstained 
ICS 
data 
collected 
within 
the 
“PE" 
detector 
for 
the 
arbitrary 
fluorescence 
values 
given. 
A
) 
Forward 
scatter 
(FSC) 
vs 
Side 
scatter 
(SSC), B) 
FSC 
vs 
Relative 
Fluorescence 
and 
C) 
SSC 
vs 
Relative 
fluorescence. >10,000 
cells 
acquired 
and 
-10,000 
single 
cell events analysed.
G r a n u la r i ty
G r a n u la r i ty
'sO y .U\ 21 OQ
$ o 'p
r;
O
V r-fo X
r” y>o C/3
o
o
o
5’
OQ
<—*•
p
zo
2.
c/3
P"
o o»-»
3
p
-i pOo
X o H<—
3’
C/3o 5*ONo ClCL P OoP £
3CL
)
r-f
o
3
5r
c
p
o o ►I
o Cl oC/3oo C/Qo P o
c/3
r-t- p5’ oS ' CfQ oCfQ oC/3o f—^"I 3
o P
2-
r—^o 55’C/3*——**2 I—* •o
< o'C/3
o
p
O CLP(—► > pC/3 S ' p
P
P 2 o1
3L o >-!p
a pC/3
o
CL
p—1
pp
p
c
CL p
*3 C/3 c/3ro P
CL P3 3’<ft) CLP
o
CL
>1a.o’ CL op CL 00l—-* o
pt <_ O
p p Oo r-r TO
o’ oo
1—1
p o
o
o TO CLC/3o
p O
C/3 TO<—>•
p“o
CL
o’►1
o
p ’
r—t
TOoo
<’
X
o *-6
o
CL
p
C/3 m
i-t
o’
P CLo
o
C/3
cr
p
P
CL
<-xo
o
o n oCl •-t
p<
P _ aTO
p
o -
TO p(T) O
>-i
p
p _
X )
c C/3p o
3. CL
o' P ’
Number of Cells
Number of Cells
Number of Cells
85
1600
1400
1200
I  1000u
tj-c
OJ
. c
£
3z
800
600
400
200
500 1000 1500 2000 2500 3000 3500 4000 4500-500
Fluorescence
Figure 4.5.12.A Normal TK6 unstained ICS data collected within the “PE" detector 
for the arbitrary fluorescence values given. >10,000 cells acquired and -10,000 
single cell events analysed ((—) Mean and (--) 2 Standard Deviations)
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Figure 4.5.12.B Normal TK6 unstained ICS data collected within the “PE” detector 
for the arbitrary fluorescence values given. >10,000 cells acquired and -10,000 
single cell events analysed ((—) Median and (—) Outliers (0.75 + (1.5 * IQR))
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The results generated for the mean and standard deviation approach, which assumes 
the threshold value at 97.5 % of the distribution, for defining a threshold value 
indicated that the population of data which were being modelled did not conform to a 
Poisson or Gaussian distribution. Within a normal distribution, 2*standard deviation 
should encompass 97.5 % of the population, however, the skewed data resulted in 
3.7 % of the ICS population being defined as a positive result within the channel of 
interest, i.e. greater than the expected 2.5 %. When this threshold value was taken 
forward onto a stained, untreated sample, 77.5 % of the population was deemed 
positive (Appendix Figure 4.5.9.A and 4.5.10.A), which corresponding well to the 
expected ratio of surface antigen negative cells within the heterogeneous parental 
TK6 population. The stated threshold value derived for this approach was 1.9351 x 
10 . The outlier approach, which assumes the threshold value to be the maximum 
value not considered an outlier, was demonstrated to produce an analogous threshold 
value to the standard deviation method when modelling an identical data set. The 
value defined was 1.7808 xlO3, and resulted in 4.5827 % of the ICS samples being 
defined as positive as well as 77.457 % of the subsequent untreated stained sample to 
be assigned as surface antigen positive (Appendix Figure 4.5.9.B and 4.5.10.B). The 
outlier approach appeared to result in a lower threshold value which subsequently 
resulted in no effect on the overall threshold for positivity within the subsequent 
population analysis. The final approach considered was upper quartile, assuming that 
the value equivalent to the 95 % upper quartile was defined as the threshold, again 
generated highly comparable results. The threshold was defined as 1.7272 x 103 
arbitrary units, which resulted in 4.9986 % of the ICS population being defined as 
positive and 77.4810 % of the subsequent population being defined as positive or 
presumed PIG-A wild type (Appendix Figure 4.5.9.C and 4.5.10.C). The results were 
highly comparable across the three proposed methods, indicating that potentially any 
of these methods could be incorporated into an assay design; however, each method 
did have subtle differences in the final population data.
When considering the location of the defined threshold with respect to the 
distribution of the population, all three methods generated slightly different results. 
As the population data was demonstrated not to be normal and hence, did not fit a 
normal distribution well, the subsequent data set had a positive skew, quite apparent 
within the distribution histograms (Appendix Figure 4.5.10). As a direct result of this
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apparent skew, the approaches which favoured population statistics descriptive of 
normal data, i.e. standard deviation, generated the most poorly fitting threshold 
value. The outlier and upper quartile approach both generated threshold values more 
fitting to the data set provided and subsequently, defined values less than the 
standard deviation approach. As a direct result of this, less of the skewed tail was 
included within threshold derivation and therefore, fitted the data more 
appropriately. The upper 95% quartile approach produced the most favourable 
threshold in terms of data distribution; however, the outlier approach generated a 
highly comparable fit to the data set. The standard deviation method was further 
visually clarified to not be the best fit to the data when the deriving variables, i.e. 
mean and standard deviation were directly compared to the median and outlier 
calculation for the outlier approach (Appendix Figure 4.5.12). The mean is visually 
skewed towards the positive on the x-axis and therefore, the resultant threshold value 
obtained is more inclusive of skew data, as previously stated. The median value 
appears to be much more appropriate for these data set, and the resultant threshold 
value utilising the approaches which incorporate the median value over the mean are 
more robust in terms of potential bias exerted on the population following increase 
or decrease within skewed data.
As well as investigating the reproducibility and fit of a preliminary defined threshold 
value, the fundamentals of flow cytometry, i.e. variance, correlations etc. were also 
evaluated for potential biasing effect on the generated data which potentially could 
influence threshold derivation and robustness. Initially, a preliminary positive 
correlation between sampling time and fluorescence appeared to be apparent within 
the inter/intra machine variability data (Appendix Figure 4.5.8.A). However, when a 
much larger sample set was evaluated, fluorescence value was demonstrated to be 
independent of time, in terms of both correlation and probability (Rho = 0.008, p = 
0.3312), similarly particle size was also demonstrated to be independent of the time 
(Rho = -0.0137, p = 0.0988). Conversely, even though a negative correlation was 
observed when time and granularity were assessed (Rho = -0.0183) a significant 
amount of variance within the data set was attributed to this relationship (p = 0.0267) 
(Appendix Figure 4.5.11). In order to address the potential bias in which the size of 
cells have on fluorescence arbitrary units, a particular worry in the context of cellular 
variability and the effect the cell cycle has on potential PIG-A data, correlation was
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investigated. Initially size (defined by FSC value) and granularity (defined by SSC 
value) were demonstrated to be significantly correlated (Rho = 0.418, p = <0.01), 
about 17.5 % of variation between the samples was explained by this. However, 
when both size and granularity were assessed for correlation against fluorescence 
independently, even though both were defined as significantly correlated (p = 
<0.01), only 0.384% of sample variance was a result of size in comparison to 
19.14% as a result of granularity (Appendix Figure 4.5.11), alluding to the fact that 
granularity or SSC value was more of a potential biasing variable in terms of 
inaccuracies during PIG-A analysis.
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4.5.4 Discussions and Conclusions
4.5.4.1 “Low Passage” TK6 Cell Line Stability post Genotoxic Exposure and
General Viability
“Low passage” TK6 cells were directly compared against the normal TK6 cell stock 
in terms of their cytotoxic response to the known genotoxicant compound EMS. The 
data was initially utilised as a dose finding study for the subsequent preliminary 
PIG-A analysis however, additional discrepancies between the two cell lines were 
identified which could offer some explanation for the variance in data obtained 
utilising homologous genotoxic end points. In general terms, the RCC and RPD data 
generated for both cell lines reflected the overall trend which was to be expected, i.e. 
a dose dependent decrease in cellular viability. However, even though analogous in 
response, subtle variations occurred between like cell stock.
The “Low Passage” TK6 cells were demonstrated to be more sensitive in terms of 
the dose of genotoxic which induced some level of cytotoxic effect, as well as more 
consistent in their response to the dose over a 48 hr time period. There was no 
apparent observation of a lag period following the dose which has become routine 
when using the TK6 cell line [29]. Following the observed discrepancies between the 
low passage and normal TK6 cells in terms of CD59 surface antigen expression, 
their genomic levels of variance is currently unknown, however, they are presumed 
genomically identical. Following typical chemical exposure, in this case EMS, the 
normal TK6 cells were observed to undergo a period of time in which no apparent 
decrease in cytotoxicity is observed. This lag is apparent across the entire dose range 
until a period of approximately 24-48 hr has passed, leading to a dose dependent 
decrease in cell viability, compound specific.
However, the “Low Passage” TK6 cells not only provide different physical and 
morphological growth dynamics, when compared to their “older” counterparts, but 
also demonstrate no lag phase (Appendix 4.5.3.1). This increase in sensitivity, in 
regards to the time period of effect as well as the dose which induced an adverse 
effect on viability is quite different between the two cultures. Potentially, variance in 
one of a number of genes integral within cell cycle regulation, p53 DNA damage
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mediated responses etc. could be the cause of these discrepancies. However, the cell 
line is very consistent in terms of how the cells behave over an extended time period 
following exposure, unlike the previously utilised normal TK6 batch, possibly 
suggesting at a greater level of genomic stability and hence, more effective recovery 
post exposure. More definitive conclusions, apart from stating that on a certain level 
of investigation these cell lines appear different, cannot be drawn without more 
extensive pair-wise genomic analysis.
Establishment of compensation matrices is a fundamental procedure when utilising 
multiple fluorescence dyes with similar emission profiles on a machine capable of 
detecting multiple fluorescence emission signals [30], The resultant compensation 
matrix generated following induced positivity, within control samples, was heavily 
focussed on the “FITC” and “PE” detector channel fluorophores. Due to the nature 
of fluorescence emission, the emission spectra is greater, in terms of wavelength, due 
to the occurrence of a stokes sift and consequently, the subsequent emission may 
partially be located within the neighbouring [31]. In this specific example, the Alexa 
Fluor® 488 dye following excitation falls partially within the band pass filter set up 
utilised to capture “PE” channel data, and therefore, when in combined use with a 
“PE” based fluorophore the Alexa Fluor® 488 signal data was negatively biased to 
reduce/remove any potential cross talk between the fluorophore and the 
neighbouring detector. This method was repeated and a finalised matrix was 
constructed and when applied, the previously demonstrating significant presence of 
the “FITC” signal within the “PE” channel, marginal presence of the PE signal 
within the “APC” channel and negligible presence of the “PE” single within the 
“FITC” channel were all removed. However, two potential inaccuracies were 
identified, firstly, the use of a different laser light to excite the 7-AAD dye, recorded 
within the “APC” detector, should have prevented any noise between the two 
additional detectors due to the physical difference in fibre optic collection, however, 
a noticeable signal overlap was detected (-10%) and secondly, due to the excessive 
induction of signal within the positive controls (Section 4.5.3.1) the resultant matrix 
was quite severe in nature (up to 40% reduction in Alexa Fluor® 488 signal was 
utilised). As a direct result of this, minor signals detected within the FITC channel 
may be indistinguishable from noise due to the bias on the subsequent detector 
sensitivity. However, if a lesser matrix was not to be used, there would be significant
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potential for erroneous false positivity within the “PE” channel signal (Appendix 
4.5.3.1.1).
4.5.4.2 Preliminery Linear Dose Response Capture Utilsing both Fluorescence- 
Area and Fluoresence-Height as Potential Descriptors
Current PIG-A mutant frequnecy assessment is undertaken through 
immunofluorensence staining and subsequent flow cytometry anaylsis. Up to date, 
all the data generated during acquisition has been collected and displayed through a 
logarithmic function [32]. However, there are alternative methods of acquiring the 
data within flow cytomery; traditonally, the majority of fluoresnece data is captured 
via a logarythmic amplifciation and displayed on a log-log or log-linear axis. The 
reason for this is the excessive variability and extensive range in arbitrary 
fluoresence units often observed within a specific sample, therefore a qualitative 
assessment is made. Linear amplification capture is utilised when recording and 
displaying data inwhich a more quantitaitive approach is required. Cell cycle data is 
the most prominent example of such data; the G2/M peak contains twice the nucleic 
acid composition of the G0/G1 peak and therefore, even though arbitrary in nature 
there is a linear relationship which defines distinct values for DNA content [33, 34].
Fluorescence signal emission, post fluorophore excitation, is generally highly 
reproducible, and generates a distinctive bell-shaped curve, analagous to a poisson or 
gaussian distribution. However, following more intrinisic investigation, especially 
prevelent within biological control data, the data is actually not normally distributed 
(shapiro Wilks, P<0.05). The reason for this is a presence of finite outlier events, 
which spike the average fluorescence values, and hence, influence the standard 
deviation providing a poor fit to the data set (Appendix igure 4.5.12). Due to 
variability in outlier fluorescence and number, the definition of positivity, i.e. the 
threshold value is often highly varied between samples. In an attempt to simplify the 
current predicament, and provide increased resolution at the lower region of the x- 
axis, the PIG-A data was assessed using linear acquisition and the possible effect this 
conceivably had on the sensitivity of the overal test system (Appendix 4.5.3.2). In
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additon to this, the actual descriptor of fluorescence was also investigated for 
potential increments in sensitivity. Fluorescence height was trialled as an alternative 
to the typical fluoresence area measure generally used within analysis [12, 35-38]. 
Fluoresence height can be thought of as the maximum amplitude of a fluorescence 
wave signal, and therefore, potentially could provide more definitive separation 
between wild type and presumed PIG-A mutant events, increasing the resolution 
between the two sub populations, which is especially usefull when specific events 
fall at the threshold value for positivity [39].
The resultant data was very intriguing, using the typical FL-A measure, the 
background mutant frequnecy was within the predicted range (0-0.5%); within a cell 
line not enriched for wild type, or alternatively depleted for pre-existing mutants, 
prior to assessment. However, utilsing the FL-H measure, the background was 
significantly higher, and reached a maxima of -2.5% of the total viable population 
(Appendix Figure 4.5.6). As well as appearing to have a distinct effect on the 
presumptive mutant frequency statistics, the final day of analysis demonstrated a 
substantial increase in the number of presuptive PIG-A mutant events (-20%). This 
exaggerated figure was most likely influenced by a limited sample size, but still was 
immesnly variable when compared to the FL-A measure which remained consistent 
(Appendix Figure 4.5.6). Fluorescence area as a measure or descriptor of 
fluorescence signal takes into account the ampltude of the signal as well as duration 
of the signal to be recorded (time of flight). However, fluoresence height, solely 
reflects the maximum amplitude of said fluorescence signal and disregards the time 
taken; hence, is not decriptive of the total properties of the wave. Due to this 
difference in descriptor, FL-H measurements are much more susceptible to increase 
variance within heterogenous populations with no fixed particle shape. The plane of 
the particle at the time of laser illumiunation and subsequent data acquisition is 
highly variable and consequently has a direct effect on the fluorescence signal 
generated.
Consider two cells, one cell is long and thin along the verticle axis and the other, 
identicle however, rotated 90°. The two events have the same fluoresence probe 
intensity and coverage. As each event passes through the path of the laser, during 
excitation, the resultant fluoresence signal appears distinctly different, as the
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orientation of the plane signifcantly affects the amplitude of said signal as well as the 
time of flight measurement. Therefore, the FL-H measurement and the FL-W 
measure are highly variable between the two different cells; however, they have the 
identicle area and therefore, their FL-A values are consitent. Aspect ratio is 
consequently, critical when using FL-H measures to generate comparable data. 
Fluorescence area providers an average signal collected over the entire signal 
duration, FL-H simply measures the maximum amplitude. The conclusion that can 
be drawn for this data is that when utilsing heterogeneous populations of cells with 
no fixed shape or aspect ratio, especially following cytotoxic exposure which may 
induce debris, fluorescence area is a more accurate descriptor; providing more robust 
data, taking into account size and shape desripencies. However, on the contrary FL- 
H and FL-W are therefore, more useful in terms of separation of cells purely based 
on physical orientation and morphology and hence, are utilised extensively to 
remove the presence of debris. Linear capture appeared to have no significant affect 
on the sensitivty and consequential dose respone data following assessment.
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4.5.4.3 Gating Strategy Assessment -  Statistical Approach
Currently, one of the major caveats associated with flow cytometry is the potential 
subjectivity implied within analysis gating; numerous control samples are required 
for correct instrument set up however, their use is highly specific to the fluorophore 
and hence, detector under assay. For example, generally PMT voltages are set 
through the use of an unstained sample and corresponding first quartile signal 
presence. However, when using fluorophores with longer emission wavelength, they 
have correspond less auto-fluorescence, and therefore, their corresponding negative 
signal should fall practically at the zero origin of the scale [39].
Utilising a standard approach of detecting auto-fluorescence within the channel of 
interest, via the use of an unstained calibration standard (ICS), and then using this 
maximum arbitrary value as the threshold for defined positivity; has generated the 
data to this point. However, this approach is subjective in specific cases when outlier 
events with fluorescence arbitrary values corresponding to extremely positive signals 
are observed within the unstained control. Following this method, the threshold is set 
to a corresponding value equivalent to a definitive positive signal and therefore, the 
subsequent PIG-A assessment data is highly obtuse. As well as the potential errorous 
results due to the inclusion of outlier events, due to the physical drawing of the 
threshold gate, retrospective analysis would potentially always result in minor 
variation between the PIG-A data; especially when multiple operators were to 
analyse the same data set.
In an attempt to refine the current threshold gating strategy, as well as identify any 
additional caveats with respect to the use of flow cytometry, three distinct methods 
of statistically deriving a method for defining a reproducible and robust threshold 
were assessed, utilising a shared data set.
Initially, consecutive same day assessment highlighted the variability as to be 
expected within biological samples, however, an additional apparent relationship of a 
correlation between sample time and fluorescence became apparent (Appendix 
Figure 4.5.8.A). This correlation was re-enforced within the time course assessment 
on machine variability, which again reflected biological variability (Appendix Figure
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4.5.8.B). Due to the highly limited sample size, in terms of independent samples 
(N=5), a sample was run over an extended period of time in which >10,000 events 
were plotted with respect to their acquisition time; the resultant data was shown to 
disprove the hypothesised correlation between acquisition time and fluorescence. 
The apparent relationship can be explained by the necessity to warm the lasers fully 
prior to assessment, as a laser warms the voltage required to generate the same signal 
intensity is reduced, hence if the signal voltage is fixed, the resultant fluorescence 
emissions signal will increase until optimum temperature is reached and remain 
consistent.
The three statistical methods were shown to individually generate analogous 
threshold values, when provided with an identical data set (Appendix 4.5.3.3.1). 
However, subtle differences within the values and the effects said differences had on 
the assay design were observed. The initial method of utilising the mean and hence, 
2*standard deviation in order to exclude the upper 2.5% (technically the 97.5 
percentile) was demonstrated to define the highest value in terms of arbitrary 
fluorescence units. However, when assessed for goodness of fit to the data, the 
model was shown to be substandard when compared to the alternative approaches. 
The reason for this is due to the nature of the data, flow cytometry data of this type is 
non-normally distributed and hence, skewed; parametric metrics will poorly fit the 
data. Therefore, even though the alternative approaches utilising the 95% upper 
percentile and outlier exclusion method provided slightly lower threshold values, 
their derivation was based on the median and 95% quartiles and therefore, more 
accurately model the data (Appendix Figure 4.5.12).
Additional relationships were also investigated for correlation via spearman’s Rho 
analysis; size (FSC) and granularity (SSC) were demonstrated to be positively 
correlated, and were also defined to be independently positivity correlated to 
fluorescence (Appendix Figure 4.5.11). Although, only 0.384% of sample variance 
was a result of size in comparison to 19.14% as a result of granularity, alluding to the 
fact that granularity or SSC value was more of a potential biasing variable in terms 
of inaccuracies during PIG-A analysis. Therefore, as a result of this potentially 
smaller (FSC), less granular (SSC) events, such as debris have a large implication as 
presumptive PIG-A mutant mimicking events during data analysis.
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In order to establish a gating system which generates the expected number of 
presumptive PIG-A mutant phenotype cells, as biology dictates, a number of 
different factors must be addressed. Initially a cellular platform with a background 
low enough to be comparable to currently validated in vitro assay systems is 
required, in addition a reproducible, non-subjective gating strategy which solely 
includes single cell events, excluding non-viable as well as debris needs to be 
implemented. When the currently assessed gating strategies were applied to control 
untreated data, -75% of the populations were deemed PIG-A phenotypic wild type, 
however, no additional gating was implemented to remove cells based on size from 
analysis. Therefore, either utilising the outlier or upper 95% upper quartile approach 
to threshold gating in conjunction with a novel gating system to remove cells not 
conforming to the correct FSC and SSC metric should offer an unbiased, robust 
approach to PIG-A analysis.
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Chapter 5: MCL-5 Optimisation, Preliminary Next Generation Sequencing and 
Continued Investigation into the in vitro PIG-A gene mutation assay platform
5.1 Introduction
Throughout confocal laser scanning, a laser beam, generally argon ion, passes 
through a light source aperture and then is focused by an objective lens onto the 
surface of a specimen. In most biological applications the specimen, usually a tissue, 
has some fluorescence properties, generally from the addition of fluorescence 
probes, and subsequent scattered and reflected laser light as well as any fluorescent 
light from the illuminated spot is then re-collected by the objective lens. The 
collected light is separated by a beam splitter, and is passed through one or a number 
of fluorescence filters to allow selective emitted fluorescence light to pass, blocking 
transmitted light, and subsequently be detected. At this stage, the light passes 
through a pinhole, which removes any un-focused light, and provides the confocal 
with its high resolution nature and the light intensity is detected by a photo detection 
device (usually a photomultiplier tube (PMT)) [40].
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5.2 Materials and Methods
5.2.5 Next Generation Sequencing
5.2.5.1 Identification of Target Sequences
Gene of interest target sequences were initially explored using the University of 
Santa Cruz (UCSC) genome bioinformatics browser [41], gene direction, exon 
number and generalised structural features were established. Utilising the promoter 
prediction tool supplied within the UCSC browser, investigating -1000 bp upstream 
of the start codon, guanine and cytosine residues were identified and their respective 
frequencies measured. Combining this information with additional classifiers and 
generalised contextual information for the specific area the browser was able to 
provide a sequence in which it believed encompassed the entire gene of interest and 
upstream promoter region, this was generated using the sequence retrieval tool. The 
generated sequence was cross referenced against a number of different browser 
based programmes, utilising the reference sequence as starting material, in order to 
quality assure the original prediction. Berkley Drosophila Genome Project -Neural 
Network Promoter Prediction [42], Promoter 2.0 Prediction Server [43] and 
SoftBerry -  FPROM [44] assessed the reference sequence and the promoter 
sequences generated were assessed for homogeneity. As an additional quality 
assurance check, Ensembl [45] references were used to confirm exon number and 
gene structure.
5.2.5.2 Sure Select Primer Design for Target Sequences
Following the establishment of a consensus decision about the structure and location 
of a gene of interest target sequence, the subsequent stage was the design of Agilent 
SureSelect oligonucleotide primers corresponding to the region. Primer design 
would be required to span the entire region with sufficient coverage to provide 
confidence and integrity with subsequent next generation sequencing results.
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SureDesign [46] was used to produce a mixture of oligonucleotides which would 
span the gene of interest based on a set of classifiers or parameters fed into the 
browser based application. Initially the species of interest was defined, consensus 
target sequences of the genes of interest bulk inputted and the parameters describing 
the coverage and stringency of the primer location and overlap edited. The browser 
based programme was able to produce primer mixtures for each gene of interest with 
an estimated coverage of >90% and a primer synthesis every 24 bp; all regions not 
claimed to be covered by SureSelect primers were assessed for their location within 
their respective gene of interest using UCSC genome browser [46]. All regions not 
covered by the design process were demonstrated to be intrinsic sequences believed 
to have less impact on protein function and folding than corresponding exonic 
regions.
5.2.5.3 DNA Extraction Pilot of Human Kidney Cells
Following FACS (Section 2.8.3), the purification and extraction of DNA within this 
section of work was carried out using a QIAamp DNA Micro Kit (50) (Cat No. 
56304, Qiagen, Manchester, UK) with a user-adapted protocol supplied by Qiagen. 
Buffers AL, ATL, AW1 and AW2 were prepared according to the instructions given 
in the QIAamp DNA Micro Handbook (page 14) supplied with the corresponding kit 
outlined above, following this, carrier RNA was prepared in buffers AE and AL 
according to the instructions given in the QIAamp DNA Micro Handbook (page 15). 
Carrier RNA (310 pg) was dissolved in 310 pL of Buffer AE and mixed thoroughly 
via pipetting (minimum of 10 times). The dissolved RNA was sequentially diluted 1 
in 99 in Buffer AL and inverted ten times to mix. 1-100 pL of media containing the 
cells under assay were transferred into a 1.5 mL eppendorf, 100 pL of ATL buffer 
was added constructing a final volume of 100 pL. Following this, 10 pL of 
proteinase K and 100 pL of AL buffer were added, eppendorf closed and pulse- 
vortexed at high speed briefly for 15 seconds. Post vortexing, the samples were 
incubated at 56 °C for 10 min -  shaken moderately during incubation -  and briefly 
centrifuged, 50 pL of ethanol (absolute) was added to the eppendorf, mixed 
thoroughly by pulse-vortexing for 15 sec, incubated for 3 min at room temperature
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and centrifuged briefly. The contents of the eppendorf were carefully transferred into 
a QIAamp MinElute ® column, centrifuged (6000 x g for 1 min) and washed with 
500 pL AW1 buffer. The column was centrifuged (6000 x g for 1 min) and washed 
with 500 pL of buffer AW2, followed by an additional homologous centrifugation. 
Pot washing in AW buffers, the column was centrifuged (20,000 x g for 3 min) to 
dry the membrane and 20-100 pL of AE buffer or distilled water was added. The 
columns were incubated at room temperature for 1 min, centrifuged (20,000 x g for 1 
min) and flow through collected within a clean sterile collection tube. The resultant 
isolated DNA was quantified using the NanoDrop ND-1000 Spectrophotometer 
(Section 4.2.5.2.2) and Qubit ® 2.0 Fluorometer (Life ™ Technologies, Paisley, UK) 
apparatus.
5.2.5.4 Qubit ® 2.0 Fluorometer Protocol
RNA and DNA yield estimation and integrity analyses were carried out using a 
NanoDrop (Appendix Section 5.2.5.3) and Qubit ® 2.0 Fluorometer apparatus. The 
Qubit ® 2.0 fluorometer was used in line with supplied manufacture’s standards and 
protocol; briefly, standards (#1, 2 and 3) were loaded into the machine, read 
sequentially, and were used to construct a calibration curve (concentration vs. 
fluorescence). Working solution, supplied within the Qubit ™ HS assay kit (Cat. 
No. Q32851, Life ™ technologies, Paisley, UK), was added, allowed to incubate for 
2 min, at room temperature, to the extracted DNA samples. Post incubation, samples 
were inserted into the machine, sequentially, and their corresponding fluorescence 
read in order to determine DNA yield. Original concentration of DNA (pg/pL) was 
back calculated via the known amount of Qubit ™ working solution added to each 
sample.
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5.2.5.5 Next G eneration Sequencing Overview
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Figure 5.1. Overall schematic of SureSelect Target Enrichment and subsequent 
Illumina Paired-End MiSeq sequencing of target specific regions. Amended protocol 
adapted from the supplied SureSelect Protol.pdf (Agilent Technologies, Wokingham, 
UK). Deviation from the hybrid capture system utilising SureSelect capture library 
and magnetic bead enrichment, major work flow amendments, key stages 
highlighted in red.
5.2.5.6 Covaris Sonication Method
The Qubit ® 2.0 fluorometer was used as outlined in (Section 5.2.5.4) to determine 
the concentration of the gDNA samples extracted from the FACS MCL-5 cells 
(260/280 absorbance ratios monitored for integrity). 200 ng of starting DNA was 
diluted with 1 X TE buffer in a 1.5 mL LoBind Tube (Cat No. 022431021, 
Eppendorf, Hamburg, Germany) to a total volume of 50 pL. The contents of the 
LoBind tube was transferred into a Covaris microTube, placed within the loading 
station and the Covaris M220 Focused-ultrasonicator ™ (Covaris, Massachusetts,
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USA), recently serviced and refilled, set to 360 sec of treatment time, 200 cycles per 
burst and bathing temperature of 4-8 °C. Post sonication, a pipette was inserted 
through the pre-split septa and the sheared DNA removed and subsequently 
transferred into a sterile 1.5 mL LoBind Tube. Optional quality assurance performed 
on a 2100 Bioanalyzer (Agilent Technologies, Wokingham, UK) can be carried out 
at this stage to ensure effective DNA shearing has occurred, a single maximum peak 
between 120-150 bp in length should be observed.
5.2.5.7 End Repair -  Blunt Ended dsDNA Construction
Using the SureSelect Library Prep Kit (ILM) a master mix was prepared containing 
the following (Nuclease free water 35.2 pL, lOx End Repair Buffer 10 pL, dNTP 
Mix 1.6 pL, T4 DNA Polymerase 1 pL, Klenow DNA Polymerase 2 pL and T4 
Polynucleotide Kinase 2.2 pL). 48 pL of the DNA sample was aliquotted into a fresh 
tube, 52 pL of master mix was added, mixed thoroughly (vortexing) and incubated 
for 30 min at 20 °C -  constructing blunt ended double stranded DNA molecules.
5.2.5.8 5’ Adenine Overhang Construction
Continuing with the use of the SureSelect Library Prep Kit (ILM) a second master 
mix was constructed for the 5’ addition of adenine for subsequent paired end adapter 
ligation. The master mix contained, Nuclease free water 11 pL, 10X Klenow 
Polymerase Buffer 5 pL, dATP 1 pL and Exo(-) Klenow 3 pL and was added to 30 
pL of DNA blunt-ended sample and consequently, incubated for 30 min at 37°C.
5.2.5.9 Adapter Ligase and Amplification
Next SureSelect Adapter Oligo Mix was diluted 1:10 in nuclease free water, and 
used to construct a master mix containing (nuclease free water 15.5 pL, 5X T4 DNA 
Ligase Buffer 10 pL, Diluted SureSelect Adaptor Oligo Mix 10 pL and T4 DNA 
ligase 1.5 pL. 37 pL of master mix was added to 13 pL of DNA, mixed thoroughly,
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and incubated at 20 °C for 15 min. During the incubation, the adaptor was ligated to 
the newly formed dsDNA, with 5’ adenine over hangs, prior to amplification, the 
following kits and reagents were used; SureSelect Library Prep Kit ( E L M ) ,  
SureSelect Target Enrichment Kit (ILM) indexing Hyb Module Box #2 and 
Herculase II Fusion DNA Polymerase (Agilent Technologies, Wokingham, UK). 
The first master mix to be constructed contained, nuclease free water 6 pL, 
SureSelect Primer 1.25 pL, SureSelect ILM Indexing Pre Capture PCR reverse 
primer 1.25 pL, 5X Herculase II Rxn Buffer 10 pL, 100 mM dNTP mix 0.5 pL and 
finally, Herculase II Fusion DNA polymerase 1 pL. 20 pL of master mix was added 
to 30 pL of the sample DNA, mixed by pipetting placed within the T100 thermal 
cycler (Bio-Rad, Hertfordshire, UK) and run.
5.2.5.10 Thermal Cycler Amplification Programme
Step 1 98°C 2 min 
Step 2 98 °C for 30 sec 
Step 3 65 °C for 30 sec 
Step 4 72 °C for 1 min
Step 5 -  Repeat Step 2 through step 4 for a total of 16-20 times 
Step 6 72 °C for 10 min 
Step 7 4 °C hold.
5.2.5.11 Sample Purification using Agencourt AMPure XP Beads
AMPure XP beads (Cat No. A63882, Beckman Coulter, High Wycombe, UK) were 
warmed to room temperature, mixed until homogenous in nature, 90 pL of the beads 
were added to a 1.5 mL LoBind tube containing -50 pL of the previously amplified 
library. The contents of the tube were mixed well, via vortexing and incubated at 
room temperature for 5 min. The tube was then transferred into a magnetic stand, 
solution was allowed to clear (3-5 min) and clear supernatant discarded. 500 pL of 
70% ethanol (Sigma Aldrich, Gillingham, UK) was added to the tube, incubated for 
1 min and then removed -  this wash step was repeated an additional time. The tube
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was then transferred into a centrifuge, spun briefly and returned to the magnetic 
stand for 30 seconds, any residual ethanol was removed at this point via a pipette. 
The samples were then transferred to a heating block and dried (37°C) for 5 min until 
all residual ethanol completely evaporated. 30 pL  of nuclease-free water was added, 
mixed well via vortexing and incubated at room temperature for 2 min. The tube was 
replaced back into the magnetic stand, incubated for 2-3 min until supernatant turned 
clear and then the supernatant was transferred into a fresh sterile LoBind 1.5mL tube 
(-30  pL). At this point an additional quality assurance step utilising a 2100 
Bioanalyzer System and DNA 1000 Assay (Agilent Technologies, Wokingham, UK) 
can be undertaken, a single peak of approximately 225-275 bp should be observed.
5.2.5.12 Hybridisation
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Figure 5.2. SureSelect Target Enrichment System Capture Process. Post 
amplification, prepped library becomes integrated with SureSelect biotinylated baits 
(capture library), which sequentially can be enriched for by the external presence of 
a magnetic field following the addition of streptavidin coated magnetic beads. Beads 
can be eluted and the resultant enriched target sequences sequenced.
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The hybridisation reaction required 750 ng of DNA in a maximum volume of 3.4 
|j.L, if the concentration of the prepped sample was too low then the use of a vacuum 
concentrator was permitted. Hybridisation buffer was constructed via the addition of 
the following components; SureSelect Hyb#l 25pL, SureSelect Hyb#2 1 pL, 
SureSelect Hyb#3 10 pL and SureSelect Hyb#4 13 pL -  if precipitation formed the 
buffer was warmed to 65°C for 5 min.
Within a PCR plate (Greiner-Bio One, Gloucestershire, UK) the SureSelect capture 
Library mix was prepared for target enrichment; for each sample 2-5 pL of 
SureSelect Library was pipetted into a well, 5-2 pL of pre-diluted SureSelect RNase 
Block was added, mixed thoroughly in order to construct a final volume of 7 pL.
SureSelect Block mix was then constructed, consisting of SureSelect Indexing Block 
#1 2.5 pL, SureSelect Block #2 2.5 pL and SureSelect Indexing Block #3 0.6 pL. 3.4 
pL of 221 ng/ pL of prepped library was added to row B of a fresh 96 well PCR 
plate, 5.6 pL of SureSelect Block Mix was added to each well within row B, and 
mixed thoroughly. Row B wells were sealed with caps and the plate transferred into 
a T100 thermal cycler, heated for 5 min at 95°C and held at 65°C. The plate was held 
at 65°C whilst 40 pL of hybridization buffer was added to each well of row A, the 
row was sealed with strip caps and kept at 65°C for 5 min. The capture library mix (7 
pL) was then added to the row C of the same PCR plate, the row was sealed with 
strip caps and incubated at 65°C for 2 min.
The plate was maintained at 65°C, whsilst 13 pL of hybridisation buffer from row A 
was added to the capture library mix in row C and mixed thorughly. The contents of 
row B (prepped library) was then transferred into the hydridisation solution within 
row C and mixed well by pipetting up and down a minimum of ten times (-27-29 pL 
total volume). Wells were sealed with new strip cap to maintain intregirty of the 
seals and incubated for 16-24 hr at 65 °C.
106
5.2.5.13 Magnetic Bead Enrichment of Target Sequence
Dynabead MyOne Streptavidin T1 solution was vigorously re-suspended on a 
vortex, at high speed, to prevent bead settling. 50 pL of Dynabeads were added to a
1.5 mL LoBind tube for reach hybridisation. 200 pL of pre-warmed (65°C) 
SureSelect Binding Buffer was added to the magnetic beads, mixed on a vortexer for 
5 seconds and the tubes transferred into a Dynal magnetic separator (Life ™ 
technologies, Paisley, UK). The tubes were allowed to stay within the magnet for a 
number of minutes, and the supernatant removed and discarded -  this step was 
repeated for a total of 3-4 washes, with a final re-suspension of the beads within 200 
pL of SureSelect Binding Buffer. Following the volume of hybridization solution 
being measured, excess evaporation can result in sub optimal capture conditions; the 
hybridisation solution was transferred directly into the bead solution mixed 
thoroughly via tube inversion. The mixture was incubated for 30 min at room 
temperature under rolling conditions, centrifuged briefly and placed within a 
magnetic separator. The supernatant as removed following a 3 minute incubation 
period within the magnet, and the beads re-suspended in 500 pL of SureSelect Wash 
1. The samples were vortexed, and incubated for 15 min at room temperature, before 
being centrifuged and replaced within the magnetic separator to remove the 
supernatant. Post supernatant aspiration the beads were re-suspended in 500 pL of 
pre-warded (65°C) SureSelect Wash 2, vortex mixed for 5 sec and incubated for 10 
min at 65°C within a temperature controlled water bath. Post incubation, the samples 
were briefly centrifuged, supernatant aspirated following magnetic separation and 
washed an additional 3 times with SureSelect Wash 2 solution. Following washing, 
the beads were re-suspended in 30 pL of nuclease-free water on a vortex mixer.
5.2.5.14 Addition of Index Tags by Post Hybridisation Amplification
The reaction mix was prepared as follows, mixed thoroughly and stored on ice ready 
for future use, 5x Herculase II Rxn Buffer 10 pL, 100 mM dNTP Mix 0.5 pL, 
Herculase II fusion DNA polymerase 1 pL and SureSelect ILM indexing Post
107
capture forward PCR primer 1 pL. 35 pL of the reaction mix was transferred into a 
fresh tube or well within a 96 well plate, 1 pL of the appropriate PCR Primer Index
1-16 was also added and the contents mixed thoroughly. 14 pL of the DNA, post
magnetic bead enrichment, was added to each well or tube and placed within a T100 
thermal cycler.
5.2.5.15 PCR programme for Amplification Post Capture
Step 1 98°C 2 min 
Step 2 98 °C 30 sec 
Step 3 57 °C 30 sec 
Step 4 72 °C 1 min
Step 5 Repeat steps 2 -  4 for a total of 12-16 times 
Step 6 72 °C 10 min 
Step 7 4 °C Hold
*The number of cycles depends upon the capture size of the target sequences, lkb -  
0.5 MB (16 cycles), 0.5 Mb -  1.49 Mb (14 cycles), >1.5 MB (12 cycles) and All 
exon (10-12 cycles).
5.2.5.16 Sample Purification using Agencourt AMPure XP Beads
AMPure XP beads were warmed to room temperature, mixed until homogenous in 
nature, 90 pL of the beads were added to a 1.5 mL LoBind tube containing -50 pL 
of the previously amplified post capture library. The contents of the tube were mixed 
well, via vortexing and incubated at room temperature for 5 min. The tube was then 
transferred into a magnetic stand, solution was allowed to clear (3-5 min) and clear 
supernatant discarded. 500 pL of 70% ethanol (Sigma Aldrich, Gillingham, UK) was 
added to the tube, incubated for 1 min and then removed -  this wash step was 
repeated an additional time. The tube was then transferred into a centrifuge, spun 
briefly and returned to the magnetic stand for 30 seconds, any residual ethanol was 
removed at this point via a pipette. The samples were then transferred to a heating
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block and dried (37°C) for 5 min until all residual ethanol completely evaporated. 30 
pL of nuclease-free water was added, mixed well via vortexing and incubated at 
room temperature for 2 min. The tube was replaced back into the magnetic stand, 
incubated for 2-3 min until supernatant turned clear and then the supernatant was 
transferred into a fresh sterile LoBind 1.5mL tube (-30 pL). At this point an 
additional quality assurance step utilising a 2100 Bioanalyzer System and DNA 1000 
Assay (Agilent Technologies, Wokingham, UK) can be undertaken, a single peak of 
approximately 250-350 bp should be observed.
5.2.5.17 QPCR -  Quantity Assessment of Index Tagged Amplified Library
QPCR NGS Library Quantification Kit (Illumina) (Cat No. G4880A, Agilent 
Technologies, Wokingham, UK) was used to determine the concentration of the 
concentration of each index-tagged captured library. A calibration or standard curve 
was prepared via the use of the supplied quantification standards included in the kit, 
according to the instruction provided in the user guide. The index-tagged captured 
library were subsequently diluted in nuclease free water in order to fall within the 
standard curve range, this generally I in the range g a 1:1000 -  1:10,000 dilution of 
the captured DNA. The master mix was prepared, including the Illumina adaptor 
specific PCR primers, and added to the template DNA. Using a QPCR system, for 
example iCycler IQ5 (BioRad, Hertfordshire, UK), the thermal profile outlined 
within the instruction manual supplied was run in combination with the SYBR green 
instrument settings, in order to facilitate the quantification of each unknown index- 
tagged library.
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5.2.5.18 Sample Pooling for Multiplex Sequencing
5.2.5.18.1 Volume of Index Equation
V (f) x C (f)
Volume of Index = -----------------------------
# x C(i)
Where,
V(f) is the final desired volume of pool
C(f) is the desired final concentration of the entire DNA in the pool, for example 10 
nM for Illumina.
# is the number of index
C(i) is the initial concentration of each index sample.
Each library was combined such that each index-tagged sample is present in 
equimolar amounts within the pool, 1 X Low TE buffer was added to each pool in 
order to standardise the final volume.
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5.2.5.19 Sequencing on the MiSeq ™
5.2.5.19.1 Illumina Reagent Preparation and MiSeq™ Set Up
The flow cell was initially inspected and cleaned thoroughly before use as outlined 
in detail within the MiSeq System User Guide, the cartridge was removed from - 
20°C storage and placed within a temperature controlled water bath filled with 
deionised water (~25°C). The cartridge thawed for approximately 60-90 min, was 
tapped dry onto tissue paper and inverted ten times to thoroughly mix the 
components. The cartridge was placed on the bench and tapped to reduce air bubbles 
within the reagent and stored on ice until ready for future use.
5.2.5.19.2 Illumina MiSeq ™ Reagent Cartridge
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Figure 5.3. The illumina MiSeq ™ Reagent Cartridge. The Cartridge is supplied 
prefilled with each well labelled with the corresponding well contents. Well 17 is the 
well designated to accept the pooled prepared denatured DNA sample for high 
resolution sequencing.
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5.2.5.19.3 Denaturation and Dilution for MiSeq ™ Sequencing
Fresh NaOH was prepared in the following manor in advance of the denaturation 
process , 200 pL of 1M NaOH was added to 800 pL of laboratory grade dH20 -  it is 
important to maintain the concentration of NaOH equal to 0.2 M in the denaturation 
solution and not more than 1 mM in the final solution post diluting with HT1 buffer. 
4 nM of DNA, within a total volume of 5 pL, was added to 5 pL of 0.2 M NaOH, 
vortexed briefly and centrifuged (280 x g for 1 min). Post centrifugation, the solution 
was incubated for 5 min at room temperature to denature the DNA into single 
strands. 990 pL of pre-chilled HT1 buffer was added to the denatured DNA solution 
and placed on ice ready for future use. Additional HT1 buffer was added at this point 
in order to dilute the 20 pM denatured DNA into appropriate concentrations, inverted 
briefly and then loaded directly within the MiSeq reagent cartridge (PhiX controls 
were simultaneously constructed in an analogous manor).
5.2.5.19.4 MiSeq ® Next Generation Sequencing (NGS)
The Illumina MiSeq® was loaded, set up and cleaned according to the Illumina 
MiSeq® system user guide, the MiSeq control software (MCS) was launched 
simultaneously and from the on screen user guided interface Sequence” selected. 
Following the sequence selection, the machine begins the run setup steps and 
prompts the user through the next generation sequencing process. Real time analysis 
of run efficiency and progress was carried out on an adjacent personal computer 
running Sequence Analysis Viewer (SAV) software (Illumina, San Diego, UK), a 
post run-wash using laboratory grade dH20 mixed with Tween20 was carried out 
following the successful run.
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5.3 Results
5.3.1 Trialled usage of HLA-DR staining to validate single marker PIG-A dose 
response data within MCL-5 cells
E2-CED:y=a*exp(bx) E 1:y= a
o bgfik -22.31
MNU CEO- 4.51
b: 0.02114
oonv : 1
d type : 1m
ci
CEOU 7.772
OO
o.o 0.5 1.0
Iog10-dose
1.5
<
CD 
CLd)
o> 
_o
voslon: 38.8 
logNh -14.79 
«T- 0.230
2,4 DNP(N
O
scaling factor on x : 1 
*yp»: 1
selected: a l
O
o
<N
9
CO
9
1.2 1.4 1.B 1.8 2.0
log10-dose
2.2 2.4
E2-CED: y=  a*exp(b>0 E 1 :y = a
ENUCOb
scaftng factor on x : 1 
dtyp* : 1
o
CN
<  o
O
Q .
S O
CN
9
9
CO
9
2.0 2.51.0 1.5
EMS
CO
o
toiling f lotor on x :
O
<
CD
CLd> CN 'o) CD o
CDCD
CN
9
0.0 0.5 1.0 1.5 2.0
log10-dose Icg10-dose
Figure 5.4 Day 4, low passage human lymphoblastoid cells (M CL-5) average 
relative phenotypic PIG-A mutant frequency following 24 hr M NU, 2,4 DNP, EMS 
and ENU exposure PROAST data, CD59 antigen utilised as reporter for mutation. 
BMDio (CEDio) and confidence intervals (CEDLio and CEDUio) derived following 
statistical modelling
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5.3.5 Next Generation Sequencing
initially, considering the PIG-A gene inclusive amplicon, there appears to be a basal level of 
coverage, the total number of reads covering a single nucleotide, across the majority of the 
^mplicon (Figure 5.5 AI, All). The basal read depth is approximately 5-10,000 reads per 
nucleotide, however, there are also areas across the amplicon with significantly higher read
i'
plepth, >200,000 reads. Single nucleotide polymorphisms (SNP) variants were called across
s
|he entire sequence (5287) (Appendix Section 5.3.5.1), with evidence indicative of specific 
plustering (Figure 5.5 and 5.6). An apparent relationship between SNP variant frequency and 
pie total number of reads at a specific nucleotide was observed, when grossly exceeding the
threshold of basal coverage. Therefore, maximum read depth was capped to ensure
i-
ptandardisation and alignment integrity during graphical analysis; 45 insertion and deletion 
mutations (indels) were also identified across the amplicon.
j.
i
\Vhen focussing on the specific PIG-A gene region, it was apparent that the majority of called 
fJNPs were located outside of exonic coding regions (4972), however, the SNPs which did 
fall within the exons (315, 5.95%) displayed corresponding high variant frequencies,
I
particularly in exon 6. All exonic regions demonstrated some level of mutational activity, 
pxcept exon 1, which is the smallest of all the coding regions within the gene (Appendix
Section 5.3.5.1). SNPs were demonstrated to be both synonymous and non-synonymous in
1
\
nature, with few proving to result in a nonsense mutation (Figure 5.6). The most frequent 
mutational variant identified within the PIG-A inclusive amplicon was supportive of the 
primary mutagenic mode of action induced by the EMS treatment, a GC-AT transition 
mutation, encompassing 27% of the total SNPs (Appendix Section 5.3.5.1).
The PIG-T inclusive amplicon was demonstrated to exhibit SNPs variants (16,141) and indels
(132) across the entire sequence, with significant evidence indicative of specific clustering
outside of the coding exonic regions (Figure 5.7). When focussing on the PIG-T gene region,
it was apparent that the majority of called SNPs were located outside of exonic coding
regions (16,137); only 0.02% of the SNPs fell within the exons (4). The majority of the
sxonic regions demonstrated no level of mutational activity, except exon 10 and 12
(Appendix Section 5.3.5.2) SNPs again were demonstrated to be both synonymous and non-
synonymous in nature, with none proving to result in a nonsense mutation. The most frequent
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mutational variant identified within the PIG-T inclusive amplicon was again the GC-AT 
xansition mutation, encompassing 25.9% of the total SNPs.
The CD59 inclusive amplicon was demonstrated to display SNPs variants across the entire
I
sequence (14,071), with again significant evidence indicative of SNP clustering outside of the 
:oding exonic regions; 121 indels were also identified (Figure 5.8). When focussing on the 
CD59 gene region, the majority of called SNPs were located outside of exonic coding regions 
[13,618). Exons 1, 2 and 6 displayed some evidence of mutational activity (3.2% of total 
SNPs (Appendix Section 5.3.5.3) in which SNPs again were demonstrated to be both 
synonymous and non-synonymous in nature, with few proving to result in a nonsense 
mutation. Similar to both the previously assessed genes regions, the most common mutational 
variant identified within the CD59 inclusive amplicon was again the GC-AT transition 
|nutation, encompassing 23.7% of the total SNPs.
finally, the CD55 inclusive amplicon displayed an analogous pattern to all the comparative 
amplicons assessed in terms of SNP (13,166) and indels (106) identification. However, not a
r
single SNP was located within the coding exonic regions (0, 0% (Appendix Section 5.3.5.4)). 
When focussing on the CD55 gene region, the entirety of called SNPs were located outside ofI
pxonic coding regions, falling within the introns (Figure 5.9). However, again, similar to all 
he previously assessed genes regions, the most common mutational variant identified within 
he CD55 inclusive amplicon was again the GC-AT transition mutation, encompassing 23.9% 
of the total SNPs.
t
The PIG-A gene inclusive amplicon demonstrated the highest level of exonic mutational
f
activity, 5.95%, when directly compared to all of the other amplicons. Even though the PIG- 
4 gene didn’t display the greatest total number of called variants, it’s significantly smaller 
length (-16 kb) than the CD59 (33 kb) gene for example can account for this. All genes 
assessed resulted in the GC-AT transition mutation as the consensus for most common 
variant, which matches the mechanism of the treatment chemical (Appendix Section 5.3.5).
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Table 5.1 - Summary o f the SNP data generated fo r  the entire PIG-A gene inclusive 
amplicon.
Percentage of 
Total Variants
A Allele Variants 2078 39.30395309
C Allele Variants 937 17.7227161
G Allele Variants 968 18.30905996
T Allele Variants 1304 24.66427085
Total Number of SNPS 5287 100
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 199 20.41025641 3.76394931
AT-GC 694 71.17948718 13.12653679
AT-TA 82 8.41025641 1.550974087
Total 975 100 18.44146019
CG-AT 375 23.11960543 7.092869302
CG-GC 160 9.864364982 3.026290902
CG-TA 1087 67.01602959 20.55986382
Total 1622 100 30.67902402
GC-AT 1438 87.15151515 27.19878948
GC-CG 77 4.666666667 1.456402497
GC-TA 135 8.181818182 2.553432949
Total 1650 100 31.20862493
TA-AT 265 25.48076923 5.012294307
TA-CG 661 63.55769231 12.50236429
TA-GC 114 10.96153846 2.156232268
Total 1040 100 19.67089086
Total 5287 Total 1 0 0
Indels 45
Table 5.2 - Summary of the SNP data generated fo r Exon 2 of the PIG-A gene region.
Percentage of 
Total 
Variants
A Allele Variants 9 14.0625
C Allele Variants 21 32.8125
G Allele Variants 2 0 31.25
T Allele Variants 14 21.875
Total Number of 
SNPS 64 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 3 33.33333333 4.6875
AT-GC 5 55.55555556 7.8125
AT-TA 1 1 1 .1 1 1 1 1 1 1 1 1.5625
Total 9 100 14.0625
CG-AT 2 9.523809524 3.125
CG-GC 5 23.80952381 7.8125
CG-TA 14 66.66666667 21.875
Total 21 100 32.8125
GC-AT 17 85 26.5625
GC-CG 2 10 3.125
GC-TA 1 5 1.5625
Total 2 0 100 31.25
TA-AT 1 7.142857143 1.5625
TA-CG 12 85.71428571 18.75
TA-GC 1 7.142857143 1.5625
Total 14 100 21.875
Total 64 Total 1 0 0
Table 5.3 - Summary of the SNP data generated for Exon 3 of the PIG-A gene region
Percentage of 
Total 
Variants
A Allele Variants 1 1 1 .1 1 1 1 1 1 1 1
C Allele Variants 4 4 4 .4 4 4 4 4 4 4 4
G Allele Variants 3 33.33333333
T Allele Variants 1 1 1 .1 1 1 1 1 1 1 1
Total Number of 
SNPS 9 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 0 0 0
AT-GC 0 0 0
AT-TA 1 100 1 1 .1 1 1 1 1 1 1
Total 1 10 0 1 1 .1 1 1 1 1 1 1
CG-AT 1 25 1 1 .1 1 1 1 1 1 1
CG-GC 1 25 1 1 .1 1 1 1 1 1 1
CG-TA 2 50 2 2 .2 2 2 2 2 2 2
Total 4 10 0 44.4444444
GC-AT 1 33.33333333 1 1 .1 1 1 1 1 1 1
GC-CG 2 66.66666667 2 2 .2 2 2 2 2 2 2
GC-TA 0 0 0
Total 3 100 33.3333333
TA-AT 0 0 0
TA-CG 1 10 0 1 1 .1 1 1 1 1 1 1
TA-GC 0 0 0
Total 1 10 0 1 1 .1 1 1 1 1 1 1
Total 9 Total 1 0 0
Table 5.4 - Summary of the SNP data generated for Exon 4 of the PIG-A gene region
Percentage of 
Total 
Variants
A Allele Variants 0 0
C Allele Variants 0 0
G Allele Variants 4 80
T Allele Variants 1 2 0
Total Number of 
SNPS 5 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 0 0 0
AT-GC 0 0 0
AT-TA 0 0 0
Total 0 0 0
CG-AT 0 0 0
CG-GC 0 0 0
CG-TA 0 0 0
Total 0 0 0
GC-AT 3 75 60
GC-CG 0 0 0
GC-TA 1 25 2 0
Total 4 100 80
TA-AT 0 0 0
TA-CG 1 100 2 0
TA-GC 0 0 0
Total 1 100 2 0
Total 5 Total 1 0 0
Table 5.5 - Summary of the SNP data generated fo r Exon 5 of the PIG-A gene region
Percentage of 
Total 
Variants
A Allele Variants 8 42.10526316
C Allele Variants 5 26.31578947
G Allele Variants 3 15.78947368
T Allele Variants 3 15.78947368
Total Number of 
SNPS 19 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 0 0 0
AT-GC 8 100 42.10526316
AT-TA 0 0 0
Total 8 10 0 42.10526316
CG-AT 1 2 0 5.263157895
CG-GC 0 0 0
CG-TA 4 80 21.05263158
Total 5 100 26.31578947
GC-AT 3 100 15.78947368
GC-CG 0 0 0
GC-TA 0 0 0
Total 3 100 15.78947368
TA-AT 1 33.33333333 5.263157895
TA-CG 2 66.66666667 10.52631579
TA-GC 0 0 0
Total 3 1 00 15.78947368
Total 19 Total 1 0 0
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Table 5.6 - Summary of the SNP data generated fo r  Exon 6 of the PIG-A gene region
Percentage of 
Total 
Variants
A Allele Variants 49 22.47706422
C Allele Variants 55 25.2293578
G Allele Variants 69 31.65137615
T Allele Variants 45 20.64220183
Total Number of 
SNPS 218 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 5 10.20408163 2.293577982
AT-GC 33 67.34693878 15.13761468
AT-TA 11 22.44897959 5.04587156
Total 49 100 22.47706422
CG-AT 16 29.09090909 7.339449541
CG-GC 5 9.090909091 2.293577982
CG-TA 34 61.81818182 15.59633028
Total 55 100 25.2293578
GC-AT 51 73.91304348 23.39449541
GC-CG 7 10.14492754 3.211009174
GC-TA 11 15.94202899 5.04587156
Total 69 100 31.65137615
TA-AT 13 28.88888889 5.963302752
TA-CG 23 51.11111111 10.55045872
TA-GC 9 20 4.128440367
Total 45 100 20.64220183
Total 218 Total 100
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Table 5.7- Summary of the SNP data generated for the entire PIG-T amplicon.
Percentage of 
Total Variants
A Allele Variants 6286 38.94430333
C Allele Variants 3350 20.75460009
G Allele Variants 3007 18.62957685
T Allele Variants 3498 21.67151973
Total Number of SNPS 16141 100
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total
SNPs
AT-CG 678 21.51697874 4.200483241
AT-GC 2160 68.54966677 13.3820705
AT-TA 313 9.933354491 1.939161142
Total 3151 100 19.52171489
CG-AT 1106 24.51784527 6.85211573
CG-GC 533 11.81556196 3.302149805
CG-TA 2872 63.66659277 17.79319745
Total 4511 100 27.94746298
GC-AT 4180 87.61265982 25.89678459
GC-CG 278 5.826870677 1.722322037
GC-TA 313 6.560469503 1.939161142
Total 4771 100 29.55826777
TA-AT 1000 26.96871629 6.195403011
TA-CG 2394 64.5631068 14.83179481
TA-GC 314 8.468176915 1.945356545
Total 3708 100 22.97255436
Indels 132
Total 16141 Total 100
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Table 5.8 - Summary of the SNP data generated fo r Exon 10 of the PIG-T gene
region.
Percentage of 
Total Variants
A Allele Variants 1 0
C Allele Variants 0 0
G Allele Variants 0 0
T Allele Variants 0 0
Total Number of 
SNPS 1 0
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 0 0 0
AT-GC 0 0 0
AT-TA 0 0 0
Total 0 0 0
CG-AT 0 0 0
CG-GC 0 0 0
CG-TA 0 0 0
Total 0 0 0
GC-AT 1 100 100
GC-CG 0 0 0
GC-TA 0 0 0
Total 1 100 100
TA-AT 0 0 0
TA-CG 0 0 0
TA-GC 0 0 0
Total 0 0 0
Total 1 Total 100
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Table 5.9 - Summary of the SNP data generated fo r Exon 12 of the PIG-T gene
region.
Percentage of 
Total Variants
A Allele Variants 1 0
C Allele Variants 2 0
G Allele Variants 0 0
T Allele Variants 0 0
Total Number of 
SNPS 3 0
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 1 100 33.33333333
AT-GC 0 0 0
AT-TA 0 0 0
Total 1 100 33.33333333
CG-AT 0 0 0
CG-GC 0 0 0
CG-TA 0 0 0
Total 0 0 0
GC-AT 1 100 33.33333333
GC-CG 0 0 0
GC-TA 0 0 0
Total 1 100 33.33333333
TA-AT 0 0 0
TA-CG 1 100 33.33333333
TA-GC 0 0 0
Total 1 100 33.33333333
Total 3 Total 100
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5.3.5.3 CD59 Gene
I AI
II
Figure 5.8. Next G eneration Sequence o f the entire CD59 am plicon (A) or specific 
CD59 gene (B), scaled and shaded blue to define exonic coding regions, following 
CD 59 reference am plicon alignm ent and variant calling of an EM S induced 
heterogeneous phenotypic PIG-A m utant population. Total coverage (I) and 
thresholded coverage <10,000 reads (II). V ariant frequency represented in (-), 
coverage (-), additional annotation undertaken to provide prelim inary identity of 
m utation frequency; nonsense (-), nonsynonym ous (-) and synonym ous (-).
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Table 5.10 - Summary of the SNP data generated for the entire CD 59 amplicon.
Percentage of 
Total Variants
A Allele Variants 5222 37.11179021
C Allele Variants 3022 21.47679625
G Allele Variants 2906 20.65240566
T Allele Variants 2921 20.75900789
Total Number of SNPS 14071 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 646 20.37212236 4.591002772
AT-GC 2164 68.24345632 15.3791486
AT-TA 361 11.38442132 2.565560372
Total 3171 100 22.53571175
CG-AT 964 26.4326844 6.85097008
CG-GC 450 12.33890869 3.198066946
CG-TA 2233 61.22840691 15.86951887
Total 3647 100 25.9185559
GC-AT 3328 85.48677113 23.65148177
GC-CG 238 6.113537118 1.691422074
GC-TA 327 8.399691754 2.323928648
Total 3893 100 27.66683249
TA-AT 930 27.67857143 6.609338355
TA-CG 2138 63.63095238 15.1943714
TA-GC 292 8.69047619 2.075190107
Total 3360 100 23.87889986
Total 14071 Total 100
Indels 121
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Table 5.11 - Summary of the SNP data generated fo r Exon 1 of the CD59gene
region.
Percentage of 
Total Variants
A Allele Variants 0 0
C Allele Variants 1 100
G Allele Variants 0 0
T Allele Variants 0 0
Total Number of 
SNPS 1 100
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 0 0 0
AT-GC 0 0 0
AT-TA 0 0 0
Total 0 0 0
CG-AT 0 0 0
CG-GC 0 0 0
CG-TA 0 0 0
Total 0 0 0
GC-AT 0 0 0
GC-CG 0 0 0
GC-TA 0 0 0
Total 0 0 0
TA-AT 0 0 0
TA-CG 1 0 100
TA-GC 0 0 0
Total 1 0 100
Total 1 Total 100
Table 5.12 - Summary of the SNP data generated for Exon 2 of the CD59gene
region.
Percentage of 
Total Variants
A Allele Variants 49 35.25179856
C Allele Variants 28 20.14388489
G Allele Variants 25 17.98561151
T Allele Variants 37 26.61870504
Total Number of 
SNPS 139 100
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 5 19.23076923 3.5971223
AT-GC 21 80.76923077 15.1079137
AT-TA 0 0 0
Total 26 100 18.705036
CG-AT 3 0 2.15827338
CG-GC 3 0 2.15827338
CG-TA 35 0 25.1798561
Total 41 0 29.4964029
GC-AT 38 88.37209302 27.3381295
GC-CG 3 6.976744186 2.15827338
GC-TA 2 4.651162791 1.43884892
Total 43 100 30.9352518
TA-AT 8 27.5862069 5.75539568
TA-CG 20 68.96551724 14.3884892
TA-GC 1 3.448275862 0.71942446
Total 29 100 20.8633094
Total 139 Total 100
Table 5.13 - Summary of the SNP data generated for Exon 6 of the CD 59gene
region.
Percentage of 
Total Variants
A Allele Variants 135 43.13099042
C Allele Variants 55 17.57188498
G Allele Variants 66 21.08626198
T Allele Variants 57 18.21086262
Total Number of 
SNPS 313 100
Number 
of SNPs
Percentage of 
Total Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 14 20.28985507 4.47284345
AT-GC 49 71.01449275 15.6549521
AT-TA 6 8.695652174 1.91693291
Total 69 100 22.0447284
CG-AT 21 0 6.70926518
CG-GC 10 0 3.19488818
CG-TA 45 0 14.3769968
Total 76 0 24.2811502
GC-AT 90 87.37864078 28.7539936
GC-CG 7 6.796116505 2.23642173
GC-TA 6 5.825242718 1.91693291
Total 103 100 32.9073482
TA-AT 24 36.92307692 7.66773163
TA-CG 34 52.30769231 10.8626198
TA-GC 7 10.76923077 2.23642173
Total 65 100 20.7667732
Total 313 Total 100
5.3.S.4 CD55 Gene
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Figure 5.9. Next G eneration Sequence o f the entire CD55 am plicon (A) or specific 
CD55 gene (B),  scaled and shaded blue to define exonic coding regions, following 
CD 55 reference am plicon alignm ent and variant calling o f an EM S induced 
heterogeneous phenotypic PIG-A m utant population. Total coverage (I) and 
thresholded coverage <10.000 reads (II). V ariant frequency represented in (-), 
coverage (-).
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Table 5.14 - Summary of the SNP data generated for the entire CD 5 5 amplicon
Percentage of 
Total Variants
A Allele Variants 4939 37.51329181
C Allele Variants 2899 22.0188364
G Allele Variants 2594 19.70226341
T Allele Variants 2734 20.76560839
Total Number of SNPS 13166 100
Number 
of SNPs
Percentage of 
Total 
Homologous 
Allele SNPs
Percentage 
of Total 
SNPs
AT-CG 574 20.90313183 4.359714416
AT-GC 1852 67.44355426 14.06653501
AT-TA 320 11.65331391 2.43050281
Total 2746 100 20.85675224
CG-AT 793 23.89993972 6.023089777
CG-GC 379 11.4225437 2.878626766
CG-TA 2146 64.67751658 16.29955947
Total 3318 100 25.20127601
GC-AT 3147 86.8137931 23.90247607
GC-CG 210 5.793103448 1.595017469
GC-TA 268 7.393103448 2.035546104
Total 3625 100 27.53303965
TA-AT 999 28.73166523 7.587725961
TA-CG 2115 60.82830026 16.06410451
TA-GC 363 10.44003451 2.757101625
Total 3477 100 26.4089321
Total 13166 Total 100
Indels 106
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5.4 Discussions and Conclusions
5.4.1 Trialled usage o f HLA-DR staining to validate single marker PIG -A  dose 
response data within MCL-5 cells
2.4 DNP has an essential function as a proton ionophore, an agent that can 
shuttle protons (electron acceptors or hydrogen cations) across biological membranes 
[47]. It therefore, defeats the proton gradient across established across the 
mitochondria and chloroplast membranes, and collapses the proton motive force that 
the cell uses to produce most of its ATP chemical energy [48]. The overall effect is 
to reduce the efficiency of the electron transport chain, limit oxidative 
phosphorylation and the subsequent production of ATP and therefore, increases 
metabolism to compensate for the loss of energy production; the energy of the proton 
gradient is extensively lost as heat. For this purpose 2,4 DNP was extensively used 
in diet pills within the early 20th century until recalled due to onset of dangerous side 
effects; i.e. increase of internal temperature, highly variable administered dose and 
rapid development of cataracts were observed [49].
5.4.4 Assay Refinement - Gating Strategy Comparison and Apoptotic 
M orphology Investigation.
5.4.4.1 Gating Strategy Direct Comparison
Using FL-W  and the reporting fluorophore of PIG-A  mutant phenotype’ FL-A 
scatter plots as a tertiary level o f single cell identification induces a significant bias 
into the gating strategy; in this case R-PE FL-A is the definitive factor in 
discriminating between wild type and mutant phenotype, and therefore, cannot be
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used to further subdivide the population regardless of the corresponding incorporated 
FL-W  measures.
Typically, FSC/SSC and then FSC-A/FSC-W  (or H) will provide you enough 
information to accurately gate an intact and single cell population. However, using 
fluorescence width of a fluorophore not directly associated with PIG-A  mutant 
phenotype definition as a supplementary factor providing additional data for doublet 
discrimination, excluding cells with a pulse width measure not linear to the FSC-A, 
appears to provide additional accuracy and sensitivity in terms of event exclusion, 
and has been observed more frequently within current literature [50]. Therefore, 
utilising this novel approach within the contest of in vitro PIG-A  analysis appears to 
establish a platform which has a perceived sensitivity comparable to analogous 
validated genetox assays measuring the equivalent end point.
5.4.4.2 Apoptotic M orphology Investigation
Due to the debated TP53, or p53 functionality within MCL-5 cells, [51, 52] it is not 
definitely known whether or not the cell line is sensitive to apoptosis; this is highly 
beneficial from an in-direct reporter mechanistic sensitivity point of view but equally 
the platform will receive scrutiny for the potential effect lack of p53 functionality 
will have on the subsequent dose response data (Section 5.3.1). Following initial 
investigation, MCL-5 cells were shown to be able to undergo both apoptosis and 
necrosis following acute Staurosporine exposure (Section 5.3.4.2); dose dependent 
increase in relative numbers of apoptosis and necrosis with respect to length of 
Staurosporine exposure was apparent, with analogous positive correlation being 
defined. Therefore, the use of viability dyes, excluding apoptotic or necrotic event 
based on Annexin V sensitivity as well as loss of membrane integrity are deemed 
essential within the in vitro PIG-A  assay design.
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5.4.5 Next Generation Sequencing
The results generated appeared to show a whole plethora of SNP variants called 
along the coding and non-coding regions o f all the genes assessed (Appendix Section 
5.3.5). However, interestingly the PIG-A  amplicon displayed the highest percentage 
o f SNP variants within the coding region (exons) when compared to any of the other 
amplicons 5.95%, PIG-T 0.02%, CD59 3.2% and CD55 0%. Typically, assuming 
that variants within the coding region have a potential larger impact on phenotype, 
the PIG-A  gene inclusive amplicon appears to be the most affected by mutational 
events. In addition to this, the PIG-A  amplicon is the only hemizygotic sequence, and 
therefore, dramatically increases the likelihood that each mutational event detected 
could result in a null-phenotype, when compared to the homozygous PIG-T , CD55 
and CD59.
Focussing on the PIG-A  inclusive amplicon, the range of variant frequency observed 
by any specific SNP was 1-98.5%, reflecting the occurrence of SNPs within the 
mixed heterogeneous population. Assuming the DNA extraction and amplification 
steps were effective and without bias, specific common SNPs were observed across 
the entire heterogeneous population. Loosely exon 6 can be classified as a “hot spot” 
of mutational activity within the PIG-A gene, as 69.2% of the total coding mutations 
occurred within this region. Similarly exon 6 within the CD59 gene saw an apparent 
69% of the total SNPs fall within the region when compared to the total SNPs over 
the entire amplicon. The other two genes of interest failed to generate any obvious 
areas of intense mutational activity.
Data analysis was undertaken in a blind manner to prevent the unnecessary biasing 
o f the data, i.e. the alignment, pileup and SNP calling were carried out by an 
appointed bioinformatician. Therefore, the subsequent data analysis, i.e. SNP 
identification, localisation and mutational finger printing were carried out 
independently of potential bias. Interestingly, each amplicon was analysed separately 
and all mutational fingerprinting results showed the sample pattern. GC-AT 
transition mutations were the most common mutational occurrence across all 
amplicons, more interestingly; they were also the most common SNP within the 
coding regions of the PIG-A gene. The main mutagenic mode of action which EMS 
operates is the 06ethyl guanine lesion which results in the miss alignment of a
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thymine residue opposite the adducted-lesion resulting in an eventual GC-AT 
mutation following replication [53-57]. Therefore, the mutational fingerprint 
observed across all the amplicons was supportive of the EMS mode of action and 
potentially indicative o f EMS treatment.
However, prior to taking any conclusions from this data the con-current negative 
control sequencing data must first be re-run and analysed prior to removing any 
common SNPs from the treated data sets. This will generate a SNP background 
across the amplicons, as a result of spontaneous mutations, and will allow the 
identification of novel SNPs as a direct result o f treatment. Therefore, until this has 
occurred, even though the data looks promising and indicative of EMS treatment, the 
data could be as a result of spontaneous mutational events independent of the 
treatments undertaken.
In addition to the control data, a second compound Benzo[a]pyrene (B[a]P) which 
operates under a different primary mechanism to EMS was also used to induce 
phenotypic PIG-A  mutant cellular populations. B[a]P is a known mutagen present as 
a bi-product o f incomplete combustion and is found within cigarette smoke and 
cooked meats. However, unlike EMS, which induces mainly abasic sites and specific 
GC-AT transition mutations, induces a large bulky adduct which results in a high 
proportion of GC-TA transversion mutations [58-60]. B[a]P requires metabolic 
activation, into the highly mutagenic epoxide, which is provided sufficiently through 
the upregulated p450 activity o f the MCL-5 cell line [51, 61]. Theoretically, as the 
mutation spectra for the two chemicals are distinctly different, with minor overlap, 
the NGS data following FACS isolation should demonstrate the ability for the PIG-A 
mechanism to identify mutations with enough integrity to observe a shift in mutation 
spectra and hence, subsequently providing additional validation to the reporting 
system. However, similarly to the EMS control data, the samples failed to be run 
successfully.
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5.5 Supplementary Work
5.5.1 Introduction
5.5.1.1 Antibody Specificity
In general, across all scientific disciplines, specificity and sensitivity are two words 
which are highly common. Both terms are of the upmost importance and are 
routinely the features which result in the sale of new technology. But aside from the 
development and sale o f novel technology sensitivity and specificity are often used 
to describe the functionality o f many aspects of molecular biology. As previously 
discussed antibodies or in this specific case immunoglobulin G (IgG), consist of four 
identical chains; two heavy chains and two light chains [62, 63]. W ithin the IgG 
structure, the chains orientate themselves in a typically “Y” shape, resulting in the 
formation of two protein binding sites. Thus these protein molecules once assembled 
can bind selectively to their desired antigen target through the active site or antigen 
binding site. However, alterative mechanisms of non-specific antibody binding are 
prevalent including Fc region mediated interactions, hydrogen bonds as well as non­
specific hydrophobic interactions [62, 64, 65]. M ost commercial companies’ now 
selling antibodies have comprehensive research and development departments 
angled at product development and validation, however, antibodies are always 
assigned a disclaimer, suggesting that the operator utilise their own evaluation prior 
to usage. Therefore, as a result of this, even though most comparable antibodies, i.e. 
monoclonal etc. raised against analogous proteins are similar there is often specific 
differences and alterations with activity. As a direct result of this, different 
antibodies suit different molecular applications, are often best suited to a single 
application, and require through testing and titration prior to usage to optimise the 
desired product.
In the specific example of the in vitro PIG-A  gene mutation assay, or any in-direct 
protein reporter system, antibody sensitivity is of the upmost importance [66-69]. 
The assay’s overall sensitivity and hence ability is defined by its quantification o f 
finite numbers of phenotypic antigen negative cells, often comprising <1% of the 
total population. Therefore, prior to assay development it is critical to deconstruct the 
protocol and validate each and every component of such protocol to assess
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functionality and weaknesses, as often such minor details have an exaggerated and 
deleterious result on the finalised properties of the test system. In the in vitro PIG-A 
test system the single or tandem use of antibody markers for GPI-associated surface 
antigens must be scrutinised for effectiveness prior to usage as the false 
identification or miss-identification of phenotypic mutants in order to understand the 
limitation of the system and provide confidence in the results generated. A failure at 
this stage to enable accurate quantitation limits if not prevents usage of a test system 
within specific applications; in the case o f drug screening and safety assessment, 
unless the test has unparalleled sensitivity, its usage is highly limited and more often 
completely restricted [69, 70].
5.5.1.2 Subtle Cell Line Differences and their effect on Chemical Exposure
During the development of a gene mutation test system, typically the initial 
compounds which are assessed and used to preliminary validate the reporting 
mechanism. These compounds are the “well-known” chemicals; they have highly 
validated mechanisms of actions as well as sufficient pier reviewed publications to 
warrant confidence. As such, these chemicals have easily predicted response metrics, 
which are directly able to be recognised and facilitate system critique. Limitations 
can be identified and solutions carried out leading to system reform. Continued 
optimisation of the test system will eventually result in re-testing and further 
validation with progressively less model chemicals. Eventually the system will 
develop to the point in which the designer will want to fully test the capabilities of 
the system, in order to define specificity and sensitivity in order to allow a more 
inclusive peer review o f the system to warrant distribution and commercial usage.
However, one aspect of chemical selection which is often overlooked is the lack of 
predictive response without pre-existing data for an analogous assay design. For 
example, chemical exposure and subsequent response metrics can easily be predicted 
assuming that there is previously published data within an analogous set up. 
Obviously depending upon the variants between the two assay designs specific 
caveats must be taken into account and the resultant data may be subtly different.
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The problem faced within the genetic toxicology word is the vast differences in 
generated data observed when using analogous test platforms. Similar cell lineages 
for example, even derived from a common ancestor can be significantly different on 
a proteomic level and therefore, the subsequent response metrics can be dissimilar. 
Therefore, prior to utilising reviewed chemicals as model compounds for exposure, 
one must generate data on the expected response of such chemical w ithin the test 
system preceding actually running the chemical in the test system; this often requires 
fundamentally deconstructing the assay design. As often is the case within 
microbiology, the most subtle differences, especially at a fundamental level, have 
colossal ramifications on phenotype.
Currently within the field of genetic toxicology, debate about p53 status and hence, 
biological relevance is often at the forefront of regulatory and safety assessment 
reform [68, 71-74]. The reason for this is not only the limitations such confounding 
factors as p53 deficiency and rodent origins have on strength of data within a weight 
o f evidence decision making strategy [75, 76] but also the lack of standardisation 
within genetic toxicology data. Subsequently, due to variation within assay designs 
the consequential generated data is often highly dissimilar when generated by 
analogous assay systems utilising the same chemical. As a result of this, data loses 
strength and the test systems themselves come under increasing criticism. In order to 
resolve this problem, the initial stage of harmonisation is comprehensive cell line 
assessment; in which all aspects of the cell line are evaluated, including responses to 
known model chemicals prior to distribution. Following cell line distribution, assay 
protocols can be harmonised and then fully validated to ensure similarity in 
subsequently generated data. Following this, data can be attributed strength and 
enables a more simplistic approach to regulatory decision making when data can be 
attributed a value or rank in respect to comparable biological data.
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5.5.1.3 The Cell Cycle as a biasing factor within the in vitro PIG -A  gene 
mutation assay
The cell cycle is the highly characterised, critically maintained, mechanisms in 
which the cell progresses prior to replication in order to facilitate genetic inheritance 
[26, 34, 77, 78]. During mitosis the cell under goes initial duplication, synthesis, of 
genomic material, which eventually resides within two identical daughter cells 
following cytokinesis [79]. The daughter cells are exact replicates with regards to 
nuclear material and organelles; however, their area is significantly reduced to 
maintain homeostasis within the cell. As cells grow, their increase in intracellular 
complexity requires an exponential increase in fuel uptake; membrane transportation 
constitutes the major intake of fuel within the cell and therefore, division is 
necessary to prevent the finite membrane surface area from  initiating cell death [80].
Therefore, the resultant cells immediately following cytosolic cleavage are under 
sized, with regards to their potential maximum intra cellular surface area, and are 
highly active to facilitate new growth and expansion. During cleavage, even though 
the concentrations of cytosolic proteins as well as mRNA and additional protein 
structures would remain consistent, the number of such macromolecules would be 
significantly diminished. Consequently, within this potential period, interphase, in 
which the cell is rapidly growing in terms o f intracellular surface area, intracellular 
components such as macromolecules are being replenished. GPI-AP proteins are 
highly associated to lipid dense, lipid rafts, regions of the cellular membrane which 
are diverse in nature. For that reason, there is an increased chance that due to 
diminished protein products laser bisection within fluorescence based applications 
could suffer a negative bias, when compared to more well established cells, within 
latter stages of the cell cycle with higher densities of GPI-AP on the cell surface.
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5.5.1.4 The versatility o f the PIG -A  reporter system, could intracellular PIG -A  
staining offer a conservative design to facilitate point of contact screening?
The effects of compound exposure are highly unique to the tissue in which said 
compound was exposed. Let’s consider an acute exposure o f a compound which 
requires metabolism in order to generate toxic metabolites, for example Paracetamol 
[81]. Paracetamol overdoses typically result in acute liver toxicity, due to the liver 
being the most metabolically active organ and hence, the resultant accumulation of 
toxic metabolites [82]. However, if paracetamol did not require metabolism and was 
toxic, then the initial point of contact associated to the mechanism of drug delivery 
would most likely be the most severe tissue presenting toxicity post exposure [83]. 
Therefore, due to this complex relationship, relying on a single test system, within a 
specific tissue type, could potentially under or overestimate adverse drug reactions; 
due to the uniqueness and complexity o f drug pharmacodynamics and kinetics [29, 
84]. A potential resolution to this problem would be the use of a systemic tissue 
model, for example peripheral circulating blood, which potentially gives a more 
holistic approach to drug exposure [7, 85, 86]. Nonetheless, inaccuracies in 
evaluating adverse drug reactions, especially within acute exposures, are possible.
The most appropriate solution to this problem would be a collective tiered approach 
to drug screening, with a variety of tissues, including metabolically active and 
primary sites of exposure, included to provide a more comprehensive screen [3]. 
However, due to the unique qualities each sub set of tissue provide, which facilitate 
the usage of particular test systems, finding a highly conservative fundamental 
mechanism which can be exploited as a test system potentially would offer a large 
benefit. Having a single, comparable genetic toxicology end point, able to be 
undertaken within a large variety of tissue could increase the robustness of generated 
data and provide a more rounded assessment of potential adverse drug reactions. 
W ithin this results chapter we begin to explore a more fundamental PIG-A  
mechanism which potentially will facilitate a w ider range of tissues to be utilised as 
a platform for the assay design.
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5.5.2 Materials and Methods
5.5.2.1 Antibody Specificity Assessment
Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2) and counted. The equivalent volum e containing lx lO 6 cells was 
transferred into fresh 15 mL centrifuge tubes (10 samples in total), centrifuged (250 
x g for 7 min) and supernatant removed. 50-100 pL  of pre-warmed media was added 
to re-suspend the cell pellets; 5 pL  of Fc blocker was added to three samples and 
incubated for 20 mins at room temperature, samples not receiving Fc blocker (seven 
samples) were kept at room temperature for 20 m in (protected from light), a single 
sample was treated as an ICS and received no staining. Post incubation all samples, 
excluding the ICS, were treated with either 20 pL  o f their respective isotype for the 
anti-human, anti-CD55/59 R-PE antibodies (Cat No. 555574 BD Biosciences, 
Hertfordshire, UK) (three samples in total) or 20 p L  anti-human, anti-CD55/59 R- 
PE antibodies and incubated for 30 min at room temperature, protected from light. 
Following incubation, samples were centrifuged (250 x g for 7 min), supernatant 
aspirated and discarded and washed in 5 mL of 1 x PBS solution. Samples were 
returned to the centrifuge, spun (250 x g for 7 min), supernatant aspirated and re­
suspended in 100 pL  1 x PBS; the three experimental samples which received 20 pL  
anti-human anti-CD55/59 R-PE antibody treatment also were treated with 10 pL  7- 
AAD to facilitate dead cell exclusion within the gating assessment. All samples were 
kept on ice for a maximum of 1 hr prior to analysis and were diluted prior to running 
the samples with excess 1 x PBS solution.
5.5.2.2 Dose Finding Study, EM S and M NU Exposure
A vial of Low Passage MCL-5 cells were established and maintained as outlined 
within (Section 2.2). Following sufficient growth to certify population fitness, cells 
were counted using a Haemocytometer as well as a  Coulter Counter (Section 2.2.1)
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f\ 0and the equivalent volume housing 1x10 cells were transferred into sterile 25 cm 
pre-labelled culture flasks. The final volume of each culture flask was adjusted to 10 
mL via the addition of fresh culture media constructing a final concentration of 
1x10s cells/mL. Prior to genotoxic handling, suitable PPE was collected, worn and 
appropriate disposal vessels collected. Ethyl methanesulfonate and N-nitroso- 
methyl-urea were collected from storage and diluted within an apt vehicle, to enable 
dissolving under minimal effort and stock concentration establishment (Section 2.4). 
Serial dilutions within DMSO were utilised to construct the required stock solutions 
and subsequent doses. Cellular cultures were treated with 100 pL  volume doses of 
EMS or MNU independently and incubated, under controlled environment, for 24 hr. 
Following treatment, cultures were washed (excess 1 X PBS) and re-suspended in 10 
mL fresh culture media and counted. Cultures were incubated for an additional 24 hr 
and counted to provide population statistics for a total of 48 hr post chemical 
treatment. Relative population doubling (RPD), relative cell counts (RCC) and 
estimated mean generation time (EMGT) were calculated from the produced cell 
counts in order to facilitate direct cell line comparisons in terms o f stability and 
sensitivity post genotoxin exposure.
5.5.2.3 Preliminary Investigations into Cell Cycle and GPI-AP Expression  
Correlation
5.5.2.3.1 Amnis Image Stream™  Investigation
MCL-5 cells were established as outlined in (Section 2.2), counted and the 
equivalent volume o f culture corresponding to 1 x 106 cells was aliquotted into a 
sterile 15 ml centrifuge tube, this was repeated six times in total to generate the 
following samples; an ICS, a single anti-CD55/CD59 R-PE, a single Hoescht 33342, 
and three Hoechst 33342 and anti-CD55/59 R-PE. Samples were centrifuged (250 x 
g for 7 min), supernatant aspirated and re-suspended in 5 mL of PBS. The samples 
were centrifuged again, supernatant aspirated and re-suspended in 100 pL  of pre­
warmed medium. The required samples were treated with 20 pL  of both anti-CD55
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and anti-CD59 R-PE antibodies and incubated at room temperature for 30 min, 
protected from light. Following the incubation, samples were centrifuged, 
supernatant aspirated and discarded and re-suspended in 10 mL o f 1 X PBS. Post 
washing, samples were again centrifuged and re-suspended in 1 mL of pre-warmed 
4% PFA solution and incubated for 15 min at 37°C. Following incubation, the 
cellular samples were centrifuged (-350  x g for 7 min), supernatant aspirated and re­
suspended in 10 mL of 1 x PBS solution. The samples were returned to the 
centrifuge, spun and re-suspended in 250 pL  of 1 x PBS and treated with 5 pL  of 10 
mg/mL RNase A solution, prior to being incubated at 37 °C for 1 hr. Following the 
incubation, the intended samples were treated with 10 pL  of the working solution of 
Hoechst 33342 (Cat No. H3570, Life ™ Technologies, Paisley, UK) (1 in 100 
dilution within dFLO) and incubated for 10 min, protected from light. Samples were 
centrifuged, and re-suspended in a final volume of 50 pL  of 1 x PBS, prior to Image 
Stream ™ analysis.
5.5.2.3.2 BD FACS Aria 1 Investigation
MCL-5 cells were established as outlined in (Section 2.2), counted and the 
equivalent volume of culture corresponding to 1 x 106 cells was aliquotted into a 
sterile 15 ml centrifuge tube, this was repeated four times in total to generate the 
following samples; an ICS, and three Hoechst 33342 and anti-CD55/59 R-PE. 
Samples were centrifuged (250 x g for 7 min), supernatant aspirated and re­
suspended in 5 mL of PBS. The samples were centrifuged again, supernatant 
aspirated and re-suspended in 100 pL  of pre-warmed medium. The required samples 
were treated with 20 pL o f both anti-CD55 and anti-CD59 R-PE antibodies and 
incubated at room temperature for 30 min, protected from light. Following the 
incubation, samples were centrifuged, supernatant aspirated and discarded and re­
suspended in 10 mL of 1 X PBS. Post washing, samples were again centrifuged and 
re-suspended in 1 mL of pre-warmed 4% PFA solution and incubated for 15 min at 
37°C. Following incubation, the cellular samples were centrifuged (-350  x g for 7 
min), supernatant aspirated and re-suspended in 10 mL of 1 x PBS solution. The 
samples were returned to the centrifuge, spun and re-suspended in 1 mL o f 1 x PBS
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and treated 10 jxL o f the working solution o f  Hoechst 33342 (Cat No. H3570, Life ™ 
Technologies, Paisley, UK) (1 in 100 dilution within dH20) and incubated for 10 
min, protected from light. Samples were centrifuged, and re-suspended in a final 
volume of 1 mL o f 1 x PBS, prior to flow cytometry analysis.
5.5.2.4 Preliminary Intracellular PIG-A Investigation
5.5.2.4.1 Proof o f principle PIG -A  monoclonal antibody binding, W estern Blott 
Analysis
W estern blott analysis was undertaken utilising primary PIG-A antibody solutions 
(Abeam and Sigma) under an analogous method as outlined in (Section 4.2.5.1). 
W hen utilised in conjunction with corresponding HRP-conjugated secondary 
antibodies, UV stimulated images are able to be detected using a ChemiDoc™  and 
corresponding band densities estimated.
5.5.2.4.2 Initial Flow Cytometry Fix and Perm® Intracellular Signal Presence 
within MCL-5 Cells and Confocal Imaging Evaluation
Intracellular staining was under taken with the usage o f a Fix and Perm ® cell 
fixation and permeabilisation kit (Cat No. GAS-003, Life ™  Technologies, Paisley, 
UK), anti-human IgG (gamma-chain specific)-R-Phycoerythrin antibody produced in 
goat (cat No. p9170-5mL, Sigma Aldrich, Gillingham, UK) and anti-PIG-A antibody 
produced in rabbit (Cat No. SAB2105628-50UG, Sigma Aldrich, Gillingham, UK). 
Primary antibody was reconstituted within dH20 generating a 1 mg/mL final 
concentration, aliquotted to prevent freeze thaw cycles and stored at -20°C until 
ready for use. Additional buffers not provided within the kit were also constructed 
including Blocking Buffer solution 5% (v/v) FBS and 2% (w/v) BSA in DPBS.
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Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2), counted and the equivalent volume of culture medium containing 1 x 
106 cells transferred into a sterile 15 mL centrifuge tube; this step was repeated in 
order to establish the required number of samples. Samples were centrifuged (-250  x 
g for 7 min) and re-suspended by flicking or gently vortexing the tube, prior to the 
addition o f 4 mL of 1 x PBS solution. Samples were centrifuged, supernatant 
aspirated and re-suspended in 100 pL  of Reagent A (fixation Medium) and incubated 
for 15 mins at room temperature. Following incubation, cells were centrifuged (400 
x g for 5 mins), supernatant aspirated and washed twice through the addition of 3-5 
mL of PBS/5% FBS solution. Following washing, samples were centrifuged, 
supernatant aspirated and re-suspended in blocking buffer (5% (v/v) FBS and 2% 
(w/v) BSA in DPBS) at room temperature for 1 hr. Post incubation, samples were 
centrifuged, supernatant decanted and re-suspended in 100 pL  of Reagent B 
(Permeabilisation Medium) and treated with 0.2 mL of 1 pg/m L of primary antibody 
(Cat No. ab69768, Abeam, Cambridge, UK) within blocking buffer. Each sample 
was vortexed briefly (1-2 sec) and incubated at room temperature for 20-30 min or 
alternatively, the tubes were sealed with parafilm, and incubated for 16 to 18 hours 
(overnight) at 4°C (fridge). Following staining, cells were washed twice in blocking 
buffer post staining. Subsequently, the cells were treated with 10 pL  of 0.5 mg/mL 
secondary antibody (Cat No. P92870.25ML, Sigma Aldrich, Gillingham, UK) within
0.2 mL of Blocking buffer and incubated at room temperature for 1 hour, protected 
from light. Samples were centrifuged (350 x g for 5 min), supernatant aspirated, and 
washed twice in blocking buffer. Finally, the samples were re-suspended in 1 mL 
PBS/Blocking buffer for immediate flow cytometry analysis.
Following flow cytometry analysis, remaining samples were centrifuged, supernatant 
discarded and re-suspended in minimal volum e (-100  pL) of 1 x PBS. The pre­
existing FCM  sample was divided into three experimental samples, as well as the 
ICS being divided into two further samples; one intended to act as an additional ICS 
for the confocal experiment as well as a sample intended to be exposed to both 
phalloidin (Alexa Fluor 594) and Hoechst but excluding the R-PE stain to enable 
removal o f background auto fluorescence. A  staining solution was established 
comprising of 1480 pL  of PBS, 10 pL  Hoechst 33342 (1 in 100 dilution with dH20) 
and 10 pL Phalloidin (Cat No. A12381, Life Technologies ™, Hertfordshire, UK),
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500 pL  was added directly to the re-suspended cell pellets within minimal PBS. 
Samples were incubated at room temperature, protected from light, for 15 min. 
Parallel to this, 300 pL  of poly-L-lysine solution (1 in 10 dilution within dFLO) was 
pipetted applied directly into the bottom of a 4 well chamber slides (Nunc® Lab 
Tek®, MA, USA) and incubated for 15 min at room temperature. Following the 
incubation, cellular samples were centrifuged (-350  x g for 7 min), supernatant 
aspirated and re-suspended in 10 mL of PBS, washed and re-suspended in 300 pL  of 
PBS. The 4-well chamber plate was washed thoroughly with dH20, and the relevant 
experimental samples transferred into each separate well and incubated for 15 min at 
room temperature. Post incubation, chambers were kept submerged in minimal PBS, 
covered with foil and stored on ice until ready to image.
5.5.2.4.3 Intracellular M ethod Optimisation; M ethanol Fixation
Low passage MCL-5 cell cultures were established and maintained as outlined in 
(Section 2.2), counted and the equivalent volume o f culture medium containing 1 x 
106 cells transferred into a sterile 15 mL centrifuge tube. Centrifuged (250-300 x g 
for 7 min), supernatant aspirated and washed in pre-cooled (4°C) 1 x PBS (5 mL), 
three times in total. The cellular samples were re-suspended within 100 pL  of 1 x 
PBS solution; simultaneously, a 50 mL aliquot of 100% methanol was placed within 
the -80 °C freezer and incubated to ensure a temperature of -  -20°C. 900 pL  of pre­
cooled absolute methanol was added to the cell suspension and re-suspended 
thoroughly and incubated for 5 min at room temperature. Post methanol fixation, 10 
mL ice-cold 1 x PBS was added, centrifuged (-650  x g for 7 min) and supernatant 
aspirated. W ashing was repeated two more times, to remove any excess fixative.
Goat serum (Cat No. G9023-5ML, Sigma Aldrich, Gillingham, UK) was forced 
through a (0.2 pm ) filter (Nalgene Syringe Filters, Thermo Scientific, MA, USA) via 
the use of a 5 mL syringe (Thermo Scientific, MA, USA) and three subsequent 
solutions were prepared; 15 mL of 10% goat serum/PBS, 5mL of 1% goat 
serum/PBS and 10 mL of 1% BSA/PBS. 2 mL of 10% goat serum/PBS solution was 
added to the washed, fixed cells and incubated for 30 min at room temperature. The
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blocking incubation must be undertaken using serum from the species of the 
secondary antibody intended on being used. Following incubation, the cells were 
centrifuged, washed thoroughly within ice cold 1 x PBS and re-suspended within 
100 pL  of primary antibody solution; either (1 in 3000) anti-histone H3 rabbit mab 
(Cat No. A bl220, Cambridge, UK) or an (1 in 40) anti-PIG-A rabbit mab within 1% 
goat serum/PBS solution. The cells were exposed for 30 min at room temperature; 
all incubations were undertaken protected from light under rolling and tilting 
conditions. Following incubation, cells were washed within 1 x PBS three times and 
re-suspended within 100 pL  of secondary antibody solution; 10 pL  of phalloidin 
A lexa Fluor 594, 1.25 pL o f (1 in 800) anti-rabbit A lexa Fluor 488 ™ goat 
secondary (Cat No. A11008, Life Technologies ™, Hertfordshire, UK) within 
1%BSA/PBS. The cells were exposed to the secondary antibody within 1% 
BSA/PBS for 30 min at room temperature, following incubation, cells were washed 
within 10 mL PBS and re-suspended in 50 pL  PBS. 25 x 25 mm cover slips were 
placed on blue roll, and a 10 pL  aliquot o f DAPI within Vector Shield (Cat No. 
H I200, Vecta Laboratories, Peterborough, UK) was pipetted into the centre. 10 pL  
o f stained MCL-5 cells were directly added to the pre-existing mountant and very 
carefully a polished glass microscope slide was dropped onto the cover slip at a 45° 
angle. A layer of nail varnish was applied around the periphery of the cover slips to 
prevent motion, and hence prevent cell shearing. Samples were stored at 2-4 °C 
either as a constructed microscope slide or alternatively, within a 15 ml BD Falcon 
centrifuge tube as a cell suspension. All samples were stored protected from light,
i.e. wrapped in foil.
5.5.2.4.5 Fluorescence Microscopy Imaging
Fluorescence microscopy was carried out using an Axio Imager M l microscope with 
attached AxioCam MRm and supplied Axiovision software in conjunction with 
either a 40x or 63x oil immersion DIC objective (Carl Zeiss, Cambridge, UK). All 
fluorochromes/fluorophores were excited using the 405, 488, 594 or 633 nm lines. 
Objectives, laser excitation intensity and laser gain settings remained consistent to 
provide comparable data sets, however, proof of principle experiments were mainly
150
undertaken to validate flow cytometric data. Retrospective image analysis was 
carried out using the ZEN software, as described within the manufacturers supplied 
information.
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5.5.3 
R
esults
In order to maintain accuracy within the in vitro PIG-A mutant assessment method, 
following the relative successful trial data for the novel refined gating system, 
antibody specificity, potential gating bias and further investigations into the 
morphological alterations observed during apoptosis were explored. Even though all 
antibodies utilised were monoclonal in nature, antibodies are able to bind 
unspecifically through Fc mediated interactions (Appendix Section 5.5.3.1), 
especially prominent within leukocytes [64].
The specificity assessment data (Appendix Table 5.5.1) showed that the average 
percentage of MCL-5 single cellular events shown to bind to the isotype control 
antibody was 0.009%, samples size exceeded 10,000 single cellular events. The 
unspecific binding efficiency, a result of Fc mediated interactions, was subsequently 
estimated at 0.006%; following the acquisition of the Fc block regent data (0.003% 
resultant antibody binding). The additional 0.003% of isotype control binding, in the 
presence of Fc block regent, was defined to not be the result of Fc region mediated 
interactions and was subsequently a result of an alternative unspecific mechanism.
The results generated were comparable to the analogous CD59 R-PE conjugate 
antibody data (Section 3.3.1); however, the CD55 antibody was shown to be the 
most specific in terms of Fc mediated interactions and generated the most optimum 
results.
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5.5.3.2 Dose Finding Study, EMS and MNU Exposure
In order to assess the MCL-5 cell line’s ability to be incorporated into the in vitro 
PIG-A assay design, initially a dose finding assessment was carried out to estimate 
an approximate LD50 value to be utilised as a descriptor for cytotoxicity within 
subsequent assessment. The LD50 or lethal dose 50 is the estimated dose in which 
cytotoxity is observed to reach 50% of the total population assessed; at the 
equivalent dose and above; any observed genotoxic results cannot be accurately 
distinguished from cytotoxity induced effects. Ethyl methane sulfonate (EMS) and 
n-methyl-n-nitrosourea (MNU) were selected as the initial chemicals to investigate 
due to their highly potent mutagenic characteristics, abundance of published 
literature and well defined mutation spectra, able to be utilised in forthcoming 
validatory sequencing analysis.
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Figure 5.5.1.A - Relative Cell Counts (RCC) for MCL-5 cell cultures, following 24 
hr acute EMS treatment (N=l).
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Figure 5.5.1.B Estimated Generation Time for MCL-5 cell cultures, following 24 hr 
acute EMS treatment (N=l).
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Figure 5.5.2.A - Relative Cell Counts (RCC) for MCL-5 cell cultures, following 24 
hr acute MNU treatment (N=l).
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Figure 5.5.2.B - Estimated Generation Time for MCL-5 cell cultures, following 24 
hr acute MNU treatment (N=l).
The results following the 24 hr acute EMS, within MCL-5 cells, appear to 
demonstrate that little or no measurable variation in growth occurred within the first 
24 hr post mutagenic exposure. The cell cultures continued to show no obvious signs 
of growth until 24-48 hr post treatment, however allowing the full 1.5-2 cell cycles 
of recovery showed the desired toxic effects post recovery and generated an apparent 
dose dependent increase in cytotoxicity; as the dose increases, there is a 
corresponding increase in cytotoxity which results in the RCC values decreases 
across the dose range. This relationship is more apparent on the fourth day of the 
experiment (96 hr) in which the top two doses of 5 and 10 pg/mL induce a 41 and 
46.3% decrease in RCC values when compared to the con-current negative controls 
(Appendix Figure 5.5.l.A). The relationship is less clear on prior experimental days 
(0-72 hr) in which minor discrepancies can be observed throughout the dose range 
without any substantial decreases in RCC values being observed. The estimated 
generation time was shown to mimic the correlation as defined by the RCC data, and 
a noteworthy increase in the generation time was observed to steady increase in a
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linear manner for doses greater than 2.5 pg/mL (Appendix Figure 5.5.1.B). 
Untreated, established MCL-5 cell cultures, generally take approximately 22-24 hr to 
divide successfully [61, 87], this value is in accordance within the generation time 
data acquired. The estimated LD50 value for acute EMS exposure, within MCL-5 
cells, was able to be defined as marginally higher than 10 pg/mL, a comparable 
metric when compared to the previously utilised TK6  cells (Section 5.3.1).
The results following acute MNU exposure showed a similar relationship with 
regards to increase in cytotoxity at the top doses when compared to the previous 
EMS exposure, however, the data does appear to show minimal lag following 
mutagenic exposure, prior to cellular growth. Following the completion of the initial 
24 hr recovery period immediately following dosing, an additional single cell cycle 
was adequate in order to assess dose dependent cytotoxicity; both 48 and 72 h data 
demonstrated a dose dependent increase in cytotoxicity. RCC values were observed 
to approximately fall to 50% at the 1 pg/mL dose, further decreases in cellular 
viability were apparent at the three addition higher doses (Appendix Figure 5.5.2.A). 
Doses greater than and including 1 pg/mL elicited significant cytotoxicity affects 
onto the treated MCL-5 cultures and resulted in a maximal 72% decrease in cellular 
viability, when compared to the concurrent controls, at the 72 hr - 2.5 pg/mL dose. 
The LD50 value can be estimated in the region of 1 pg/mL for MNU within MCL-5 
cultures and therefore, can be used as the top dose for future routine screening.
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5.5.33 Preliminary Investigations into Cell Cycle and GPI-AP Expression 
Correlation
5.5.3.3.1 Amnis Image Stream™ Investigation
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Figure 5.5.3. Preliminary Cell Cycle and GPI-AP expression correlation analysis 
within untreated 4% PFA fixed MCL-5 cells, stained with Hoechst 33342 and anti- 
CD55/59 R-PE antibodies. A) Aspect ratio defined single cell gate, B) Focal smear 
gate, C) relative fluorescence intensity for the nucleic acid stain and D) relative 
fluorescence intensity of the GPI-AP markers (-1 ,000 Events Captured).
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Figure 5.5.4. Preliminary Cell Cycle and GPI-AP expression correlation analysis 
within untreated 4% PFA fixed MCL-5 cells, stained with Hoechst 33342 and anti- 
CD55/59 R-PE antibodies and implemented mask feature to prevent spectral overlap. 
A) Aspect ratio defined single cell gate, B) Focal smear gate, C) relative 
fluorescence intensity for the nucleic acid stain and D) relative fluorescence intensity 
of the GPI-AP markers (-1 ,000 Events Captured)
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Figure 5.5.5. Bi-nucleate images derived from a selected bin within the estimated 
G2/M population within untreated 4% PFA fixed MCL-5 cells, stained with Hoechst 
33342 and anti-CD55/59 R-PE antibodies. A) Bi-nucleate derived independently of 
the mask feature and B) Bi-nucleate derived within the mask feature, compensating 
for potential spectral overlap of the nucleic acid dye (-1 ,000 Events Captured)
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Figure 5.5.6. Preliminary estimation at the relative GPI-AP marker fluorescence with 
respect to the nucleic acid dye intensity; hence, the correlation between GPI-AP 
expression and cell cycle progression within untreated MCL-5 cells. Samples were 
RNase treated, fixed in 4% PFA and stained with Hoechst 33342 and tandem anti 
CD59/55 RPE antibodies (<1,000 events captured).
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In order to evaluate the possible relationship between GPI-AP expression and 
nucleic acid quantity, immediately following cytokinesis a potential time period in 
which surface antigen expression is reduced when compared to a more established 
cell, the Image Stream™ platform in conjunction with Hoechst 33342 and anti- 
CD55/59 R-PE tandem exposure was utilised. Initially, cells were visualised and 
characterised through their relative aspect ratio and particle size, and non-focussed 
events were excluded from data analysis due to their potential effect on subsequent 
interpretation.
At first, in the absence of any retrospective masking or features applied, the single 
cell population with the stained MCL-5 population, were demonstrated to exhibit a 
typically normal cell cycle profile; the majority of cells within the population having 
nucleic acid dye content analogous to G0/G1 phase, the minor population had 
significantly larger quantities of DNA and therefore, were labelled as cells post DNA 
replication i.e. G2/M (Appendix Figure 5.5.3). Cells binned within the G2/M phase 
were visually inspected for their nucleic acid dye content, and the resultant images 
were clearly bi-nucleate in nature with distinctive hemispheres of content (Appendix 
Figure 5.5.5.A).
The corresponding GPI-AP data demonstrated a typical Gaussian like distribution; 
with the inclusion of outlier events and an apparent visual skew (Appendix Figure 
5.5.3). DNA content, i.e. cell cycle progression was shown to apparently not be 
correlated to GPI-AP expression, as the resultant graphical interpretation of the data 
was not clearly linear in nature and displayed limited evidence for any positive 
correlation (Appendix Figure 5.5.6).
The identical data set was retrospectively assessed utilising an applied mask and 
feature, in which potential spectral overlap was compensated for by the inclusion of 
a nuclear acid dye mask within the extra-cellular surface space. The masked data 
demonstrated analogous results to the previously reported data, there was a highly 
similar DNA content profile for the cellular population (Appendix Figure 5.5.4), a 
typical GPI-AP expression and no clear correlation between GPI-AP expression and 
relative DNA content; the gating system was again evaluated by the binning of 
selected specific DNA content events and visually inspected to ensure concordance. 
The only potential difference in the two distinctly different analysis methods was the
1 6 1
clarity of DNA nuclear content, visually within the selected binned images, the mask 
feature appeared to slightly increase focus (Appendix Figure 5.5.5.B), when directly 
comparing images
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5.5.3.3.2 BD FACS Aria 1 Investigation
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Figure 5.5.7. Cell cycle and GPI-AP correlation re-evaluation utilising the BD FACS 
aria Platform within untreated MCL-5 cells. Cells were un-treated, fixed in 4% PFA 
and stained with Hoechst 33342 nucleic acid dye in conjunction with tandem anti- 
CD55/59 R-PE antibodies; A) FSC-A vs SSC-A scatter plot, B) Doublet 
Discriminant gate, C) Cell cycle analysis and D) GPI-AP expression, correlated to 
Cell cycle progression (>12,000 events scored, -10,000 single cell events scored 
analysed).
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Figure 5.5.8. Cell cycle and GPI-AP correlation assessment utilising the BD FACS 
aria Platform within untreated MCL-5 cells. Cells were un-treated, fixed in 4% PFA 
and stained with Hoechst 33342 nucleic acid dye in conjunction with tandem anti- 
CD55/59 R-PE antibodies (>12,000 events scored, -10,000 single cell events scored 
analysed).
To provide additional weight of evidence for no significant correlation between GPI- 
AP expression and relative nucleic acid content, flow cytometry was implemented in 
conjunction with Hoechst 33342 and tandem CD55/59 R-PE staining. Initially, cells 
were assessed for their respective light scatter profiles and a crude single cell 
population was defined, this in turn was further refined by the inclusion of doublet 
discrimination (Appendix Figure 5.5.7 B).
The single cell population, were demonstrated to exhibit a cell cycle profile 
consistent with an increase in the latter G2/M phase and a subsequent minor 
population presence within the earlier stages of the cell cycle; the majority of cells 
within the population having a relatively high nucleic acid dye content analogous to 
G2/M phase, a phenotype consistent with direct pre-division (Appendix Figure 
5.5.7.C). The corresponding GPI-AP data demonstrated a typical Gaussian like 
distribution, with the inclusion of outlier events and no apparent visual skew.
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DNA content, i.e. cell cycle progression was again demonstrated to not be 
significantly correlated to GPI-AP expression, as the resultant graphical 
interpretation of the data only demonstrated minor evidence for a minimal increase 
in average florescence emission for cells within G2/M when compared to early 
stages of the cell cycle (Appendix Figure 5.5.7.D). This relationship was investigated 
further via the addition of a supplementary figure describing the direct relationship 
between GPI-AP expression and nucleic acid content (Appendix Figure 5.5.8); again 
no direct relationship was distinctly apparent, with minor evidence for a positive 
correlation.
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5.5.3.4 Prelim inary Intracellular PIG-A Investigation
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Figure 5.5.9. Discreet proteins bands following secondary-HRP conjugated antibody 
probing, within total protein extracted from human lymphoblastoid cell lines, and 
visualised following UV exposure; A) anti-B-actin primary antibody and B) anti- 
PIG-A primary antibody (Abeam). 20 pg of total protein loaded into each well along 
in conjunction with the use of known molecular weight precision plus protein 
standard.
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Figure 5.5.10. Discreet proteins bands following secondary-HRP conjugated 
antibody probing, within total protein extracted from human lymphoblastoid cell 
lines, and visualised following UV exposure; A) anti-B-actin primary antibody and 
B) anti-PIG-A primary antibody (Sigma Aldrich). 20 pg of total protein loaded into 
each well along in conjunction with the use of known molecular weight precision 
plus protein standard.
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20 pm
Figure 5.5.14 - Intracellular IHC staining and sequential fluorescent microscopy 
imaging of minimal 100% methanol fixed MCL-5 cells; Isotype Control - exposed to 
no primary antibody, anti-rabbit R-PE secondary antibody treatment (Green), with 
retrospective Phalloidin (596 nm) (Red) and DAPI nuclear staining (Blue), captured 
on the x 63 oil immersion objective
Figure 5.5.15 - Intracellular IHC staining and sequential fluorescent microscopy 
imaging of minimal 100% methanol fixed MCL-5 cells; exposed to anti Histone-H3 
primary and corresponding anti-rabbit R-PE secondary antibody treatment (Green), 
with retrospective Phalloidin (596 nm) (Red) and DAPI nuclear staining (Blue), 
captured on the x 63 oil immersion objective
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Following the initial failure of the high throughput flow cytometry assessment of the 
intracellular in vitro PIG-A background frequency (data not shown), initially western 
blott analysis was implemented to assessed the efficacy of the purchased novel anti 
PIG-A primary antibodies. The abeam purchased anti-PIG-A primary antibody was 
shown to generate distinct comprehensive protein bands for both the house keeper 
(B-actin) and the anti-PIG-A primary following 20 pg total protein extraction within 
the MCL-5 cell line; the distinct dense protein bands were approximately 40 and 50 
KDa in size respectively (Appendix Figure 5.5.9). The sigma antibody, which was 
previously utilised for the background frequency assessment, demonstrated a clear 
protein band for the housekeeper (b-actin) at approximately 40 KDa; no visible 
bands were detected when exposed to the anti-PIG-A primary (Appendix Figure 
5.5.10). The identical raw protein fraction was utilised in both cases to allow a 
directly comparable assessment to be undertaken.
Following selection of the abeam manufactured primary antibody, in combination 
with the pre-purchased Fix and Perm ™ (Life Technologies ™, Hertfordshire, UK), 
a second assessment of the potential intracellular PIG-A background mutant 
frequency likely to be observed within MCL-5 cells was undertaken by flow 
cytometry acquisition and subsequent analysis. The data demonstrated highly limited 
evidence for any significant PIG-A protein presence within the MCL-5 parental 
population when utilising both the 30 min room temperature and 12 hr cold room 
primary incubations, both in combination with corresponding 1 hr room temperature 
secondary exposure; irrespective of gating strategy utilised, maximum PIG-A protein 
presence was recorded as 0.4997 and 0.5033% respectively (Table 5.5.2). When 
utilising a highly extended IHC staining protocol, 12 hr primary (cold room) in 
conjunction with a 72 hr secondary (cold room) exposure, 65.9 and 97.83% of the 
parental MCL-5 population were demonstrated to express the PIG-A protein when 
utilising the conservative and highly inclusive gating strategies respectively (Table 
5.5.2).
The extended IHC staining protocol sample was retrospectively stained with an 
additional cytoskeletal phalloidin (596 nm) dye and then assessed in tandem with a 
single stained phalloidin sample to assess the internalisation and origin of the PIG-A 
signal on the confocal microscope. The resultant data for the tandem stain sample 
displayed a significant presence of a phalloidin signal around the periphery of the
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cell, with extensive staining apparent associated just under the extracellular 
membrane (Appendix Figure 5.5.11). In addition to this, the sample displayed a 
similar signal for the PIG-A antibody, with a distinct extracellular localisation, with 
some evidence for a more internalised presence. The single stained phalloidin sample 
was also analysed and displayed a highly similar staining profile in both PIG-A and 
phalloidin signal channels; a reduced analogous PIG-A staining signal was presence, 
in the absence of the PIG-A primary antibody within the staining protocol. The PIG- 
A stained sample was shown to have an increased signal strength, demonstrated by 
heat map analysis (data not shown) when compared to the unstained phalloidin 
control, with the additional signal strength being solely located to the extracellular 
surface of the antibody.
Methanol fixation was assessed for its ability to both fix and permeabilise the MCL- 
5 extracellular membrane to facilitate complete intracellular access for antibody 
binding applications. The extended methanol fixation protocol was assessed within 
two fluorescence microscope samples utilising different primary antibodies, one 
specific to histone H3 and one for PIG-A; subsequent data were collected and 
displayed within separate channel and composite images. The initial histone H3 
sample displayed three apparently mono nucleated MCL-5 cells each comprising of 
a highly reduced cytoplasmic fraction volume, with some evidence to suggest of 
cellular membrane rapture and subsequent cytoplasmic projected into the 
surrounding area. The histone H3 signal was strong across all three cells and highly 
comprehensive across the entire DAPI stained nuclear area with no distinct 
localisation (Appendix Figure 5.5.12). The subsequent PIG-A stained specimen 
demonstrated two neighbouring MCL-5 cells, one mono-nucleated and the other 
apparently bi-nucleated in nature in terms of selective DAPI staining. Again the cells 
showed extensive cytoplasmic shrinkage, with the cytoskeletal marker barely 
protruding the nuclear boundaries. There was some evidence for a strong PIG-A 
signal presence within the intracellular region of the cells, no distinctive localisation 
of the stain (Appendix Figure 5.5.13).
The effects in terms of penetrance and cellular morphology of reducing the methanol 
fixation exposure was assessed within three subsequent samples, an isotype control, 
a histone H3 and PIG-A primary antibody specimen. Within the isotype control 
sample, three single mono-nucleated cells were detected, again displaying similar
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cytoplasmic shrinkage, however, slightly less in terms of nuclear association when 
compared to the extended protocol. The DAPI staining resulted in distinctive nuclear 
boundary establishment, with a more granulated appearance, as expected with the 
leukocyte nature of the cell line; little evidence was present to infer a significant 
antibody signal within the captured images (Appendix Figure 5.5.14). The histone 
H3 specimen sample displayed two distinct mono-nucleate cells, with some evidence 
for a cytoplasmic fraction outside the clear nuclear membrane boundaries. The DAPI 
signal provided evidence for large intact nuclei with a corresponding comprehensive 
histone H3 signal present across the entire nuclear area, no data to suggest potential 
histone H3 presence within the cytoplasm (Appendix Figure 5.5.15). Finally, the 
PIG-A stained specimen demonstrated two mono-nucleated MCL-5 cells, with 
strong granular nuclei, as defined by DAPI staining, with a fair cytoplasmic fraction 
present. The PIG-A signal itself was strong and highly localised within definitive 
positions within the nucleus, with a more comprehensive less specific presence 
within the cytoplasm, inferring a strong intracellular presence (Appendix Figure 
5.5.16).
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5.5.4 Discussions and Conclusions
5.5.4.1 Antibody Specificity Assessment
Prior to the continued development of the in vitro PIG-A assay protocol, antibody 
specificity must be challenged again following the incorporation of novel tandem 
markers. Even though the antibody raised against the novel surface antigen (CD55) 
is the same isotype as the previously utilised anti-CD55 RPE (igG 2 K) it is critical 
that integrity of the assay design is maintained. As described previously, the MCL-5 
cell line resides within the lymphoblastoid lineage and therefore, has a constitutively 
high expression of Fc receptors on the cell surface; their activity 
stimulates phagocytic or cytotoxic cells to destroy microbes, or infected cells 
by antibody-mediated phagocytosis [88, 89]. Due to this existence, there is a 
potential for un-specific Fc receptor mediated antibody binding indiscriminately to 
PIG-A mutant cells generating a false positive signal during flow cytometry analysis. 
The subsequent results of the experiment demonstrated that the isotype control (IgG 
k molecule lacking the variable region sensitive to the CD55/59 epitope) did not bind 
at any notable frequency to the surface within the chosen MCL-5 cell line (0.009%). 
Due to the accuracy involved in low dose quantitative screening, even an unspecific 
0.009% binding frequency potentially contributes 90 falsely phenotypic wild type 
cells for every 1 million cells scored; this is especially protuberant when a 
statistically significant increase in mutant frequency can be an equivalent number of 
events. However, as this minimal error is carried through to all experimental 
samples, the conclusion is that primarily the antibody is operating under the correct 
specific mechanism to facilitate qualitative and potential future quantitative dose 
response modelling.
1 7 7
5.5.4.2 Dose Finding Study, EMS and MNU Exposure
Limitations and caveats associated with routine drug screening data are apparent 
within pharmaceutical drug testing, however, recognising such limitations and 
providing a comprehensive strength of evidence based approach to a decision, 
enables more accurate hazard and risk assessment. Within genetic toxicology 
screening, confidence within data interpretation is critical, and therefore, 
indistinguishability and additional sources of potential error must be standardised in 
order to enable accurate decision making. Cytotoxicity and genotoxicity even though 
distinctly different mechanisms resultant from potentially independent events, often 
share a number of common inducers, phenotypic alterations or morphological 
changes during progression. Due to this, when cytotoxicity is elevated within a 
sample, the end point assessment data can no longer be assumed to be as a direct 
consequence of solely genotoxicity derived mode of actions and therefore, the data 
consequentially loses strength. In order to maintain data integrity, protocols have 
undergone standardisation, in which test compounds are assessed up to a pre­
determined dose resulting in a set level of cytotoxicity, in an effort to prevent 
ambiguity within the subsequent data [90, 91].
Following the selection of MCL-5 as the potential future platform for the in vitro 
PIG-A assay, prior to preliminary compound assessment, cytotoxicity screening was 
undertaken. For the purpose of assay protocol development, compounds are to be 
assessed up to the lethal dose 50 percent (LD50), a dose in which 50% of cells 
undergo cell death as a result of exposure or treatment. As mentioned previously, 
subtle variation within highly similar cell lines can result in dramatically different 
dose response kinetics, and therefore, in order to make a well informed decision on a 
chosen screening platform, sufficient dose response data requires to be generated. 
Cell lines known for homozygous p53 functionality, such as TK6, are relatively 
sensitive to chemical exposure, not overly sensitive, readily undergo apoptosis and 
have unique characterised recovery periods post exposure [92]. MCL-5 cells, even 
though are highly similar to TK6, have a less well defined TP53 genotype and 
therefore, are potentially more sensitive, exhibit delayed apoptosis and increasingly 
prone to acquire genotoxic damage [52, 93, 94]. The MCL-5 population currently
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utilised have been experimentally demonstrated to undergo apoptosis, through PS 
inversions, and therefore, appear to have some basal level of p53 functionality 
(Section 5.3.4.2).
MCL-5 cells were shown to take on average 22-26 hr to divide, and therefore, would 
require a longer recovery period to truly gauge the effects of the toxic treatment, 
when compared to similar AHH-1 or TK6 cell lines. Following acute EMS treatment 
the cell cultures displayed limited immediate growth, potentially reflecting the 
presence of the Gl/S checkpoint following p21 induction [77], until 24-48 hr post 
treatment. However, incorporating the OECD advised, 1.5-2 cell cycles of recovery 
allowed the desired toxic effects to be apparent [95]. 94 hr post exposure, an 
apparent dose dependent increase in toxicity was observed; the RPD value for the 
top dose tested had dropped to approximately 50% (Appendix 5.5.3.2). MNU data 
were slightly different; the cells began to grow immediately following seeding and 
treatment, no obvious lag was observed. Allowing the full 1.5-2 cell cycles of 
recovery again showed the desired toxic effects and generated an obvious dose 
response (Appendix 5.5.3.2). LD50 values were estimated for both compounds, -10 
and 1 pg/mL respectively, to be utilised as the respective top doses tested within 
future assay design.
Some preliminary conclusions can be taken from the data; initially MCL-5 cells 
appear to have functional p53 due to the presence of a potential checkpoint arrest 
following genotoxin exposure, as well as observed physical signs of apoptosis. MNU 
a known more potent alkylating agent when compared to EMS resulted in more 
severe cytotoxity, in line with published data, providing additional authentication to 
the data sets [55].
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5.5.4.3 Preliminary Investigations into Cell Cycle and GPI-AP Expression  
Correlation
Due to the limitations in intracellular area imposed on the cell via a fixed maximum 
expansion of the cellular surface membrane, all cells must undergo cleavage to 
enable continued metabolic activity, at a relatively fixed rate [96, 97]. Therefore, 
cells are continuously progressing through the cell cycle, resulting in cytokinesis and 
cellular division creating two identical daughter cells; this process facilitates the 
direct replacement of dead, dying or damaged cells [80]. The cell cycle is a higher 
regulation of cellular progression and function, which can be exploited by 
homeostatic mechanisms to prevent excessive uncontrolled growth; p53 mediated 
checkpoint arrest, DNA damage repair or induced apoptosis [26, 77]. However, as 
often observed within many cancer cases, patient present novel mutations within 
critical genes controlling such vital stages within cellular progression. As a direct 
result of such mutations, uncontrollable increase in growth rate, elevated 
angiogenesis, to overcome hypoxia, and down regulation of know tumour suppressor 
genes are common; facilitating the cancer phenotype [77, 78, 98, 99]. The cell cycle 
may however, also play a potential biasing role within the constraints of the in vitro 
PIG-A gene mutation assay design, as an analysis biasing factor; especially within 
the image stream ™ platform.
Theoretically, when a cell progresses through the final stage of the cell cycle, and is 
for want of a better term, split into two genetically identical daughter cells, the 
precise details in terms of mRNA division and regulation as well as surface 
membrane morphology and topography is vague. Therefore, presumably, due to 
cytoplasmic cleavage through a vesicle mediated furrow [100], the mRNA as well as 
pre-existing protein levels are fundamentally divided, potentially somewhat 
unevenly, resulting in differential proteomic concentration, as well as surface 
profiling within the daughter cells. From a genetic point of view, this has little 
impact on the assay design; however, as the assay utilises an in-direct reporting 
mechanism, reliant upon protein expression, un-uniform or distribution within such a 
fundamental cellular process could induce bias within analysis. Especially prominent 
within CCD reliant imaging, un-even surface distribution as a result of mitosis would
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heavily impact the scoring of positive or negative events, in regards to their GPI-AP 
surface protein expression.
Newly synthesis daughter cells therefore, are theoretically more likely to have 
underestimated GPI-AP presence and score as false negative events, during the 
immediate period following cytokinesis. Within this potential lag period newly 
synthesis cells are discriminated against in terms of analysis, and the extent in which 
this potential bias prevails within latter stages of the cell cycle is unknown; 
presumably expansive intracellular metabolism will rapidly return a more normal 
extracellular phenotype. As well as this, this potential lag period could be cell line 
dependent; within erythrocytic cells the presence of GPI-AP expression is vital for 
cellular survival through complemented inhibition. However, within leukocyte cell 
lineages often GPI-AP expression is reduced and their respective function less 
critical in terms of cell survival [101], and therefore, theoretically could have a much 
more exaggerated lag period post cytokinesis.
Initially, the potential biasing effect of the cell cycle in terms of relative GPI-AP 
expression was assessed on the Image Stream ™ platform, and then further 
investigated on the BC FACS Aria flow cytometer. The Image Stream displayed the 
PFA fixed MCL-5 cells within a typical cell cycle distribution, in terms of DNA 
content, with the majority of the population appearing to be within the initial stages 
of the cell cycle (G0/G1/S) (Appendix 5.5.3.3). Due to the limitations associated 
with the lack of filter wheel presence; there was a significant chance of spectral 
overlap and hence, the DNA content signal being present within the respective GPI- 
AP signal channel. In order to counteract this, a complex mask and subsequent 
feature was established; in which the intracellular fluorescence signals were omitted 
from analysis during GPI-AP expression profiling, via the removal of the pixels 
containing a light emission with an intracellular origin. Both data sets were analysed 
and resulted in highly comparable outputs in terms of DNA content distribution and 
subsequent GPI-AP expression. When the data set were modelled for correlation 
between GPI-AP surface signal intensity against DNA content, the resultant data 
displayed limited evidence to suggest any potential positive correlation. DNA 
content appeared to be independent of GPI-AP expression.
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In order to re-assess these preliminary finding, the BD FACS Aria was utilised to 
repeat this protocol and generate a comparable distribution within the same cell type. 
The subsequent generated data resulted in a DNA content distribution typical of a 
population with a potential G2/M checkpoint arrest; with the majority of cells being 
present within the latter stages of the cell cycle. This is common quite commonly 
observed within immortalised cell lines following compound exposure [102, 103], 
particularly common following p53 mediated genotoxin exposure [77]. However, 
additional external environmental stimuli may also account for such a distribution; 
cellular stress as a result of hypoxia, within the sealed preparative centrifuge tubes, 
can result in up regulation of HIF-1 and hence, contribute to G2/M arrest [104].
However, when the BD Aria data was assessed for positive correlation between 
DNA content as well as GPI-AP expression, or relative intensity, there again was 
little strong evidence to suggest such a relationship. Within this data one could say 
that there was some evidence to suggest that larger cells, in terms of surface area and 
DNA content, had higher relative GPI-AP signals; G2/M population data displayed 
GPI-AP fluorescence intensity greater than both G0/G1 and S phase phenotypic 
populations (Appendix 5.5.3.3). However, in the context of this assay platform, the 
variance observed was minimal and should not play any critical role in biasing 
subsequent analysis data.
The data within this section, displayed strong evidence to suggest that utilising 
multiple flow cytometric platforms, DNA content and GPI-AP expression profiling 
was both practical and achievable. The subsequent collected data, across both 
platforms, suggested that there was little evidence to confirm a strong positive 
correlation between GPI-AP expression and cellular DNA content. Therefore, 
smaller cells in terms of cellular surface area, as well as lower DNA content, did not 
appear to exhibit a significantly lower GPI-AP expression signal to any other cellular 
phenotype which could induce bias within the ensuing in vitro PIG-A analysis.
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5.5.4.4 Preliminary Intracellular PIG-A Investigation
The unique characteristic of in-direct mutation reporting, as exploited by both the in 
vivo and in vitro PIG-A gene mutation assays, is a significant advantage as well as a 
point of contention. The simplicity of the reporting system lends itself well to the 
nature and robustness of erythrocytic cell lineages; however, it also is a major 
weakness for cell lineages with differential or sporadic GPI-AP expression and 
limited attachment [6, 11, 105, 106]. Some degree of ambiguity within the 
corresponding data analysis can be directly associated to the in-direct reporting 
system, as the likelihood of inaccurate reporting is potential; unless a number of 
mitigating factors have been implemented. If however, a high throughput analogous 
PIG-A mutation assay can be developed with a more direct reporter system, utilising 
the current conserved mechanism [12], there is a potential for extensive diverse 
tissue usage as well as interspecies expansion.
In brief, the current reporter system describes a phenotypic PIG-A negative event 
based on the statistically most prominent cause of the GPI-AP deficient phenotype; 
as the PIG-A gene is the only sex linked and hence hemizygous gene statistically it is 
the most common genotypic alteration resulting in the null phenotype. However, as 
mentioned previously, recently the human PNH condition has been observed within 
patients presenting an intact PIG-A gene, a double recessive mutations within the 
PIG-T alleles [107]. In addition to PIG-T there are upwards of 20 additional genes 
critically involved with the direct synthesis of the GPI-AP structure as well as the 
intracellular modification and transporting [106]. However, if a direct reporter 
system quantitatively measuring a sex linked gene product could be established 
within a commonly used tissue type and made accessible to high throughput scoring, 
the foundations of a potentially highly sensitive gene mutation assay are established 
[3,4, 108, 109].
Initially, intracellular PIG-A reporting was investigated within MCL-5 cells; to 
enable a direct comparison if low dose modelling data were to be undertaken, with 
the ideology of mimicking the developed in vivo method, initially utilising primary 
haemopoetic cell lineages and then expanding the technique to comprise primary 
hepatic tissue. The initially collected data, data not shown, reported an extensive lack
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of signal following untreated wild type intracellular PIG-A assessment, utilising the 
Fix and Perm® Life Technologies ™ kit. However, this was further investigated and 
attributed to a defective primary antibody; western blott analysis was utilised on total 
protein extracts to evaluate the specificity and efficacy of novel primary antibody 
binding. The resultant data demonstrated that the Sigma Aldrich antibody was unable 
to bind to the PIG-A protein presence within the extractions (Appendix Figure 
5.5.10), whereas the independently obtained Abeam antibody displayed 
comprehensive binding within the extracted samples. The establishment of a generic 
immunohistochemical staining protocol comprised of a number of different primary 
and secondary incubations, under different conditions, was established to enable 
conceptual assay development. The standard, more typical IHC protocols utilising 
the analogous Fix and Perm® kit demonstrated minimal or absence of corresponding 
PIG-A protein signal within the parental populations (Appendix Table 5.5.2), 
however, the significantly elongated protocol resulted in comprehensive binding. 
When assessed for signal validity via confocal microscopy, the data was 
demonstrated to be as a result of unspecific binding, heavily associated to the 
extracellular surface of the cell membrane as well as spectral overlap from the 
phalloidin signal, utilised for cellular morphology visualisation purposes. An 
immediate conclusion of lack of cellular permeability was recognized, due to the 
successful nature of the analogous western blott data, and a more abrasive 
pemeabilising agent was investigated for use, when compared to the 2% 
formaldehyde and pemeabilising agent combination within the pre-purchased kit.
Methanol fixation was demonstrated to be a more comprehensive fixative and 
pemeabilising agent, not requiring the use of individual solutions. Precipitating 
(or denaturing) fixatives, such as methanol, act by reducing the solubility of protein 
molecules, through disruption of hydrophobic interactions and hence, compromising 
tertiary structure [62]. However, the fixation period when utilising 100% methanol is 
highly variable depending upon the tissue type, and as such the initial incubation 
must be assessed individually for chosen cell type. The extended methanol fixation 
protocol demonstrated extensive cell damage, with highly apparent morphological 
disruption of the typical cell phenotype (Appendix Figures 5.5.11 -  5.5.13). The 
cytoplasmic composition of the cell was highly reduced, with cytoplasmic shrinkage 
an obvious adverse effect of fixation, subsequently distinguishing between the
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origins of the phalloidin cytoskeletal dye and the intracellular PIG-A signal was 
highly complex and potentially misleading. Therefore, utilising a reduced fixation, 
the resultant high resolution fluorescence microscopy images demonstrated an 
apparent intra-cellular PIG-A signal with stronger weight of evidence to suggest a 
more valid localisation and origin, following known location house keeper protein 
visualisation (histone H3).
i
I
The conclusion which can be taken from this initial work is that it does appear 
distinctly possible to undertake an intracellular PIG-A gene mutation assay, in 
potentially any primary tissue type, utilising methanol fixation and subsequent 
permeabilisation. However, the sensitivity of such a system is unknown, and 
therefore, flow cytometry based validatory assessment will be required to estimate 
the apparent background or pre-existing number of phenotypic PIG-A mutants prior 
to any low dose response modelling, this ideally supported by sequencing analysis. 
The use of a more direct reporting system could remove the ambiguity of the identity 
of presumptive phenotypic PIG-A mutant events within the sequential flow 
cytometry based analysis. However, the establishment of this generic protocol with 
the apparent successful IHC validation images puts forward a strong foundation for a 
high throughput assay development, with little need for high content screening; the 
current need for the addition of such specific morphological markers is due to the 
distinct impact morphological alterations can have on subsequent GPI-AP 
expression. Utilising a direct reporter system removes the potential for the additional 
genes involved in GPI-AP synthesis, protein shuttling and extracellular expression
| (PIG genes) genes to have a significant impact on reporting PIG-A phenotype.
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Chapter 6: Human PIG-A -  A Potential Biomarker Tool for Epidemiology Bio-
Monitoring Studies
6.2 Materials and Methods
6.2.3.3.2.2 The Possible Effect Anticoagulant has on Spontaneous PIG-A 
background Mutant Frequency
Blood was collected from a healthy control donor via a venous puncture into the 
median cubital vein. Venous blood was removed directly into a heparinised 5 ml 
vaccutainer as well as a 5ml EDTA coated vaccutainer. From the first vaccutainer, 5 
mL of heparinised blood was transferred using a sterile 10 ml pipette onto a 10 mL 
mixture of histopaque ® 1077 as well as histopaque ® 1113 within a 15 ml Falcon 
tube. This was repeated from the second vaccutainer containing EDTA treated blood.
Both samples were centrifuged at 2000 RPM for 30 min at room temperature, plasma 
layer carefully removed and very precisely the layer of MNC (mononuclear Cells) 
isolated and transferred into fresh falcon tubes. As well as this, carefully the next 
layer of cells (100 pL suspected granulocytes and RETs) were also isolated and 
collected. Excess RPMI media/PBS 10 mL was added, centrifuged at 1600 RPM, at 
room temperature, for 10 mins.
Following centrifugation, very accurately the supernatant was removed, and the cell 
pellet re-suspended in RPMI media (0.5 mL) initially, and then continued to add 
excess until the tube was full (-10 mL). The samples were centrifuged, 1600 RPM 7- 
10 mins, supernatant aspirated. This wash step was repeated 2-3 times in order to 
remove any residual histopaque® from the solutions. Post washing, the cells were re­
suspended in 0.5-1 mL of 1XPBS solution.
20 pL of anti-CD 15 APC was added samples incubated in the dark, at room 
temperature, for 30 minutes (both WBC and suspected RET layer were stained for 
granulocyte presence). Following 15 min of the incubation, samples were treated 
with FLAER; a previously constructed aliquot of FLAER was removed from the 
cold room and allowed to warm to room temperature. 5pl of FLAER (lx  stock as
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made up previously) was added to the samples and allowed to incubate for a further 
15 min at room temperature protect from light.
1 mL of VersaLyse solution (IX) was added and vortexed immediately (1 sec) and 
allowed to incubate for 10 min at room temperature, protected from light. 
Immediately following incubation, each sample was centrifuged, (150 x g for 5 min), 
supernatant aspirated and re-suspended in 3 mL of Wash buffer (0.2% BSA/PBS). 
The samples were centrifuged, re-suspended in 1 mL of Wash Buffer and treated 
with 5 pL of Propidium Iodide, and allowed to incubate for 5 min on ice, protected 
from light on ice, prior to acquisition on the flow cytometer.
187
6.3 Results
6.3.3.3.2.2 The Possible Effect Anticoagulant has on Spontaneous PIG-A 
background Mutant Frequency
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MeanPopulation______________________________________________________________________
|  Leucocytes 1,069,296 100.0 7 ~  4
■  CD1S Positive 10,600 1 0 493 407
|  Doublet Discrimination 9,093 85.8 398 337
|  Fluorocbrome discrimination 1,726 19.0 1,382 1,144
□  Granulocytes WT 1,705 98.8 1,398 1,157
f l j  NOT(Granulocytes WT) 21 1 2 74 103
Population fE vents %Paren1
FITC-A
Mean
2C
APC-A
Mean
|  Leucocytes 590,598 99.3 508 213
■  CD15 Positive 232,853 39.4 842 425
|  Doublet Discrimination 202,941 87.2 802 402
|  Fluorocbrome discrimination 193,134 95.2 804 402
□  Granulocytes WT 171,123 88.6 879 409
|  NOTfGranulocytes WT) 22,011 11.4 221 351
Figure 6.1. Direct comparison between the population statistics derived from 
variable direct anticoagulant capture; EDTA (1) and Heparin (2) utilised as trialled 
anticoagulants. A) Crude size and granularity assessment utilising FSC and SSC 
measurements, B) relative frequency of events staining positive for FLAER binding 
(phenotypic PIG-A wild types) and C) comparable results table displaying the 
subsequent population statistics, detailing the hierarchical approach.
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The experimental design was to aid investigation into the initial combined use of 
histopaque ® 1077 and 1119 as well as assess the potential effects different 
anticoagulants had on cell isolation and phenotype stability. The PNC layer 
theoretically was to be trapped between the two specific density histopaque ® 
solutions utilised in order to facilitate effective and robust granulocyte capture.
The initial results we generated were very poor in terms of layer separation as well 
as granulocyte capture (data not shown) quite different; within the two different 
patient samples, we were unable to see any potential granulocyte layer (PNCs) 
within either the histopaque® or on top of the erythrocyte pellet. Following 
temperature sensitive adjustments, as well as an increase in centrifugation intensity, 
the results captured were able to compare and contrast anti-coagulant effects.
The subsequent results generated showed a distinctive granulocyte (PNC) layer 
within the EDTA sample, however, it was located on top of the erythrocyte pellet 
and not between the two different histopaque ® solutions. The heparin sample gave 
no distinct granulocyte layer at all, and therefore, for the purpose of this experiment 
the equivalent section of the sample was removed and FCM assessed. The EDTA 
sample generated a 40% CD 15 positive leukocyte population, allowing the collection 
of >500,000 events within a suitable time frame. Implementing the revised gating 
system, 200,000 granulocytes positive events were scored and approximately 88.6% 
of these were PIG-A positive; a significant increase in event enrichment, however, 
poor results with respect to PIG-A phenotype assessment.
However, the heparin sample only yielded an approximate 1% CD 15 positive 
sample; even though > lx l0 6 events were scored, following gating, only a 1,726 
events were classified as neutrophils with a corresponding PIG-A phenotypic wild 
type frequency of 98.8%. Typically heparin is used within clinical applications in 
terms of sample collection as well as storage, however, the results demonstrate that 
EDTA generate significantly higher CD 15 capture, and only marginal loss of PIG-A 
phenotype. Both methods generated in-efficient CD 15 populations in terms of PIG-A 
mutant sensitivity and therefore, would require further optimisation prior to routine 
use for PIG-A assessment within human granulocytes (Appendix Figure 6.1).
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6.4 Discussions and Conclusions
6.4.3.3.2.2 The Possible Effect Anticoagulant has on Spontaneous PIG-A 
background Mutant Frequency
Throughout the optimisation of the human PIG-A assay platforms we have operated 
under the assumption that the blood collection within heparin coated vaccutainers is 
not biasing or influencing the data acquisition in any way. Heparin is a 
sulphated glycosaminoglycan and is widely used as an injectable anticoagulant 
[110]. It has a highly negative charge density [111] and its commercially utilised 
heavily within the medical industry to form an inner anticoagulant surface on various 
experimental and medical devices. It operates under the premise of binding to the 
enzyme inhibitor anti-thrombin III (AT), causing a conformational change that 
results in its activation through an increase in the flexibility of its reactive site loop. 
Activated AT, inactivates thrombin and other proteases involved in blood clotting, 
most notably factor Xa. Heparin has the ability of increasing the rate of inactivation 
of such proteases by up to 1,000 -  fold [112]. Heparin’s excessive negative charge 
has the effect of dramatically increasing its ability to interact within the AT enzyme 
as well as providing an excessively favourable environment for inhibition following 
Ca2+ ions interaction [113]. However, heparin is also associated with heparin- 
induced thrombocytopenia (HIT), caused by an immunological reaction that 
makes platelets a target of immunological response [114], the potential impact of this 
as well as the charged nature of heparin may have deleterious effects on the cells 
within the blood sample and negatively influence their PIG-A assessment.
Therefore, in order to generate some comparable data a second anti-coagulant was 
also trialled, ethylenediaminetetraacetic acid (EDTA) is an aminopolycarboxylic 
acid. Its usefulness within the field of biology directly relates to its ability to act as a 
chelating agent [115]; EDTA binds metal ions such as Ca2+and Fe3+’ following 
binding metal ions remain in solution but exhibit diminished reactivity [116]. 
Therefore, it activity inhibits the Calcium induced clotting cascade and readily is 
utilise as an anti-coagulant [117]. However, its uses remain more commercial,
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especially prominent within specific scientific buffers, but yet to be highly associated 
to clinical applications.
As well as trialling the effects specific anticoagulants have on the spontaneous PIG- 
A mutant frequency, this experiment was also designed to incorporate a second 
distinct histopaque® solution within the method in an attempt to aid enrichment. 
Histopaque ® 1077 and 1119 g/mL will be utilised to potentially capture and isolate 
the PNC (poly nuclear cells) layer. The initial results were very poor (data not 
shown), the centrifugation failed to result in any separation of the whole blood 
samples, however after a detailed literature search, a single paper [118] providing 
sufficient details within their analogous method to enable potential solution. The 
centrifugation speed was increased to be in line with the publication and the 
subsequent results showed a distinctive “granulocyte” layer within the EDTA 
sample; although, the localisation of the layer was highly proximal to the top of the 
RBC pellet and not the between the histopaque® solutions as expected. The heparin 
sample gave no distinct granulocyte layer at all; however, for the purpose of this 
experiment the equivalent section of the sample was removed and assessed.
The EDTA sample generated a subsequent 40% CD 15 positive population following 
centrifugation, the capture of 500,000 morphological leukocytes events within the 
pre-allotted time for analysis. Combining this method with the trialled novel gating 
system, 200,000 defined granulocytes were scored with a respective phenotypic 
mutant PIG-A frequency of 11.4%. The heparin sample yielded a 1% CD 15 positive 
constitution within the blood sample, and therefore, resulted in a highly limited 
(-2,000) granulocyte population to be scored. Although, within this population on
1.2% were phenotypic PIG-A mutants, a significant increase in sensitivity when 
compared to the EDTA sample.
The results of this experiment in terms of enrichment were highly promising, 
especially for the EDTA sample, facilitating -5 x l0 5 cells scored easily within the 
acquisition time. However, both heparin and EDTA generated unacceptably high 
spontaneous background PIG-A mutant frequencies, preventing any potential 
quantitative data modelling for the HBM (Appendix Figure 6.1). The reason why 
heparin resulted in a much lower granulocyte enrichment from a biological 
standpoint are unknown, however, the observed results are most likely due to some
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element of user error as the construction of the sample pre-centrifugation, as well as 
cell harvesting are particular advanced. Therefore, limited conclusions can be drawn 
from this experiment except that yet again, additional factors introduced within the 
experimental design can have a significant impact on the sensitive of the measurable 
endpoint and deleteriously affect the overall assay platform performance.
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6.5 Supplementary Work
6.5.1 Introduction
Flow cytometry gating is still a prominent potential source of experimental error 
within scientific research. Until relatively recently, few publications on analysis 
standardisation have impacted the field and resultantly, analysis is often highly 
varied and subjective [39, 50, 119-123]. This has a direct effect on robustness, data 
integrity and transferability. However, recent movements within the field have 
resulted in an attempt to harmonize approaches and have significantly refined the 
publication procedure; consequently standards have greatly improved [124]. As the 
field develops, increasing properties of the fluorescence signal are being utilised 
within analysis to provide additional features to enable more detailed and 
comprehensive population assessment [50, 125, 126]. However, as the technical 
level of analysis increases, so does the knowledge base required to interpret the data. 
Therefore, as often is the case within scientific research, the technology advances 
beyond the understanding required to fully comprehend the intellectual need. 
Consequently, incorrect usage of the novel features can potentially have deleterious 
effects on the integrity of the generated data; noticeably bias can be introduced 
which fundamentally significantly reduces the weight of evidence attributed to the 
data.
In an endeavour to increase flow cytometry resolution within data analysis and 
fundamentally increase the sensitivity of the assay, the ability of incorporating novel 
pulse-width measures within the test system were investigated. Pulse width can 
provide increased refinement of sub population identification and significantly 
provide additional information in terms of morphological size and form, to enable 
more accurate phenotypic scoring. Therefore, more accurately identifying and 
removing doublets, debris and any cell type which does not resemble normality 
should increase reporting accuracy and reduce the risk of false negative/positive 
results. Nevertheless, the benefit from introducing significantly more complex gating 
strategies can be heavily outweighed by the deleterious consequences if the gating is
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not true and remains critical to unbiased reporting. Introducing ever increasing 
limiting strategies to remove outlier events also runs the risk of excluding actual 
viable events from analysis.
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6.5.2 Materials and Methods
6.5.2.1 Gating Strategy Advancements: Investigations into Potential Analysis 
Bias
A single patients under went venepuncture, bled from the Median Cubital Vein 
located on the ventral surface of the forearm, into a 5 mL heparin coated 
Vaccutainer. The tubes receiving antibody treatment, pre-lysis, were treated with 20 
pL of anti-CD 15 APC and incubated in the dark, at room temperature, for 30 
minutes. Following 15 minutes, the samples were treated with FLAER. A previously 
constructed aliquot of FLAER was removed from the cold room and allowed to 
warm to room temperature. 5 pL of FLAER (lx  stock as made up previously) was 
added to the samples and allowed to incubate for a further 15 min at room 
temperature protect from light.
1 mL of VersaLyse solution (IX) was added, vortexed immediately (1 sec) and 
allowed to incubate for 10 min at room temperature, protected from light. 
Immediately following incubation, the samples were centrifuged, 150 x g for 5 min, 
supernatant aspirated and washed, via the addition of 3 mL of wash buffer (0.2% 
BSA/PBS). The samples were centrifuged as above, and re-suspended in 1 mL of 
Wash Buffer, samples were treated with 5pL of Propidium Iodide, allowed to 
incubate for 5 mins, protected from light, on ice. Samples were analysed 
immediately on the flow cytometer.
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Table 6.5.1.A) Summary o f the preliminary population statistics derived from a lysed 
healthy control patient donor; stained with anti-CD 15 APC neutrophil marker in 
conjunction with PI.
Sample ID All Events Leukocytes CD15Positive
Percentage 
of Parent 
(%)
Viable
Cells
Percentage 
of Parent
(%)
Sample 1 2024878 14270 14145 99.1 13802 97.6
Sample 2 1086108 10736 10539 98.2 10303 97.8
Sample 3 4700000 31075 30875 99.4 30044 97.3
Average 2603662 18693.67 18519.67 98.9 18049.67 97.57
Table. 6.5.1.B) Summary o f the population statistics derived from a lysed healthy 
control patient donor; stained with anti-CD15 APC neutrophil marker in 
conjunction with FLAER, utilising the FLAER FL-W gating strategy.
FITC - Pulse Width (Time of Flight Measurement)
Sample
ID
Doublets and 
Debris 
exclusion
Percentage 
of Parent
(%)
PIG-A
WT
Percentage 
of Parent
(%)
PIG-A
Mutants
Percentage 
of Parent
(%)
Sample 1 13180 95.5 13180 100 0 0
Sample 2 10000 97.1 10000 100 0 0
Sample 3 28949 96.4 28949 100 0 0
Average 17376.33 96.33 17376.33 100 0 0
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Table. 6.5. l.C) Summary o f the population statistics derived from a lysed healthy 
control patient donor; stained with anti-CD15 APC neutrophil marker in 
conjunction with FLAER, utilising the CD15 FL-W gating strategy.
APC - Pulse Width (time of flight measurement)
Sample ID
Doublets and 
Debris 
exclusion PIG-A WT
Percentage 
of Parent
(%)
PIG-A
Mutants
Percentage 
of Parent
(%)
Sample 1 12391 12390 100 1 0
Sample 2 9246 9246 100 0 0
Sample 3 27273 27273 100 0 0
Average 16303.33333 16303 100 0.333333 0.002%
In order to assess the feasibility of increasing assay sensitivity, initially at low 
sample number, without lysis enrichment, and then scaling up for larger 
enumerations of phenotypic mutant event, two novel gating strategies were trialled. 
Analogous to previous optimisation work within the in vitro PIG-A gene mutation 
assay, a generic “healthy” human patent sample was initially analysed in order to 
construct a baseline of mutant frequency. Following this, the inclusion of novel 
highly sensitive gating strategies utilising pulse width measures were included to 
evaluate the potential of induced assay bias. The resultant initial data generated an 
average capture of ~2.6xl06 single cell events, of which 18,000 were identified as 
leukocytes due to their crude unique FSC vs SSC profiles. Following this, 98.9% of 
the parental leukocyte population were demonstrated to be positive for the CD 15 
lineage specific antigen and less than 2.5% of the population showed loss of cellular 
membrane integrity, the latter was omitted from analysis (Appendix Table 6.5.1.A).
The two trialled gating strategies delivered similar but distinctive results, utilising 
the FITC-A vs FITC-W measures, approximately 17,000 leukocytes were identified 
of which 96.3% were defined CD 15 positive, activated neutrophils, and 0 average 
cellular events were scored as phenotypic PIG-A mutants (Appendix Table 6.5.l.B). 
APC-A vs APC-W generated analogous population statistics with approximately
16,000 leukocytes, however, the average phenotypic mutant frequency was defined
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as 0.002% (Appendix Table 6.5. l.C). Utilising the FL-W measure of the PIG-A 
phenotypic reporter marker in conjunction with the FL-A data, resulted in a strong 
correlation to an absence of phenotypic PIG-A mutant events. The FITC-A vs FITC- 
W pulse data showed some evidence for a biasing effect on sequential PIG-A 
scoring.
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6.5.4 Discussions and Conclusions
6.5.4.1 Gating Strategy Advancements: Investigations into Potential Analysis 
Bias
Granulocytes when compared to the other cell type within whole blood have elevated 
levels of cytotoxicity within their culture, specifically demonstrating high levels of 
cellular death and apoptosis (Section 6.3.3.2). This is due to their nucleated status, 
permitting them to undergo apoptosis as well as their unique role within innate 
immunity within the human body [127]; systemic exposure to micro-environments 
inducive of pro-inflammation and DNA damage [127-130] .These factors have the 
potential effect of generating putative PIG-A deficient phenotype events within the 
heterogenous population, resulting in false positive FCM data. PIG-A mutants are 
isolated on the flow cytometer via their lack of phenotypic marker associated 
fluorescence, homologous to the in vivo erythrocyte Pig-a assay [131], therefore, 
putative non-viable cells which have the “correct FSC vs SSC profile” (recently 
undergoing apoptosis for example) could lose their phenotypic PIG-A marker on the 
cell surface via localised membrane inversion/integrity or associated gene expression 
with apoptotic death pathways [132]; apoptosis progression in general provides 
increased difficulties for accurate cell identification [123].
Initially to account for potential false positive events, a complex compensation 
matrix utilising single stained positive control samples to account for any potential 
spectral overlap from introducing three different coloured fluorochromes within the 
assay design was presented (data not shown). In combination with the compensation 
matrix a gating system similar to the novel strategy introduced within the in vitro 
assay (Section 5.3.4) was trialled in combination with the use of propidium iodide, a 
generic intercalating fluorescent dye to measure membrane integrity [126, 133]. The 
results indicated that not only did this version of the assay platform surpass the 
previous lowest spontaneous background mutant frequency (0.01%), but 
significantly increased assay sensitivity (0.002% putative PIG-A mutant frequency). 
Apparently the combination of improvements generated a highly accurate method for
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putative false positive PIG-A mutant detection and exclusion via a combination of 
viability dye incorporation and pulse width measurement. However, limited solid 
conclusions can be taken from the data due to the limited sample size, approximately
15,000 events, as well as the potential bias within the resultant data.
Utilising the APC-W measure the assay sensitivity was significantly shown to 
increase, as the APC detector was measuring the CD 15 specific fluorescent signal. 
However, when the FLAER associated FITC-W signal was utilised the background 
mutant frequency was unable to be estimated as not a single phenotypic PIG-A 
mutant event was scored. The nature of the FL-W measure utilised as an additional 
size discriminator has a massive impact on the resultant PIG-A data. Therefore, 
within future applications, and FL-W measure directly associated to mutant 
phenotype scoring within FCM analysis will not be able to be utilised as an 
additional discriminate. The reason for this is the events which have a smaller FL-W 
(even utilising FITC-W in this case) are not necessarily biased against when scored, 
however, in combination with the FL-A measure and a limited specific population 
gate their ability to be incorporated into further analysis stages is highly biased 
against. Therefore, using the FL-W of an un-associated fluorescence signal from the 
phenotypic scoring is apparently appropriate.
The main conclusions which can be taken from this is that the assay platform design 
can be directly transferred, replacing propidium iodide with 7-AAD, in its current 
form into the human RET PIG-A assay design in order to potentially increase assay 
sensitivity. Additional larger sample sizes will be required to be captured prior to 
further conclusive remarks.
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